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Summary
Tamoxifen and chemotherapy are key treatments for breast cancer patients. Tamoxifen, 
an oestrogen antagonist, is a non-steroidal that acts as a selective oestrogen receptor 
modulator (SERM). It competitively inhibits the interaction of oestrogen with the 
oestrogen receptor, blocking the effects of E2 and inhibiting receptor activity. 
Chemotherapy uses cytotoxic drugs to kill cancer cells, by preventing them from 
multiplying, invading and metastasing. Despite the extensive use of both treatments, 
failure to respond to them is a major clinical problem and this is the cause of significant 
morbidity and mortality. To overcome this and to improve patients’ treatment options, we 
need to understand the mechanisms regulating the development of resistance.
The Ras/Raf-l/MAPK pathway regulates multiple cellular processes such as 
proliferation, apoptosis, differentiation, senescence and migration. MAPK activation 
results in phosphorylation of more than 50 substrates within the cytosol and nucleus. One 
key substrate of MAPK is the oestrogen receptor (ERa). Activated MAPK directly and 
indirectly phosphorylates serine 118 and 167, respectively, in the AF-2 domain of the 
receptor. Stimulation of the Ras pathway results in the ligand-independent activation of 
the ERa. Consequently, this pathway has been identified as a key player in the 
development and progression of tumourigenesis. Research suggests that activation of this 
pathway mediates response to tamoxifen, by activating ERa in a ligand-independent 
manner, and to chemotherapy, by increasing cell proliferation. This current study 
investigated the hypothesis that expression and activation of Ras/Raf-l/MAPK influences 
patient outcome and treatment response, using breast tumours from three different patient 
cohorts and an immunohistochemical approach. It also examined the relationship
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between MAPK and oestrogen receptor, both can localise to the cytoplasm and/or nuclei 
of cells but it is unclear how and where they interact. Therefore, \n vitro studies, 
including immunofluorescence, were performed to investigate the relationship between 
MAPK and ERa, and their role in driving tamoxifen resistance.
The pilot study, comprised of ER positive and negative patients who received a 
range of treatments, revealed that increased expression of N-Ras in breast tumours was 
related to reduced disease-free and overall survival time. It also highlighted the 
unexpected finding that Ras localised to the nuclei of breast tumour cells. The presence 
of nuclear Ras was confirmed by in vitro studies.
The expression of Ras, Raf-1 and MAPK proteins was investigated further, in 
tumours from ER positive patients, who were treated with tamoxifen (STB study), and in 
tumours from ER positive and negative patients who received chemotherapy treatment 
(NEAT/BR9601 study). These two studies highlighted that the Ras pathway mediated 
outcome in patients treated with Tamoxifen but not chemotherapy. High expression 
levels of N-Ras, pRaf(ser338), and MAPK were related to a shortened response time to 
Tamoxifen. Activated Raf-1 was also associated with a reduced disease-free and overall 
survival time. The implications of this study was that whilst N-Ras and MAPK were 
associated with the development of tamoxifen resistance and emphasised the importance 
of the Ras pathway, it was nuclear pRaf(ser338) that was the principal candidate for 
identifying patients failing to respond to tamoxifen. Patients with increased tumour 
expression of pRaf(ser338) were more likely to require additional or alternative therapies 
such as chemotherapy, aromatase inhibitors or Raf-1 inhibitors. In this STB study 
elevated levels of activated Raf-1 in tumours appeared to predict for poor response to
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tamoxifen, however it also seemed to identify patients who benefited from a combined 
treatment regime of tamoxifen and chemotherapy. It was therefore speculated that Raf-1 
and MAPK partially controlled cells response to chemotherapy. However, analysis of the 
NEAT study revealed no evidence that either Raf-1 or MAPK were predictive for 
response to chemotherapy. The exact role of Raf-1 and MAPK in mediating response to 
chemotherapy is controversial and perhaps further work in a larger cohort of 
chemotherapy treated patients is required to enhance our knowledge of the mechanism 
driving resistance.
Having shown a significant link between expression and activation of the Ras 
pathway and tamoxifen resistance, the interaction between this pathway and ERa was 
investigated in MCF-7 breast cancer cells. This study confirmed that ligand-mediated 
phosphorylation was associated with rapid nuclear localisation of ERot, probably due to 
oestrogen binding and that ERa was phosphorylated at serine 118 in a ligand- 
independent manner, via MAPK. It suggested that pMAPK has to translocate to the 
nucleus to induce expression of phosphorylated ER in the nucleus. Preventing nuclear 
translocation of pMAPK reduced the levels of ligand-independent but not ligand- 
dependent phosphorylation of ER, confirming that oestrogen phosphorylation of serine 
118 is reliant on a kinase other than MAPK, Previous studies have identified CDK7 as 
the kinase responsible for oestrogen-dependent phosphorylation of serine 118. 
Additionally, this study suggested that the ligand-independent activation of ERa was 
dominant over oestrogen-dependent activation. Heregutin mediated signalling determined 
the subcellular localisation of ER, even in the presence of oestrogen.
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This research highlights the impact of the Ras pathway on breast cancer patients’ 
response to treatment. It also reveals some interesting findings regarding the interaction 
between MAPK and ER, and offers a possible mechanism for the development of 
Tamoxifen resistance.
i
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1 Introduction
1.1 Breast Cancer: Incidence and prevalence
As the most commonly diagnosed cancer in women, breast cancer accounts for one in 
three of all female cancers, and is second to lung cancer in causing female-cancer specific 
deaths. Worldwide, over a million women are diagnosed with breast cancer each year, 
accounting for a tenth of all new cancers and 23% of all female cancers (1). The lifetime 
risk of UK women developing breast cancer is 1 in 9. More than 42,000 British women 
are diagnosed with breast cancer each year (1). In 2002 an estimated 172,000 women 
were alive in the UK with breast cancer (1). 80% of women survive at least five years 
after diagnosis. Furthermore, the 20 year survival rate for women has risen from 44% in 
the early 1990s to 64% in the period 2001-2003. However Britain has one of the highest 
death rates in Europe; approximately 13,000 women die each year from breast cancer (2).
Several important genetic and environmental risk factors are associated with breast 
cancer. Approximately 5-10% of breast cancers have a genetic link; two thirds of these 
cases have mutations in the tumour suppressor genes BRCAl and BRCA2. Mutations in 
these genes are associated with familial/hereditary breast and ovarian cancer, early age of 
onset, and cancer in both breasts (3). The main risk factor for sporadic breast cancer is 
age: the risk of developing breast cancer by the age of forty is 0.5%; by the age of eighty; 
it is 10% (4). Other risk factors include family history of breast cancer, prolonged 
exposure to oestrogen (onset of menstruation before age 12, menopause after age 50, first 
child born after the age of 30), alcohol abuse and obesity.
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1.2 Breast Cancer Pathology
1.2.1 Normal Breast Anatomy
The female breasts are milk-producing glands, composed of lobules/glands, milk ducts, 
fat and connective tissue. Each breast contains 15-20 lobes, comprising lobules, which 
end in glands that produce milk in response to hormone signalling, arranged in a circular 
fashion. Ducts deliver milk to the nipple, thus connecting lobes, lobules and glands. Fatty 
tissue fills the spaces between the lobules and the ducts (Fig 1.1). Blood and lymph 
vessels form a network throughout each breast. The mammary gland undergoes three key 
phases of development and differentiation under the control of hormones and growth 
factors (5;6): lobule development, between the ages of 10-25; glandular development, 
under the influence of menstrual hormones between the ages of about 13-45, and 
involution, or shrinkage of the milk ducts, from about age 35.
During the menstrual cycle, oestrogen stimulates milk duct growth; following 
ovulation, halfway through the cycle the hormone progesterone continues to stimulate 
milk gland formation. If pregnancy does not occur, the breasts return to normal size and 
the cycle begins again. During early (mammogenesis) and late (lactogenesis 1) phases of 
pregnancy, the final stages of development and differentiation occur. Mammogenesis is 
characterized by proliferation of the distal elements of the ductal tree, creating multiple 
alveoli (acini) of variable size and shape. Lactogenesis 1 occurs later and is characterized 
by differentiation of resting mammary cells into lactocytes, with the potential to secrete 
the unique fats, carbohydrates, and proteins characteristic o f milk. The breast of 
nuiliparous women contains more undifferentiated structures whereas the breast of parous 
women is comprised of more differentiated lobules (5). During lactation, mammary 
lobules become enlarged and milk is synthesised and released into the ductal system.
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Accumulation of milk in ducts has an inhibitory effect on the production of milk. This 
results in a series of involutional changes in the mammary gland, which reduces the 
volume of secretory epithelial cells and inhibits their secretory activity (5).
Hormone regulation is important, not only in the development and differentiation 
of the breast but also in the development of disorders, such as benign breast disease, and 
breast cancer.
Chest waN 
Pectoralis m uscles
Nippie
duo
Fafly tissue
Skin
Figure 1.1: Anatomy of female breast
The breast is a milk-producing gland comprised o f lobules, lobes, ducts and fatty tissue
1.2.2 Breast Histology
1.2.2.1 Non-neoplastic breast disease
These disorders usually involve alterations of the breast stroma or glands. These changes 
can be fibrocystic (dilation of ducts to form cysts, apocrine metaplasia, stromal fibrosis) 
and adenocystic (benign proliferation of glands). Epithelial hyperplasia is an increase in 
the number of layers of cells lining the ducts (normally two layers). Atypical hyperplasia 
is an intermediate disorder between hyperplasia and carcinoma in situ, and is associated 
with an increased risk of developing a carcinoma.
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1.2.2.2 Neoplasms of the Breast
• Benign Neoplasms
The most common is a fibroadenoma, characterised by proliferation of the breast ducts
and stroma. Others include the phyllodes tumour and benign intraduct papilloma. These 
are associated with a moderate increase in the risk of a carcinoma developing.
• Carcinoma In Situ (Ductal and Lobular Carcinoma In  Situ DCIS/LCIS)
DCIS is the most common form of non-invasive breast cancer. Cells within the breast
ducts are cancerous; however, the tumour cells proliferate only within the ducts and have 
not breached the basement membrane and spread throughout the breast tissue and into the 
lymph nodes. DCIS can be classified into three grades: low, intermediate and high. 
Higher grade (comedo) DCIS is most likely to develop into invasive cancer (Table 1.1).
Type of Carcinoma In 
Situ Pathological Characteristics
Solid DCIS Cancerous cells completely fill the affected breast ducts
Cribriform
Cells are very uniform in size and very regularly placed in 
relation to one another. Epithelial cells fill and expand the ducts 
and form defined glandular spaces separated by bridges of cells.
Papillary/Micropapillary Commonly occurs in association with cribriform DCIS.
Comedo DCIS
Ducts are expanded due to proliferation of large pleomorphic 
cells. Characterised by mitotic figures and necrosis in the centre 
of the duct.
LCIS
Cells within breast lobes have undergone morphologic changes 
but are not cancerous. Lobules are expanded and filled by small, 
evenly spaced epithelial cells, which do not form ducts.
Table 1.1: Types of Carcinoma In Situ
Carcinoma In Situ can be categorised as Ductal or Lobular.
•  Invasive Ductal Carcinoma (IDC)
Approximately 70-80% of cancers diagnosed are invasive and ductal, originating in the 
breast ducts, but invading fatty tissue and metastasising to other parts of the body. 
Variants include invasive tubular carcinoma (cancerous cells form defined tubular or 
ductal structure but with no solid nests of cells or single cell invasion), mucinous
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carcinoma (malignant cells are suspended in pools of mucin), cribriform, carcinoma, and 
medullary carcinoma.
• Invasive Lobular Carcinoma (ILC)
Approximately 10% of diagnosed cancers are invasive and lobular. ILC has a better 
prognosis than IDC, but is more likely to be bilateral.
• Others
Type of Cancer Pathological Charactersistics
Inflammatory Breast Cancer Cancer cells block the lymph ducts in the breast 
and prevent fluid from being drained from the 
tissue, resulting in inflammation of the breast.
Paget’s Disease Beginning in the breast ducts, cancer spreads to the 
nipple and areola.
Table 1.2: Other types of breast cancer
Inflammatory breast cancer and Pagets Disease are two rarer forms o f breast cancer, 
accounting for 1-3% and 1%) o f all cases respectively.
1.3 Predictive & Prognostic Markers
1.3.1 Breast tumour grade
The grade of a tumour depends on its histological appearance and reflects differentiation 
associated with neoplasia. Grading breast tumours is based on tubule formation (% of 
cancer cells composed of tubular structures), nuclear pleomorphism (changes in cell size 
and uniformity) and mitotic count (rate of cell division), each of which is scored from 1 
to 3. Scores are totalled to provide a final score, ranging between 3 and 9, dividing 
tumours into three grades. Tumours with scores of 3-5 are considered Grade 1, well- 
differentiated tumours. Grade 2 tumours (score 6-7) are moderately differentiated, whilst 
tumours scoring 8-9 are Grade 3 (poorly-differentiated). Patients with grade 1 tumours 
have a better prognosis than those with grade 3 tumours. (7;8).
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1.3.2 Breast Tumour Stage
Stage is a measure of tumour size and the extent of disease spread. The TNM staging 
system - where T represents the size of the primary tumour, N corresponds to nodal 
involvement, and M confirms whether or not the cancer has metastasised - is commonly 
applied to breast cancer (Table 1.3). Patients with stage 1 tumours have a better prognosis 
than those patients with stage IV tumours (7).
Stage Tumour Size Lymph Node Involvement Metastasis
I Less than 2cm No No
II 2-5cm No, or in same side of breast (0-3 axillary lymph nodes involved) No
III More than 5 cm Yes, on same side of breast (> 4 axillary and/or internal mammary lymph node) No
IV Any size Any lymph nodes Yes
Staging of a breast tumour depends on the tumour size, lymph node involvement and 
metastasis, and ranges from stage I  to stage IV.
1.3.3 Nottingham Prognostic Index
In 1982, a retrospective analysis was performed to investigate the prognostic capabilities 
of nine factors in primary, operable breast cancers: age, menopausal state, size, lymph 
node stage, tumour grade, cellular reaction, sinus histiocytosis, and oestrogen receptor 
expression (9). Three remained significant, following multivariate analysis. These 
independent prognostic markers, lymph node stage, histological grade and tumour size 
were combined to form the Nottingham Prognostic Index (NPl), (8;9) calculated using 
the following formula:
NPI = (0.2 X tumour size (cm)) + lymph node stage (1-3) + histological grade (1-3) 
Rather than determining therapy choice on a single prognostic marker, the NPl score is 
used to select the appropriate treatment options (Table 1.4).
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NPI
Score
Annual
Mortality
15 years 
survival Adjuvant Therapy
<3.4 3% 80% No systemic adjuvant treatment
3,4-5.4 7% 42% Choice dependent on ER/PgR status, menopausal status & axillary disease
>5.4 30% 13% Aggressive adjuvant treatment: chemotherapy
Table 1.4: Vottingham Prognostic Index (NPI)
NPI scores, calculated using tumour size, lymph node stage and grade, are used to 
determine the most appropriate treatment regime for patients.
1.4 Current Treatment Options
1.4.1 Surgery
The objective of surgery is to remove disease and identify extent of disease spread 
(staging). Surgery to the breast involves either a lumpectomy or partial/segmental 
mastectomy, removing only the breast lump and a marginal area of normal tissue. A total 
mastectomy removes the entire breast. However, the more common procedure is a simple 
mastectomy that removes the entire breast and some of the axillary nodes to assess 
disease spread beyond the breast.
1.4.2 Radiotherapy
High-energy radiation kills cancer cells. A review of clinical trials involving radiotherapy 
over the last 40 years showed a significant reduction (~ two-thirds) in the number of 
patients relapsing following radiotherapy. Radiotherapy reduces breast-cancer related 
deaths but increases deaths from other causes, in particular vascular-related deaths (10).
1.4.3 Chemotherapy
Adjuvant chemotherapy is standard treatment for women with node-positive breast 
cancer. In a 10 year overview of approximately 100 clinical trials, for patients treated 
with adjuvant chemotherapy, recurrence risk was reduced by 22-37%, and risk of death 
by 14-27% (11). Adjuvant polychemotherapy produced an improvement of about 7-11%
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in 10-year survival for women aged under 50 presenting with early breast cancer, and by 
2-3% for those aged 50-69 (12). Adjuvant chemotherapy is also beneficial to node­
negative breast cancer patients. However, benefits must outweigh the risks of receiving 
cytotoxic agents. Chemotherapy is recommended for patients with moderately to poorly 
differentiated invasive tumours larger than 1cm or ER negative tumours (NCI 
Guidelines). In the UK, patients’ NPI scores guide chemotherapy use and the 
combination of epirubicin and Cyclophosphamide, Methotrexate and 5-Fluorouracil 
(CMF) is now a common adjuvant practice. In 2002, NICE recommended the use of 
combined chemotherapy regimes including anthracyclines.
Cyclophosphamide, an alkylating agent that is cell cycle specific, causes DNA 
strands to break apart, and impairs DNA replication. Methotrexate and 5-fluorouracil are 
cell cycle phase specific antimetabolites that inhibit the conversion of folic acid to its 
active form, folinic acid, preventing cell division and killing rapidly dividing cells (13). 
Anthracyclines, such as epirubicin, are antibiotics that induce apoptosis in tumour cells 
by disrupting the structure of the DNA. They do this by intercalating into the base pairs 
in the DNA minor grooves, and by causing free radical damage of the deoxyribose in the 
DNA (13).
In recent years, taxanes, such as paclitaxel and docetaxel, have been shown to be 
active cytotoxic antitumour agents(l4). Taxanes act by shifting the dynamic equilibrium 
between tubulin and microtubules in the direction of microtubule assembly. Cells become 
blocked during the G2 and M cell cycle phases and cannot form a normal mitotic spindle 
and divide. Essentially, these microtubules are excessively stable and therefore 
dysfunctional (15). A recent review demonstrated that treatment with taxanes improved
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overall survival, time to progression, and overall response in women with metastatic 
breast cancer (16).
Despite the use of chemotherapy as adjuvant treatment, failure to respond to 
chemotherapy is a major problem. Chemotherapy resistance can be categorised into three 
types: kinetic, biochemical and pharmacologic (13). However, the mechanisms 
underlying the development of resistance to chemotherapy are not fully understood.
1.4.4 Endocrine Therapy
An important determinant of patient treatment is the tumour hormone receptor status. 
Between 70-80% of breast cancers are oestrogen receptor (ER) positive and potentially 
oestrogen dependent. Allred demonstrated that the presence of ER positive cells in breast 
tumours increases patients’ chances of survival following endocrine therapy (17). Front 
line therapy for locally advanced ER positive breast cancer includes therapies that reduce 
the levels of oestrogen (Aromatase Inhibitors; Luteinising-hormone-releasing hormone 
agonists); antagonise the effects of oestrogen on the receptor (SERMS such as 
Tamoxifen); and down-regulate the receptor (Fulvestrant).
1.5 Oestrogen & Oestrogen Receptor
1.5.1 Oestrogen
Oestrogens are steroid hormones (18). Oestrone (El), 17(3 oestradiol (E2) and oestriol 
(E3) are three naturally occurring oestrogens, of which E2 is the main oestrogen from 
menarche to menopause. Following menopause, El becomes the predominant source of 
oestrogen. Oestrogens are synthesised in the ovary and testis, but also in peripheral 
tissues via the aromatisation of androgens. Ovarian synthesis of E2 dramatically declines
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at menopause. The majority of breast cancers are diagnosed post-menopause, and non- 
ovarian sources of E2 are important in breast cancer development and progression.
In addition to its role in female reproduction, oestrogen is required for 
maintaining bone density and cholesterol levels (18). George Beatson demonstrated over 
100 years ago that oopherectomy reduced breast cancer growth (19). Oestrogen 
antagonists are now vital for the treatment of hormone dependent breast cancer (18).
1.5.2 Oestrogen Receptor
In 1962, Jensen and Jacobson concluded that a receptor protein mediated the effects of 
E2 (20). In 1986, two groups cloned the oestrogen receptor (ERa) (21 ;22). There are two 
known isoforms of the oestrogen receptor, ERa and ER(3 (discovered in 1996) (23), 
encoded by different genes (ERa chromosome 6q and ER(3 chromosome 14q) (24;25).
ERa, a member of the steroid hormone nuclear receptor family, is a 65kDA, 
ligand-activated transcription factor. 15-20% of normal breast cells express ERa, and 
these cells are generally non-dividing. Oestrogen promotes release of growth factors by 
ERa positive breast cells, which stimulate proliferation, in a paracrine manner, of 
neighbouring ERa negative cells. In breast tumours, ERa positive cells undergo 
proliferation. The causes underlying transformation from non-dividing to proliferating 
cells are not understood (26). Patients diagnosed with ERa positive tumours have a 
better prognosis than patients with ERa negative breast cancers. Proliferation rates in 
ERa negative DCIS cells are greater than in ERa positive DCIS cells (27). Also , 
ERa tumours are more responsive to hormonal therapy than ERa negative tumours (28- 
30).
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1.5.3 Oestrogen Receptor Structure
ERa comprises six functional domains, annotated as domains A-F. (Figure 1.2) (31-34).
• A/B Domain (N-termiiial): Poorly conserved, contains the hormone independent 
activation function (AF-1), which activates target genes by interacting with 
transcriptional machinery or co-activators. Amino acids 41-150 are required for AF-1 
activity; and residues 91-121 for ligand binding domain synergy, which facilitates 
maximum transcriptional activity.
• C Domain (DNA binding domain): Highly conserved DNA binding domain 
with two zinc finger motifs, each with four conserved cysteines. These zinc finger motifs, 
in combination with the P-Box (sequence critical for target DNA-DNA recognition and 
specificity), are responsible for binding to oestrogen response elements (ERE) of target 
genes, and in combination with a D-box, control dimérisation of the receptor on the 
EREs.
• D Domain (Hinge domain): Allows for ERa “flexibility”, contains amino acids 
required for stable DNA binding. It also stabilises interactions with accessory proteins.
• E Domain: Highly conserved, contains ligand binding domain (LBD) and the 
ligand-dependent transactivation function (AF-2). Comprising 12a helices, forming a 
ligand binding pocket. Ligand binding changes conformation, and helix 12 caps the 
pocket, trapping ligands in a hydrophobic environment and forming a surface for co­
activators to bind to (35). It contains regions required for anti-oestrogen agonistic 
activity, dimérisation, nuclear localisation, hsp90 binding and co-activators/co-repressors 
interactions.
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•  F Dom ain (C -Term inal): Little is known o f  this domain. It is thought to 
contribute to the transactivation function o f  the ER a and to play a role in distinguishing 
between agonists and antagonists, perhaps through interactions with cell specific factors,
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Figure 1.2: Functional D om ains o f  O estrogen R eceptor
The oestrogen receptor comprises six functional domains A-F. The diagram shows the 
function o f  each domain.
1.5.4 Oestrogen Receptor Cofactors
ER a interacts with nuclear proteins that modify its effects on transcription. Co-activators 
interact directly with ERa and enhance transcription, whilst co-repressors suppress ERa- 
mediated transcription. Inactive ERa, or ERa bound to antagonists, associates with co­
repressors. Following ligand binding, ERa undergoes a conformational change that 
allows it to bind co-activators (35).
•  C o-activators
There are many co-activators, such as the pi 60/SRC family, CBP/p300 and the 
TRAP/DRIP co-activator com plex. The pi 60/SRC family consists o f  three members: 
SRC-1 (p l6 0 - l ,  N -C o A l), SRC-2 (TIF-2, G R IPl, NC oA 2) and SRC-3 (A lB l, P/C IP, 
ACTR, RAc3, T R A M l) (35). Co-activators bind to a nuclear-receptor interaction 
domain, consisting o f  a LXXLL m otif within the AF-2 activation domain (18). The SRC 
co-activators recruit hi stone acetyltransferases (HAT) to the promoter region o f  E2
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regulated genes, which facilitates DNA unwinding, allowing transcription to begin. 
CBP/P300 possess acetyltransferase activity, and its binding requires SRC co-activators 
(34). The TRAP/DRIP co-activator complex recruits the transcription machinery (36).
• Co-Repressors
N-CoR and SMRT are key co-repressors. Both prevent ERa mediated transcription by 
recruiting proteins that have histone-deacetylase (HDAC) activity to the promoter region 
of the gene. This prevents transcription by maintaining chromatin in a condensed state 
and inhibiting access to transcription machinery (37).
1.5.5 Ligand-dependent activation of oestrogen receptor
In the absence of ligand, ERa is maintained in a multiprotein inhibitory complex with
Heat Shock Proteins (HSPs). Hsp90 binds regions of the receptor required for 
homodimerisation, nuclear localisation and DNA binding. It regulates several of the 
ligand binding functions of ERa and maintains the receptor in its inactive form (32).
The classic “genomic” action of ERa requires ligand binding, which induces 
phosphorylation, dissociation fiom Hsps, conformational changes, homodimerisation and 
nuclear translocation. Nuclear ERa binds directly to ERE sequences in the promoter 
region of E2 regulated genes (38). This leads to recruitment of co-activators, co­
repressors and transcription machinery to the promoter. Depending on cell and promoter 
context, ERa positively or negatively regulates gene transcription (29;39;40).
ERa also modulates gene expression via AP-1 or Sp-1 sites in an ERE- 
independent manner. ERa binds indirectly to DNA via transcription factors, such as c-jun 
or c-fos. Here ERa functions as a co-activator, either stabilising binding of transcription 
machinery to the DNA, or by recruiting other coactivators (34;41) (Figure 1.3).
33
Recently, studies have revealed that whilst some ERa binding sites were located 
directly adjacent to target genes, the majority of binding sites were found significant 
distances from the transcriptional start sites. It was suggested that ERa interactions with 
ERE sites were important, but insufficient to enable ERa-chromatin association. 
Forkhead factor binding sites were present near authentic ERE sites, and Forkliead factor 
(FoxAl) binding was required for ERa-chromatin interactions. Downregulation of 
FoxAl inhibited ERa associating with its binding sites (42).
E2/ERa interaction controls expression of genes involved in cell proliferation, 
apoptosis, invasion, metastasis and angiogenesis. High-density gene expression profiling 
of hormone response in ERa positive T-47D breast cancer cells identified 137 ERa- 
regulated genes, of which only 89 were direct ERa target genes. These 89 genes were 
also identified as ERa targets in MCF-7 cells and in breast tumours (43)
Activation of ERa requires both AF-1 and AF-2 activation domains. These 
domains can function independently or synergistically. AF-2 activation requires ligand 
binding, whereas AF-1 function seems to play a role in both ligand-dependent and ligand- 
independent mediated transcription, and is regulated via phosphorylation. Binding of E2 
stimulates increased phosphorylation of the receptor. However, ERa is also 
phosphorylated in a ligand-independent manner.
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Figure 1.3: Ligand-Dependent Activation of the Oestrogen Receptor
The classic genomic action o f the ERa requires ligand binding, which induces ERa to 
bind directly to the ERE domains in the promoter region o f oestrogen regulated genes, 
leading to the recruitment o f  coactivators, such as AIBl, and the attachment o f  
transcription machinery to the promoter. Alternatively ERa is able to modulate the 
expression o f genes containing AP-1 or Sp-1 sites in an ERE-independent manner, by 
binding indirectly to the DNA via other transcription factors, such as c-jun or c-fos. 
HSPs =  Heat shock proteins, E2 =  Oestrogen, ERa  =  Oestrogen Receptor
1.5.6 Oestrogen Receptor Phosphorylation
Phosphorylation o f  ER a is stimulated in a ligand-dependent manner, via E2 binding, and 
in a ligand-independent manner, through signal transduction pathways (see below). Key 
ERa phosphorylation sites include: serine 104/106, 118, 167, 236 and tyrosine 537.
Phosphorylation o f  AF-1 serine residues 118 and 167 results in transactivation 
and is mediated by MAPK and AKT pathways. MAPK directly and indirectly
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phosphorylates SI 18 and 8167 respectively, in an E2 independent manner. However, 
Cdk7, and not MAPK, is believed to be the kinase responsible for E2 mediated 
phosphorylation o f  8118 (44). The Cdk2 kinase com plex phosphorylates serines 104/ 
106, (45) increasing receptor trans-activation. Protein Kinase A (PKA) phosphorylates 
8236 within the DBD, inhibiting E R a dimérisation, in the absence o f  ligand, or presence 
o f  antagonists, and preventing DNA binding (46). Phosphorylation o f  the AF-2 tyrosine 
residue 537 is mediated by 8 re kinases, and regulates ligand binding, dimérisation and 
trans-activation (47). ERa phosphorylation enhances dimérisation, ligand-binding, 
nuclear localisation, cofactor recruitment and gene transcription (Figure 1.4).
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Figure 1.4: Oestrogen Receptor Phosphorylation Sites
The oestrogen receptor is phosphorylated by multiple kinases. The AF-1 domain residues 
are phosphorylated by the growth factor pathways (MAPK and Akt) and cyclin dependent 
kinases. PKA phosphorylates serine 226 in the DNA binding domain, whilst Src-kinases 
are thought to be responsible for phosphorylating Tyrosine 537. Cdk = Cyclin dependent 
kinase, PKA -  Protein Kinase A, Ser =  Serine, Tyr =  Tyrosine
1.5.7 Ligand-Independent Activation of Oestrogen Receptor
In addition to activation by E2, ER a can be phosphorylated and activated in a ligand-
independent manner. Kinases mediate ERa phosphorylation (section 1.5.6) in both the 
AF-1 and AF-2 domains. Additionally E2 independent phosphorylation o f  co-activators 
and co-repressors can increase ER a transcriptional activity.
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Multiple signalling pathways activated by growth factors, stress or cytokines are 
linked to E2-independent activation of the ERa. Activation of the receptor tyrosine 
kinases (EGFR, HER2-4) results in activation of two key pathways: Ras/Raf/MAPK and 
Ras/PI3k/AKT, and appears to play a key role In ERa activation (see below).
1.5.8 Non-Genomic Activity of Oestrogen Receptor
The primary function of ERa is to mediate gene transcription (Genomic activity). 
However, rapid E2 mediated effects (seconds to minutes) and a membrane localised 
ERa, identified an alternative, non-genomic receptor function. E2 binding to membrane 
bound ERa activates signal transduction cascades. Membrane-bound ERa effects are 
rapid and unaffected by transcriptional inhibitors (48). E2 stimulates ERa association 
with Src and She, activating Ras signalling cascades. In vitro studies show increased 
MAPK and AKT phosphorylation and activation following E2 stimulation, suggesting a 
positive feed back loop resulting in phosphorylation and activation of nuclear ERa (49- 
51). Membrane ERa transactivates the epidermal growth factor receptor (EGFR), by 
activating matrix metalloproteinases, which cleave heparin-bound Epidermal Growth 
Factor (EGF), which subsequently activates EGFR (52).
1.5.9 Oestrogen Receptor p (ERp)
There is a relatively high degree of homology between ERa and ERp in the ligand (60%) 
and DNA (97%) binding domain. However, there is less similarity in the N-Terminal 
(18%) domain (38). Expression of ERa and ERp differ between different tissue types. 
ERp appears to have a more limited expression pattern.
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ERa and ERP can form either homo- or heterodimers when co-expressed in cells 
(53). Although ERa and ERp interact with the same DNA response elements and have 
similar binding affinities for E2 (38), ERp appears to respond differently to E2 agonists 
and antagonists. A recent study highlighted that E2 induced transcription via ERa bound 
to AP-1 sites, but that it inhibited transcription via ERp (54). ER knockout mice revealed 
that ERa, but not ERp was required for normal mammary gland development (55;56). 
The role of ERp in breast cancer remains controversial. Approximately 70% of breast 
tumours express ERp, and most tumours co-express ERa and ERp (57;58). Expression of 
both ERs has been associated with higher grade tumours and lymph node positivity (59). 
A negative correlation was observed between expression of ERp and the progesterone 
receptor. ERp has also been linked to increased cell proliferation and invasiveness (60). 
However, conflicting studies suggest that expression of ERp is associated with lymph 
node negativity, lower grade tumours and improved prognosis (61-63)
1.5.10 Oestrogen and Oestrogen Receptor Targeted Therapies
1.5.10.1 Luteinising-hormone-releasing hormone (LHRH) agonists
LHRH agonists, such as goserelin, are commonly used to treat pre-menopausal breast
cancer patients. Goserelin acts by decreasing the secretion of luteinising hormone by the 
pituitary, resulting in a block in follicular activity, which reduces the production of E2 in 
the ovaries (64).
1.5.10.2 Tamoxifen
For the last 20 years. Tamoxifen treatment has been the gold standard for ERa positive 
breast cancer patients. It is currently one of the most effective but least toxic drug
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therapies. An oestrogen antagonist, it is a non-steroidal that acts as a selective oestrogen 
receptor modulator (SERM). It competitively inhibits the interaction of E2 with the ERa, 
by directly binding to the AF-2 transcriptional activation domain, blocking the effects of 
E2 and inhibiting receptor activity (Figure 1.5). Tamoxifen binding to the ERa induces a 
conformational change, so that helix 12 of the LBD is positioned over the co-activator 
binding sites, preventing their recruitment to the ERa (18;65). Tamoxifen induces co­
repressor recruitment, further repressing ERa activation.
Tamoxifen inhibits only AF-2 functions; it does not interfere with AF-1 
activation. Consequently Tamoxifen may function as both an ERa antagonist and 
agonist. Tamoxifen activity depends on the tissue and the availability of co-activators and 
co-repressors. In breast epithelium, ERa activity is mostly dependent on AF-2 functions, 
and Tamoxifen acts as an antagonist. However, in the uterus, ERa activity is more reliant 
on AF-1 activation; therefore Tamoxifen functions as an agonist. Thus Tamoxifen 
reduces the risk of osteoporosis, but also stimulates endometrial proliferation, which 
increases the risk of endometrial cancer (-2.5 fold) (66). Other side effects include 
venous thrombosis, pulmonary embolus and stroke.
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Figure 1.5: Tamoxifen Interaction with Oestrogen Receptor
Tamoxifen binding to the AF-2 domain o f  the oestrogen receptor prevents E2 from 
binding. Tamoxifen induces ERa interactions with co-repressors, such as N-CoR, rather 
than co-activators, such as AIBl.
The standard five-year course o f  treatment with tamoxifen produces a 51% reduction in 
recurrence and a 28% reduction in deaths(40). However, approximately 50% o f  breast 
cancers, despite being ERa-positive, fail to respond to tamoxifen (67), whilst the 
majority o f  women who are initially sensitive to the endocrine therapy develop resistance 
to the treatment over time (67-69).
1.5.10.3 Fulvestrant
To combat the agonistic effects o f  Tamoxifen, “pure antioestrogens” that do not 
demonstrate agonistic behaviour were developed. Fulvestrant (Faslodex), has no
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agonistic effects and has a 100 fold greater binding affinity for ERa than Tamoxifen, and 
is approved for treatment of ERa positive, metastatic, post-menopausal breast cancers. 
Fulvestrant binds ERa, prevents DNA binding and promotes ERa degradation, markedly 
reducing cellular receptor levels (70). Tamoxifen resistant cell lines respond to 
Fulvestrant (71).
1.5.10.4 Aromatase Inhibitors
Post-menopausal women depend on the cytochrome P450 aromatase enzyme for E2 
synthesis. Aromatase catalyses the conversion of androgens to oestrogens, in peripheral 
(e.g. fat, muscle) tissues and locally within tumours. Aromatase inhibitors (AÏ) inhibit the 
enzyme, reducing E2 levels by 97% in post menopausal women (72). Type 1 AIs 
(Exemestane) are steroid analogues of androstenedione, which bind to the aromatase 
enzyme complex resulting in irreversible inactivation. Type 2 AIs (Anastrazole and 
Letrozole) are non-steroidal and bind the enzyme complex, reversibly (73).
Recent evidence suggests AIs are superior to other therapies in the treatment of 
tamoxifen-resistant advanced breast cancers and also in the neoadjuvant setting (74;75). 
Several clinical trials are underway, investigating the role of the three mentioned AIs as 
adjuvant treatment in early stage breast cancers. These trials analyse the role of AIs in 
three different treatment situations; initial adjuvant treatment: (ATAC, TEAM, BIG-1- 
98), sequenced after 2-3 years of Tamoxifen treatment (lES), or after completing five 
years Tamoxifen therapy (MA-17). Although the results of these trials cannot be directly 
compared, they all provide data to suggest that AIs are superior to Tamoxifen in the 
treatment of breast cancer in terms of disease-free survival (76-78). It is thought that the 
superiority of AIs over Tamoxifen may be a consequence of aromatase inhibition,
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resulting in an increased reduction in tumour proliferation (76). Additionally, treatment 
with AIs seemed to reduce the adverse side effects observed with Tamoxifen treatment. 
However, questions remain about the long term safety of AIs (79;80).
As more data regarding the efficiency of AIs from the various trials is released, 
they might challenge Tamoxifen for the role of first-line therapy. However, to optimize 
use of such therapies, it would be beneficial to establish predictive markers to identify 
patients who are likely to develop Tamoxifen resistance and would respond to A1 
treatment. Results suggest that ERa positive, progesterone receptor (PR) negative breast 
tumours and HER2 overexpressing tumours are more responsive to AIs than to 
Tamoxifen (81). A further understanding of the mechanisms driving Tamoxifen 
resistance is required to enable improved treatment of breast cancer patients.
1.6 Mechanisms of Tamoxifen Resistance
Despite the extensive use of Tamoxifen as first-line therapy for ERa positive breast 
cancer patients, resistance to tamoxifen treatment, either at primary treatment {de novo 
resistance) or arising during treatment (acquired resistance), causes significant morbidity 
and mortality.
1.6.1 Down-Regulation of ER a
ERa expression is generally maintained in breast tumours that lose sensitivity to 
Tamoxifen (40). Several studies highlight that in Tamoxifen-resistant patients, tumour 
growth and progression is still regulated by the ERa, and that they remain sensitive to 
other therapies, such as Fulvestrant or AIs (71).
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1.6.2 Mutations & Splice Variants of the ER a
ERa mutations that might account for the loss of sensitivity to Tamoxifen have been 
identified; however, most mutations were silent changes that would not alter ERa amino 
acid sequence (82). Only 1% of breast tumours present with an ERa mutation within the 
coding region, and most failed to alter ERa expression at the protein level (83). 
Alternatively spliced, variant ERa mRNA has been discovered that encodes for a 
truncated form of the ERa. However, research of clinical samples has failed to reveal a 
role for these variants in Tamoxifen resistance (82),
1.6.3 Effects of ERp
ERp has opposing effects from ERa on tumour growth. A recent study highlighted that 
when antioestrogens bound to ERp at an AP-1 site, they functioned as agonists rather 
than antagonists (54). Likewise, increased ERp expression is associated with tamoxifen 
resistance (84;85), However, other studies suggest high ERp levels inhibit tumour growth 
if Tamoxifen is present, and ERa positive tumours expressing low ERp levels are 
Tamoxifen resistant (86-88).
1.6.4 Hypersensitivity to Oestrogen
Breast tumours can adapt to their environment and become hypersensitive to the 
oestrogenic effects of Tamoxifen, allowing tumour progression and growth. Tamoxifen- 
resistant cells show an increase in the basal levels of phosphorylated ERa and tamoxifen 
promotes, rather than inhibits, growth of these cells (89).
1.6.5 Availability of Co-activators and Co-Repressors
To function as an antagonist. Tamoxifen induces interactions with co-repressors and 
prevents interactions with co-activators. However, overexpression or mutation of co­
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activators could alter response to endocrine therapies. AIBl is amplified in 5% and 
overexpressed in 65% of breast tumours (90). These high levels of co-activators may 
increase the agonistic activity of Tamoxifen (91-93). AlBl is often co-expressed with 
HER2 (94), and under these conditions, Tamoxifen acts as an agonist, and ERa binds 
AlBl, rather than co-repressors (93). It is unclear how co-activators bind to Tamoxifen- 
bound ERa, since its conformation should prevent them binding. One proposal is that 
AlBl binds to the AF-1 domain of ERa, rather than the Tamoxifen bound AF-2 domain. 
Conversely, if levels of co-repressors are low, this might also facilitate the development 
of Tamoxifen resistance.
1.6,6 Cross-Talk between ER and Growth Factor Receptor Pathways
The signalling pathways Ras/Raf/MAPK and Ras/P13K/AKT both phosphorylate and
activate the ERa in a ligand-independent manner. Likewise, membrane-associated ERa 
can activate these two pathways, which ultimately activate the nuclear receptor. Ligand- 
independent activation of the ERa via signalling pathways, e.g. Ras/Raf/MAPK 
(29;39;95;96), results in transcription of E2-regulated genes and cell proliferation. Ras 
activation increases ER sensitivity to low E2 concentrations, via ERa phosphorylation by 
MAPK and AKT, causing tamoxifen resistance(68;69;97).
1.7 Human Epidermal Growth Factor Receptor (HER) Family
The four members of the Human Epidermal Growth Factor Receptor (HER) family are
key factors that interact with and influence ERa activation status.
1. Epidermal Growth Factor Receptor (EGFR)/HER1: Localised to chromosome 
7pl2 encodes a 170kDa transmembrane protein.
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2. HER2: Her2 located on chromosome 17q21 encodes a 185kDa transmembrane 
glycoprotein that has intrinsic kinase activity. Originally identified as a transforming 
oncogene in rat neuroglioblastomas, the receptor is activated in human breast and ovarian 
cancer as a result of amplification and overexpression.
3. HER3: In 1989 a DNA fragment related to EGFR and HER2 was identified (98) 
as HER3, a 148kDa transmembrane protein. The gene is located at chromosome 12ql3.
4. HER4; The HER4 gene localised to chromosome 2q33 encodes a ISOkDa 
transmembrane protein.
The type I tyrosine kinase receptors (RTKs) control cellular responses to the external 
environment. Through ligand binding, the receptors activate signal transduction 
pathways, which determine the fate of the cell. All the receptors have the same basic 
structure: an extracellular ligand binding domain, containing cysteine rich residues and 
possible glycosylation sites; a membrane-spanning region; a short intracellular juxta 
membrane region; a cytoplasmic protein tyrosine kinase domain; and a carboxy tail 
which contains tyrosine phosphorylation sites (99). There is a high degree of sequence 
homology in the tyrosine kinase domain of EGFR, HER2 and HER4, highlighting the 
domains’ importance. HER3 has substitutions in four key amino acids in this domain and 
lacks kinase activity (99). The growth factor receptors remain inactive on the plasma 
membrane, until ligand binding occurs. Each receptor, with the exception of HER2, binds 
a narrow spectrum of ligands (Table 1.5). Currently there is no known ligand for HER2.
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RECEPTOR LIGAND
HERl (EGFR)
Epidermal Growth Factor (EGF), Transforming Growth Factor a  
(TGFa ), p-Cellulin (BTC), Heparin-binding Growth Factor (HB- 
EGF), Amphiregulin (AR), Epiregulin (EPR)
HER2 Unknown
HER3 Heregulin (HRG), Neuregulins 1 +2 (NRG 1 + 2)
HER4 Heregulin (HRG), Neuregulins 1-4 (NRG 1-4), (3-Cellulin (BTC), Heparin-binding Growth Factor (HB-EGF),Epiregulin (EPR)
Table 1.5: Ligands associated with the HER family
All o f the HER family members, with the exception o f HER2, require ligand binding for  
activation. The above table lists the ligands for EGFR, HER3 and HER4.
Upon ligand binding, receptors either homo- or hetero-dimerise. The preferred partner for 
EGFR, HER3 and HER4, is HER2. HER2 increases the binding affinity of these 
receptors with ligands, resulting in extended activation of signal transduction. 
Dimérisation activates tyrosine kinase domains, and promotes autophosphorylation of 
specific tyrosine residues (100). In HER2 overexpressing cells, HER2 is thought to 
spontaneously homodimerise (99). Receptor activation initiates signal transduction 
pathways, utilising multiple elements, and integrates signals to the nucleus.
1.7.7 HER family and Breast Cancer
RTKs are expressed on the plasma membrane, and ERa in the nucleus, yet the two show 
strong evidence of cross-talk, mediated predominantly via the Ras/Raf/MEK/MAPK and 
PI3-K/AKT pathways (30;69;100;101). Expression of the RTKs is a strong indicator of 
both prognosis and treatment choice (99; 102). Studies within our group indicated 
increased expression of HER 1-3 correlated with reduced survival, while expression of 
HER4 was associated with improved survival (103-105). It is also accepted that there is a 
negative correlation between expression of the ERa and EGFR/HER2, and probably 
HER3.
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Approximately 25-30%  o f  all breast cancers overexpress HER2 (19). This is 
associated with greater proliferation o f  breast cancer cells and subsequently a poorer 
prognosis (106). Treatment with Tamoxifen is less effective in patients overexpressing 
HER family members. The response rate to tamoxifen is reduced from 50% in ERa 
positive breast cancer with normal HER2 expression to 17% in HER2 overexpressing 
breast cancer (107), and this effect can be reversed by the use o f  aromatase inhibitors 
(81).
1.8 The Ras/Raf/Mek/MAPK Pathway
The mitogen-activated protein (M AP) kinase cascade, is a three-tiered kinase model that 
conveys signals from the plasma membrane to the nucleus. This model consists o f  a MAP 
kinase or Extracellular Regulated Kinase (ERK) being activated by a MAPK/ERK kinase 
(MEK or MAPKK), which in turn is activated by a MEK kinase (MEKK or MAPKKK). 
The Ras/Raf/Mek/MAPK pathway is a classic example o f  this cascade (Figure 1.6).
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Figure 1.6: Mitogen-activated protein (MAP) kinase cascade
The Ras/Rqf/MEK/MAPK is a classic example o f  the mitogen-activated protein (MAP) 
kinase cascade. Raf (MAPKK) phosphorylates and activates MEK 1/2 (MAPKK), which in 
turn phosphorylates and activates MAPK (MAPK).
Activation o f  this pathway follow s membrane RTKs binding ligands, dimerising and 
undergoing autophosphorylation (99; 100). RTKs in association with growth factor 
receptor bound protein 2 (Grb2) and Son o f  Seven less (SOS), translocate Ras to the
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plasma membrane where it is activated, and promotes Raf-1 phosphorylation and 
activation (108-115). Raf-1 phosphorylates and activates MEK, which subsequently 
activates MAPK, which phosphorylates and activates multiple substrates (116; 117).
Overexpression and activation o f  the MAPK cascade is involved in the 
development and progression o f  tumours. The pathway regulates proliferation, apoptosis, 
metastasis and angiogenesis, and links the RTKs, localised to the plasma membrane, with 
nuclear ERa. MAPK phosphorylates and activates ER in a ligand-independent manner 
(29;39;95;96). Activation o f  the Ras pathway is believed to be a key mechanism driving 
tamoxifen resistance (Figure 1.7).
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Figure 1.7: Ras/Raf/Mek/MAPK Pathway
Schematic representation o f the Ras/Raf-l/MAPK pathway.
1.8.1 Ras
The Ras superfamily o f  genes, comprising over 65 members, encode GTPases that 
control multiple cellular processes. These include six subfamilies: Ras, Rho, Rab, Ran
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Rad and Arf. The Ras family is further subdivided into four sub-sub-families: Rap (Rap- 
lA; Rap-1 B; Rap-2A; Rap-2B); R-Ras (R-Ras. TC21/R-Ras2, R-Ras3); Ral (RalA,
RalB) and Ras (H-Ras, K-RasA, K-RasB and N-Ras) (118).
1.8.1.1 Ras Genes
There are three isoforms of Ras: Harvey Ras {H-Ras), found on chromosome 11 
(11 p i5.5); Neuroblastoma Ras {N-Ras), localised to chromosome 1 (lpl3); and Kirsten 
Ras {K-Ras), found on chromosome 12 (12pl2.1) (35,36,37). H-Ras, and K-Ras genes 
were identified as viral oncoproteins of Harvey, and Kirsten murine sarcoma viruses, 
whilst N-Ras was discovered in a neuroblastoma cell line (118).
H-, K- and N-Ras share a similar genetic structure, possessing four exons and a 5’ 
non-coding exon. However, K-Ras has two alternative fourth exons (4A and 4B), 
yielding two protein isoforms (K-RasA and K-RasB). From this point on, K-Ras refers to 
K-Ras B. There are major differences between the introns of H-, K-, and N-Ras in terms 
of both size and sequence. The genomic DNA sequences for K-Ras spans approximately 
35kbp, N-Ras only 7 kbp and H-Ras only 3 kbp. The Ras genes are regulated by TATA- 
less but GC rich promoters (111).
1.8.1.2 Ras Protein Structure
The proteins encoded by Ras genes are composed of 188-9 amino acids and are 
monomeric, membrane localised, guanine nucleotide binding proteins, with a molecular 
weight of approximately 21kDa. The proteins cycle between an inactive guanine 
dinucleotide (GDP)-bound state and an active guanine trinucleotide (GTP)-bound state. 
The proteins contain four domains and appear to have highly conserved regions in their N 
terminal. Within the N-terminal, catalytic domain, there is 100% homology between the
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Ras proteins in the first 86 residues Domain), and approximately 79% homology in 
the following 78 residues (2"  ^ Domain) (119). However, the homology between the 
proteins in the final 25 carboxy-terminal residues (residues 165-188/189) is only 10-15%; 
consequently, this region is termed the hypervariable region (HVR, 3*^  ^ domain) (120) 
(Figure 1.8). The HVR is essential for Ras translocation to, and association with, the 
plasma membrane (PM) (121). The final four residues of the HVR comprise the carboxy 
terminal CAAX motif (C=cysteine, A=aliphatic amino acid; leucine, isoleucine or valine, 
X=serine or methionine, 4^ ’’ Domain). HVR and the CAAX motif undergo post- 
translational modifications to enable Ras translocation to the PM. The Effector domain 
(residues 32-40) is required for Ras binding to its substrates. Five non-contiguous regions 
are essential for Ras function: residues 5-63, 77-92, 109-123, 139-165 and 186-189 
(CAAX motif) (118). There are also two switches present at residues 30-38 (switch I) and 
60-76 (switch II). Switch I is involved in the binding of substrates and GTPase activating 
proteins (GAPs), whilst switch II is implicated in the binding of Guanine nucleotide 
exchange factors (GEFs). The only structural differences observed between the active and 
inactive form of Ras are within the two switch domains (122-124)(Figure 1.8).
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Figure 1.8: Ras Protein Structure
Comparison o f the protein sequences highlights a high degree o f homology in the N- 
terminal between the H-, K- and N-Ras proteins. However, there is less homology 
between the proteins in the hypervariahle region. Within the HVR, is the carboxy- 
terminal, CAAX motif at residues 186-189 (highlighted in red). There are also residues 
upstream o f the CAAX motif essential fo r membrane targeting (highlighted in green). 
These residues along with the CAAX motif undergo post-translational modifications to 
enable Ras translocation to the PM.
1.8.1.3 Post-Translational Modifications
Ras proteins are synthesised in the cytosol as inactive precursors. Activation requires post 
translational modifications and translocation to the plasma membrane (108;111). The first 
modification involves the addition o f  a fam esyl ( C 1 5 )  group to the cysteine residue o f  the 
CAAX motif, by protein famesyl transferase (FT). Research suggests that when FT’s are 
inhibited, K-Ras and N-Ras can undergo the alternative modification o f  geranyl- 
geranylation (addition o f  a C20 group) (113). Farnesylation directs Ras to the cytosolic 
surface o f  the endoplasmic reticulum, where an endopeptidase, R eel, cleaves the three 
downstream amino acids (A A X ), followed by méthylation o f  the farnesylated-cysteine 
residue by Isoprenylcysteine carboxyl methyltransferase (Icmt). These modifications
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increase the hydrophobicity of the carboxy-terminal region of the protein, thus 
strengthening the association between proteins and inner surface of the PM (125-127).
Further modifications stabilise the binding of the proteins to the PM. Both H- and 
N-Ras undergo palmitoylation (addition of palmitic acid) of cysteine residues within the 
HVR. H-Ras has two palmitoylation sites, cysteine 181 and 184, whereas N-Ras has only 
one, cysteine 181, (Figure 1.8, cysteine residues highlighted in green) (128). Unlike 
farnesylation, palmitoylation is reversible (129), Palmitoylation of H- and N-Ras allows 
them to traffic through the golgi to the lipid rafts of the plasma membrane (127).
K-Ras is faraesylated but not palmitoylated; it has a polybasic stretch of amino 
acids in the HVR domain (Figure 1.8, highlighted in green) that targets it to the bulky 
region of the plasma membrane. It is thought that this polybasic domain allows K-Ras to 
localise to the negatively charged PM via a simple diffusion mechanism, and that there 
are high-affinity electrostatic interactions between K-Ras and acidic phospholipids and 
other negatively charged groups on inner surface of the PM. Hence H- and N-Ras are 
targeted to the PM via the Golgi, whereas K-Ras is relocalised in a golgi-independent 
manner (117;126-128;130;131). Due to its electrostatic interactions with the PM, K-Ras 
is localised to its bulky, disordered regions. In contrast, H- and N-Ras are directed to the 
lipid raft region of the PM. Inactive and active H- and N-Ras cycle between the lipid raft 
and bulky domain of the plasma membrane. It is thought that the FIVR linker domain is 
crucial for the translocation of Ras from the lipid rafts to the bulky domain (128). 
Evidence suggests that N-Ras spends a longer period of time in non-raft domains (Figure 
1.9)(132;133).
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Figure 1.9: Post-translational modifications of Ras
Inactive Ras is located in the cytosol. Activation requires post translational modification 
and translocation to the plasma membrane (35,38). Post translational modifications 
include farnesylation and palmitoylation.
1.8.1.4 Ras Activation
Ras acts as a molecular switch and a link between the PM and its downstream signalling 
cascades. It is activated in response to stimulation o f  receptor and non-receptor tyrosine 
kinases, by mitogen and differentiation factors, and by external stimuli, such as UV  
radiation. Phosphorylation o f  the tyrosine residues o f  dimerised HER receptors, permits 
binding o f  GRB2, via Src Hom ology 2 (SH 2) domains. GRB2 also contains two SH3 
domains, which bind to a proline rich region o f  SOS. This com plex brings SOS into close 
proximity with Ras, allowing the two proteins to bind (134; 135). The docking protein. 
She, can act as an intermediate between the HERs and Grb2. She binds to the
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phosphorylated receptors at the phosphotyrosine-binding domain (PTB) or at the SH2 
domain. Subsequently She is phosphorylated and binds Grb2. All four HERs (HER 1-4) 
can bind Grb2 via She, but only EGFR, HER2 and HER4, can bind Grb2 directly (136). 
She also mediates Ras binding to non-receptor tyrosine kinases, such as c-Src (137). The 
binding of SOS to Ras results in a conformational change and catalyses the dissociation 
of GDP, allowing Ras to bind GTP and become activated. Ras is rapidly deactivated 
through the hydrolysis of GTP to GDP, via the action of GAPs (108; 134; 135). Ras has 
low intrinsic GTPase activity, and requires interactions with GAPs to be inactivated. 
GAPs bind Ras-GTP and induce a transition state between Ras-GTP and Ras-GDP, 
reducing the half-life of Ras GTPase activity from minutes to seconds. The most common 
mutations in the Ras genes, at codons 12, 13, 59 and 61, reduce the intrinsic GTPase 
activity of Ras and prevent GAP-induced GTP hydrolysis (138).
It was believed that Ras was only activated at the PM; however, recent research has 
revealed that it can also be activated at the golgi. EGF stimulation results in rapid and 
transient activation of Ras at the plasma membrane, but a delayed and sustained 
activation of Ras at the golgi membranes (130; 139). The mechanism of Ras activation at 
the golgi is believed to be different from that at the PM. Growth factors activate Src, 
which stimulates phospholipase Cy. This generates diacylglycerol and Ca^ '^ which 
activate the Ras guanine nucleotide releasing protein (Ras-GRP) family of GEFs. This 
causes their translocation to the golgi membrane, where they can mediate Ras activation 
(140;141)
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1.8.1.5 Ras Effectors
There are currently multiple proteins considered to be Ras effectors. Perhaps the most 
established of these are Raf, PI3K and Ral-GDS. Ras activates Phosphatidylinositol 3- 
kinase (PI3-K), a lipid kinase. Activated PI3-K then promotes the phosphorylation of 
phosphatidyl inositol (4,5)- bisphosphate (PIP2) to phosphatidyl inositol (3,4,5)- 
trisphosphate (PIP3). PIP3 activates AKT/PKB, a serine/threonine kinase, which induces 
anti-apoptotic responses. Ral-GDS is a guanine nucleotide exchange factor for RalA and 
RalB. In response to growth signals, Ral-GDS binds to activated Ras and stimulates the 
exchange of GDP for GTP on Ral (142).
1.8.1.6 Ras Function
Ras proteins regulate multiple cellular processes via activation of signal transduction 
pathways, such as Raf/MAPK, PI3K/Akt and MEKKl/JNK/SAPK. Ras mutations 
promote tumour metastasis and angiogenesis, via induction of the angiogenic growth 
factors and metalloproteinases (143). Ultimately Ras function depends on the cell type, 
the presence of membrane receptors and duration of Ras activation.
Ras proteins play a key role in the control of the cell cycle. Ras expression is 
necessary for progression through the G1 phase of the cell cycle. Activated Ras increases 
Cyclin D1 expression, which shortens the G1 phase of the cell cycle and enhances cell 
growth. Cyclin D1 is amplified in 15-20% and overexpressed in 30-50% of breast 
cancers. This increase in expression is thought to be an early event in tumour 
development (144)
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1.8.1.7 Ras Expression & Function: - Differences between the Ras 
isoforms
H-, K“ and N-Ras are not functionally redundant. Ras is expressed in all tissues, though 
expression of Ras isoforms varies between tissues. H-Ras is highly expressed in skin and 
skeletal muscles; K-Ras is strongly expressed in colon and thymus; and N-Ras in male 
germinal tissue and thymus (120). Ras expression was significantly higher in immature 
cells, as opposed to differentiated cells, suggesting a role for Ras in differentiation (111).
The various Ras isoforms have different functions: K-Ras but not H- or N-Ras is 
required for development, and K-Ras gene knockout is embryonically lethal (132; 145). 
H-, K-, and N-Ras vary in their ability to induce transformation and stimulate cell 
motility (133). The different Ras iso forms also vary in their ability to efficiently activate 
downstream effectors, such as Raf-1 and P13-K. K-Ras appears to be the most effective 
activator of Raf-1, whilst H-Ras is the least effective. Conversely, H-Ras is more 
effective as an activator of the PI3-K/Akt pathway (132;133;135;146). It has been 
reported that Raf-1 is not involved in the activation of MAPK via H-Ras, but that N-Ras 
modulates activation of this pathway (138). Differences in function, at least in terms of 
activating effectors, is partly due to compartmentalisation of H-, K- and N-Ras at the PM.
1.8.1.8 Ras and Breast Cancer
Ras is one of the most commonly mutated genes in cancer (147). H-Ras mutations are 
found in bladder (10%) and kidney (10%) tumours whilst N-Ras is mutated in 
melanomas (13%), liver cancer (30%) and acute myelogenous leukaemia (30%). K-Ras 
mutations are seen in non-small cell lung cancer (33%), colorectal cancer (44%) and 
pancreatic cancer (90%) (145; 148). However, less than 5% of breast tumours present 
with Ras mutations (118). Regardless, overexpression of Ras occurs in 70% of breast
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cancers, and this, in combination with upregiilation of Ras activity, means Ras still plays 
a key role in the development and progression of breast cancer (149).
There are two key explanations for the upregulation of Ras activation. Firstly, 
RTKs are commonly overexpressed in breast tumours. Increased expression of RTKs is 
correlated with their increased phosphorylation and activation, which results in activation 
of Ras. Secondly the adaptor protein, Grb2, is overexpressed in breast tumours compared 
to normal breast tissue (150). This offers an alternative mechanism by which Ras 
activation might be enhanced.
Overexpression of Ras both at the mRNA and protein level, has been obseiwed in 
breast tumours (151-153). However, it is still controversial whether overexpression of 
Ras is associated with a poor or improved prognosis. In vitro and in vivo studies revealed 
that the introduction of constitutively activated Ras into human breast cancer cell lines 
induces cellular transformation and results in the formation of tumours in nude mice. 
Furthermore, expression of activated Ras in hormone-dependent MCF-7 cells can induce 
anchorage-independent growth in the absence of hormone. Activated Ras partially 
mediates hormone-independent tumour growth in nude mice, suggesting Ras activation is 
a factor in tamoxifen resistance. Overexpression of the Ras/Raf/MAPK pathway is 
associated with resistance to chemotherapeutic agents in breast cancer cells (154; 155).
1.8.2 Raf
Raf proteins were the first identified Ras effectors. There are three Raf isoforms: A-Raf, 
B-Raf and Raf-1 (C-Rai^. Raf-1 is localised to chromosome 3 (3p25) (156). A R a fl  
pseudogene is found on chromosome 4 (157), A~Raf and were identified and
localised to the X chromosome (Xpl 1.4-11.2) and chromosome 7 (7q34) respectively
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(158; 159). The Raf proteins are a family of serine/threonine kinases, which share a 
similar structure of three conserved regions (CRl, CR2, CR3). The three isoforms vary in 
size: A-Raf is the smallest at 68kDa (606 amino acids); B-Raf is alternatively spliced and 
yields proteins ranging from 75 to 100 kDa (765 amino acids); and Raf-1 is 74kDa (648 
amino acids). Despite a relatively high degree of homology between the three proteins, 
there are isoform specific functions and tissue expression patterns.
Raf-1 is ubiquitously expressed, whereas A-Raf and B-Raf have more limited 
expression. A-Raf is highly expressed in urogenital organs and B-Raf in neuronal tissues 
(160). These isoforms vary in their basal kinase activity and their ability to interact with 
and be activated by Ras proteins. Each of the Raf proteins performs different functions. 
A-Raf is essential for intestinal and neurological development; B-Raf controls 
vascularisation, neuronal survival and suppresses programmed cell death; while Raf-1 
stimulates cellular proliferation and tissue formation (114; 161-163). Furthermore, unlike 
Raf-1 and A-Raf, B-Raf is frequently mutated in human cancers (164). However, of the 
three isoforms, Raf-1 is the most widely studied.
1,8.2.1 Raf-1 Structure
Raf-1 has two domains -  an N-terminal regulatory domain and a C-terminal catalytic 
domain. The conserved regions, CRl (residues 55-184) and CR2 (residues 254-269), are 
localised within the N-terminal, whilst CR3 (residues 349-609) is found in the C- 
terminal. The CRl region, containing the Ras binding domain (RBD, residues 55-131) 
and cysteine rich domain (CRD, residues 139-184), is crucial for Raf-1 translocation to 
the membrane and activation via Ras binding (112;161;165). The CR2, serine/threonine 
rich region, when phosphorylated regulates localisation and activation of Raf-1 (112).
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CR3 is a catalytic kinase domain, with an activation segment whose function is regulated 
by phosphorylation (112). The N-R egion, located before CR3, possesses a negative 
charge and phosphorylation sites that are crucial for Raf-1 activation (Figure 1.10).
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Figure 1.10: Raf-1 Protein Structure
Raf-1 sites highlighted in blue are phosphorylated when Raf-1 is in its inactive form, 
whereas those sites highlighted in red are phosphorylated when Raf-1 is activated. RBD 
=  Ras Binding Domain, CRD = Cysteine Rich Domain
1.8.2.2 Regulation of Raf-1 by Ras
Raf-1 regulation is dependent on association with activated Ras, interactions with 
scaffold proteins and key phosphorylation events. However the mechanisms leading to its 
activation are not com pletely understood, though binding to Ras is an integral part.
Following RTK activation and transition o f  Ras-GDP to Ras-GTP, Ras binds 
Raf-1 and translocates it to the membrane where it can be activated. In order to activate 
Raf-1, Ras must dimerise (166) allowing Ras to first bind the RBD and then form 
secondary interactions with the CRD region o f  Raf-1, via its effector domain (161; 167). 
The CRD negatively controls Raf-1 catalytic activity by interacting with the kinase 
domain; Ras binding to the CRD overrides inhibition o f  R af activity and permits 
phosphorylation o f  key sites (114; 161). Ras binding also triggers the déphosphory lation 
o f  inhibitory sites.
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1.8.23 Inactive Raf-1: - formation of an anto-inhibitory complex
Inactive Raf-1 is localised to the cytosol, where it forms a multi-protein complex of 300-
500 kDa (161). Raf-1 activity is inhibited in the cytoplasm via interactions between the 
N-terminal regulatory domain and the C-terminal kinase domain. Phosphoiylation and 
association with proteins, such as the heat-shock proteins (Hsp70 and Hsp90) and the 
dimeric 14-3-3 proteins, also maintain Raf-1 in its inactive form. The Hsps act as 
chaperones to Raf-1, whilst the 14-3-3 proteins serve to protect Raf-1 from 
dephosphorylation, and to act as a linker between Raf-1 and other proteins (168). In 
resting cells, inactive Raf-1 is phosphorylated at three serine sites: S43, S259 and S621 
(Figure 1.11) (169), Phosphorylation at S43 prevents the interaction between the effector 
domain of Ras and Raf-1 RBD (170). Phosphorylation of botli S259 and $621 provide 
docking sites for the 14-3-3 proteins. Binding o f 14-3-3 to Raf-1 produces an inactive 
conformation by bringing the N-terminal domain into contact with the C-terminal 
(171;172). S259 is a target of both AKT and cAMP activated protein kinase (PKA) 
(112; 173; 174). PKA also increases phosphorylation of S43 and S233. This latter site has 
been identified as a third docking site for 14-3-3 proteins (175).
S259 is a key player in Raf-1 inhibition. Mutations of this residue produce a 
constitutively active form of Raf-1. Déphosphorylation of S259 is an essential activation 
step. The binding of Ras to Raf-1 stimulates the dephosphorylation of S259 by 
destabilising the interaction between 14-3-3 and phospho-S259. Translocation of Raf to 
the membrane brings it into the vicinity of protein phosphatase 2A (PP2A), which 
dephosphorylates S259, freeing one arm of the 14-3-3 dimer (176). This enables 14-3-3 
to recruit upstream activators and allows the phosphorylation of crucial Raf-1 activation
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sites. Only once Raf-1 is dephosphorylated at S259, can it be activated in response to 
mitogens and other stimuli (Figure 1.11).
1.8.2.4 Activation of Raf-1 mediated by phosphorylation
Raf-1 activation requires phosphorylation of several sites, via direct or indirect signalling
fi’om Ras. These include serine-338, tyrosine-341 (upstream of the kinase domain), and 
threonine-491, serine-494 (within the activation loop) (114;115;161). Of these sites S338 
and Y341 are the most studied, and their phosphorylation is required for Raf activation. 
Mutations of either residue generally render Raf-1 inactive. S338 phosphorylation is 
induced by growth factors, integrins and Ras, and is a relatively reliable marker o f Raf-1 
activation. However, debate exists over the kinase(s) responsible for the phosphorylation 
of S338. It is established that the serine/threonine kinases, PAKs, phosphoiyiate Raf-1; 
however, it is thought they do this in a Ras-independent manner (167). It is therefore 
likely that an unidentified kinase mediates phosphorylation of S338 in a Ras-dependent 
manner. Phosphorylation of Y341 by Src-family kinases may negate inhibitory effects of 
the N-terminal on the C-terminal catalytic domain (161).
The final two activating sites, T491 and S494, are located in the activation 
segment of the CR3 region (167). As with S338, they are both phosphorylated in a 
mitogen-dependent manner; their mutation prevents Raf activation, although, the kinase 
that mediates their phosphorylation is unknown. It is speculated that these sites undergo 
autophosphorylation, in a manner similar to the HERs (177) (Figure 1.11).
1.8.2.5 Regulation of Raf-1 via scaffold proteins
Activation of Raf-1 and the mediation of its effects are also controlled by scaffold 
proteins. There are scaffold proteins that enhance the effects of Raf-1, such as Sur-8,
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KSR (Kinase Suppressor of Ras) and CNK (Connector Enhancer of KSR), whilst those, 
such as RKIP (Raf Kinase Inhibitor Protein), inhibit Raf-1 signalling. S259 
dephosphorylation and the release of one arm of the 14-3-3 dimer enables 14-3-3 to 
interact with the KSR scaffolding protein. KSR binds MEK and ERK, and links Raf to its 
downstream substrates (168;178;179). Sur8 complexes with Ras-GTP and Raf-1 and 
enhances the activation of Raf-1 via EGF and Ras (161). Likewise, CNK binds Raf-1, 
and with Ras, stimulates Raf-1 activation (177).
RKIP inhibits the Ras/Raf-l/MAPK pathway by binding Raf-1, MEK and MAPK 
and prevents interaction between Raf-1 and MEK, regardless of Raf-Is activation status 
(180). Therefore, RKIP prevents activated Raf-1 from stimulating the rest of the kinase 
cascade. Another important inhibitor of the Raf-1 pathway is Spred, which, through 
binding Ras, does not prevent Raf translocation to the membrane, but does impede its 
phosphorylation and activation by an unknown mechanism (167)(Figure 1.11).
1.8.2.6 Negative-feedback regulation of Raf-1
A major point of interest is the termination of Raf-1 activation. The binding affinity that 
Ras-GTP has for Raf-1 is stronger than that for any other protein with which it interacts, 
including GAPs. Theoretically this should mean that once Ras-GTP binds Raf-1, this 
association should be maintained and Ras constitutively activated. However, this is not 
the case, but the exact mechanism by which Ras dissociates from Raf-1 and Raf-1 
activation is inhibited is unknown. Phosphoiylation of S43, which prevents interaction 
between Ras and Raf, is induced by PKA and also growth factors (114). Therefore, 
growth factors may positively regulate Raf-1 activation via phosphorylation of sites, such 
as S338, but may also negatively regulate activation by causing Ras to dissociate from
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Raf via phosphorylation of S43 (114). However, the kinase that phosphorylates S43 in 
response to growth factor stimulation is unknown. Downregulation of Raf-1 is also 
dependent on negative feedback following mitogen stimulation, inhibition of MEK, and 
MAPK signalling preserved Raf-1 in its active conformation (178; 181). Six residues on 
Raf-1, S29, S43, S289, S296, 8301 and 8641, become hyperphosphorylated in response 
to MEK signalling, and this corresponds to Raf-I inactivation (182). MAPK was 
identified as the kinase responsible for phosphorylating all sites, bar 843. This study 
proposed that hyperphosphorylation of Raf-1 induced a conformational change, 
preventing it from binding to Ras-GTP and responding to growth factor stimulation. 
Mutations of these residues resulted in increased Ras binding and activation of Raf-1 
through phosphorylation of 8338. Interestingly, this hyperphosphorylated form of Raf-1 
was not a signal for it to be degraded, but rather that it should be recycled into a 
signalling-competent state (“desensitised”). Raf-1 was maintained in its 
hyperphosphorylated form for several hours, and it was suggested that all Raf-1 present 
within the cell, not just the active form, is hyperphosphorylated. PP2A and the prolyl 
isomerase Pinl were identified as key proteins responsible for dephosphorylating and 
inactivating Raf-1, allowing the cycle of activation to begin again (Figure 1.11).
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Figure 1.11: Regulation of Raf-1
Rqf-1 regulation is dependent on association with activated Ras, interaction with scaffold 
proteins and key phosphorylation events.
1.8.2.7 Raf-1 Substrates & Function
The most highly characterised substrates o f  Raf-1 are the dual specific threonine/tyrosine 
kinases, M EKl and MEK2. Interestingly, o f  the three iso forms, Raf-1 is not the most 
effective activator o f  MEK 1/2: B-R af binds and phosphorylates MEK 1/2 with the most 
efficiency. B-R af is the main activator o f  M EK(177;183); it can phosphorylate MEK 1/2 
directly, or it can interact with and activate Raf-1, which subsequently phosphorylates 
MEK 1/2. It is now hypothesised that Raf-1 regulates the levels and duration o f  MEK 1/2, 
activated by B-Raf. MEK 1/2 was previously the only identified substrate o f  Raf-1; 
however, there is now evidence that Raf-1 can function independently o f  MEK/MAPK. 
Raf-1 translocates into the nucleus to bind and phosphorylate the Retinoblastoma (Rb) 
protein (184), promoting cell cycle progression and proliferation. It is also thought Raf-1 
interacts with and phosphorylates Bad, resulting in cell survival (177).
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1.8.2.8 Role of Raf-1 in cancer
Due to its key positioning in the MAPK cascade, i.e. downstream of the HERs and 
upstream of MAPK, and its interactions with other proteins, such as Rb, the activation of 
Raf-1 is a fundamental step in controlling tumour cell growth, proliferation, apoptosis, 
metastasis and angiogenesis. Overexpression of HERs, in particular HER2, is associated 
with a poor outcome in breast cancer patients. This overexpression results in increased 
activation of Raf-1. HER2, in comparison to EGFR, lengthens the time that Raf-1 is 
localised to the PM, and prolongs its activation status, enhancing activation of the MAPK 
cascade (185). This increased activation of Raf-1 via HER2 is perhaps one explanation 
for the poor prognosis of patients with HER2 overexpressing tumours, and highlights the 
importance of Raf-1. Down-regulation of Raf-1, using small interfering RNA (siRNA), 
inhibits tumour growth (186). Raf-1 is not only implicated in the development and 
progression of breast cancer, but also in the responsiveness of breast tumours to 
therapies, such as Tamoxifen and chemotherapy.
1.8.3 MEK 1 and MEK2
Mekl and Mek2 are dual specific threonine/tyrosine kinases. Mekl is localised to 
chromosome 15 (15q21) and Mek2 to chromosme 7 (7q32). There is approximately 80% 
homology between the two isoforms. However, there is evidence that the two isoforms 
have different functions: Mekl deficient mice die in early gestation while Melc2 deficient 
mice develop normally (187) . The main activators of Mekl/2 are the Raf kinases (177). 
However they are also regulated by other kinases, such as MEKK I, Tpl-2 and Mos. 
Phosphorylation of Mek 1/2 at serine 218 and serine 222, within its activation loop, 
results in activation. MEK proteins have two consensus kinase motifs, one that regulates
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phosphorylation of serine/threonine motifs, and one that controls phosphorylation of 
tyrosine residues (188). Only MAPK (ERKl and ERK2) are identified as Mek targets.
1.8.4 MAPK
Several proteins are classified as mitogen activated kinase proteins (MAPKs). These 
include extracellular regulated kinase 1/2 (ERK 1/2, p44/42 MAPK), JNK, p38MAPK 
and ERK5. However, for the purpose of this thesis, MAPK refers to ERK 1/2. Erkl is 
localised to chromosome 16 (16plL2), whilst Erk2 is found on chromosome 22 
(22pl 1.2) (189). ERKl and ERK2 are 44 and 42kDa proline-directed serine/threonine 
kinases. Both proteins share a high degree of structural and functional similarity.
1.8.4.1 M APK interaction with MEK
The activation of MAPK is regulated via stimulation of Ras/Raf-l/MEKl/2. MAPK is 
the only identified effector o f activated MEK 1/2. However, MEK and MAPK also 
interact with each other in their inactive fonns, via a basic and hydrophobic region within 
the N-terminal domain of MEK 1/2, and several sites within MAPK including a cytosolic 
retention sequence (CRS) domain, and residues within both the N- and C-terminal 
domain (190-193). The binding of MEK to MAPK results in the export of inactive 
MAPK from the nucleus and its retention in the cytoplasm. However, MEK mediated 
phosphorylation of the Tlireonine-Glutamine-Tyrosine motif within the activation loop of 
MAPK (phosphorylation of threonine 202 and tyrosine 204 on ERKl and threonine 183 
and tyrosine 185 on ERK2), results in its activation. This phosphorylation results in 
approximately lOOO-foId increase in the activity of MAPK (194). Furthermore, it causes 
dissociation from MEK and liomo-dimerisation, which facilitates nuclear translocation 
(195). Phosphorylated MAPK also forms heini-active dimers with unphosphorylated
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MAPK, facilitating the translocation of unphosphorylated MAPK into the nucleus (195). 
MAPK possess a nuclear export signal (MELDDLPKEKLKEL). However, dimer 
formation may prevent MAPK nuclear export, as this signal is hidden within the interface 
of the dimer(195).
MAPK activation results in phosphorylation of more than 50 substrates within the 
cytosol and nucleus (116; 117). MAPK substrates generally contain the consensus 
sequence, Pro-X-Ser/Thr~Pro. Nuclear substrates include c-Fos and Elk-1. c-Fos, which 
together with c-Jun, forms AP I, a transcription factor that regulates early transcriptional 
events, such as proliferation, differentiation and oncogenic transformation, requires 
phosphorylation via MAPK to remain in a stabilised state (196). However, MAPK can 
also promote anti-apoptotic effects through phosphoiylation of cytoplasmic substrates, 
such as p90RSK and BAD (197). Furthermore, cellular response is dependent on the 
duration of MAPK activation and signalling. Transient activation of MAPK results in an 
unphosphoiylated and unstable form of c-fos, whereas sustained activation leads to 
p90RSK phosphorylation. This, in combination with MAPK, phosphorylates and 
stabilises c-fos (198). This generates different biological responses, for example, in PC12 
cells, treatment with nerve growth factor stimulates sustained MAPK activation and 
promotes cell differentiation, whereas treatment with epidermal growth factor results in 
transient MAPK activity and cell proliferation (199;200).
1.8.4.2 MAPK and tbe Oestrogen Receptor
ERa is a key substrate of activated MAPK. MAPK directly phosphorylates ERa within 
the AF-2 domain at SI 18 (39;20l). Residues suiTounding SI 18 comprise the MAPK 
consensus sequence, Pro-Gln-Leu-Ser-Pro. MAPK also indirectly phosphorylates ERa at
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s  167 via p90rsk (197). E2 independent phosphorylation of SI 18 and SI67 leads to an 
increase in the activity of the receptor. Under these circumstances, E2 is not recruited and 
not required for the activation of the receptor. Phosphoiylation of ERa, via MAPK, is 
rapid and transient in comparison with E2 stimulated phosphorylation (202).
Interestingly, several studies have suggested that the relationship between MAPK 
and ERa may be even more complex. ERa levels may decrease in response to increasing 
expression levels of MAPK. Overexpression and increased activation of EGFR/HER2, 
and subsequently MAPK in ERa positive breast cancer cells, promotes ERa loss and 
subsequently reduces expression of E2-regulated genes, such as PR (203;204). 
Furthermore, ERa negative breast tumours tend to present with overexpression of the 
growth factor receptors and elevated levels o f MAPK (203). The relationship between 
MAPK activation and ERa expression has been examined in MCF-7 breast cancer cells. 
Several studies have shown that hyperactivation of MAPK results in downregulation of 
ER levels (205-207). Activation o f MAPK in MCF-7 cells corresponds to increased 
activation of Nucleai* Factor-icB, and it is thought that this is partially responsible for the 
down regulation of ERa (206). A more recent study suggests that hyper-activation of 
MAPK in ERa positive cancer cells is a key mechanism in driving the change from an 
ERa positive to a ERa negative phenotype, and that there is a “hyperactive MAPK 
signature” set of genes that identify ERa negative tumours (208).
1.8.43 MAPK and Breast Cancer
As a result of its role in cell proliferation, differentiation and migration, combined with 
its relationship with ERa, MAPK has been implicated in the development and 
progression of breast cancer. In vitro studies investigating the effects of MEK inhibitors
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revealed that MAPK was associated with cell proliferation and motility in breast cancer 
cell lines (209;210). Similarly, evidence suggests that MAPK activity is required, not 
only for the maintained growth of various breast cancer cell lines, but also for their 
sui-vival (211). The interaction between MAPK and ERa is critical in the progression of 
tumours. MCF-7 cells, transfected with constitutively active MEKl, displayed increased 
levels of ER mediated transcription in the presence of low levels of E2. Furthermore, m 
vivo studies highlighted that MEKl active MCF7 cell tumours were approximately three 
times larger than the parental MCF-7 cell tumours (212). Breast tumours frequently 
present with elevated levels of activated MAPK (194), Increased expression of activated 
MAPK is thought to be associated with breast tumourgenesis and tumour progression. 
One study showed that approximately 50% of breast cancer patients exhibited an increase 
in the level of activated MAPK in their primary breast tumours, in comparison with 
normal breast tissue (213). This study suggested that increased levels of MAPK were 
associated with tumour metastasis and a poor outcome. This is further supported by 
another study, indicating that activation of MAPK in tumours is associated with node 
positive breast cancers, and is linked to a poor outcome (214). However, this relationship 
is controversial. Studies suggest that activation of MAPK is associated an increased time 
to patient relapse and improved outcome (215). A recent study indicated that the effect 
of MAPK activation and expression on patient outcome depended on its subcellular 
location. Increased expression levels of nuclear MAPK in breast tumours was correlated 
with a shortened overall survival time, but conversely cytoplasmic expression was 
associated with an improved outcome, longer disease-free survival time and overall 
survival time (204).
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1.9 The Role of Ras/Raf-I/MAPK in Response to Breast Cancer 
Treatments
1.9.1 The Ras/Raf-l/M APK cascade and Tamoxifen resistance
A substantial proportion of the research into the mechanisms driving tamoxifen resistance
has focused on the role of the MAPK cascade. One of the outcomes of activation of 
MAPK is the ligand-independent phosphoiylation and activation of the ERa. This 
ultimately results in the transcription of oestrogen-regulated genes and cell proliferation, 
which may partially explain the development of Tamoxifen resistance (69;97;107)
Phosphorylation of the AF-1 domain o f ERa by kinases, such as MAPK, results 
in increased interactions with co-activators, rather than co-repressors, and enhances the 
transcriptional activity o f the receptor when bound by Tamoxifen (202). Therefore, this 
ligand-independent phosphorylation over-rides the antagonistic activity of Tamoxifen and 
may play an important role in the development of Tamoxifen resistance.
MAPK, in addition to pliosphorylating ERa, is able to phosphorylate co­
activators, such as SRC-1 and AIBl (216-218). This enables the co-activator to bind to 
Tamoxifen-bound ERa and increase ER mediated transcription, and is yet another bypass 
mechanism of the antagonist effects of Tamoxifen. Furthermore, phosphoiylation of the 
CO-repressor, N-CoR, causes it to translocate out of the nucleus, preventing i t  from 
inhibiting transcription (202;219) (Figure 1.12).
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Figure 1.12: Mechanism of Tamoxifen Resistance -  Cross talk between growth 
factor receptors and ER
There is bidirectional cross talk between the growth factor receptors (RTKs) and ERa, 
and this is thought to be a key mechanism in the development o f  Tamoxifen resistance, (a) 
Phosphorylation o f  the AF-I domain o f  the ERa by MAPK, results in increased 
interactions with co-activators and enhances the transcriptional activity o f  ERa when 
Tamoxifen bound. (b)MAPK phosphorylates co-activators, such as AIBl, enabling co­
activators to bind to Tamoxifen-bound ERa and increasing ERa mediated transcription, 
(c) Phosphorylation o f the co-repressor, N-CoR, causes it to translocate out o f  the 
nucleus, preventing it from binding to ERa and inhibiting transcription. RTKs =  
Receptor Tyrosine Kinases, Tam =  Tamoxifen, ERE = Oestrogen Response Element
In vitro studies have highlighted the importance of growth factor signalling pathways,
and in particular MAPK expression and activation, in contributing to the development of
tamoxifen resistance. Increased expression of activated Ras induces hormone-
independent growth of MCF-7 cells and tumours in nude mice. Constitutive activation of
Raf-1 enabled the growth of MCF-7 cells in the absence of oestrogen (220). Analysis of
several ERa positive breast cancer cell lines has revealed that increased expression of
MAPK is associated with tamoxifen resistance, and that high levels of MAPK support the
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growth of these cells during adaptation to long-term oestrogen deprivation (203;221). 
Tamoxifen-resistant cells also present with elevated levels of phosphoiylated EGFR, 
MAPK and ERa at SI 18 and 8167 (50;222). An immunohistochemistry (IHC) study of 
clinical breast cancers revealed that approximately 80% of ERa positive patients had an 
increase in the levels of pliosphorylated MAPK in their tamoxifen resistant tumours, in 
comparison with their tamoxifen sensitive tumour (223). Another study of breast tumours 
demonstrated that expression of phosphorylated MAPK was associated with a poor 
response to tamoxifen (224). Increased expression of the activated form of MAPK was 
observed in the breast tumours of patients who exhibited de novo tamoxifen resistance 
(225). However, contradictory reports suggest MAPK activation is not involved in the 
development of tamoxifen resistance (212;213), and increased tumour activated MAPK 
levels are associated with good outcome in tamoxifen treated patients (226).
1.9.2 The Ras/Raf-l/M APK cascade and Chemotherapy resistance
Failure to respond to chemotherapy is a major clinical problem, and again, the
mechanisms underlying the development of resistance to chemotherapeutic agents are not 
completely understood. The Ras/Raf-l/MAPK pathway is implicated in mediating 
resistance to chemotherapeutic agents, such as epirubicin and doxorubicin. All research 
investigating the relationship between the Ras/Raf/MAPK pathway and anthracycline 
resistance has been performed in cell lines. The role of the MAPK cascade in mediating 
response to chemotherapy is still controversial. Some studies suggest that increased 
expression of Raf-1 and MAPK decrease responsiveness to cytotoxic agents and 
contribute to the development of chemotherapy resistance (227-229). Others suggest that
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down-regulation of Raf-1 is linked to paclitaxel resistance, and that MAPK activation 
promotes cell death in the presence of anthracyclines (230).
1.9,3 Inhibiting the MAPK cascade:- therapeutic implications
The Ras/Raf-l/MAPK pathway is often upregulated in cancer cells, either through
mutation or overexpression; hence it represents an appropriate target for anticancer 
treatments. There are currently drugs that inhibit Ras, Raf-1 and Mek activity, and these, 
either alone or in combination with other therapies, such as Tamoxifen, offer a possible 
alternative treatment option for patients.
1.9.3.1 Ras & Therapeutic Implications
As a result of the common occurrence of Ras mutations in human cancers, Ras has 
become a key therapeutic target. Presently the most effective treatment targeted against 
Ras are the Farnesyl Transferase Inhibitors (FTIs). FTIs prevent Ras from being 
farnesylated, thus inhibiting its translocation to the PM and its activation. There are three 
classes of FTIs: farnesyl pyrophosphate analogues, which compete with the isoprenoid 
substrates for FT; peptidomimetic inhibitors, which mimic the CAAX motif and compete 
with Ras for FT; and bisubstrate analogues, which are a combination of the other two 
(231). Tipifarnib and lonafarnib are two of the most commonly studied FTIs. Evidence 
exists that the Ras isoforms have different sensitivities to FTIs. Whilst H-Ras is very 
sensitive, N-Ras is partially sensitive, and K-Ras is resistant to many FTIs (113;232).
Originally FTIs were designed to combat against Ras mutations; however, they 
are also effective against wild type Ras. Thus, they are of use in the context of breast 
cancer. Tipifarnib has been shown to be effective in inhibiting the growth of MCF-7 
xenografts (233). It has also been shown that treatment of MCF-7 cells with FTI-277, in
73
combination with Tamoxifen, is superior to either treatment alone (234). Therefore, since 
activation of Ras and its signalling pathways is believed to be associated with resistance 
to treatments, such as Tamoxifen and chemotherapy, it is thought that combined 
treatment with FTIs might overcome this resistance and improve patient outcome.
1.9.3.2 Raf-1 Inhibitors
The Raf-1 inhibitor, Sorafenib (BAY 43-9006), is a bi-aryl urea that prevents Raf-1 and 
B-Raf activity (235). It binds to Raf-1 and prevents the activation segment of Raf-1 from 
binding and pliosphorylating downstream substrates (236). BAY 43-9006 exhibits anti­
tumour activity in human tumour xenogiaft models of colon, pancreas, breast and non­
small cell lung cancer. In most of these cases, the anti-tumour activity was a consequence 
of the down-regulation of MAPK activation. BAY 43-9006 is currently in clinical trials.
1.9.3.3 MEK Inhibitors
The specificity of the interaction between MEK 1/2 and MAPK means that MEK 1/2 
represents an ideal target for inhibition of the MAPK cascade. Two of the first MEK 
inhibitors were PD98059 and U0126. Both these compounds down-regulated MAPK 
activation and reduced cellular proliferation and activation of MAPK regulated proteins 
in multiple cancer cell lines (237-239). Unfortunately, neither PD98059 nor U0126 were 
suitable for clinical testing; hence PD184352, an orally active Mek 1/2 inhibitor, was 
synthesised (240). The binding of inhibitor induces conformational changes in the 
unphosphoiylated form of MEK 1/2, rendering it inactive. It is also thought that, whilst in 
this inactive form, it is insensitive to upstream kinases (241). PD 184352 reached phase II 
trials; however, the results were slightly disappointing. Consequently, a second- 
generation MEK inhibitor, PD0325901, has been synthesised and shown to have anti­
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tumour activity in a range of human tumour grafts (242). It is now cuiTently under testing 
in phasel/II trials.
It is thought that the use of MEK inhibitors will be most beneficial in combination 
with cytotoxic agents, such as cisplatin and paclitaxel, to induce apoptosis (242). An in 
vitro study of MCF-7 and MDA-MB-231 cells revealed that treatment with docetaxei was 
more effective in the presence o f U0126 (243). Likewise, if these inhibitors downregulate 
MAPK activity, they might be of particular use in overcoming the effects of MAPK 
mediated tamoxifen resistance.
1.10 Statement of Aims
The research presented in this thesis investigated the role of the Ras/Raf-l/MAPK 
pathway in the development and progression of breast tumourigenesis. Using breast 
tumours fiom three different patient cohorts and an immunohistochemical approach, 
expression of Ras, Raf-1 and MAPK proteins was determined. The various studies tested 
the hypothesis that increased expression and activation of the components of this pathway 
in breast tumours, was linked to clinical parameters, such as disease-free and overall 
survival. Additionally it was speculated that increased expression and activation of the 
Ras pathway in breast tumours was associated with poor response to tamoxifen and 
chemotherapy treatment regimes, and this theory was also explored.
As the ligand-independent activation of ERa is believed to be a key step in the 
development of tamoxifen resistance, the relationship between the Ras/Raf-l/MAPK 
pathway and ERa was scrutinised. In vitro studies were designed in order to compare the 
effects of E2-dependent versus ligand-independent phosphorylation and activation on the
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localisation of ERa. Particular attention was paid to the interaction between MAPK and 
ERa.
Ultimately the goal of this research was to try and further our understanding of the 
mechanisms that drive the development of resistance to tamoxifen and chemotherapy in 
breast cancer patients.
Research Aims
• To determine the levels of Ras and Raf-1 proteins in breast tumours, from a 
cohort of ER positive and negative patients, and to investigate if protein 
expression is associated with patient outcome. (Pilot Study)
• To investigate the localisation of Ras proteins in breast tumour cells.
• To determine if increased expression of Ras and Raf-1 is a consequence of 
gene amplification.
• To determine the levels of Ras, Raf-1, and MAPK proteins in breast tumours, 
from a cohort of ER positive patients treated with Tamoxifen, and to 
investigate if increased expression and activation of the Ras pathway is a key 
mechanism in the development of Tamoxifen resistance.
• To determine the levels of Raf-1 and MAPK proteins in breast tumours, from 
a cohort of ER positive/negative patients treated with chemotherapy, and to 
investigate if Raf-1 and MAPK mediate response to chemotherapy.
• To compare the ligand-dependent and ligand-independent phosphorylation 
and activation of ERa in breast cancer cells.
• To investigate the interaction between MAPK and ERa in breast cancer cells.
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2. Materials & Methods
2.1 Patient Cohorts
2.1.1 Pilot Study
This patient cohort was comprised of 206 breast cancer patients treated at Glasgow Royal 
Infirmary between 1984 and 1993. Patients were selected randomly for inclusion in this 
study. Consequently these patients represented both ER positive and negative breast 
cancers, and the treatment regimes varied. Treatment included radiotherapy (37.4% 
patients), chemotherapy (13.8%), and tamoxifen (74.4%). Clinical and pathological 
characteristics, including ER status, grade, nodal status, histology, tumour size, NPI and 
age, are shown in Table 2.1. There were 98 breast cancer specific deaths and 80 breast 
cancer relapses. Ethical approval was obtained from the Glasgow Royal Infirmary Local 
Research Ethics Committee.
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Number/Total %
-ve 78/175 44.6
ER Status +ve 97/175 55.4
Unknown 31
Ductal 182/202 90.1
Lobular 14/202 6.9Histology Other 6/202 3.0
Unknown 4
1 30/200 15
Grade 2 75/200 37.53 95/200 47.5
Unknown 6
0 88/176 50.0
Nodal Status 1-3 54/176 30.744- 34/176 19.3
Unknown 30
<3.5 78/170 45.9
NPI 3.5-4.5 54/170 31.84.5 38/170 22.3
Unknown 36
T1 (<20mm) 44/198 22.2
T2 (20-50mm) 130/198 65.7
T3 (>50mm) 24/198 12.1
Unknown 8
<50 years 15/198 7.6
Age >50 years 183/198 92.4
Unknown 8
Table 2.1: Pilot Study Patient Clinical & Pathological Variables
ER = Oestrogen Receptor. Tumours were considered ER positive i f  >10% nuclei were 
stained at any intensity. Grade = Bloom and Richardson grade; Nodal Status = Number 
o f positive nodes; Pathological Type: Ductal = invasive ductal carcinoma; Lobular = 
invasive lobular carcinoma; Others include three mediillaty, one mucoid, one squamous 
and one tubular carcinomas.
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2.1.2 Steroid Resistant Tumour Bank (STB) Study
This cohort was retrospectively selected from patients presenting with operable breast 
cancer at the Glasgow Royal Infirmary between the years 1980 and 1999. Initially six 
hundred and eighty six ER positive or ER unknown patients who had undergone adjuvant 
treatment with tamoxifen were selected. However, the number of patients was reduced to 
four hundred and fifty six, as a result of incomplete follow-up (n=52, 8%), or unavailable 
tissue blocks, or blocks with insufficient tissue, as judged by a pathologist (n=177, 26%). 
There was no significant difference between the final data set of 456 patients and the 
original cohort, in terms of patients’ age, tumour size, grade or nodal status. Additionally, 
immunohistochemical staining for ER was performed. Tumours were considered ER 
positive if >10% nuclei were stained at any intensity. 402/ 456 patients had ER positive 
breast tumours, while 20 had ER negative tumours. For 34 cases there was insufficient 
material for ER IHC. For all studies only the 402 ER positive cases were analysed.
All 402 patients received adjuvant tamoxifen for a median of 5 years (range 0.03- 
16 years), and follow-up data was available for a median of 6.45 years (range 0.11-18.42 
years). In addition to receiving tamoxifen, 99 patients (24.8%) received chemotherapy 
(three unknown), whilst 110 patients (27.5%) received radiotherapy (three unknown). 
Information regarding the clinical and pathological characteristics of these patients, such 
as age at diagnosis, nodal status, tumour histology, size and grade was also available, and 
is shown in Table 2.2. There were 74 breast cancer specific deaths and 112 breast cancer 
relapses, 85 of which occurred during tamoxifen treatment. This allowed for survival 
analysis in terms of disease fiee-survival, recurrence whilst on tamoxifen and overall
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survival. Ethical approval was obtained from the local research ethics committee. Miss 
Sian Tovey was responsible for establishing this database and performing the ER IHC.
2.1.3 NEAT Study
The Scottish Cancer Trials Breast Group in conjunction with the CRC Trials Unit 
established the second group of patients. All the women were part of the Scottish NEAT 
(National breast cancer study of Epirubicin & CMF versus classical CMF Adjuvant 
Therapy -  Study Number BR9601) clinical trial designed to compare the effects of 
Cyclophosphamide, Methotrexate and 5-Flourouracil (CMF) alone against that of 
sequential Epirubicin followed by CMF as adjuvant chemotherapy in women with early 
breast cancer. The primary objectives were to compare the effects of both treatments on 
patients, disease-free and overall survival time. The study included women with early 
breast cancer, with between 4 and 9 positive nodes, though other patients were still 
eligible if their clinician deemed them suitable for chemotherapy treatment.
Eligible patients were randomly selected for treatment with 4 cycles of epirubicin, 
followed by 4 cycles of CMF given intravenously every three weeks or treatment with 8 
cycles of classical CMF given intravenously every three weeks. In total 318 patients were 
included in our study. 155 (48.74%) of these patients received the combination treatment 
of Epirubicin and CMF, while the remaining 163 (51.26%) received only CMF. In 
addition, 224 (70.44%) received hormone therapy, whilst 255 (80.19%) also received 
radiotherapy.
For these patients there was a median follow up of 4.95 years (range 0.27-8.52 
years). Details regarding the clinical and pathological characteristics of these patients, 
such as the patient’s age, tumour size, grade, ER and nodal status, were also available and
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are listed in Table 2.2. In this study there were 84 breast cancer related deaths and 111 
breast cancer recurrences (local and distant recurrences).
STB Patie
Number/total
nts
%
McNEAT Pa 
Number/Total
tients
%
Ductal
Histology
Unknown
322/397
45/397
30/397
5
81.1
11.3
7.6
1
Grade ^
unknown
99/391
193/391
99/391
11
25.32 
49.36
25.32
20/305
100/305
185/305
13
6.55
32.79
60.66
0
Nodal 1-3 
status 4+
un known
193/369
107/369
69/369
33
52.3
29.0
18.7
43/313
176/313
94/313
5
13.74
56.23
30.03
T1 (<20mm) 
T2 (20-50mm) 
T3 (>50mni) 
unknown
154/380
204/380
22/380
22
40.53
53.68
5.79
94/308 
203/308 
11/308
30.52
65.91
3.57
<3.5
Missing
128/344 
106/344 
110/344 
58
37.21
30.81
31.98
65/311
148/311
98/311
7
20.9
47.59
12.86
<50 years
Age >50 years Missing
73/401
328/401
1
18.2
81.8
90/318
228/318
28.3
71.7
+ve
ER Status Unknown
402/402 100.0 174/278
104/278
40
62.59
37.41
_   ^  ^ Epi&CM F  Treatment n/an/a
155/318
163/318
48.74
51.26
Table 2.2: STB & NEAT study patient clinical & pathological characteristics
Grade = Bloom and Richardson grade, Nodal status = number o f positive nodes, NPÎ = 
Nottingham Prognostic Index = grade+nodal status^0.02'^she in mm. Age = age at 
diagnosis. ER = Oestrogen Receptor. Tumours were considered ER positive i f  >10% 
nuclei were stained at any intensity.
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2.2 Immunohistochemistry
2.2.1 Pilot Study
Immunohistochemistry allows for the detection of a cellular protein or other antigen 
within cells and tissues using an antibody specific for the desired antigen. The low 
abundance of many intracellular proteins means that in most cases the signal generated 
by the “primary” antibody (which binds directly to the target molecule) is “amplified”, 
using an indirect immunohistochemical approach. This involves using a second or 
“secondary” antibody, labelled with either a visible marker (fluorochrome) or an enzyme, 
that binds to the primary antibody bound to the antigen. This indirect approach generates 
an amplified signal. The method for investigating the expression of the Ras and Raf-1 
proteins in breast tumour tissue used the LSAB (labelled streptavidin-biotin) visualisation 
kits. This method relies on the high affinity that avidin has for biotin. Firstly a 
biotinylated link antibody, which recognises the primary antibody, is applied to the 
tissue, followed by streptavidin labelled with peroxidase (HRP), which binds to the 
biotin. This peroxidase then reacts with diaminobenzidine (DAB) to produce an insoluble 
brown precipitate, which represents the target antigen (Figure 2.1).
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Step 1 : Incubation with prim ary 
antibody — binds to target antigen
Step 2; Incubation with biotinjrtated 
link antibody — binds to primary 
antibody
Step 3; Incubation with streptavidin 
labelled w ith peroxidase (HRP) -  
binds to biotin
Step 4; Incubation with 3,3’- 
diaminobenzidine (DAB) — bm ds to 
peroxidase & produces insoluble 
brown precipitate
Figure 2.1: Pilot Study Indirect Immunohistochemistry Method
Schematic representation o f the indirect immunohistochemistry method used in the pilot 
study to amplify the signal generated by the primary antibody. This method relies on the 
high affinity that avidin has fo r  biotin.
•  Tissue Preparation and Dewaxing/ Dehydration
The tissue specim ens were formalin-fixed and embedded in wax and 3-4pm  sections 
were cut and mounted on 3-aminopropylethoxysilane coated slides. Prior to 
immunohistochemical staining, tissue sections were dewaxed and rehydrated through a 
series o f  xylene (2x2m inutes) and alcohol (100% (2x2minutes), 90% (lx2m inutes), 
70%( 1 x2minutes)) washes.
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• Antigen Retrieval
As a result of formalin-fixation and wax embedding, the antigen under investigation may 
lose its immunoreactivity, thus either binding weakly to the appropriate primary antibody 
or not at all. This is due to the formation of methylene bridges during fixation, which 
cross link proteins and therefore mask antigenic sites. Thus, it was necessary to include 
an antigen retrieval step, to break the protein cross-links and expose the antigenic binding 
site, in order to optimise immunohistochemical staining. Two different heat mediated 
methods of antigen retrieval were used for the antigens studied. The first involved 
incubating the tissue sections in lOmM citrate buffer (1:10 dilution of Epitope Retrieval 
Buffer, DAKO) for twenty minutes at 96°C in a water bath, followed by a twenty minute 
cool down period. The alternative method heated tissue sections under pressure in IL of 
TE buffer (ImM EDTA (Sigma), 5mM Tris (VWR), pH 8.0) for five minutes in a 
microwave, again followed by a twenty minute cool down period (Table 2.3).
•  Reduction of background staining: - Blocking steps
Peroxidase reacts with diaminobenzidine, therefore the presence of endogenous 
peroxidase activity in tissues is a common problem in IHC since it is a cause of 
background staining. Endogenous peroxidase activity was blocked by incubating the 
slides in 0.3% hydrogen peroxide (H2O2) (VWR) for twenty minutes, followed by a wash 
in water. A further cause of background staining is the foimation of hydrophobic bonds 
between immunoglobulins and tissue proteins that results in the primary and secondary 
antibodies binding non-specifically to the tissue section rather than just the target antigen. 
To reduce this non-specific binding, tissue sections were incubated in 1.5% nonnal horse 
serum (Vector Laboratories) in antibody diluent (DAKO). Just as excess peroxidase
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produces high levels of background staining, so too does the presence of endogenous 
biotin since the streptavidin labelled with peroxidase would be able to bind directly to the 
tissue in addition to the target antigen. Breast tissue generally expresses elevated levels of 
biotin protein in comparison with other tissues and this in addition to the inclusion of a 
severe antigen retrieval step often results in false positive staining. Hence a further biotin 
blocking step (Avidin/Biotin Blocking Kit -  Vector Laboratories) was required. This 
involved pretreating the slides with Avidin D solution for fifteen minutes, to bind any 
excess biotin on the tissue section. Slides were washed for five minutes in TBS buffer 
(O.IM Tris/HCl, L5M NaCl, pH 7.4) followed by incubation with the biotin solution for 
fifteen minutes, to block the remaining biotin sites on the avidin. Finally slides were 
washed in TBS buffer for five minutes before incubation with the desired antibody.
• Incubation with Primary Antibody
In this study antibodies for the following proteins were used: H-Ras, N-Ras, Pan-Ras 
(Pan-Ras Ab and RasAb-1) and Raf-1. For each, a dilution series was performed, 
investigating various antibody titrations, incubation times and temperatures, to establish 
the optimal conditions in which to achieve the highest quality of staining, i.e. strongest 
specific antigen staining with the lowest non-specific background. The required 
concentration and incubation time for each antibody is recorded in Table 2.3.
• Quality Assurance
It was essential to have both a positive and negative control each time IHC was 
performed. The positive control confirmed that the chosen IHC method was working 
whilst the negative control checked the specificity of the antibody involved. Tonsil tissue, 
placenta tissue or breast tissues previously shown to have strong expression of the desired
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antigen were incubated with the appropriate antibody and used as positive controls. The 
same tissues were used for negative controls by treating them with a negative isotype 
matched control reagent (DAKO).
• Incubation with Secondary Antibody
Following incubation with antibody or negative control, the slides were thoroughly 
washed in TBS buffer for five minutes. Detection of the proteins within breast tissue 
required binding the primary antibody to a biotinylated secondary antibody, which would 
then bind to peroxidase-conjugated streptavidin molecules. The visualisation of the 
antigen occurred via a colour reaction. A substrate chromagen binds to the peroxidase 
molecules producing a brown coloured product, corresponding to the protein being 
investigated. In order to do this the DAKO LSAB+ Kit, Peroxidase was utilised. The 
slides were firstly incubated with Link solution (biotinylated secondary antibody) for 
thirty minutes at room temperature. Next, the slides were washed in TBS buffer for five 
minutes and then incubated in the Streptavidin Peroxidase solution for one hour. Slides 
were then washed in TBS for five minutes.
•  Detection & Visualisation
The chromagen used for staining the tissue sections was 3,3’-diaminobenzidine (DAB) -  
(5ml distilled water (dHgO), 2 drops of buffer solution, 4 drops of DAB stock solution, 
and 2 drops of Hydrogen Peroxidase solution -Vector Laboratories). Slides were 
incubated with DAB for five to ten minutes to allow brown staining to develop and were 
then washed in water for ten minutes.
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• Counterstaining
Tissue sections were counterstained with haematoxylin and Scott’s Tap Water Substitute 
(S.T.W.S). Slides were immersed in the haematoxylin for approximately thirty seconds, 
until a red colour was produced in the tissue section; if the tissues appeared to be too red 
the slides were dipped in acid alcohol to remove some of the colouring. Following this 
they were then submerged in S.T.W.S for another thirty seconds, to produce a blue 
colour, in contrast to the brown positive staining of the antigen. The last steps involved 
dehydrating the tissues through a series of alcohol washes: (70% (Ixlmin), 90% 
(Ixlmin), 100%(2xlmin)) and xylene (2x1 min), and then mounting the slides onto 
coversiips using DPX mountant (Dibutyl Phthalate containing Xylene).
Detection of all the proteins, with the exception of Raf-1, was performed as described 
above. Raf-1 was detected using the Super Sensitive Non-Biotin HRP Detection System 
(BioGenex, CA, USA). Following antigen retrieval, peroxidase activity was blocked by 
incubating slides in 3% hydrogen peroxide (H2O2) (VWR) for twenty minutes, followed 
by a wash in water. Tissue sections were then incubated in 1.5% normal horse serum 
(Vector) in antibody diluent (DAKO), washed in TBS and incubated with the Raf-1 
antibody. Afterwards slides were washed in TBS for five minutes and treated with 
SuperBlock reagent for twenty minutes at room temperature. Sections were then rinsed in 
TBS for five minutes before being incubated with Poly-HRP reagent for thirty minutes at 
room temperature. Finally slides were washed three times in TBS for five minutes and 
then treated with Substrate Solution (one drop (38pl) of DAB Chromagen mixed with
87
1ml of Substrate Buffer) for ten minutes until brown staining developed. Lastly slides 
were washed in water for ten minutes. Tissue sections were then counterstained and 
mounted as described above.
Protein Antibody AntigenRetrieval
H2O2
Cone"
Antibody
Cone"
Incubation 
Time & 
Temperature
H-Ras H-RasMouse Monoclonal 
IgG, Ab, F235, 
Santa Cruz
TE Buffer 0.3% 20pg/ml Overnight at 
4°C
N-Ras N-RasMouse Monoclonal 
IgGl Ab,F155, 
Santa Cruz
TE Buffer 0.3% 20pg/ml Overnight at 
4''C
Pan-Ras Pan-Ras
Mouse Monoclonal 
IgGzb Ab, F132, 
Santa Cruz
Citrate Buffer 0.3% 20pg/ml Overnight at 
4 T
Pan-Ras Ras Ab-1 Rabbit Polyclonal 
IgG, Ab, 
Neomarkers,
Citrate Buffer 0.3% 20|Lig/ml 30 minutes at 
room
temperature
Raf-1 Raf-1
Mouse Monoclonal 
IgGl Ab, E-10, 
Santa Cruz
TE Buffer 3.0% 5pg/ml Overnight at 
4 T
Table 2.3: Pi ot Study Antibody Information
Details o f  the antibodies used in the pilot study to detect H-Ras, N-Ras, Pan-Ras and Raf- 
1 proteins. Information regarding the antibody source, antigen retrieval method, 
concentration and incubation time required are all recorded.
TE Buffer = heating under pressure in ImM  EDTA, 5mM Tris buffer, p H  8.0 fo r  5 
minutes in a microwave, Citi'ate Buffer = incubation in 10 mM citrate buffer at 96C for  
20 minutes. 1.5% Horse Serum blocking reagents was used for all five antibodies
2.2.2 Histoscore Method (Pilot Study)
Two observers, John Bartlett and myself, independently scored all the tissue sections for 
cytoplasmic and nuclear staining, using a semi-quantitative weighted histoscore method 
(244). The intensity of staining was categorised as negative (0), weak (1), moderate (2)
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and strong (3) and the percentage of tumour cells within each category estimated 
(Appendix 1 & 2). The histoscore was calculated using the following formula:
Histoscore = 0 x % negative tumour cells + 1 x % weakly stained tumour cells + 2 x 
% moderately stained tumour cells + 3 x % tumour cells stained strongly 
The histoscore ranged from a minimum of zero to a maximum of 300. Agreement 
between the two observers was monitored. Results were considered discordant if the 
scores differed by more than 50. These cases were re-evaluated by both observers. Both 
intra- (variation in individual scoring) and inter- (variation between tv\o observers) class 
correlation coefficients were calculated (245). Agieement was considered excellent if an 
ICCC score greater than 0.7 was obtained. Comparison of both LM and JB scores 
showed that agreement between observers was excellent with ICCC scores between 0.76- 
0.91. Intra- and inter- class correlation coefficients are shown in Table 2.4.
Protein Cytoplasmic Nuclear
Scoring Scoring
H-Ras 0.91 0.86
N-Ras 0.82 0.76
Pan-Ras 0.85 0.80
0.82 0.88Ras Ab-1 0.87* 0.82*
Raf-1 0.73 0.73
Table 2.4: Pilot Study Inter- & Intra-- class correlation coefficients (ICCC)
Two observers, JB & LM, independently scored breast tissue sections fo r  cytoplasmic 
and nuclear staining, fo r  H-Ras, N-Ras, Pan-Ras, Ras Ab-1 & Raf-1, using a semi- 
quantitative weighted histoscore method. Agi'eement between scores was measured using 
inter-class coiTelation coefficients. The intra-class correlation coefficient (variation 
between individual scorer (myself)) fo r  Ras Ab-1 is shown. The inter-class correlation 
coefficients fo r  all antibodies are listed in the table. Agreement was considered excellent 
i f  an ICCC score was above 0.7. Hntra-class correlation coefficient fo r  Ras Ab-1.
2.2.3 Tissue MicroArray Construction (STB & NEAT Study)
As a result of the large number of patients in both the STB and NEAT cohorts, it was
deemed more appropriate to construct tissue microarrays (TMAs) rather than use whole
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tumour tissue sections. Construction of the arrays involved haematoxylin and eosin 
staining of tissue sections to identify areas of tumour. A pathologist identified tumour 
areas, and subsequently cores of breast tumour were removed from the designated areas 
and transferred to recipient paraffin blocks to form the tissue arrays.
For the STB study three 0.6mm^ cores were removed from each breast tumour to 
form five different TMAs (TMA A = 100 cores, TMA B -  119 cores, TMA C = 100 
cores, TMA D = 60 cores & TMA E =77 cores), each in triplicate. To each of the TMAs, 
cores of smooth muscle, normal breast, skeletal muscle, lung, skin, testes, prostate, lymph 
node, placenta and tonsil were added as controls. Each triplicate TMA was constructed 
fiom cores from different areas within the same tumour in order to achieve the most 
accurate representation of the whole tumour section. The use of replicate TMAs also 
meant that it was more likely that results could be obtained for all cases, since there were 
three chances of having informative cores.
For the NEAT study three arrays (TMA 1=117 cores, TMA 2 = 100 cores, TMA 
3 = 101 cores) were constructed in quadruplicate from the 318 breast tumours; however, 
for analysis only three of each arrays were used.
There are several advantages to using arrays as opposed to whole tissue sections. 
Firstly it is an invaluable way of saving scarce human tissue for research. If whole 
sections were used only a limited number of studies could be performed, whereas the use 
of TMAs significantly increases the availability of this resource. Secondly the use of 
TMAs is far more economical in terms of time and finance. Lastly the use of TMAs 
enables experimental uniformity since all experiments can be performed on all the
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tumour tissue at the same time, which would be highly unlikely in the case of whole 
tumour tissue sections.
2.2.4 Immunohistochemistry on STB & NEAT TMAs
The same principle as described in section 2.2.1 applies to both the STB and the NEAT 
study. In the STB study expression and activation of the components of the 
Ras/Raf/MAPK pathway were investigated: H-Ras, K-Ras, N-Ras, Raf-1, phospho- 
Raf(ser259), phospho-Raf(ser338), p44/42MAPK and phospho- 
p44/42MAPK(thr202/tyr204). Whereas in the NEAT study only expression levels of 
phospho-Raf(ser259), phospho-Raf(ser338), p44/42MAPK and phospho- 
p44/42MAPK(thr202/tyr204) were examined.
From each of the TMA blocks, 3-4pm thick paraffin wax sections were cut and 
mounted on 3-aminopropylethoxysilane coated slides. The same basic IHC protocol 
described in section 2.2.1 was used; however, the signal visualisation steps were 
different. Slides were dewaxed and rehydrated and antigen retrieval performed. 
Endogenous peroxidase activity in the tissue was blocked with hydrogen peroxide and 
non-specific staining reduced by incubating sections in either 1.5% normal horse serum 
in antibody diluent or Casein (Vector Laboratories) solution. Slides were then incubated 
with the appropriate antibody. Table 2.5 includes details of the antigen retrieval method, 
H2O2 concentration, blocking solution, antibody concentration and incubation conditions 
required for each of the proteins investigated.
In the previous protocol the Labelled StreptAvidin Biotin (LSAB) based method 
was used to visualise the antigens; however, for immunohistochemical staining of the 
TMAs the Envision system (DAKO) which involves dextran polymer technology was
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used. This system enables a large number o f  enzym e m olecules such as horseradish 
peroxidase to bind to the secondary antibody via a dextran backbone (Figure 2,2). The 
advantages o f  this include increased sensitivity and reduced non-specific background 
staining. The additional biotin-blocking step that was compulsory in the LSAB method 
was not required when using Envision. The Envision detection method was used for all 
antigens except K-Ras, which required use o f  the Super Sensitive Non-Biotin HRP 
Detection System (as described in section 2.2.1).
A IA
Step 1 : Incubation 
with primary 
antibody -  binds to 
target antigen
Step 2; Incubation 
with secondary 
antibody — 
peroxidase linked 
envision — binds to 
primary antibody
Step 3: Incubation 
with 3.3’- 
diaminoben/.idine 
(D A B )-b in d s  to 
peroxidase & 
prcxiuces insoluble 
brown precipitate
Figure 2.2: Immunohistochemistry Method Using Envision
Schematic representation o f  the indirect immunohistochemistry method used in the STB 
and NEAT study to amplify the signal generated by the primary antibody. This method 
used the Envision system (DAKO), which involves dextran polymer technology. This 
system enables a large number o f enzyme molecules such as horseradish peroxidase to 
hind to the secondary antibody via a dextran backbone.
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Having been incubated with antibody, slides were washed with TBS for five minutes 
before being treated with Envision solution for thirty minutes at room temperature. Slides 
were then washed in TBS for five minutes and treated with DAB chromagen (Substrate 
buffer and DAB+ Chromagen were mixed in a ration of 50:1) (DAKO) for ten minutes to 
allow brown staining of the antigen to develop. Slides were washed in water for ten 
minutes and tissue nuclei counterstained with haematoxylin before being dehydrated 
through a series of alcohol and xylene washes. Slides were then mounted onto coversiips 
using DPX.
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Protein Antibody Antigen
Retrieval
H2O2
Cone"
Blocking
Solution
Antibody
Cone"
Incubation 
Time & 
Temperature
H-Ras H-Ras
Mouse Monoclonal 
IgGi Ab, F235, 
Santa Cruz,
TE Buffer 0.3% 1.5%normal
horse
serum
20pg/ml Overnight at 
4°C
K-Ras K-Ras
Mouse Monoclonal 
IgG2K Ab 
clone 234-4.2 
Sigma,
TE Buffer 3.0% Caseinsolution
20pg/ml Overnight at 
4°C
N-Ras N-Ras
Mouse Monoclonal 
IgGl Ab,F155, 
Santa Cruz,
TE Buffer 0.3% 1.5%normal
horse
serum
20pg/ml Overnight at 
4°C
Raf-1 Raf-1
Mouse Monoclonal 
IgGl Ab,
E-10,
Santa Cruz,
TE Buffer 0.3% 1.5%
normal
horse
serum
5pg/mi Overnight at 
4 T
pRaf(ser259) pRaf(ser259) 
Rabbit Polyclonal 
Cell Signaling 
Teclmology,
Citrate Buffer 0.3% Caseinsolution 4pg/ml Overnight at 4 T
pRaf(ser338) pRaf(Ser338) 
Mouse Monoclonal 
Upstate
Citrate Buffer 0.3% Caseinsolution 4pg/ml Overnight at 4 T
p44/42
MAPK
p44/42 MAPK 
Rabbit Polyclonal 
Cell Signaling 
Technology,
Citrate Buffer 0.3% 1.5%
normal
horse
serum
0.5jixg/ml Overnight at 
4°C
Phospho-
p44/42
MAPK
p44/42MAPK 
(Thr202/Tyr204) 
Rabbit Polyclonal 
Cell Signaling 
Technology,
Citrate Buffer 0.3% 1.5%normal
horse
serum
0.5p.g/ml Six hours at 
room
temperature
Table 2.5: STB & NEAT Study Antibody Information
Details o f the antibodies used in the STB and NEAT study to detect H-Ras, N-Ras, K-Ras, 
Raf-1 and MARK proteins. Information regarding the antibody source, antigen retrieval 
method, blocking reagents and concentration and incubation lime required are recorded. 
All the listed antibodies were used in the STB study, but only pRaf(ser259), pRaf(ser338), 
MARK and pMARK(thr202/tyr204) were used in the NEAT study.
TE = heating under pressure in Im M  EDTA, 5mMTris buffer, pH  8.0, fo r 5 minutes in a 
microwave, Citrate ^  incubation in 10 mM citrate buffer at 96 X! fo r  20 minutes.
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2.2.5 Histoscore Method (STB & McNEAT Study)
The same semi-quantitative histoscore method described in section 2.2,2 was used for 
scoring cytoplasmic and nuclear staining within tumour cores. Since TMAs were made in 
triplicate, the final histoscore for each tumour was based on the average score from all 
available core scores. I scored all tumour cores, whilst 10% of cores were double scored 
by Dr. Tove Kirkegaard. As before, agreement between the two observers was monitored, 
and results were considered discordant if the scores differed by more than 50. These 
cases were re-evaluated by both observers. Agreement was considered excellent if an 
ICCC score greater than 0.7 was obtained. Comparison of both LM and TK scores 
showed that agreement between obsei'vers was excellent with ICCC scores between 0.75- 
0.97. Table 2.6 lists the inter-class correlation coefficients for all antibodies for the STB 
and the NEAT study.
Protein Cytoplasmic
ICCC
Nuclear
ICCC
H-Ras 0.91 0.91
N-Ras 0.87 0.75
K-Ras 0.83 0.89
Raf-1 0.89 0.78
pRaf(ser259) 0.92 0.84
PRaf(ser338) 0.86 0.83
MAPK 0.96 0,88
pMAPK 0.88 0.87
Table 2.6: Inter-class correlation coefficients for STB & NEAT studies
Two observers, LM & TK, independently scored breast tumour cores fo r  cytoplasmic and 
nuclear staining, fo r H-Ras, N-Ras, K-Ras, Raf-1, pRaf(ser259), pRaf(ser338), MAPK & 
pMAPK using a semi-quantitative weighted histoscore method. Agi'eement between 
scores was measured using inter-class correlation coefficients. The ICCC scores for all 
antibodies are listed in the table. Agreement was considered excellent i f  an ICCC score 
was above 0.7.
2.3 Statistical Analysis for Immunohistocheinistry Studies
Statistical analysis was performed using the SPSS statistical package (version 9.0 for
Windows). Basic descriptive statistics were performed to calculate the frequencies, mean,
95
median and inter-quartile ranges for the histoscores for each antibody. These values were 
then used to establish appropriate cut-off points to define tumours as either low or high 
expressers of the desired protein.
Correlations between a protein’s expression level in the various subcellular 
compartments and associations between the expression of different proteins were 
calculated using the Spearman Rank Correlation Test. Pearsons chi-square test was used 
to correlate protein expression with known prognostic factors, namely tumour size, grade, 
ER and nodal status.
Kaplan-Meier life-table analysis and Cox’s multiple regression (multivariate 
analysis) were performed to estimate differences in breast cancer related suiwival, in 
terms of disease-free survival (DFS), overall survival (OS) and recurrence whilst on 
tamoxifen (ROT -  possible for the STB study only), due to the decreased or increased 
presence of the protein of interest in patients tumours. Multivariate analysis combined the 
biological marker of interest with tumour size, grade, ER and nodal status to establish if it 
was independent of these known predictive markers in influencing patient outcome.
For survival analysis and chi-square tests, patients were split into two groups, those 
whose tumours expressed high levels of protein and those whose expressed low levels. 
To establish the relative risk of a patient relapsing or dying as a result o f either high or 
low levels of a particular protein in their breast tumour, hazard ratio analysis was 
performed.
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2.4 Fluorescence Iii-Situ Hybridisation (FISH)
Fluorescence In Situ Hybridization (FISH) is a technique that uses fluorescent!y labelled 
DNA probes to visualise gene or chromosome abnormalities. FISH probes are single 
stranded DNA that can bind to the complimentary DNA strand on the gene/chromosome 
of interest and subsequently allow the fluorescence detection of the gene/chromosome.
FISH was performed on selected STB TMAs, using probes for H-Ras, N-Ras and 
Raf-1, produced for this project by DAKO (DAKO, Glostrup, Denmark). Probe mixes 
consisted of Texas Red-labeled DNA cosmid clones covering the gene (H-Ras, N-Ras or 
Raf-1) and fluorescein isothiocyanate (FITC)-labeled peptide nucleic acid (PNA) probes 
for each specific chromosome (chromosomes 11, 1 and 3 respectively). The mix was 
tested for specificity on metaphase spreads of normal cells.
The FISH experiments were performed using buffers from DAKO’s Histology 
FISH Accessory kit. Initially, the tissue was incubated for one hour at 56°C before being 
dewaxed and rehydrated through a series of xylene ( 2 x 5  minutes) and alcohol washes 
((100% (2x2minutes), 90% (lx2minutes), 70% (lx2minutes)).
Following this slides were rinsed twice in wash-buffer (diluted 1:20) (DAKO) for 
three minutes. Tissue sections were then incubated for 10 minutes at 96°C in pre­
treatment buffer (diluted 1:20) (DAKO), followed by a 15 minute cool down period. Next 
the tissue was rinsed twice in wash-buffer (diluted 1:20) for three minutes before 
treatment with cold ready-to-use Pepsin reagent (DAKO) for 19 minutes at 25°C. The 
pepsin was removed and the slides rinsed twice in wash buffer. Slides were again rinsed 
twice in wash buffer for three minutes, dehydrated through a graded series of ethanol 
washes (70% lx2minutes, 85% lx2minutes and 99% lx2minutes) and subsequently air
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dried. The tissue digestion was checked under the microscope. If the digestion was 
sufficient lOpl of probe was added, and the tissue sections concealed with a coverslip and 
sealing agent. The probe and tissue was denatured at 82°C for 22 minutes and then the 
probe allowed to bind to its complementary sequence, by placing slides in a preheated 
humidified chamber for 14-20 hours at 45°C.
The following morning tissue was rinsed in cold stringent wash buffer (diluted 
1:20) and subsequently washed in stringent wash buffer (DAKO) for 10 minutes at 65°C. 
Slides were rinsed twice in wash buffer for three minutes before being dehydrated 
through a series of alcohol washes (70% lx2minutes, 85% lx2minutes and 99% 
lx2minutes). Finally slides were allowed to air dry before being mounted onto coverslips 
using Vectashield mounting media with 4-6-Diamidino-2-phenylindole (DAPI) (I35pl 
Vectashieid with DAPI: 565pl Vectashield) (Vector Laboratories). DAPI is known to 
form fluorescent complexes with natural double-stranded DNA, making it a nuclear 
counterstain in fluorescent techniques. Signals corresponding to both gene and 
chromosome were visualised using a fluorescent microscope.
1 am indebted to Miss Fiona Campbell and Miss Suba M for performing the 
described FISH experiments.
2,4.1 FISH Scoring
Twenty nuclei from each TMA core were scored, with the number of visible red (H-Ras, 
N-Ras or Raf-1 gene) and green signals (chromosome) counted. As with the histoscore 
method one individual scored twenty nuclei in all TMA cores, and a second scorer 
independently assessed 10% of all cores, in addition to scoring all difficult and borderline 
cases. Since the TMAs were produced in triplicate, the final FISH score for tumours was
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the average of available scores. Gene amplification status was determined as the ratio of 
red signals to green signals. Genes were considered amplified if the ratio was above 2.0 
and deleted if the ratio was below 0.8, according to manufacturers guidelines.
I am grateful to both Miss Suba M and Miss Fiona Campbell for scoring the TMAs.
2.5 In- vitro studies
2.5.1 Culturing of breast cancer cell lines
Cell lines used included MCF-7, MDA-MB-231 and MDA-MB-453 (American Tissue 
Culture Collection ATCC / European Collection of Cell Cultures ECACC). These cell 
lines represented both ER positive and negative breast cancers, and expressed varying 
degrees of the tyrosine kinase receptors; EGFR(HERl) and HER2-4. Table 2.7 exhibits 
the ER and RTK status, growth properties and morphology of the cell lines used.
All the cell lines were grown in Dulbecco's Modified Eagle Media (DMEM) 
(In vitro gen), supplemented with heat-inactivated foetal calf serum (10%) (Invitrogen), 
2mM L-glutamine (Invitrogen) and penicillin/streptomycin (50 units/ml, 50pg/ml) 
(Invitrogen). Cells were maintained in 5% C02 at 37°C, with their medium changed 
regularly; they were grown in T-75 flasks (Gibco).
Before any treatments were performed on cells, they were washed twice in 
warmed Phospho-Buffered Saline (PBS) (Invitrogen) and then incubated in serum- and 
phenol red free DMEM (Invitrogen), supplemented with 2mM L-glutamine, 
penici 11 in/ streptomycin (50 units/ml, 50pg/ml) and ImM Sodium Pyruvate (Invitrogen) 
overnight (between 18-20 hours).
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Cell Line GrowthProperties
Morphology ER
Status
EGFR
Status
HER2
Status
HER3
Status
HER4
Status
MCF-7 Adherent Epithelial + + +
MDA-
MB-231 Adherent Epithelial - +
MDA-
MB-453 Adherent Epithelial - + +
Table 2.7: ER & RTK status of breast cancer cell lines
Three breast cancer lines were used in the course o f  this research: - MCF-7, MDA-MB- 
231 and MDA-MB-453. The oestrogen receptor (ER) and tyrosine kinase receptor status 
(EGFR, HER2-4) fo r  each cell line is listed.
2.5.2 Trypsinisatioii of Cells
Cells were routinely passaged to prevent cells becoming too dense and forming clumps. 
Old medium was removed from the flasks and the cells washed with warmed PBS before 
Trypsin (Invitrogen) was added to the flask (3mls Trypsin per T-75 flask). Washing the 
cells with PBS removed serum, which contains trypsin inhibitors, and lowered the 
concentration of both calcium and magnesium, both of which inhibit trypsinisatioii. Cells 
were incubated with trypsin for 3-5 minutes in 5% CO2 , 37°C, in order to detach the cells 
from the flask. Once cells were no longer adherent, trypsin was inactivated by adding an 
equal volume of DMEM. Cells were gently pipetted up and down to dislodge any cell 
clumps that may have formed to produce a single cell suspension to allow for an accurate 
cell count using a haemocytometer. Having counted the number of cells present within 
the suspension cells were seeded into new flasks containing I Omis of new DMEM at the 
required density, this depended on the cell line and experiment being used.
2.5.3 Freezing Cells
Having trypsinised the cells, aliquots of the cells could be stored for future use. The cell 
suspension was transferred from the flask to a 50ml centrifuge tube and centrifuged at 
1200rpm for ten minutes to form a cell pellet. The medium was removed and the pellet
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resuspended in 1ml of Freeze Medium (Invitrogen). Since the Freeze Medium contained 
DMSO, the cells were immediately transferred to -80°C for several hours before being 
transferred to liquid nitrogen (-180°C) for long-term storage.
If these cell aliquots were required at a later date, they were removed from liquid 
nitrogen and warmed in a 37°C water bath before being quickly transfened to a flask 
containing lOmls of pre-warmed DMEM. It was essential not to leave the cells defrosting 
too long in the freeze medium, as the DMSO would be toxic to them.
2.5.4 Drug Treatments
• Oestrogen (17-p oestradiol) (Sigma)
Oestrogen is the ligand for the oestrogen receptor; binding of oestrogen results in 
receptor phosphorylation and activation. ER positive cells (MCF-7) were treated with 
InM and lOnM oestrogen (E2). These two concentrations were decided upon following 
an experiment investigating the effects of various concentrations (0.0InM, O.lnM, InM 
and lOnM) of oestrogen on the nuclear localisation of its receptor. InM and lOnM E2 
Vvere shown to be the optimal concentrations for the purpose of our studies. A stock 
solution of lOmM E2 was prepared in Ethanol and stored at 2-8°C, from which InM and 
lOnM solutions were made. Treatment time with E2 ranged from five minutes to three 
hours.
• Heregulin a  (Sigma)
Heregulin a  (HRG), is the ligand for FIER3/4, binding to HER3 results in 
phosphorylation and dimérisation with HER2 and activation of the growth factor receptor 
pathways. HER3 positive cell lines (MCF-7, MDA-MB-453) were treated with InM and
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lOnM HRG. Previous studies undertaken in our group had shown InM and lOnM HRG 
to be the most effective concentrations. A stock solution of 1.42pM was made and stored 
at -20°C. Treatment time with HRG ranged from five minutes to three hours.
• Epidermal Growth Factor (Sigma)
Binding of Epidermal Growth Factor (EGF) to its receptor (EGFR) results in 
phosphorylation and either homo- or hetero-dimerisation, which activates growth factor 
receptor signalling pathways. The EGFR positive cell line, MDA-MB-231 was treated 
with InM and lOnM EGF. As with HRG, these concentrations were determined in 
previous studies performed within our group. A stock solution of lOpg/ml was prepared 
in PBS. Treatment time with EGF ranged from five minutes to thirty minutes.
• Felodipine (4-(2,3-Dichiorophenyl)-l,4-dihydro-2,6“dimethyl“3,5“ 
pyridinecarboxylic acid ethyl methyl ester) (Sigma)
Felodipine is a L-type calcium channel blocker. It is a calcium antagonist that has, as one 
of its properties, the ability to prevent activated MAPK from translocating from the 
cytoplasm to the nucleus without inhibiting MAPK activation. A 2.6mM stock solution of 
Felodipine (FEE) was prepared in DMSO and stored at room temperature. Titration 
experiments using lOpM, 30pM and lOOpM FEE, revealed that this drug was most 
effective in preventing pMAPK nuclear translocation when cells were pre-treated with 
30pM FEE for two hours before exposure to growth factors or oestrogen. Treatment time 
with Felodipine ranged from five minutes to three hours.
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• U0I26 ( l,4-Diamino-253-dicyano-l,4 -bis(o-amiiiophenylmercapto)butadiene)
(Sigma)
A specific inhibitor of MEKl and MEK2, which prevents phosphorylation and activation 
of MAPK. A lOmM stock solution of U0126 was prepared by dissolving 5mg in 1.31ml 
of DMSO. Titration experiments investigating lOpM, 30pM and lOOpM U0126, revealed 
that the optimal inhibition of pMAPK was obtained by using U0126 at a concentration of 
lOpM. Cells were incubated with this inhibitor for two hours prior to receiving the 
required treatment for the desired time. Treatment time with U0126 ranged from 5 
minutes to thirty minutes.
Details of all the drugs used are listed in Table 2.9
Drug
Molecular
Weight
(Daltons)
Drng
prepared
in
Stock
Concentration
Final
Concentration
Pre­
treatment
Oestrogen
(E2) 272.38 Ethanol lOmM InM & lOnM NO
Heregulin
(HRG) 7000 PBS l,42pM InM & lOnM NO
Epidermal 
Growth 
Factor (EGF)
6200 PBS 1.61mM l nM& lOnM NO
Felodipine
(FED 384.25 DMSO 2.6mM 30pM
YES
U0126 380.49 DMSO lOmM lOpM YES
Table 2.8: Drug Information
Details o f  all the drugs used throughout the course o f this study; pre-treatment involved 
exposure to drugs fo r  2 hours prior to other treatments.
2,6 Immunofluorescence (IF) Studies
Immunofluorescence (IF) is a technique that permits the detection of a specific protein or 
antigen in cells or tissue sections by fluorescent visualisation. As with IHC there are two 
types of immunofluorescence staining methods, direct and indirect immunofluorescence.
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The first requires using a primary antibody labelled with fluorescent dye, whereas the 
indirect approach involves the use of a secondary antibody labelled with a fluorescent 
marker capable of binding to the primary antibody that is bound to the antigen. The 
protein of interest is then visualised using a fluorescent microscope. This indirect method 
was used to investigate the expression and localisation of proteins in breast cancer cells 
following different treatments. In addition to detecting only one protein in treated cells, it 
was also possible to perform double IF experiments to enable the visualisation of two 
different proteins within the one cell.
2.6.1 IF of untreated and Heregulin/Epidermal Growth Factor-
stimulated MCF-7 & MDA-M B-231 cells with H-Ras, N-Ras, K- 
Ras
Approximately 1000 MCF-7 or MDA-MB-231 cells were seeded onto 8-well culture 
slides (VWR) and grown for three days in DMEM. On day 3, DMEM was removed and 
cells washed twice with warmed PBS before treatment with serum and phenol-red free 
DMEM, supplemented overnight with 2mM L-glutamine and penicillin/streptomycin (50 
units/ml / 50pg/ml) and ImM sodium pyruvate. On day 4, serum and phenol-red free 
medium was removed and cells washed with warmed PBS before treatment with either 
InM/lOnM HRG or EGF (lOOpl of drug was added per well) for 0,5, 15 or 30 minutes.
At each time point there was an untreated control. Cells were treated with serum- 
and phenol red-free medium only. They were incubated at 37°C, in 5% CO2, Following 
drug treatment cells were washed twice with ice-cold PBS, before being fixed to the 
culture slides by incubation in ice-cold methanol (500pl of methanol per well) for three 
minutes. Excess methanol was removed by washing the cells three times in dH20 for five 
minutes. To reduce non-specific binding of the antibody, cells were incubated in 500pl of
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1,5% normal horse serum (Vector) in antibody diluent (DAKO) for twenty minutes. As 
of this point all steps were performed on an orbital shaker and at room temperature.
Cells were incubated with the appropriate primary antibody for 1 hour (lOOpl of 
antibody per well) before being washed three times with TBS for ten minutes. Following 
this, cells were incubated with either lOOpl biotinylated mouse or rabbit secondary 
antibody (3pg/ml in antibody diluent) (Vector Laboratories) for thirty minutes. Cells 
were again washed three times with TBS for ten minutes, before being treated with lOOpl 
of Fluorescein Avidin D (diluted 1:100 in TBS) (Vector Laboratories) for thirty minutes. 
Fluorescein Avidin D has an excitation at 495 nm and an emission at about 515 nm; 
therefore treated cells fluoresced green. Once the cells were treated with the fluorescent 
protein, slides were covered in foil and all future steps performed in semi-darkness, to 
prevent the fluorescence from fading. Finally cells were washed with TBS three times for 
ten minutes. At this stage culture slides were either mounted onto coverslips, or the 
procedure continued to enable detection of a second protein.
For double immunofluorescence, following incubation with the first 
fiuorochrome, the cells were incubated in 1.5% horse serum, again for thirty minutes, 
then with the second primary antibody for one hour, and then with the appropriate 
secondary for thirty minutes, using the same protocol described above. Since the first 
protein was detected using Fluorescein Avidin D and would fluoresce green, an 
alternative fiuorochrome was required for the second protein to be visualised. Therefore, 
Texas Red Avidin D was used. Cells were incubated with lOOpl of Texas Red Avidin D 
for thirty minutes before undergoing three ten minute washes with TBS. Texas Red 
Avidin D is deep red in colour; it excites at 595 nm and emits at 615 nm. Therefore for
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double IF the first protein of interest fluoresces green, whereas the second fluoresces red. 
Having completed the procedure, culture slides were mounted on to coverslips using 
Vectashield mounting media with 4'-6-Diamidino-2-phenylindole (DAPI) (635pi 
mountant media : 65pl mountant media with DAPI )(Vector Laboratories). When bound 
to double-stranded DNA, DAPI has an absorption maximum at 358 nm and an emission 
maximum at 461 nm, producing a blue fluorescence, in contrast to the green or red 
fluorescence of the proteins of interest. There is very little fluorescence overlap between 
DAPI and green-fluorescent molecules, like fluorescein, or red-fluorescent stains, like 
Texas Red. DAPI stains nuclei specifically, with little or no cytoplasmic labeling. The 
protein of interest was then visualised using a fluorescent microscope with either a DAPI 
(detects both the fluoroscien avidin D or Texas Red signal) or green or red filter. Table 
2.9 lists the antibodies used in the IF studies, the concentration used, the secondary 
antibody used and the double IF experiments that were performed.
Originally it was planned to perform IF experiments on MCF-7 and MDA-MB- 
453 cell lines. However, the MDA-MB-453 cells proved unsuitable for the IF studies, the 
cells tended to clump together when grown in the culture slide wells, which prevented 
visualisation of proteins within single cells. Therefore, an alternative ER negative cell 
line was used, MDA-MB-231 cells.
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Antibody Concentration Secondary Antibody Used Single IF
Double IF 
with
H-Ras 7pg/pl Mouse YES ( FaD) N-Ras (TR) K-Ras (TR)
K-Ras 1 pg/ml Mouse YES (FaD) H-Ras (FaD) N-Ras (FaD)
N-Ras 7pg/pl Mouse YES (FaD) H-Ras (FaD) K-Ras (TR)
Table 2.9: Ras antibodies used in single and double immunofluorescent studies
This table includes details o f  the Ras antibodies used in single and double 
immunofluorescent studies. It highlights the concentration o f antibody and the species o f  
the secondary antibody required. The final column reveals what antibodies were used 
together fo r  double IF experiments. The first protein o f interest was visualised with 
Fluorescein avidin D (FaD), whilst the second was targeted with Texas Red (TR). For 
example, H-Ras and N-Ras were both visualised together in the same cells — H-Ras was 
labelled green with FaD and N-Ras was labelled red with TR.
2.6.2 IF of untreated and Heregulin/Estrogen/Felodipine stimulated 
MCF-7 cells with MAPK, pMAPK, ER, pER(118) & pER(167)
As described in section 2.6.1, MCF-7 cells were grown on culture slides for three days 
before being treated with serum- and phenol-red free DMEM for approximately 18 hours. 
MCF-7 cells were then washed twice with warmed PBS before being treated with the 
required drug. For this experiment the cells were exposed to multiple drug treatments. In 
total there were 16 treatments over six time points. Cells were incubated with InM and 
lOnM HRG and E2, both individually and in combination, and in the presence and 
absence of FEE for 5, 15, 30 minutes and 1, 2 and 3 hours. Table 2.10 lists all the drug 
treatments given to the breast cells.
A problem to be addressed in this study was that three drugs were used, prepared 
in three different solvents: HRG in PBS, E2 in ethanol, and FEE in DMSO. To ensure 
experimental uniformity, each of the drug cocktails given to the cells had to have the 
same concentration of ethanol (0.02M) and DMSO (0.023M) present.
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As in the previous study, untreated controls were required for all the time points. 
However, this time several controls were necessary. First, cells were treated with only 
serum- and phenol red-free medium, whereas the second required the cells be incubated 
with serum- and phenol red-free DMEM that contained 0.02M ethanol and 0.023M 
DMSO. The purpose of this second control was to determine the effects, if any, of 
ethanol and DMSO on the breast cells, independently of the various drugs. The last 
control required treating cells with FEE alone, to investigate the effects of this drug on 
the localisation of MAPK or ER, irrespective of treatment with HRG or E2. Figure 2.3 
shows the layout of the culture slides and the drug treatment assigned to each well. All 
drug combinations were prepared in Eppendorff tubes directly before treatment, to ensure 
that drugs were thoroughly mixed and that experimental consistency was maintained 
throughout all the time points. To each well, lOOpl of drug or control was added for the 
required time. Those cells receiving FEE required a two hour pre-treatment with the drug 
before incubation with HRG, E2, or both plus FEE for the desired time.
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5,15,30 minutes & 1 ,2 ,3  hours treatments
lOnM E2 lOnM E2 
lOnM HRG
lnM E 2 lnM E 2  
lOnM HRG
lOnMHRG lOnM E2 
InM HRG
InM HRG lnM E 2  
InM HRG
30nM FEE 
10nME2
30fj,M FEE 
lOnM FIRG 
lOnM E2
30itM PEL 
lnM E 2
30hM FEE 
lnM E 2  
lOnM HRG
30|iM FEE 
lOnMHRG
30|iM FEE 
lOnM E2 
InM FÎRG
30pM FEE 
InM HRG
30iiM FEE 
InM E2 
InM HRG
Control Slides
3 his UT  (with 
DMSO/EtOH)
2hr UT (with 
DMSO/EtOH)
Ihr EFT (with 
DMSO/EtOH)
30 mins UT 
(with
DMSO/EtOH)
15mins EFT 
(with
DMSO/EtOH)
5mins UT (with 
DMSO/EtOFI)
UT w/out 
DMSO/EtOH
UT w/out 
DMSO/EtOH
2hrs FEE & 
3 hi s FEE 
only
2hrs FEE & 
2hrs FEE 
only
2hrs FEE & 
Ihr FEE only
2hrs FEE & 
30mins FEE 
only
2hrs FEE & 
15mins FEE 
only
2hrs FEE & 
5 mins FEE 
only
2hrs FEE 
only
2hrs FEE 
only
Figure 2.3; Slide layout for Immunofluorescent Study
Slide layout o f drug treatments and controls fo r immunofluorescence studies with 
pMAPK, ER, pER(serll8) andpER(serl67).
Following drug treatment the same protocol as described in section 2.5.1 was 
employed. Consequently, cells were fixed, incubated in 1.5% horse serum, primary 
antibody, secondary antibody and lastly Fluorescein Avidin D. As this study was 
designed to investigate the localisation of MAPK and the ER, the following antibodies 
were used: pMAPK(thr202/tyr204), ER, pER(serl67) and pER(serll8). Table 2.11 lists 
the concentration of antibody used and the required secondary antibody.
In addition to investigating the localisation of MAPK and ER proteins in MCF-7 
cells it had been hoped to perform similar experiments in a second ER positive cell line,
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BT-474 or MDA-MB-361. However, both of these cell lines failed to grow adequately on 
culture slides.
Drug Treatment Additional Ethanol or DMSO 
required
InM HRG 0.02M EtOH & 0.023 DMSO
lOnM HRG 0.02M EtOH & 0.023 DMSO
InM E2 0.023M DMSO
lOnM E2 0.023M DMSO
InM HRG & InM E2 0.023M DMSO
InM HRG & lOnM E2 0.023M DMSO
lOnM HRG& InM E2 0.023M DMSO
lOnM HRG& lOnM E2 0.023M DMSO
InM HRG & 30pM Felodipine 0.02M EtOH
lOnM HRG & 30pM Felodipine 0.02M EtOH
InM E2 & 30pM Felodipine -
lOnM E2 & 30pM Felodipine -
InM HRG & InM E2 & 30pM Felodipine -
InM HRG & lOnM E2 & 30pM Felodipine -
lOnM FIRG & InM E2 & 30pM Felodipine -
lOnM HRG & lOnM E2 & 30pM Felodipine -
Untreated Control #1 
Serum- & phenol-red free DMEM
-
Untreated Control #2 
Serum- & phenol-red free DMEM
0.02M EtOH & 0.023M DMSO
Felodipine Control: 30pM Felodipine 0.02M EtOH
Table 2.10: Drug treatments for Immunofluorescent Studies
MCF-7 breast cancer cells were treated with Heregulin (HRG), Oestrogen (E2) and 
Felodipine for 5, 15 and 30 minutes and 1, 2 and 3 hours. Listed are the nineteen 
different combinations o f  treatments. Each drug was dissolved in a different solvent, 
Heregulin in PBS, Oestrogen in ethanol and Felodipine in DMSO, however all drug 
treatments had the same final concentration o f  ethanol (0.02M) and DMSO (0.023M). 
Therefore this table highlights i f  treatments required additional ethanol (EtOH) or 
DMSO.
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Antibody Concentration Secondary Antibody Used
pMAPK(thr202/tyr204) 0.5pg/ml Rabbit
ER 0.2mg/ml Mouse
pER(serll8) 0.3pg/ml Mouse
pER(serl67) 0.4pg/ml Rabbit
Table 2.11: MAPK and ER antibodies used in immunofluorescent studies
This table includes details o f the MAPK and ER antibodies used in single 
immunofluorescent studies. It highlights the concentration o f antibody and the species o f  
the secondary antibody required.
2.6.3 IF of Heregulin, Oestrogen, Felodipine stimulated MCF-7 cells with 
pMAPK, and pE R (serll8) for 5 ,15  and 30 minutes.
This study used the same methods described in sections 2.6.1 and 2.6.2. However, unlike
the experiments described in section 2.6.2, the number of time points and drug treatments 
were reduced. It was established from the first set of experiments in section 2.6.2 that the 
time points of greatest interest, in terms of changes to protein localisation, were 5, 15 and 
30 minutes. Likewise it was deemed more appropriate to investigate only InM HRG/InM 
E2 and lOnM HRG/lOnM E2 drug combinations, as opposed to InM/lOnM mixtures. 
Therefore, for this particular study, there were 12 different drug treatments over three 
time points (5, 15 and 30 minutes), all of which are listed in Table 2.12.
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Drug Treatment Additional Ethanol or DMSO 
required
InM HRG 0.02M EtOH & 0.023 DMSO
lOnM HRG 0.02M EtOH & 0.023 DMSO
InM E2 0.023M DMSO
lOnM E2 0.023M DMSO
InM HRG & InM E2 0.023M DMSO
lOnM HRG & lOnM E2 0.023M DMSO
InM HRG & 30pM Felodipine 0.02M EtOH
lOnM HRG & 30pM Felodipine 0.02M EtOH
InM E2 & 30pM Felodipine -
lOnM E2 & 30pM Felodipine -
InM HRG & InM E2 & 30pM Felodipine -
lOnM HRG & lOnM E2 & 30pM Felodipine -
Table 2.12: Drug treatments for pMAPK and pER(serll8) Immunofluorescent 
Studies
MCF-7 breast cancer cells were treated with Heregulin (HRG), Oestrogen (E2), and 
Felodipine for 5, 15 and 30 minutes. Listed are the twelve different combinations o f  
treatments. Each drug was dissolved in a different solvent, Heregulin in PBS, Oestrogen 
in ethanol, and Felodipine in DMSO; however all drug treatments had the same final 
concentration o f ethanol (0.02M) and DMSO (0.023M). Therefore, this table highlights i f  
treatments required additional ethanol (EtOH) or DMSO.
The controls used remained unchanged, but each treatment was performed in 
quadruplicate. In addition to this the experiments were performed in triplicate. Therefore, 
in total there were twelve sets of cells for each treatment condition available for analysis. 
Figure 2.4 shows the layout of the culture slides and the drug treatment assigned to each 
well. Following drug treatment the protocol remained unaltered from the one previously 
described. The final difference between this study and the previous one was that only 
pMAPK and pER(serl 18) protein localisation was monitored. These were both visualised 
using a fluorescent microscope.
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30 MINS (x4 each slide)
lOnM E2
lOnMHRG
10nME2
InM E2
InM HRG 
InM E2
lOnMHRG 30mins UT 
(with
DMSO/EtOH)
InM HRG UT w/out 
DMSO/EtOH
30pM Pel 
lOnM E2
30nM Eel 
1 OnM HRG 
lOnM E2
30|iM Pel 
InM E2
30|iM  Pel 
InM HRG 
lnM E 2
30|aM Pel 
lOnM HRG
2hrs PEL & 
30mins PEL 
only
30|iM Pel 
InM HRG
15 MINS(x4 each slide)
lOnM E2
I OnM HRG 
lOnM E2
InM E2
InM HRG 
InM E2
1 OnM HRG ISmins UT 
(with
DMSO/EtOH)
InM HRG UT w/out 
DMSO/EtOH
30(iM Pel 
lOiiM E2
30)iM Pel 
lOnM HRG 
lOnM E2
30|iM Pel 
InM E2
30^M Pel 
InM HRG 
InM E2
30nM Pel 
lOnM HRG
2hrs PEL & 
ISmins PEL 
only
30|iM Pel 
InM HRG
5 MINS (x4 each slide)
I OnM E2
I OnM HRG 
lOnM E2
InM E2
InM HRG 
lnM E 2
1 OnM HRG 5mins UT (with 
DMSO/EtOH)
InM HRG UT w/out 
DMSO/EtOH
30tiM Pel 
lOnM E2
30jaM Pel 
1 OnM HRG 
lOnM E2
30|.iM Pel 
lnM E 2
30nM Pel 
InM HRG 
InM E2
30iiM Pel 
I OnM HRG
2hrs PEL & 
5mins PEL 
only
30nM Pel 
InM HRG
2hrs PEL only
Figure 2.4: Slide Layout for Triplicate Immunofluorescent Studies
Slide layout o f drug treatments for immunofluorescence studies with pMAPK and 
pER(serl 18).
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2.6.4 Immunofluorescent Scoring
In order to semi-quantify the levels of fluorescent protein detected, a scoring method 
similar to that of the histoscore was devised. Only protein expressed within the nuclei 
was scored using this method. As with the histoscores, the intensity of nuclear staining 
was categorised as negative (0), weak/speckled (1), moderate (2) and strong (3) 
(Appendix 3). Approximately 200 cells, from four random areas (-50 cells per area), 
were counted in each well as being 0, 1,2, or 3 positive. From this the percentage of 
tumour cells within each category was calculated. The IF score was generated using the 
following formula:
0 X % negative tumour cells + 1 x % weakly stained tumour cells + 2 x % 
moderately stained tumour cells + 3 x % tumour cells stained strongly
The IF score ranged from a minimum of zero to a maximum of 300.
2.7 Time Course Treatments of MCF-7 breast cancer cell lines
To establish the effects of ligand-dependent and ligand-independent activation of the ER,
the ER positive cell line, MCF-7, was treated with E2 and HRG, singly and in 
combination.
2.7.1 Treatment of MCF-7 cells with Heregulin and Oestrogen for 5 ,15  
& 30 minutes
MCF-7 cells were grown in T-75 flasks (44 flasks were required) until just below 80% 
confluence, when the medium was removed and the cells washed twice in warmed PBS. 
Subsequently, cells were incubated in serum- and phenol red-free DMEM overnight. The 
next day, medium was removed and the cells rinsed in warmed PBS in preparation for the
114
appropriate drug treatment. For this study cells were treated with HRG and E2, both 
singly and in combination (Table 2,13).
Again, as in the IF studies, since E2 was prepared in ethanol, it was essential to 
ensure that the HRG treatments contained the same final concentration of ethanol 
(0.02M). Therefore, the InM and lOnM HRG solutions were supplemented with 0.02M 
ethanol. There were three different treatment times, 5, 15 and 30 minutes, and all 
treatments were performed in duplicate at each time point. There was also an untreated 
control (cells treated with serum- and phenol red free DMEM with 0.02M ethanol) 
included at each of these time points. Additionally, there was a completely untreated 
control, MCF-7 cells, that received nothing but serum- and phenol red-free DMEM 
(without EtOH).
Drug Treatment Additional Ethanol or DMSO required
InM HRG 0.02M EtOH
1 OnM HRG 0.02M EtOH
lnM E2 -
lOnM E2 -
InM HRG & InM E2 -
lOnM HRG & lOnM E2 -
Untreated Control # 1 
Serum- & phenol-red free DMEM
-
Untreated Control #2 
Serum- & phenol-red free DMEM
0.02M EtOH
Table 2,13: Drug Treatments for MCF-7 Time Course Experiments
MCF-7 breast cancer cells were treated with Heregulin (HRG) and Oestrogen (E2) for 5, 
15 and 30 minutes. Listed are the six different combinations o f treatments. Each drug was 
dissolved in a different solvent: Heregulin in PBS and Oestrogen in ethanol; however all 
drug treatments had the same final concentration o f ethanol (0.02M). Therefore, this 
table highlights i f  treatments required additional ethanol (EtOH).
All drugs were prepared in large enough volumes to provide enough for all time 
points to ensure experimental uniformity. Each flask was treated with 2mls of drug or 
control, ensuring that all cells were completely covered, and incubated at 37°C in 5%
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C02 for the required time. All the 30 minute treatments were performed together, 
followed by the 15 minute treatments, and then finally the 5 minute treatments.
Having been incubated for the desired time, the drug was removed from the flask 
and cells carefully rinsed twice, with ice-cold PBS. It was important to remove as much 
of the PBS, using a pipette, as possible, since it would dilute the lysis buffer. From this 
point onwards all treated flasks were kept on ice. The next step involved lysing the cells 
to enable collection of the protein. This was done using cell lysis buffer (Cell Signaling 
Technology) and a non-denaturing method. The buffer used was comprised of the 
following: 20mM Tris-HCl (pH 7.5), 150mM NaCl, ImM Na2EDTA, ImM EGTA, 1% 
Triton, 2.5mM sodium pyrophosphate, ImM beta-glycerophosphate, ImM sodium 
orthovanadate (Na3V0 4 ), and Ipg/ml leupeptin. Directly before use, this buffer was 
diluted ten times in dH2Û and ImM phenylmethlysulfonyl fluoride (PMSF), a serine 
protease inhibitor, added. This prepared buffer was stored on ice at all times. To each 
flask 500pl of buffer was added and cells incubated in the buffer on ice for five minutes. 
Following this cells were scraped from the flask into the buffer, being careful to remove 
as many of the cells as possible. The cell lysate was transferred to an appropriately 
labelled 1.5ml eppendorff tube and stored on ice, until all treatments had been performed.
All samples were centrifuged at 14,000 rpm at 4°C to separate the protein from 
cell debris. The supernatant containing the isolated protein was then carefully transferred 
to a labelled eppendorff tube and subsequently stored at -70°C.
This experiment was performed twice; therefore, in total there were four protein 
samples for each treatment condition available for analysis.
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2.8 Subcellular Fractionation
Subcellular fractionation was used to study the activation and interaction of proteins, 
such as MAPK and ER, within the cytoplasm, nuclei and plasma membrane of MCF-7 
breast cancer cells.
2.8.1 Fractionation of MCF-7 cells treated with Heregulin for 5 ,15  and 
30 minutes
A preliminary fractionation experiment was performed on MCF-7 cells. Twenty flasks of 
MCF-7 cells were grown until nearly 70% confluent, when their medium was replaced 
with serum and phenol red-free medium overnight. The following morning cells were 
washed with warmed PBS, and incubated with either InM or lOnM HRG for 5, 15 or 30 
minutes (2mls per flask). Treatments were performed in duplicate and untreated controls 
were present at each time point.
After incubation, the drug was removed and cells rinsed twice with ice-cold PBS 
and trypsinised as described in section 2.5.2. Following trypsinisation, lOmls of DMEM 
was added, and the cell suspension was centrifuged at 12000 rpm for ten minutes. The 
supernatant was carefully removed from the pelleted cells, which were washed in 1 Omis 
of ice-cold PBS before being centrifuged again at 12000rpm for another ten minutes and 
the supernatant again discarded. The cell pellet was resuspended in I ml ice-cold PBS and 
transferred to an Eppendorf tube. It was stored on ice until all samples were ready to 
undergo fractionation, using the FractionPREP™ Cell Fractionation System (Biovision), 
to generate four subcellular protein fractions: - cytosol, membrane, nucleus and 
cytoskeletal. The following buffers were supplied within the kit: Cytosol Extraction 
Buffer (CEB), Membrane-Extraction Buffer-A (MEB-A), Membrane Extraction Buffer-B 
(MEB-B), and Nuclear Extraction Buffer (NEB). Prior to fractionating cells, 2pl of IM
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Dithiothreitol (DTT) and 2jiil of Protease inhibitor Cocktail (both provided in the kit) 
were added per ml of CEB, MEB-A and NEB. Buffers were stored on ice throughout the 
experiment, and all centrifugation procedures were performed at 4*^ C.
The resuspended cell pellets were centrifuged at 700g for 5 minutes and the 
supernatant discarded. Cell pellets were resuspended in 400pl of CEB-Mix (CEB + DTT 
+ protease inhibitor cocktail), by pipetting the mix up and down several times. Samples 
were incubated on ice for 30 minutes, with gentle tapping every 5 minutes, before being 
centrifuged at 700g for 10 minutes. The resultant supernatant was the Cytosolic fraction. 
This was removed and transferred to a labelled eppendorf tube, and either stored on ice 
until the end of the experiment or immediately transferred to -80°C for long term storage.
The remaining cell pellets were resuspended in 400pl of MEB-A mix, thoroughly 
mixed by pipetting and voitexing for 10-15 seconds. To this 22pl of MEB-B was added, 
samples were vortexed for a further 5 seconds and then incubated on ice for 1 minute. 
Samples were vortexed again for 5 seconds before being centrifuged at lOOOg for 5 
minutes. This supernatant contained the membrane fraction, and this was transferred to a 
pre-chilled, labelled Eppendorf tube. It was either stored on ice or transferred to a -80°C 
freezer.
The next step generated the nuclear fractions; cell pellets were resuspended in 
200pl of NEB-Mix and vortexed for 15 seconds. Samples were stored on ice for 40 
minutes, with constant vortexing for 15 seconds every 10 minutes. Finally the samples 
were centrifuged at top speed for 10 minutes. The resultant supernatant was the nuclear 
fraction, and this was transferred to a pre-chilled, labelled Eppendorf tube. The residual 
pellet was the cytoskeletal fraction, and this was very difficult to resuspend. It proved
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easiest to add lOOjxl of SDS-PAGE sample buffer to it. All protein samples were then 
stored at -80°C for future use.
The protein fractions were shown to be specific for their particular subcellular 
compartments by western blotting using subcellular markers (Appendix 4).
2.8.2 Fractionation of MCF-7 cells treated for 5 minutes with Heregulin, 
Oestrogen and Felodipine
From the IF studies (section 2.6.3), it was suggested that the most significant time points
for investigating changes in protein localisation, following treatment with either HRG or 
E2, were 5 and 15 minutes. Therefore, fractionation experiments were performed at these 
time points.
MCF-7 cells (30 T-75 flasks were required) were grown to just below 70% 
confluence, when they were washed with PBS and incubated in serum- and phenol-red 
free DMEM overnight, before undergoing various drug treatments. To ensure conformity 
with the IF study (section 2.6.3), the same drug treatments and controls were performed 
on these cells prior to subcellular fractionation commencing. The treatments and controls 
are shown in Table 2.14.
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Drug Treatment Additional Ethanol or DMSO 
required
InMHRG G.G2M EtOH & G.G23 DMSO
lOnM HRG G.G2M EtOH & G.G23 DMSO
InM E2 G.G23M DMSO
lGnME2 G.G23M DMSO
InM HRG & InM E2 G.G23M DMSO
lOnM HRG & lOnM E2 G.G23M DMSO
InM HRG & 30jLiM FEE G.G2M EtOH
lOnM HRG & 30|aM FEE 0.02M EtOH
InM E2 & 30pM FEE -
lGnME2&3GpM FEE -
InM HRG & InM E2 & 3GpM FEE -
IGnM HRG & IGnM E2 & 3G|aM FEE -
Untreated Control # 1 
Serum- & phenol-red free DMEM
-
Untreated Control #2 
Serum- & phenol-red free DMEM
G.G2M EtOH & 0.023M DMSO
FEE Control: 3GpM FEE G.02M EtOH
Table 2.14: Five Minute Drug Treatments for MCF-7 Subcellular Fractionation
MCF-7 breast cancer cells were treated with Heregulin (HRG), Oestrogen (E2), and 
Felodipine (PEL) fo r 5 minutes. Listed are the twelve different combinations o f 
treatments and the various controls. Each drug was dissolved in a different solvent, HRG 
in PBS, E2 in ethanol, and FEE in DMSO; however all drug treatments had the same 
final concentration o f ethanol (0.02Af) and DMSO (0.023M). Therefore, this table 
highlights i f  treatments required additional ethanol (EtOH) or DMSO.
Again, as described in the IF and time course treatment methods, all drugs and controls, 
with the exception of untreated control #1, had to be prepared with the same final 
concentration of DMSO (0.023M) and ethanol (0.02M). Likewise, as in the previous 
experiments, all treatments were performed in duplicate. Flasks were incubated with 
2mls of each drug or control for 5 minutes, and from this point onwards the method was 
identical to that described in section 2.8.1.
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2.8.3 Fractionation of MCF-7 cells treated for 15 minutes with 
Heregulin, Oestrogen, Felodipine and U0126
The final fractionation study was a slightly modified version of the one described in
section 2.8.2. In this particular study cells were again treated with HRG, E2 and 
Felodipine but also the MEK-1/2 inhibitor, U0126. Table 2.15 displays the various drug 
combinations and controls used throughout this experiment. Additionally the cells were 
exposed to the drugs for a longer period of time, 15 as opposed to 5 minutes. With the 
exception of these changes the protocol used for this experiment was exactly the same as 
that described in sections 2.8.1 and 2.8.2. This study was performed twice.
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Drug Treatment Additional Ethanol or DMSO 
required
InM HRG 0.02M EtOH & 0.023 DMSO
1 OnM HRG 0.02M EtOH & 0.023 DMSO
InM E2 0.023M DMSO
lOnM E2 0.023M DMSO
InM HRG & InM E2 0.023M DMSO
10nMHRG& 10nME2 0.023M DMSO
lnM HRG&30|dM FEL 0.02M EtOH
lOnM HRG & 30pM FEE 0.02M EtOH
InM E2 & 30pM FEE -
lOnM E2 & 30pM FEE -
InM HRG & InM E2 & 30pM FEE -
lOnM HRG & lOnM E2 & 30pM FEE -
lnM HRG&  lOpM U0126 0.02M EtOH
lOnM HRG & lOpM U0126 0.02M EtOH
lnM E 2&  lOpM U0126 -
10nME2& lOpM U0126 -
InM HRG & InM E2 & lOpM U0126 -
lOnM FIRG & lOnM E2 & lOpM U0126 -
Untreated Control #1 -
Serum- & phenol-red free DMEM
Untreated Control #2 0.02M EtOH & 0.023M DMSO
Serum- & phenol-red fiee DMEM
FEE Control; 30pM FEE 0.02M EtOH
U0126 Control: -  lOpM U0126 alone 0.02M EtOH
Table 2.15: Fifteen minute drug treatments for MCF-7 subcellular fractionation
MCF-7 cells were treated with different combinations o f Heregulin (HRG), Oestrogen 
(E2), Felodipine (FEE), and U0126 fo r 15 minutes before subcellular fractionation was 
performed. Three different solvents were used to prepare the drugs. HRG was dissolved 
in PBS, E2 in Ethanol (EtOH) and FEE and U0126 in DMSO. Therefore, all drug 
treatments were prepared with 0.02M EtOH and 0.023M DMSO. Also shown are the 
various controls included in the experiment.
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2.9 Western Blotting
Western blotting (immiinoblotting) is a technique that enables the detection and 
quantification of the levels of a specific protein in tissue or cell samples. The basic 
principle requires preparing protein samples from tissues or cells and then separating the 
denatured proteins by gel electrophoresis and transferring them to a PVDF membrane. 
The membrane is then probed with a primary antibody specific to the protein of interest, 
followed by a secondary antibody that recognises the antibody-antigen complex. Proteins 
are detected using a chemiluminsecent and chemifluorescent method. This method was 
used to verify the specificity of all antibodies, and also to measure the levels of proteins 
in samples from the time course treatment and subcellular fractionation studies.
2.9.1 Determination of Protein Concentration in Prepared Samples
Before performing immunoblotting, it was necessary to determine the concentration of
protein present in the samples to be tested. Knowing this enabled experimental 
consistency, as the same volume of protein was used from all the samples. The method 
used was Bio-Rad's protein assay, which was based on the Bradford dye-binding 
procedure (Bradford 1976), and involves a colorimetric assay for measuring total protein 
concentration.
Samples were prepared for a low-concentration assay in disposable cuvettes 
(Gibco). First, 200pl of Bio-Rad Protein Assay Reagent (Bio-Rad) was added to the 
cuvette, followed by 795pl of dFIiO. Subsequently 5pi of protein sample was included to 
the mix. The solution was thoroughly mixed with a pipette to ensure even distribution of 
the protein for an accurate concentration reading. In order to have something to compare 
the concentration of the samples with, protein standards were prepared using Bovine 
Serum Albumin (BSA) (Sigma). The BSA was supplied at a concentration of 2mg/ml,
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but for the purpose of this study it was diluted to 1 mg/ml with dHzO. One reference and 
seven protein standards were prepared in cuvettes as follows.
Volume of 1 mg/ml BSA required (pi) Volume of dH^O required (ul)
0 (REFERENCE) 800
1 799
5 795
10 790
15 785
20 780
25 775
50 750
To each of these was added 200pl of Bio-Rad Protein Assay Reagent. A gradual increase 
in the intensity of the blue colour was obseiwed in parallel to the increasing concentration 
of the standards. Once prepared the reference and standards were used to calibrate the 
spectrophotometer (Bio-Rad) Protein 595 assay programme. This assay is based on a 
colour change of Coomassie brilliant blue G-250 dye in response to the binding of the 
dye to basic and aromatic acid residues. Protein concentration was determined due to the 
change in the absorbance of the coomassie dye when bound to protein. When bound it 
has an absorption spectrum maximum of 595nm, whereas unbound it has an absorbance 
maximum of 470nm. Therefore, the increase of absorbance at 595nm is proportional to 
the amount of protein within the sample.
The optical density at 595nm (O.D. 595nm) was measured for the reference and 
the seven protein standards. The O.D 595 was then read for all the samples and the 
concentration of protein present generated from the standards concentration. The 
spectrophotometer calculated the amount of protein (pg/ml) present, but the theory 
behind it involves plotting a graph of absorbance at 595nm against protein concentration
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of standards. This standard curve is then used to determine the concentration of the 
protein present in the samples from its O.D. 595 value.
However, the concentration (pg/ml) was calculated from a diluted protein sample 
(1:200). From this the final concentration in mg/ml was determined as follows:
Protein reading (pg/ml) x 0.2 = Final protein concentration (mg/ml)
For western blotting either 25pg or 40pg of protein was used and the volume of sample 
required was calculated from the final concentration.
2.9.2 Western blotting of Protein Samples
• Preparation of SDS-PAGE (Sodium Dodecyl Sulphate -  PolyAcrylamide Gel 
Electrophoresis) gels
All western blots were performed using the Bio-Rad Mini-PROTEAN 3 Electrophoresis 
System. For all the proteins analysed it was deemed appropriate to use 10% resolving 
gels, and they were prepared as follows:
Reagents 10% Gel
40% Acrylamide/Bis-Acrylamide 12.49ml
(Sigma)
0.5M EDTA 330pl
2M Tris, pH 8.9 8.35ml
10% SDS 50ppl
dHzO 28.33ml
10% APS 300 pi
TEMED 3Qpl
Gels are formed from the polymerisation of the aery lam ide and N-N-methylene-bis- 
acrylamide (bis). Bis acts as the cross linking agent for the gel, and the TEMED and APS 
are the catalysts for gel polymerisation. The separation of proteins within the gel is
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governed by the size of the pores within the gel, which is determined by the amount of 
acrylamide-bis present. As the amount of acrylamide present increases, the pore size 
decreases. Generally a higher percentage of resolving gels are used for smaller proteins, 
whereas lower percentage gels are more effective for separating larger proteins.
Two gels of different thickness (0.75mm and 1.5mm) were used throughout the 
various studies; they were produced using either a 0.75mm or a 1.5mm spacer plate 
respectively. Once the gel mix was prepared with everything but the TEMED and APS 
added, the gel plates and gel casting apparatus were assembled. Having correctly 
assembled the plates, the TEMED and APS were added to the resolving gel mix, which 
was then slowly poured in between the two glass plates, using a plastic pastette, to a level 
that still allowed for the stacking gel and comb to be added. Finally a layer of isopropanol 
was applied to the top of the gel to remove any air bubbles and to flatten the top of it. The 
resolving gel was then left to polymerise for approximately one hour.
Once set, the isopropanol was removed from the top of the resolving gel and the 
4.5% stacking gel prepared as follows:
Reagents 4.5 % Gel
40% Acrylamide/Bis-Acrylamide 5.63ml
0.5M EDTA 400pl
IMTris, pH 8.9 6.25ml
10% SDS 50pjxl
dHzO 37.22ml
10% APS 3ppl
TEMED iPpl
Again, the TEMED and APS were the last two reagents to be added to the gel mix. The 
stacking gel was then poured onto the resolving gel until it reached the top of the plates;
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the gel comb (10 or 15 well comb depending on the number of samples being run) was 
then inserted and the gel allowed to polymerise for approximately 30 minutes.
At this stage the gel (wrapped in cling film) could be stored at 4°C until required.
• Protein dénaturation
To enable the primary antibody to recognise and bind to its epitope, it was necessary to
denature the proteins, i.e unfold the protein to allow the antibody access. Denaturing the
proteins also enabled them to run more efficiently through the gels.
Having previously measured the concentration of protein within each sample, the
same amount of protein (either 25pg or 40pg) was removed from each sample and
transferred to a new Eppendorf tube. This was stored on ice, and to each sample was
added 2X Laemmli's sample reducing buffer which was comprised of:
1.0ml 0.5M Tris-HCl pH 6.8 
0.8ml Glycerol
1.6ml 10% sodium dodecyl sulphate (SDS)
0.4ml 2-Mercaptoethanol
0.2ml Bromophenol Blue (0.05% w/v)
4.0ml dH20
The samples were thoroughly mixed and then boiled at 100°C for two minutes. The SDS 
within the sample buffer is a detergent, with a highly negative charge that has a 
hydrophobic tail that binds to the proteins, causing them to become negatively charged. 
Additionally, SDS disrupts the tertiary structure of the protein, resulting in their 
unfolding. The 2-Mercaptoethanol prevented the reformation of disulphide bonds and 
helped maintain the protein in its denatured state. Boiling the samples also contributed to 
the denaturing of the proteins by unfolding them completely. Boiled samples were 
immediately stored back on ice. The molecular weight marker (Biotinylated Protein
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Ladder -Cell Signaling Technology) that was used to determine the size of the detected 
protein was also boiled for two minutes.
• Gel Electrophoresis
The principle behind electrophoresis is that an electrical charge moves the proteins down 
the polyacrylamide gel. This is made possible by the SDS, which transfers a negative 
charge onto the proteins, thus allowing them to be attracted towards the positive anode. 
The pores produced by the acrylamide result in smaller protein molecules travelling 
through the gel at a faster rate than the larger molecules; therefore, they progress further 
down the gel. Thus, proteins are separated by gel electrophoresis according to their 
molecular weight.
Gels were placed into the electrode assembly in the mini buffer tank. Combs were 
removed from gels and the wells rinsed and the tank filled with IX running buffer 
(details in table 2.16). Denatured protein samples and ladder (7pl) were then carefully 
loaded into the wells using a fine tipped pipette. It was important to prevent overspill 
between the wells. Once all samples were loaded the gel was run at 40mA for 
approximately one hour.
• Protein Transfer
To enable protein detection by a primary antibody, the protein had to be transferred from 
the polyacrylamide gel to PVDF (polyvinylidene difluoride) membrane. This step proved 
to be the most problematic, and several different methods were tried, including wet 
transfer for various times and semi-dry transfer methods. Eventually, optimal transfer 
was achieved by using the Mini-Trans Blot Cell (Bio-Rad) and transferring the proteins 
onto the membrane overnight.
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Once the proteins had run sufficiently through the gel, protein transfer to the 
PVDF membrane (Biorad) could begin. For optimal transfer, PVDF membrane, cut 
slightly bigger than the size of the gel, was pre-treated in 100% methanol for one minute 
before being soaked in IX Transfer Buffer (Details of which can be found in table 2.16). 
Fiber pads and 3M Whatman paper, cut the same size as the membrane, were also soaked 
in transfer buffer. The gels were then carefully removed from the glass plates; the 
stacking gel was discarded, and the remaining resolving gel equilibrated, for 
approximately five minutes in transfer buffer. This step prevented the gel from shrinking 
during the transfer process.
Next the transfer sandwich, comprised of fiber pads, 3M Whatman paper, gel and 
PVDF membrane was assembled on the gel holder cassettes, as shown below in Figure 
2.5
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Black side o f  cassette 
(Negative)
Fiber Pad
3 sheets o f  3M Whatman Paper
Gel
PVDF Membrane
3 sheets o f  3M Whatman Paper
Fiber Pad
Clear side o f  cassette 
(Positive)
Figure 2.5: Schematic Representation of Western Blot Transfer Sandwich
Schematic representation o f the assembly o f  the transfer sandwich on the cassettes, the 
sandwich was comprised offiber pads, 3M Whatman paper, gel and PVDF membrane, 
all o f which had been equilibrated in transfer buffer.
While building the sandwich, it was important to make sure that there were no air bubbles 
present, as these would prevent efficient transfer; therefore, after each new layer was 
applied, air bubbles were removed by gently rolling a glass rod over the top surface. The 
assembled sandwich was then slotted into the electrode assembly and placed in the mini­
tank, which was filled with transfer buffer. To reduce the temperature o f  the buffer during 
the transfer process, the Bio-Ice cooling unit was used. Additionally a magnetic stirrer 
was used to maintain even buffer temperature and ion distribution. Proteins were
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transferred from the gel (negative/cathode) to the membrane (positive/anode) overnight 
(approximately 18 hours) at 10 volts.
• Blocking of Membrane 
Since the proteins transferred from the gel bind to the PVDF membrane, it was equally 
likely that the antibody used to detect the protein would also bind non-specifically to the 
membrane. Therefore, to prevent these interactions between antibody and membrane, and 
to ultimately reduce background staining, it was necessary to mask the membrane.
This was achieved by incubating the membrane in 5% Non-Fat Dry Milk 
(Maivel) blocking solution, prepared in TBS-Tween (TTBS) (Details of buffers listed in 
table 2.16) for one hour at room temperature. This step and all future steps were 
performed on an orbital shaker.
An alternative blocking solution of 5% BSA (Bovine Serum Albumin), prepared 
in TTBS was also tried, but failed to reduce background staining as efficiently as 5% 
Non-Fat Dry Milk blocking solution.
At this point it was also possible to stain the gel with Coomassie blue, to 
determine how efficient the transfer was. Coomassie blue bound to any protein that 
remained on the gel. The gel was stained for 40 minutes with Coomassie blue and then 
destained overnight (see table 2.16 for details of both Coomassie blue stain and destain). 
The following morning any protein that remained on the gel was visible as blue bands.
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Buffer Reagents
1 OX Running Buffer 200mM Tris, 2M Glycine, 1% SDS 
(For IX dilute in dHiO)
lOX Transfer Buffer 248mM Tris, 1.3M Glycine, 20% Methanol 
(For IX dilute in dHzO)
lOX TBS O.IM Tris/HCl, 1.5M NaCl, pH = 7.4 
(For IX dilute in dHzO)
0.001% TTBS lOOOul of Tween 20 per litre of IX TBS
Coomassie Blue Stain l.SlmM Coomassie blue R250, 
454ml 50% Methanol,
46 ml Glacial Acetic Acid
Destain 25ml Methanol,
37.5ml Glacial Acetic Acid, 437.5ml dH20
Table 2.16: Buffers used in western blotting
Details o f the buffers and solutions used in western blotting
•  Incubation of membrane with primary antibody
Having sufficiently blocked the membrane, the next step was incubation in primary 
antibody. All antibodies were prepared in 5% Non-Fat Dry Milk/TTBS solution, to 
further reduce non-specific binding. Membranes were incubated with primary antibody 
overnight (approximately 18 hours) at 4°C. For the size of membrane being used 1 Omis 
of antibody was adequate to cover the entire membrane. Table 2.17 lists the 
dilutions/concentrations of all the antibodies used in western blotting.
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Antibody Dilution Concentration
H-Ras 1:500 0.4pg/ml
K-Ras 1:500 0.2pg/ml
N-Ras 1:500 0.4pg/ml
Pan-Ras 1:100 2pg/ml
Ras Ab-1 1:100 lOpg/ml
Raf-1 1:500 0.4p,g/ml
pRaf(ser259) 1:500 0.2p,g/ml
pRaf(ser338) 1:250 0.4pg/ml
MAPK 1:500 0.2pg/ml
pMAPK(thr202/tyr204) 1:500 0.2pg/ml
ER 1:250 83pg/ml
pER(seiT 18) 1:250 0.4pg/ml
pERserl67) 1:250 0.4pg/ml
Actin 1:1000 0.1 pg/ml
Tubulin 1:1000 0.1|ag/ml
Table 2.17: Dilutions/Concentrations of antibodies used in western blotting
Details o f the dilutions and concentration o f  all the antibodies used fo r  western blotting. 
All antibodies were prepared in 5% Non-Fat Dry Milk/TTBS solution and incubated with 
membranes overnight at 4 TT.
• Incubation of membrane with secondary antibody
Following incubation with primary antibody, the membrane was washed in TBST three 
times for 10 minutes, to remove any excess antibody. As in IF, detection of the protein of 
interest required a secondary antibody bound to either biotin or an enzyme conjugate, 
such as horseradish peroxidase (HRP) that was species-specific to the primary antibody. 
The secondary antibodies used were HRP-linked anti-mouse IgG (Cell Signaling 
Technology) and anti-rabbit IgG (Cell Signaling Technology). The anti-mouse antibody 
was used at dilution of 1:10000, whereas the anti-rabbit was used at a dilution of 1:5000. 
In addition to requiring a secondary antibody to recognise the primary antibody bound to 
its protein, one was also needed for detection of the biotinylated ladder. For this the anti­
biotin HRP linked antibody (Cell Signaling Technology) was used at a dilution of 1:1000.
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The anti-biotin and anti-mouse/rabbit secondaries were prepared together in 1 Omis of 5% 
Non-Fat Dry Milk/TTBS solution and were incubated with the membranes for one hour 
at room temperature. Table 2.18 lists the required secondary antibody for each primary 
antibody.
Mouse Secondary H-, K-& N-Ras 
Pan Ras & Ras Ab-1 
Raf-1
ER& pER(serll8)
Actin
Rabbit Secondary pRaf(Ser259) & pRaf(Ser338) 
MAPK & pMAPK(thr202/tyr204) 
pER(167)
Tubulin
Table 2.18: Secondary Antibodies for Western Blotting
All the antibodies used for western blotting required either a mouse or a rabbit 
secondary for detection. Listed are those primary antibodies that required a mouse 
secondaiy and those that required a rabbit secondary.
• Protein visualisation
The last steps in the western blotting protocol involved detection of the protein of interest
using a chemiluminescent method. Luminescence is the emission of light due to the 
dissipation of energy from a substance in an excited state. Horse-radish peroxidase 
catalyzes oxidation of luminol, a chemiluminescent substrate, in alkaline conditions. 
Oxidation results in the luminol being in an excited state which then decays to ground 
state via a light emitting pathway. For this method ECL plus (Amersham) was used. The 
principle behind this is that horse-radish peroxidise, conjugated to the secondary 
antibody, oxidises the ECL Plus chemiluminescent substrate Lumigen PS-3 Acridan, 
which produces thousands of acridinium ester intermediates per minute. These 
intermediates then react with the peroxide to produce a sustained, high intensity
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chemiluminescence with a maximum emission at 430nm. This light is then detected on 
autoradiography film.
Following incubation with the secondary antibody, membranes were washed three 
times in TTBS for ten minutes. While the membranes were washing, the ECL plus 
reagents were warmed to room temperature. Once the reagents had warmed sufficiently, 
solution A and solution B were mixed in a ratio of 40:1 ; 3mls of solution was an adequate 
amount per membrane. When using the ECL reagents all steps were performed in semi- 
darkness. Membranes were placed protein side up on a sheet of saran wrap. The ECL 
solution was pipetted onto the membrane ensuring complete coverage. The membrane 
was incubated with the reagents for five minutes, and excess solution was then removed 
and the membrane transferred to a fresh piece of saran wrap, which it was subsequently 
enveloped in. Finally the membrane was transferred to a film cassette where it was 
exposed to autoradiography film for various times. Generally the incubation times were 
1, 15, 15 and 30 minutes. The film was then developed and both the marker and protein 
bands visualised.
• Stripping Membranes 
To prevent re-running of samples, primary antibody was removed from probed 
membranes using Restore Western Blot Stripping Buffer (Pierce). Membranes were 
incubated in 20mls of stripping buffer at 37°C for 15 minutes, before being washed in 
TTBS three times for 10 minutes. Consequently, membranes were blocked in 5% Non- 
Fat Dry Milk/TTBS and then probed with the next primary and secondary antibody as 
described above. This was performed a maximum of three times.
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3. Pilot Study: Effect of Ras and Raf-1 protein overexpression 
on breast cancer patients’ outcome
3.1 Introduction
Activation of the Ras/Raf-l/MAPK pathway is thought to play a role in the development 
and progression of breast cancer. However, data on the clinical significance of Ras and 
Raf-1 expression in breast cancer remains sparse. This pilot study aimed to investigate 
the expression of Ras and Raf-1 in breast tumours and test the hypothesis that 
overexpression of these proteins influences disease-free and overall survival in breast 
cancer. Using an immunohistochemical approach (see Chapter 2.2.1), the expression of 
pan-Ras, H-Ras, N-Ras and Raf-1 was analysed in breast tumours of patients treated at 
the Glasgow Royal Infirmary, to determine if expression was linked to reduced survival.
3.2 Expression & Localisation of Ras and Raf in Breast Tumours
Due to the limited availability of breast tumour tissue, the number of patients tested for
expression of pan Ras, Ras Ab-1, H-Ras, N-Ras and Raf-1, was 80, 147, 139, 138 and 74 
respectively. The pan-Ras and Ras isoform specific antibodies all detected Ras protein in 
the cytoplasm and nuclei of invasive tumour cells, but not in normal breast epithelial 
cells. Additionally, almost no membrane staining was detected for any of the Ras 
antibodies, hence for the rare cases (1%) that displayed membrane staining, this was not 
scored. Table 3.1 provides details of the descriptive statistics (minimum, maximum, 
mean, median, lower and upper quart!le) for the histoscores of all the antibodies used.
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3.2.1 Total Ras Expression in Breast Tumours
Two pan-Ras antibodies were used for this study: the rabbit polyclonal Pan-Ras antibody 
(Santa Cruz, F132) and the mouse monoclonal Ras Ab-1 antibody (Neomarkers). Both 
antibodies detected all three Ras isoforms. Ras Ab-1 was produced from a synthetic 
peptide, corresponding to amino acids 31 -43 (EYDPTIEDSYRKQ), from the L2 loop of 
human Ras protein. Unfortunately the epitope for the Pan-Ras antibody was not mapped.
Both Pan-Ras and Ras Ab-1 detected higher levels of nuclear, rather than 
cytoplasmic Ras (Figure 3.1a & 3.2a). Ras Ab-1 detected cytoplasmic and nuclear Ras in 
92.8% and 99.3% of tumours, while with Pan-Ras the proportions were 86.2% and 
98.7%. The frequency and intensity of staining in the cytoplasm and nuclei of tumour 
cells for both antibodies is shown in Figures 3.1b,c & 3.2b,c.
Results obtained for the expression of nuclear and cytoplasmic pan-Ras were 
strongly correlated for both antibodies, suggesting the distribution of Ras is linked in both 
compartments (Spearman Rank Test, p<0.0005, pan-Ras R^=0.686, Ras Ab-1 R^=0.628). 
To evaluate the efficiency of both antibodies in detecting Ras, correlations comparing 
results for Pan-Ras and Ras Ab-1 antibodies were also performed (Figure 3.3), 
cytoplasmic Pan-Ras expression correlated with both cytoplasmic and nuclear Ras Ab-1 
expression (R  ^ = 0.372, p=0.001 and R^=0.296, p=0.008 respectively), whereas nuclear 
Pan-Ras expression correlated only with nuclear Ras Ab-1 expression (R^= 0.248,
p—0.026).
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Figure 3.1: Pan-Ras Immunohistochemistry
(a) Breast tumour stained with Pan-Ras antibody. Ras was detected in both the cytoplasm 
and nuclei o f  tumour cells. Insert shows the negative control, (b) Scatter graph 
comparing cytoplasmic and nuclear expression o f  Ras using Pan-Ras antibody, (c) 
Histogram showing the intensity o f  Pan-Ras expression in the cytoplasm o f  tumour cells, 
(d) Histogram showing the intensity o f  Pan-Ras expression in the nuclei o f tumour cells.
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Figure 3.2: Ras Ab-1 Immunohistochemistry
(aj Breast tumour stained with Ras Ab-1 antibody. Ras was detected in both the 
cytoplasm and nuclei o f  tumour cells. Insert shown negative control, (b) Scatter graph 
comparing cytoplasmic and nuclear expression o f  Ras using Ras Ab-I antibody, (c) 
Histogram showing the intensity o f  total Ras expression in the cytoplasm o f tumour cells, 
(d) Histogram showing the intensity o f  total Ras expression in the nuclei o f  tumour cells.
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Figure 3.3: Scatter Graphs Comparing Pan-Ras and Ras Ab-1 Expression
Scatter graph comparing the expression o f  Ras using two different antibodies, Pan-Ras 
and Ras Ab-1. (a) Scatter graph comparing cytoplasmic Ras expression, (b) Scatter 
graph comparing nuclear Ras expression.
3.2.2 Specificity of Antibodies
The low correlation coefficients between the expression levels o f  Ras detected with Pan- 
Ras and Ras Ab-1 led me to test the specificity o f  all antibodies used. The specificity o f  
all the antibodies was confirmed by western blotting (Figure 3.4). Western blotting with 
Pan Ras and Ras Ab-1 suggested that these antibodies were not, in fact, specific for the 
Ras antigen. Therefore, they were not included in future studies. However, H-Ras, N-Ras 
and Raf-1 all appeared to be specific for their antigen.
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Figure 3.4: Specificity of Antibodies
Western blotting was performed to test the specificity o f  all the antibodies used. 
Untreated and InM Heregulin (HRG) stimulated MCF-7 and MDA-MB-453 (453) cells 
were used as controls. The two pan-Ras antibodies (a,b) appeared to be unspecific fo r the 
Ras antigen (21kDa). The H-Ras (c) and N-Ras (d) antibodies appeared to be specific fo r  
the Ras antigen (21kDa). The Raf-1 antibody (e) seemed to detect only the R a f I antigen 
(74kDa).
3.2.3 H-Ras Expression in Breast Tumours
H-Ras expression was observed in both the cytoplasm and the nuclei o f  tumour cells in 
96.4% and 93.4% o f  tumours, respectively (Fig 3.5). Generally the cytoplasm o f  tumour 
cells exhibited higher expression levels o f  H-Ras than the nuclei. There was a positive 
correlation between cytoplasmic and nuclear H-Ras expression: patients whose tumours
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strongly expressed cytoplasmic H-Ras tended to express higher levels o f nuclear H-Ras
(R^ = 0.360, p<0.0005). 
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Figure 3.5: H-Ras Immunohistochemistry
(a) Breast tumour stained with H-Ras antibody. H-Ras was detected in both the 
cytoplasm and nuclei o f tumour cells. Insert shows negative control, (b) Scatter graph 
comparing cytoplasmic and nuclear expression o f H-Ras. (c) Histogram showing the 
intensity o f  H-Ras expression in the cytoplasm o f tumour cells, (d) Histogram showing 
the intensity o f H-Ras expression in the nuclei o f tumour cells.
3.2.4 N-Ras Expression in Breast Tumours
N-Ras was detected in the cytoplasm and nuclei o f  tumour cells in 97.8% and 94.9% o f  
patients respectively (Figure 3.6). Tumours showed elevated levels o f  cytoplasmic N-Ras 
expression in comparison to nuclear levels. There was, however, a positive correlation
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between the expression o f  N-Ras in the two subcellular compartments (R^= 0.452, 
p<0.0005).
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Figure 3.6: N-Ras Immunohistochemistry
(a-c) Breast tumour stained with N-Ras antibody. N-Ras was detected in both the 
cytoplasm and nuclei o f  tumour cells, (a) Negative control, (b) Example o f  tumour with 
low N-Ras expression (IHC score < UQ), (c) Example o f  tumour with high N-Ras 
expression (IHC score > UQ). (d) Scatter graph comparing cytoplasmic and nuclear 
expression o f N-Ras. (e) Histogram showing the intensity o f N-Ras expression in the 
cytoplasm o f tumour cells, (f) Histogram showing the intensity o f  N-Ras expression in the 
nuclei o f  tumour cells.
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3.2.5 Co-expression of H- and N-Ras in Breast Tumours
O f the 136 breast tumours that were analysed for both H-Ras and N-Ras, three patients
did not express H-Ras, whilst only one was negative for N-Ras. N o tumour was negative 
for both isoforms. There did appear to be a relationship between the expression patterns 
o f  the two isoforms: tumours that expressed high levels o f  cytoplasmic H-Ras also 
expressed increased levels o f  N-Ras (R^=0.275, p=0.001) (Figure 3.7). Additionally, 
tumours with elevated nuclear H-Ras exhibited stronger levels o f  nuclear N-Ras 
(R^=0.264, p=0.002) (Figure 3.7). Tumours were more likely to express the cytoplasmic 
form o f  the protein but not the nuclear counterpart. Twelve patients lacked nuclear but 
not cytoplasmic H- or N-expression. N o breast tumour that displayed cytoplasmic Ras 
was negative for both H- and N-Ras in the nuclei. Furthermore, the median nuclear scores 
for both H- and N-Ras were significantly lower than their cytoplasmic counterparts 
(W ilcoxon Signed Ranks Test, p<0.0005 for both)
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Figure 3.7: Scatter Graphs Comparing H and N-Ras Expression
(a) Scatter graph comparing H- and N-Ras cytoplasmic expression, (b) Scatter graph 
comparing H- and N-Ras expression.
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3.2.6 Raf-1 Expression in Breast Tumours
Raf-1 protein expression was predominantly localised to the cytoplasm of invasive 
tumour cells. Weak nuclear staining was evident in some tumours: 94.6% of patients 
expressed Raf-1 in the cytoplasm of their tumours, whereas only 36.5% exhibited the 
nuclear form of this protein (Figure 3.8). Additionally, when expressed in the nuclei, the 
levels were exceedingly low (Median Nuclear Histoscore = 0, IQ Range 0 -  5). 
Consequently, nuclear Raf-1 was excluded from statistical analysis. Interestingly, there 
was a negative correlation between H-Ras nuclear expression and Raf-1 cytoplasmic 
expression (R^=-0.250, p=0.035). No significant relationship between Raf-1 and N-Ras 
expression was observed.
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Figure 3.8: Raf-1 Immunohistochemlstry
(a) Breast tumour stained with Raf-1 antibody. Raf-1 was detected primarily in the 
cytoplasm o f tumour cells; weak nuclear Raf-1 expression was evident in relatively few  
tumours. Insert shows negative control, (b) Scatter graph comparing cytoplasmic and 
nuclear expression o f Raf-1. (c) Histogram showing the intensity o f  Raf-1 expression in 
the cytoplasm o f tumour cells, (d) Histogram showing the intensity o f  Raf-1 expression in 
the nuclei o f tumour cells.
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Ras
Nuc
Ras
Ab-i
Cyt
Ras
ab-1
Nuc
H-
Ras
Cyt
H-
Ras
Nuc
N-
Ras
Cyt
N-
Ras
Nuc
Raf-1
Cyt
Raf-1
Nuc
Minimum 0 0 0 0 0 0 0 0 0 0
Maximum 205 204 240 250 268 205 245 185 208 70
Mean 46 76 55 107 113 48 116 50 76 4
Median 25 73 45 108 110 35 125 40 74 0
LQ 15 45 15 60 70 13 79 15 30 0
UQ 65 105 75 150 165 70 153 80 110 5
Table 3.1; Descriptive Statistics for Histoscores
For each antibody, descriptive statistics were performed on the generated histoscores. 
The table shows the minimum and maximum histoscore, the mean, median, the lower and 
upper quartile values fo r  each antibody. LQ~Lower Quartile, UQ=Upper Quartile
3.3 Effects of Ras & R af Overexpression on Patient Outcome
In this pilot study, patient outcome was measured in terms of disease-free and overall
survival, where recurrence and death were the end-points for each respectively. For all 
proteins under investigation, patients were divided into two groups: those expressing low 
levels of the protein of interest, and those expressing high levels. The cut-off point for 
defining low and high expressers for each protein was the upper quartile histoscore value.
3.3.1 Effects of Pan-Ras, H-Ras and Raf-1 expression on Breast Cancer 
Survival
No significant relationship between total Ras, H-Ras, or Raf-1 expression and patient 
disease-free or overall survival was observed.
3.3.2 Effects of N-Ras on Breast Cancer Survival
Increased levels of N-Ras in patients’ tumours were significantly associated with a 
reduction in time to relapse and death. Patients with tumours expressing high levels of 
cytoplasmic N-Ras (IHC score > 153) had a reduced disease-free suivival time 
(p=0.0128, 5.46 years vs. 7.95 years) and overall survival time (p“ 0.0209, 6.80 years vs. 
8.98 years) (Figure 3.9). These patients showed a relative risk of 1.8 (95% Cl 1.13 -  2.97, 
p=0.0142) and 1.8 (95% Cl 1.1 —3.1, p=0.0229, CR) for relapse and death respectively.
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Likewise, patients whose tumours had nuclear staining in the upper quartile (IHC 
score > 80) showed a significant reduction in time to recurrence (p=0.0345, 5.51 years vs. 
8.19 years) and overall survival time (p=0.0071, 6.30 years vs. 9.50 years). The relative 
risks of relapse or death in cases with high nuclear N-Ras were 1.7 (95% Cl 1.0 -  2.8, 
p=0.0366) and 2.0 (95% Cl 1.2 -  3.4, p=0.0083) respectively.
However, multivariate Cox-Regression revealed no evidence that N-Ras 
expression was independent of tumour size, grade, ER or nodal status in influencing 
survival. Only ER and nodal status (p<0.00005 and p=0.0005 respectively) proved to be 
independent markers of patient survival in this dataset.
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Figure 3.9; N-Ras Disease Free &  Overall Survival Curves
Kaplan Meier survival curves showing disease-free and overall survival in patients 
whose tumours express cytoplasmic or nuclear N-Ras. (a,h) Survival curves showing a 
significant reduction in disease-free and overall survival time in patients whose tumours 
express high levels o f cytoplasmic N-Ras (p^O.0128 and p=0.0209 respectively). (c,d) 
Survival curves showing a significant reduction in overall survival time in patients whose 
tumours express high levels o f  nuclear N-Ras (p^O.0345 and p=0.0071 respectively).
HR = Hazard Ratio (95% Cl)
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3.4 Relationship between Ras and Raf-1 expression and known 
prognostic markers
The expression of Ras and Raf-1 proteins was analysed to establish if there was a link
between increasing levels of these proteins and known prognostic markers, namely 
tumour size, grade, nodal and ER status.
It was observed that patients whose tumours over-expressed cytoplasmic N-Ras 
were more likely to present with a tumour of a higher grade (grade=3) (x^p^O.016). 
There was no significant relationship between N-Ras expression and tumour size, nodal 
or ER status.
Increasing levels of cytoplasmic H-Ras were also associated with tumours of a 
higher grade (grade=3) p=0.003). Additionally, patients' tumours expressing higher 
levels of cytoplasmic H-Ras were more likely to be ER negative p=0.0I9). 
Expression levels of H-Ras did not significantly impact on either tumour size or nodal 
status.
Similarly, no correlation was observed between pan-Ras or Raf-1 expression and 
tumour size, grade, nodal status, or ER status.
3.5 Discussion
There were two main discoveries in this pilot study: the first was the novel observation 
that Ras localised to the nuclei of tumour cells, and the second was that N-Ras expression 
influences patient outcome.
Until recently, it was thought that Ras and Raf-1 localised only to the cytoplasm 
and plasma membrane. However, it is now accepted that the Ras/Raf-1 pathway is also 
activated at the endoplasmic reticulum and the golgi (246). It is also acknowledged that 
Raf-1 is expressed in the nucleus, since several studies demonstrate that activated Raf -1
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translocates to the nucleus, in order to bind and phosphorylate the retinablastoma (Rb) 
protein (184). Our data suggests that a nuclear function for Ras may also exist. The recent 
findings that the Ras/Raf-1/MAPK pathway is activated at sites other than the plasma 
membrane might suggest that the nucleus is another subcellular location for activation of 
this pathway.
In this pilot study, both Ras and Raf-1 were shown to localise to the nucleus. 
Other reports have shown that GRB2 is also overexpressed in breast tumour cells, and 
that it predominantly localises to the nuclei (150). These factors suggest a role for the 
Ras/Raf-1 pathway in the nucleus. Perhaps activation within the nucleus enables Raf-1 to 
interact with and inactivate Rb, which enables cell cycle progression and cell 
proliferation.
Wurzer et al identified an oncogenic form of Ras, H-Ras^^"^' that showed both 
cytoplasmic and nuclear localisation (247). However, since less than 5% of breast 
tumours show mutation of Ras, it seems unlikely that levels of nuclear Ras detected in 
our subset of breast tumours is due to expression of mutated Ras. Another explanation is 
that the detected nuclear Ras is due to alternative splicing of the Ras, pre-mRNA, which 
generates a modified Ras protein. Guil et al demonstrated that H-Ras pre-RNA can 
undergo alternative splicing of its last encoding exon, and that the product of this, p i9 
Ras, localises to both the cytoplasm and nucleus (248). The unexpected finding that Ras 
was localised to the nuclei of tumour cells directed a proportion of the later studies. 
Having identified nuclear Ras in breast tumour tissue, the subcellular localisation of Ras 
was further investigated in vitro. The findings from these studies are discussed in the 
proceeding chapter.
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Expression of cytoplasmic and nuclear N-Ras was associated with early relapse 
and reduced overall survival time (Figure 3.9), confirming previous results linking Ras 
with poor prognosis (249;250) in breast cancer. High N-Ras expression was associated 
with increased tumour grade, but not tumour size, stage or ER status, all of which 
independently affect patient outcome. These results suggest that high N-Ras expression 
may identify a group of patients who require alternative therapies, e.g., farnesyl 
transferase inhibitors, in order to improve their long-term prognosis. Increased 
cytoplasmic H-Ras expression positively correlated with high tumour grade and ER 
negativity. Surprisingly, however, our results imply that H-Ras expression does not 
significantly impact on patient disease free or overall survival.
There are several possible explanations as to why N-Ras but not H-Ras expression 
influences patient outcome. It is well documented that the various Ras isoforms have 
different functions. H- and N-Ras vary in their ability to induce transformation and 
stimulate cell motility (251). There is also increasing evidence that membrane 
localisation of Ras is dependent on post-translational modifications, which differ between 
the isoforms, and thus modify the compartmentalisation and function of these proteins. 
H- and N-Ras undergo farnesylation and palmitoylation that targets them to the plasma 
membrane lipid rafts, via the Golgi and endoplasmic reticulum (117;246). Differences in 
plasma membrane localisation influence the ability of Ras to activate its downstream 
effectors, since concentrations ol Raf-1 and PI3-K vary within plasma membrane 
microdomains. Raf-1 is believed to be activated at the bulky region of the plasma 
membrane, whereas PI3-K is present in the lipid rafts (252). Activated H- and N-Ras 
cycle between the lipid raft and bulky domain of the plasma membrane, and there is
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evidence that N-Ras spends a longer period of time in the non-raft domain. Accordingly, 
N-Ras appears to be the more effective activator of Raf-1, whilst H-Ras is more effective 
as an activator of the PI3-K/Akt pathway (132;251). Therefore, it is plausible that Akt, as 
opposed to H-Ras, is a better predictor of patient survival. Likewise, activated Raf-1 or 
MAPK may be more appropriate predictive markers than N-Ras. It has been reported that 
Raf-1 is not involved in the activation of MAPK via H-Ras, but that N-Ras modulates 
activation of this pathway (138). The association between increased N-Ras expression 
and reduced patient survival could reflect greater activation of MAPK via Raf-1, 
resulting in enhanced tumour proliferation and subsequently poorer survival. Work from 
our group suggests that Raf-1 activation of MAPK may be associated with the 
development of hormone resistance in prostate cancer (253).
Evidence also exists that the Ras isoforms have different sensitivities to farnesyl 
transferase inhibitors: whilst H-Ras is very sensitive, N-Ras is only partially sensitive 
(113). This further supports the hypothesis that H- and N-Ras have different functional 
properties mediated via their different locations on the plasma membrane. The effect of 
differential plasma membrane localisation of H- and N-Ras on protein function and 
patient survival requires further investigation.
This is one of the first studies to show evidence of Ras expression in the nuclei of 
tumour cells and to suggest that N-Ras expression significantly influences patient 
survival. It highlights that Ras, in particular N-Ras, may represent an important 
therapeutie target in breast cancer.
The findings from this pilot study directed the course of the majority of the later 
studies. As previously mentioned, the novel nuclear localisation of Ras was investigated
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and is discussed in the following chapter. In addition, having highlighted the possible
importance of Ras, particularly N-Ras, in mediating breast cancer progression and
ultimately patients’ outcome, the role of these proteins in a larger cohort of patients and
in the context of different treatment regimes was investigated. It was deemed appropriate
to determine the importance of the Ras pathway, rather than Ras itself; therefore, the
investigation was extended further downstream to Raf-1 and MAPK. The role of the 
«
Ras/Raf-1/MAPK pathway was therefore analysed in patient cohorts treated with 
tamoxifen or chemotherapy. The findings from these studies are discussed in later 
chapters.
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4. Localisation of Ras Proteins
4.1 Introduction
Analysis of the expression of Ras in breast tumours from the pilot study (chapter 3) 
revealed an unexpected finding. H-Ras and N-Ras were both localised to the cytoplasm 
but were also expressed in the nuclei of tumour cells. As discussed in chapters 1 and 3, 
inactive Ras is localised to the cytoplasm but translocates to the plasma membrane to be 
activated. The literature previously suggested that Ras could only be activated and 
stimulate kinase cascades at the plasma membrane, but more recently it has been reported 
that Ras can function at the ER and Golgi. However, few studies have shown a nuclear 
form of this protein. The findings from the pilot study, that Ras localised to the nuclei and 
that expression of nuclear N-Ras was associated with a poor outcome, led to further 
investigation of Ras localisation, in particular N-Ras, in breast cancer cell lines, using 
immunofiuorescent and subcellular fractionation techniques.
4.2 Immunofluorescent detection of H , K , and N-Ras in breast cancer
cells
Immunofiuorescent (IF) techniques (described in chapter 2) were used to examine the 
localisation of the three Ras isoforms, H-, K-, and N-Ras, in MCF-7 and MDA-MB-231 
breast cancer cells. MCF-7 and MDA-MB-231 cells were either untreated or stimulated 
with Heregulin (HRG, MCF-7) or Epidermal Growth Factor (EGF, MDA-MB-231) for 5, 
15 and 30 minutes. Subsequently the subcellular location of each of the individual Ras 
isoforms was monitored (Single IF). However, it was also necessary to investigate the co­
localisation patterns of the Ras isoforms. Co-localisation studies were performed in pairs: 
H- and K-Ras; H- and N-Ras; and K- and N-Ras (Double IF),
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4.2.1 Localisation of H-, K  , and N-Ras in MCF-7 & MDA-MB-231 cells
4.2.1.1 H-Ras
111 untreated MCF-7 cells, H-Ras was localised to the cytoplasm. It remained in the 
cytoplasm following a 5-minute treatment with InM HRG; however extended stimulation 
for 15 and 30 minutes induced low levels of H-Ras to translocate into the nucleus. The 
presence of nuclear Ras was most apparent following the 30-minute treatment (Figure 
4.1). A similar pattern was obsei*ved when cells were stimulated with lOnM HRG. 
However, using lOnM HRG triggered more rapid translocation of H-Ras into the nucleus. 
Nuclear H-Ras was detectable following the 5-minute treatment, with higher levels 
noticeable after the 15 and 30-minute stimulations. Expression of cytoplasmic H-Ras was 
maintained throughout the course of the timed treatments (Figure 4.1).
A different expression pattern for H-Ras was observed in MDA-MB-231 cells. As 
with MCF-7 cells, no detectable nuclear H-Ras was evident in untreated MDA-MB-231 
cells. However, stimulation with InM and lOnM EGF failed to promote nuclear 
translocation of H-Ras. Even after 30 minute treatments, H-Ras was undetectable in the 
nuclei of MDA-MB-231 cells. Furthermore, cytoplasmic H-Ras expression appeared to 
be considerably weaker than, and not as uniformly expressed as, that observed in the 
MCF-7 cells. Instead H-Ras was compartmentalised in a region next to the nuclei. It was 
speculated that this location was in fact the golgi complex and, perhaps, the endoplasmic 
reticulum (Figure 4.2).
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Figure 4.1: H-Ras Immunofluorescence on MCF-7 cells
Immunofluorescence o f MCF-7 cells stimulated with InM  Heregulin (A) and lOnM 
Heregulin (B) for 0, 5, 15 and 30 minutes and treated with H-Ras antibody and 
Fluorescein avidin D. H-Ras was localised to the cytoplasm and nuclei o f MCF-7 cells. 
Block Arrows highlight cells expressing nuclear Ras. Thin arrows highlight cells 
expressing cytoplasmic Ras.
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Figure 4.2: H-Ras Immunofluorescence on MDA-MB-231 cells
Immunofluorescence o f MDA-MB-231 cells stimulated with InM EGF (A) and lOnM 
EGF (B) for 0, 5, 15 and 30 minutes and treated with H-Ras antibody and Fluorescein 
avidin D. H-Ras was compartmentalised to a region next to the nuclei, hypothesised to be 
the golgi and the endoplasmic reticulum. Low levels o f H-Ras were also detected in the 
cytoplasm. Block Arrows highlight cells expressing Ras at the golgi/endoplasmic 
reticulum. Thin arrows highlight cells expressing cytoplasmic Ras.
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4.2.1.2 K-Ras
K-Ras was detectable only in the cytoplasm of untreated MCF-7 cells. Upon stimulation 
with HRG, K-Ras was predominantly localised to the cytoplasm but was also present 
within some nuclei. After only 5 minutes of InM HRG treatment, low levels of nuclear 
K-Ras were evident. But as with H-Ras, the highest levels of nuclear K-Ras were 
observed after the 30 minute treatment. However, the levels of nuclear K-Ras were 
slightly lower when treated with lOnM HRG (Figure 4.3).
The K-Ras isoform failed to localise to MDA-MB-231 nuclei, despite stimulation 
with EGF. However, in contrast to the H-Ras pattern of expression, K-Ras was detected 
at relatively strong levels throughout the cytoplasm of the cells at all time points. 
Consequently, K-Ras did not appear to localise to the same confined subcellular body 
(golgi and endoplasmic reticulum) as H-Ras. K-Ras was observed at this location in only 
a few cells (Figure 4.4).
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Figure 4.3: K-Ras Immunofluorescence on MCF-7 cells
Immunofluorescence o f MCF-7 cells stimulated with InM  Heregulin (A) and lOnM 
Heregulin (B) for 0, 5, 15 and 30 minutes and treated with K-Ras antibody and 
Fluorescein avidin D. K-Ras was localised to the cytoplasm and nuclei o f MCF-7 cells. 
Block Arrows highlight cells expressing nuclear Ras. Thin arrows highlight cells 
expressing cytoplasmic Ras.
160
B0 mins 5 mins 15 mins 30 mins
Figure 4.4: K-Ras Immunofluorescence on MDA-MB-231 cells
Immunofluorescence o f MDA-MB-231 cells stimulated with InM EGF (A) and lOnM 
EGF (B) for 0, 5, 15 and 30 minutes and treated with K-Ras antibody and Fluorescein 
avidin D. K-Ras was predominantly localised to the cytoplasm o f cells, but weaker levels 
were detected at a region next to the nuclei, hypothesised to be the golgi and the 
endoplasmic reticulum. Block Arrows highlight cells expressing Ras at the 
golgi/endoplasmic reticulum. Thin arrows highlight cells expressing cytoplasmic Ras.
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4.2.1.3 N-Ras
Only cytoplasmic N-Ras was evident in untreated MCF-7 cells. The level of N-Ras 
present within the cytoplasm seemed to remain fairly constant throughout the timed 
treatments. Stimulation with HRG induced N-Ras to translocate into the nuclei of the 
cells. The 15 minute treatment with both InM and lOnM HRG produced the strongest 
levels of nuclear N-Ras (Figure 4.5).
The expression and localisation of N-Ras in the MDA-MB-231 cells paralleled 
that observed with H-Ras. Yet again, there was no evidence of N-Ras being localised to 
the nuclei of cells, and expression in the cytoplasm was sparse. However, strong levels 
were detected at the proposed site of the golgi complex and the endoplasmic reticulum 
(Figure 4,6).
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Figure 4.5: N-Ras Immunofluorescence on MCF-7 cells
Immunofluorescence o f  MCF-7 cells stimulated with InM  Heregulin (A) and lOnM 
Heregulin (B) for 0, 5, 15 and 30 minutes and treated with N-Ras antibody and 
Fluorescein avidin D. N-Ras was localised to the cytoplasm and nuclei o f  MCF-7 cells. 
Block Arrows highlight cells expressing nuclear Ras. Thin arrows highlight cells 
expressing cytoplasmic Ras.
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Figure 4.6: N-Ras Immunofluorescence on MDA-MB-231 cells
Immunofluorescence o f MDA-MB-231 cells stimulated with InM EGF (A) and lOnM 
EGF (B) for 0, 5, 15 and 30 minutes and treated with N-Ras antibody and Fluorescein 
avidin D. N-Ras was compartmentalised to a region next to the nuclei, hypothesised to be 
the golgi and the endoplasmic reticulum. Low levels o f  N-Ras were also detected in the 
cytoplasm. Block Arrows highlight cells expressing Ras at the golgi/endoplasmic 
reticulum. Thin arrows highlight cells expressing cytoplasmic Ras.
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4.2.2 Co-localisation of H-, K-, and N-Ras in MCF-7 and MDA-MB-231 
cells
4.2.2.1 Co-localisation of H- and K-Ras
For the double IF studies, H-Ras was detected using green fluorescence (Fluorescein 
avidin D), whilst K-Ras was detected with a red fluorochrome (Texas Red). 
Consequently, when the two proteins co-localised, a yellow fluorescence was evident. In 
the MCF-7 cells, H-Ras and K-Ras co-localised to the cytoplasm, evident from the 
yellow fluorescence throughout the cytoplasm. However, within the untreated cells, there 
were regions of the cytoplasm where K-Ras was more apparent than H-Ras, depicted by 
the red fluorescence. Surprisingly, only very low levels of both H-Ras and K-Ras were 
detected in the nuclei of cells (Figure 4.7).
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Figure 4.7: Co-localisation of H-Ras & K-Ras in MCF-7 cells
Immunofluorescence o f MCF-7 cells stimulated with InM  Heregulin (A) and lOnM 
Heregulin (B) for 0, 5, 15 and 30 minutes and treated with H-Ras antibody and 
Fluorescein avidin D (green) followed by K-Ras antibody and Texas Red (red). When H- 
Ras and K-Ras were co-expressed in cells, a yellow fluorescence was emitted. H-Ras and 
K-Ras co-localised to the cytoplasm and, to a lesser extent, to the nuclei o f MCF-7 cells.
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4.2.1.2 Co-localisation of H- and N-Ras
As described above, H-Ras was detected in cells using the green Fluorescein avidin D, 
whilst N-Ras was detected with Texas Red. Again, when the two proteins were co­
expressed, a yellow fluorescence was emitted. Both H- and N-Ras were co-expressed in 
the cytoplasm of the MCF-7 cells throughout all timed treatments. Once more very low 
levels of nuclear Ras, either H- or N-Ras, were detected (Figure 4.8).
In the MDA-MB-231 cells, H- and N-Ras were again shown to co-localise. As 
observed in the single IF studies, both H- and N-Ras expression was very weak in the 
cytoplasm, but both were co-localised and strongly expressed in the subcellular 
compartment thought to be the golgi and endoplasmic reticulum (Figure 4.9).
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Figure 4.8: Co-localisation of H-Ras & N-Ras in MCF-7 cells
Immunofluorescence o f MCF-7 cells stimulated with InM Heregulin (A) and lOnM 
Heregulin (B) for 0, 5, 15 and 30 minutes and treated with H-Ras antibody and 
Fluorescein avidin D (green) followed by N-Ras antibody and Texas Red (red). When H- 
Ras and N-Ras were co-expressed in cells, a yellow fluorescence was emitted. H-Ras and 
N-Ras co-localised to the cytoplasm and, to a lesser extent, to the nuclei o f MCF-7 cells.
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Figure 4.9: Co-localisation of H-Ras & N-Ras in MDA-MB-231 cells
Immunofluorescence o f MDA-MB-231 cells stimulated with InM  EG F (A) and lOnM 
EOF (B) fo r  0, 5, 15 and 30 minutes and treated with H-Ras antibody and Fluorescein 
avidin D (green) followed by N-Ras antibody and Texas Red (red). When H-Ras and N- 
Ras were co-expressed in cells, a yellow fluorescence was emitted. H-Ras and N-Ras co­
localised to the cytoplasm and to the supposed Golgi and endoplasmic reticulum region.
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4.2.1.3 Co-localisation of K- and N-Ras
In order to investigate the co-localisation of K- and N-Ras, N-Ras was bound to 
Fluoroscein Avidin D, whilst K-Ras was bound to Texas Red. In the MCF-7 cells, the 
cytoplasm fluoresced yellow, indicating that both K-Ras and N-Ras were co-expressed in 
the cytoplasm. As in the single IF experiments, the levels of cytoplasmic Ras appeared to 
remain constant throughout the timed treatments (Figure 4.10).
As perhaps expected, following the results from the single IF performed on the 
MDA-MB-231 cells, K-Ras and N-Ras exhibited slightly different expression patterns. 
Only K-Ras was prominently localised to the cytoplasm of the cells. However, both were 
co-expressed at the Golgi and endoplasmic reticulum. As before, neither Ras isoform was 
expressed in the nuclei, even when stimulated with EOF (Figure 4.11).
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Figure 4.10: Co-localisation of K-Ras & N-Ras in MCF-7 cells
Immunofluorescence o f MCF-7 cells stimulated with InM Heregulin (A) and lOnM 
Heregulin (B) for 0, 5, 15 and 30 minutes and treated with N-Ras antibody and 
Fluorescein avidin D (green) followed by K-Ras antibody and Texas Red (red). When N- 
Ras and K-Ras were co-expressed in cells, a yellow fluorescence was emitted. N-Ras and 
K-Ras co-localised to the cytoplasm and, to a lesser extent, to the nuclei o f MCF-7 cells.
71
AB
0 mins 5 mins 15 mins 30 mins
Figure 4.11: Co-localisation of K-Ras & N-Ras in MDA-MB-231 cells
Immunofluorescence o f MDA-MB-231 cells stimulated with InM EG F (A) and lOnM 
EGF (B) for 0, 5, 15 and 30 minutes and treated with N-Ras antibody and Fluorescein 
avidin D (green) followed by K-Ras antibody and Texas Red (red). When K-Ras and N- 
Ras were co-expressed in cells, a yellow fluorescence was emitted. K-Ras and N-Ras co­
localised to the cytoplasm and to the supposed Golgi and endoplasmic reticulum region. 
However, K-Ras expression seemed to be more predominant in the cytoplasm than N- 
Ras.
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4.3 Investigation of N-Ras localisation in MCF-7 cells using sufocellular 
fractionation
To further verify the existence of a nuclear form of Ras, subcellular fractionation was 
performed on MCF-7 cells. The preliminai'y fractionation experiment investigated the 
localisation of N-Ras in membranous, cytoplasmic, nuclear and cytoskeletal fractions of 
MCF-7 cells that were either untreated, or had been stimulated with HRG. This 
experiment again highlighted that N-Ras was expressed in the nuclei of breast cancer 
cells. N-Ras was detected in the membrane, cytoplasmic and nuclear fractions but not in 
the cytoskeletal fractions of both untreated and stimulated cells (Figure 4.12).
The localisation of N-Ras was further probed in MCF-7 cells that had been treated 
with HRG, E2 and MAPK inhibitors, Felodipine and U0126. These subcellular 
fractionation experiments provided further evidence of the presence of a nuclear form of 
N-Ras. Figures 4.13 and 4.14 highlight the localisation of N-Ras to the membrane, 
cytoplasm and nuclei of MCF-7 cells.
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Figure 4.12: Subcellular Fractionation of MCF-7 Cells
Western blot o f MCF-7 protein fractions probed for N-Ras (21kDa). MCF-7 cells were 
either untreated or stimulated with InM and lOnM Heregulin (HRG) fo r 5, 15 and 30 
minutes before subcellular fractionation was performed. N-Ras was detected in the 
membrane, cytoplasmic and nuclear fraction. Tubulin was used as a loading control.
C= Control (untreated MDA-MB-453 cells), M  = Membrane fraction, CP =  Cytoplasmic 
fraction, N  =  Nuclear fraction, CS  =  Cytoskeletal fraction
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Figure 4.13: Detection of N-Ras in protein fractions following 5 minute treatment 
with HRG, E2 and FEL
MCF-7 cells were treated with 1/1 OnMHeregulin (HRG) and Oestrogen (E2), singly and 
in combination, and in the presence or absence o f Felodipine (FEL), fo r  5 minutes. 
Subcellular fractionation was then performed, generating membranous, cytoplasmic and 
nuclear fractions. Western blotting was performed on 25pg o f membrane, nuclear and 
cytoplasmic protein fractions and samples probed fo r  N-Ras (2lkDa) expression. Tubulin 
and Actin were used as loading controls.
UT= Untreated control without DMSO & EtOH, UT time pt = 5 minute untreated control 
with DMSO & ETOH, FEL control= 30/jM  Felodipine only
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Figure 4.14: Detection of N-Ras in protein fractions following 15 minute treatment 
with HRG, E2, FEL and U0126
MCF-7 cells were treated with InM  Heregulin (HRG) and Oestrogen (E2), singly and in 
combination, and in the presence or absence o f Felodipine (FEL) and U0126, for 15 
minutes. Subcellular fractionation was then performed, generating membranous, and 
nuclear fractions. Western blotting was performed on 25pg o f membrane and nuclear 
protein fractions and samples probed fo r N-Ras (21kDa) expression. Tubulin was u.sed as 
a loading control.
UT= Untreated control without DMSO i& EtOH, UT time pt = 5 minute untreated control 
with DMSO &, ETOH, FEL control^ 30pMFelodipine only, U0126 control = lOmM 
U0126 only
4.4 Discussion
This in vitro study confirmed the pilot study observation (Chapter 3) that Ras localises to 
the nuclei o f  breast tumour cells. Using both immunofluorescence and subcellular 
fractionation techniques, H-, K- and N-Ras were all localised to the nuclei o f  MCF-7 
breast cancer cells. As discussed in the previous chapter, only a few reports support the 
findings o f  a nuclear form o f  Ras. One study identified an oncogenic form o f  Ras, H- 
Ras^^"\ that presented in the nuclei o f  cells (247). However, there is no indication that 
MCF-7 cells carry this mutation. In fact, Ras mutations are a very rare occurrence in 
breast cancer cells. Additionally, it has been shown that H-Ras mRNA can undergo
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alternative splicing of its last encoding exon, to produce a 19kDa product that localises to 
both the cytoplasm and nuclei of cells (248). However, this may justify the presence of 
H-Ras in the nucleus, but does not offer any explanation for the localisation of either K- 
Ras or N-Ras to the nucleus. There is no evidence that N-Ras mRNA undergoes 
alternative splicing to produce a nuclear isoform, and while it is well established that K- 
Ras has two alternative fourth exons that yield K~RasA and K-RasB, there has been no 
indication that there is a nuclear K-Ras isoform. Consequently, there must be other, as of 
yet undiscovered, explanations for the presence of the Ras isoforms in the nuclei of cells.
As previously mentioned, until recently it was thought that Ras could only be 
activated at the plasma membrane. However, it is now well established that Ras can be 
activated at the Golgi and the endoplasmic reticulum, and that this activation is sufficient 
to stimulate phosphorylation and activation of MAPK (130;139;141). It is, therefore, 
feasible to hypothesise that the nucleus is an additional subcellular location for the 
activation of Ras, or that activation of Ras, at either the plasma membrane or the Golgi, 
induces it to translocate into the nucleus. Analysis of the MCF-7 IF studies highlight that 
Ras is not detectable in the nucleus of untreated cells, but that treatment with HRG 
induced the expression of Ras in the nucleus, generally after 15 minutes. Since the 
antibodies used throughout this study detect total Ras, i.e, inactive and active forms, this 
perhaps suggests that Ras is activated outside the nucleus and then translocates in. The 
delay in expression of nuclear Ras is particularly interesting since several studies have 
demonstrated that there are distinct differences between the kinetics of Ras activation at 
the plasma membrane, versus the golgi and endoplasmic reticulum. Evidence suggests 
that activation of Ras at the plasma membrane is rapid (< 5 minutes) and transient, whilst
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activation at the Golgi is delayed (10-20 minutes) and sustained (130; 139). Furthermore, 
it has been proposed that inactivation of Ras at the plasma membrane and its activation at 
the Golgi are regulated by the Src/Phospholipase Cy/RasGRPl pathway. Growth factors 
activate Src, which mediates phosphorylation of Phospholipase Cy (PLCy), which 
increases the levels of intracellular calcium ions. This subsequently results in the 
activation of the GEF, RasGRPl, which is translocated to the Golgi, where it assists in 
the activation of Ras. Simultaneously increased levels of calcium ions cause the GAP, 
CAPRI, to move to the plasma membrane, where it facilitates in the inactivation of Ras 
(141;254). Perhaps, activation of the RTKs initially stimulates activation of Ras at the 
plasma membrane, and then induces its inactivation, but simultaneously it promotes its 
activation at the golgi and its translocation into the nuclei. It is of interest that in the pilot 
study, a negligible percentage of breast tumours presented with membranous Ras, 
whereas approximately 94% exhibited the nuclear form of Ras. Analysis of MCF-7 cells 
may have confirmed the findings from the pilot study, but the MDA-MB-231 IF 
experiments generated slightly different results.
Despite Ras being detected in the nuclei of MCF-7 cells, in both IF and 
subcellular fractionation experiments, it was not evident in the nuclei of MDA-MB-231 
cells. Even following stimulation of the cells with EGF, Ras failed to localise to the 
nuclei of MDA-MB-231 cells. There were, in fact, several crucial differences in the 
expression and localisation of Ras between the two cell lines. All three Ras isoforms 
were shown to co-localise in the MCF-7 cells, whereas in the MDA-MB-231 cells, the 
patterns of expression were very similar for H- and N-Ras, whilst K-Ras showed a more 
distinct expression profile. H-Ras and N-Ras expression was very limited in the
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cytoplasm of MDA-MB-231, in contrast to the strong and uniform MCF-7 cytoplasmic 
expression. However, both appeared to be compartmentalised to a region next to the 
nuclei. It was speculated that this region was in fact the Golgi and the endoplasmic 
reticulum. Evidence from other studies investigating the expression of proteins at the 
Golgi using IF methods support this hypothesis (255-258).
K-Ras, on the other hand, was predominantly expressed in the cytoplasm of cells, 
with weaker levels detected at the proposed site of the Golgi and ER. The differences 
between the localisation of H-/N-Ras and K-Ras confirm previous findings that H- and 
N-Ras are targeted to the plasma membrane, via the Golgi and endoplasmic reticulum, 
but that K-Ras is relocalised from the cytoplasm to the membrane in a Golgi-independent 
manner (I17;126-128;130;131).
This IF study raised the question: why was the localisation of the Ras isoforms 
different in the two breast cancer cell lines? In an attempt to answer this, the differences 
between the two cell lines must be addressed. There were two major distinctions between 
the MCF-7 and MDA-MB-231 cells. The first is that MCF-7 cells are ER positive whilst 
the MDA-MB-231 cells are ER negative. The second difference relates to the expression 
of the RTKs: MCF-7 cells express HER2 and HER3 whereas MDA-MB-231 cells are 
EGFR positive. Perhaps, the localisation of Ras to the nuclei is dependent on the presence 
of either the ER or the RTKs. It is worth noting that the EGFR has a stronger association 
with Src, than HER2/HER3. Possibly the presence of EGFR in the MDA-MB-231 cells 
stimulates the Ras pathway at the Golgi via its interaction with Src.
This study, combined with the pilot study, provides evidence of nuclear Ras in 
both clinical tumour samples and in a breast cancer cell line, using three different
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tecniques, immunohistochemistry, immunofluorescence and subcellular fractionation. 
Nonetheless, the proposal that Ras localises to the nucleus will undoubtedly be met with 
scepticism. However, it should be noted that, until recently, the theories that activated 
Raf localised to the nucleus, and that a membranous form of ERa existed were both 
rejected. Now, it is accepted that Raf translocates into the nucleus to bind and activate the 
retinoblastoma protein, and that ERa is expressed at the membrane to mediate the rapid 
effects of E2 (48; 184).
This study confinns that Ras localises to the nucleus; however, the mechanism by 
which it does this and its function requires further investigation. This is particularly 
important, as the results from the pilot study suggest that expression of nuclear N-Ras is 
associated with shortened disease-free and overall survival time. As mentioned above, the 
nucleus is possibly another subcellular compartment where Ras can activate signal 
transduction cascades, such as the MAPK pathway. This theory is supported by the 
finding that Grb2, which facilitates the activation of Ras, is overexpressed in breast 
cancer cells and is predominantly localised to the nuclei of cells (150). An alternative 
explanation is that Ras remains bound to Raf when it translocates into the nucleus, to 
maintain Raf in its active conformation. Further research must be performed to enable us 
to understand the mechanisms by which Ras translocates into the nucleus and to reveal its 
function. Due to the interesting results obtained from both studies, investigation of the 
role of Ras and also its downstream targets in regulating breast cancer progression and 
patient outcome continued. Consequently, this directed the focus of my research towards 
two key studies examining the role of the Ras pathway in mediating breast cancer
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patients’ response to endocrine and chemotherapeutic treatments. The results of these will 
be discussed in the following chapters.
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5 Expression and localisation of Ras, Raf and MAPK proteins 
in breast tumour tissue microarrays.
5.1 Introduction
The previous two chapters highlighted the unexpected localisation of Ras proteins to the 
nuclei of tumour cells, and the pilot study suggested that increased expression levels of 
N-Ras in breast tumours significantly influenced patient survival. It was therefore 
appropriate to further investigate the expression and localisation of all three Ras isoforms 
in a larger cohort of breast tumours. The expression levels of proteins downstream of 
Ras, namely Raf-1 and MAPK, were also monitored. H-, K- and N-Ras and Raf-1 
expression was investigated in the Steroid-Resistant Tumour Bank (STB) cohort, whilst 
the inactivated and activated form of Raf-1, pRaf(ser259) and pRaf(ser338) respectively, 
and MAPK and pMAPK, were analysed in both the STB and NEAT/BR9601 cohort of 
patients. As in the pilot study, expression of all proteins was monitored using an 
immunohistochemical approach (chapter 2.2). Additionally, genetic modifications of H- 
Ras, N-Ras and Raf-1 were examined in a subset of patients from the STB cohort, using 
FISH. This chapter aims to present the data generated from the IHC and FISH studies, in 
terms of the distribution and localisation of the Ras, Raf-1 and MAPK proteins. The 
relationship between gene and protein expression for H-Ras, N-Ras and Raf-1 is also 
investigated. The effects of these proteins on patient outcome and response to treatment 
are discussed in the next two chapters.
5.2 Specificity of antibodies
The specificity of all the antibodies was confirmed by western blotting (Figure 5.1). The 
specificity of H-Ras, N-Ras and Raf-1 was confirmed previously (Chapter 3, Figure 3.5).
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IFigure 5.1: Specificity of Antibodies
Western blotting was performed to test the specificity o f all the antibodies used. 
Untreated and InM  Heregulin (HRG) stimulated MCF-7 and MDA-MB-453 (453) cells 
were used as controls fo r all antibodies except K-Ras. KNRK (a normal rat kidney [NRK] 
cell line transformed by Kirsten murine sarcoma virus) control cells were used for testing 
the specificity o f  the K-Ras antibody. All antibodies appeared to be specific for their 
antigen: (a) K-Ras (21kDa); (b) pRaf(ser259) (74kDa); (c) pRaf(ser338) (74 kDa): (d) 
p44/42 MAPK (44/42kDa); (e) Phospho-p44/42MAPK (44/42kDa).
5.3 Ras expression in Steroid-Resistant Tnmonr Bank (STB) Tissue 
MicroArrays (TMAs)
As previously shown, H- and N-Ras proteins were localised to both the cytoplasm and 
nuclei o f  tumour cells. K-Ras, like the other two Ras isoforms, was also expressed in both 
subcellular compartments. Very few  tumours were shown to express any o f  the Ras 
isoforms at the plasma membrane. Table 5.1 provides details o f  the descriptive statistics 
(minimum, maximum, mean, median, lower and upper quartile) for the histoscores for the 
Ras isoforms. Negative controls for all Ras antibodies are shown in Appendix 5.
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H-Ras Cyto H-Ras Nuc K-Ras Cyto K-Ras Nuc N-Ras Cyto N-Ras Nuc
Minimum 0 0 0 0 28 5
Maximum 232 150 162 130 250 200
Mean 122 47 56 34 146 98
Median 125 40 53 23 147 10
LQ 90 20 27 8 113 80
UQ 157 70 85 50 180 117
Table 5.1: Descriptive Statistics for Ras Histoscores
For each antibody, descriptive statistics were performed on the generated histoscores. 
The table shows the minimum and maximum histoscore, the mean, median, lower and 
upper quartile values fo r  each antibody. LQ—Lower Quartile, UQ=Upper Quartile
5.3.1 H-Ras Expression
Localisation and expression of H-Ras in breast tumours was investigated in 391/402 
(97.3%) STB patients (Figure 5.2). Only four tumours failed to express any H-Ras 
protein, whereas 363/391 (92.8%) tumours displayed both cytoplasmic and nuclear forms 
of this protein. The remaining patients either expressed only cytoplasmic (22 patients) or 
nuclear (2 patients) H-Ras in their tumours. As in the pilot study, H-Ras appeared to be 
expressed at higher levels in the cytoplasm as opposed to the nuclei of tumour cells. 
However, unlike the pilot study, no correlation was observed between the expression 
levels of cytoplasmic and nuclear H-Ras.
Patients were split into two groups, those that were defined as expressing low 
levels of H-Ras and those defined as expressing higher levels of the protein. For all 
proteins analysed, it was deemed most appropriate to use the histoscore upper quartile 
value as the cut off point for characterising the patients. The upper quartile value was 
chosen, since the range of histoscore values for each of the proteins for both nuclear and
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cytoplasmic expression was not normally distributed. For cytoplasmic and nuclear H-Ras, 
the histoscore cut-off values were 157 and 70 respectively. 106 and 104 patients 
expressed high levels of H-Ras in the cytoplasm and nuclei of their tumours respectively. 
However, only 7.7% tumours (30 cases) overexpressed both cytoplasmic and nuclear H- 
Ras.
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Figure 5.2: H-Ras Immunohistochemistry
(a) Histogram showing the intensity o f H-Ras expression in the cytoplasm o f tumour 
cells, (b) Histogram showing the intensity o f H-Ras expression in the nuclei o f tumour 
cells, (c) Scatter graph comparing distribution o f cytoplasmic and nuclear H-Ras 
expression, (d) Breast tumour stained with H-Ras antibody. H-Ras was detected in both 
the cytoplasm and nuclei o f  tumour cells. Insert shows negative control.
5.3.2 K-Ras Expression
As with H- and N-Ras, K-Ras was expressed in both the cytoplasm and nuclei o f  breast 
tumour cells but not at the plasma membrane. A total o f  388 (96.5% ) tumours were 
analysed for K-Ras expression, o f  which only four were negative for this protein. 
342/388 (88.1% ) tumours presented with both cytoplasmic and nuclear K-Ras
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expression; 13/388 (3.4%) tumours expressed only nuclear K-Ras, whereas 29/388 
(7.5%) of patients’ tumours were positive only for cytoplasmic K-Ras (Figure 5.3). 
Despite the high frequency of patients expressing both cytoplasmic and nuclear K-Ras, 
there was no significant relationship between the expression levels of K-Ras in the two 
locations.
As described for H-Ras, patients were separated into two groups using the K-Ras 
cytoplasmic (IHC score > 85) and nuclear (IHC score > 50) histoscore upper quartile 
values. Accordingly, 99 and 101 patients expressed high levels of K-Ras in the cytoplasm 
and nuclei of their tumours. Furthermore, 29 patients (7.5%) presented with tumours that 
expressed high levels of K-Ras in both subcellular locations.
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Figure 5.3: K-Ras Immunohistochemistry
(a) Histogram showing the intensity o f  K-Ras expression in the cytoplasm o f tumour cells, 
(h) Histogram showing the intensity o f  K-Ras expression in the nuclei o f tumour cells, (c) 
Scatter graph comparing distribution o f cytoplasmic and nuclear K-Ras expression, (d) 
Breast tumour stained with K-Ras antibody. K-Ras was detected in both the cytoplasm 
and nuclei o f  tumour cells. Insert shows negative control.
5.3.3 N-Ras Expression
Expression levels o f  N-Ras were determined in 387/402 (96.3% ) tumours. Unlike H- and 
K-Ras, all 387 patients’ tumours exhibited both cytoplasmic and nuclear N-Ras protein
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expression (Figure 5.4). However, cytoplasmic levels of N-Ras tended to be higher than 
those observed in the nuclei of tumour cells.
Cytoplasmic histoscores > 180 and nuclear histoscores >118 were used to split 
the patients into those expressing either low or high levels of N-Ras in their tumours. 
Consequently 100 patients were defined as expressing high levels of cytoplasmic N-Ras 
in their tumours, whilst 96 presented with high tumour levels of nuclear N-Ras. Only 26 
patients (6.7%) had high levels of both cytoplasmic and nuclear N-Ras in their tumours.
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Figure 5.4: N-Ras Immunohistochemistry
(a) Histogram showing the intensity ofN-Ras expression in the cytoplasm o f tumour cells, 
(h) Histogram showing the intensity o f  N-Ras expression in the nuclei o f tumour cells, (c) 
Scatter graph comparing distribution o f cytoplasmic and nuclear N-Ras expression, (d-f) 
Breast tumour stained with N-Ras antibody. N-Ras was detected in both the cytoplasm 
and nuclei o f  tumour cells, (d) Negative control, (e) Example o f  tumour with low N-Ras 
expression (IHC score < UQ), (f) Example o f  tumour with high N-Ras expression (IHC 
score > UQ).
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5.3.4 Combined Expression of H-, K , and N-Ras in breast tumours
A total of 373 patients’ tumours was investigated for expression of all three Ras isoforms.
Of all the tumours analysed, 315 were positive for H-, K- and N-Ras expression in both 
the cytoplasm and nuclei of tumour cells, whereas 328 and 356 tumours expressed all 
three isoforms in the nuclei and cytoplasm of tumour cells respectively. Table 5.2 
presents the frequency and percentage of patients whose tumours expressed increased 
levels of none, one, two or all three of the Ras isoforms in the cytoplasm or nuclei.
Cytoplasmic Nuclear
No. of Ras 
isoforms highly 
expressed 
(0, 1,2 or 3)
No. of patients 
(Total no of 
patients =373)
% Patients No. of patients 
(Total no of 
patients =373)
% Patients
0 181 48.5 177 47.5
1 108 29.0 118 31.6
2 63 16.9 63 16.9
3 21 5.6 15 4.0
Table 5.2: Frequency of patients overexpressing 0 ,1,2 or 3 Ras isoforms in 
cytoplasm or nuclei of tumour cells.
A total o f 373 patients’ tumours were analysed fo r  expression o f all three Ras isoforms. 
Listed in the table is the frequency and percentage o f patients who expressed high levels 
o f none, one, two or three o f the isoforms (H-, K~ and N~Ras) in the cytoplasm and nuclei 
o f tumour cells.
Further analysis suggested that there was a relationship between the expression of H-, K- 
and N- Ras in the cytoplasm and in the nuclei. Tumours that expressed high levels of one 
Ras isoform in the cytoplasm were more likely to display increased levels of the other 
two isoforms. The same trend was observed for the nuclear localisation of the three Ras 
isoforms (Table 5.3). However, these results should be treated with some caution, albeit 
that the p~ values are less than 0.05, which is generally the value considered to be
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statistically significant. The correlation coefficients (R^) are low (<0.4) for some of the 
correlations. For a correlation to be considered statistically significant, the correlation 
coefficient values should ideally be higher. Therefore, examination of the scatter plots 
(Figure 5.5) for the various correlations suggest that, despite various correlations 
appearing to be statistically significant, the strongest relationship is between H~ and N- 
Ras protein expression, in both the cytoplasm and the nuclei of tumour cells.
H-Ras Cyto H-Ras Nuc K-Ras Cyto K-Ras Nuc N-Ras Cyto N-Ras Nuc
H-Ras Cyto R  ^=0.058 
p=0.251
R^=0,279
p<0M 05
R^=-0.106 
P =0.039
R^=0.437
p<0.0005
R^=-0.104 
P=0.044
H-Ras Nuc R^=-0.023
p=0.661
R^=0,230
p<0.0005
=0.058
p=0.251
R"=0.410
p<0.0005
K-Ras Cyto R^=0.042
p=0.413
R^=0.441
p<0.0005
R^=5.066
p=0.199
K-Ras Nuc R^=0.056
p=0.277
R^^=0.225
P<O.OOOS
N-Ras Cyto R^=0.100 
p=0.049
Table 5.3: Correlations between H-, K- and N-Ras expression in breast tumours
Spearman-Rank correlations were performed to analyse the relationship between 
expression o f the three Ras isoforms in the cytoplasm and in the nuclei o f tumour cells. 
Those correlations deemed to be statistically significant, taking into account the p-value 
and correlation coefficient, are highlighted in bold. R^ = correlation coefficient, p-values 
< 0.003 were deemed statistically significant, using Bonferroni ’s correction.
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Figure 5.5: Scatter Graphs comparing H-, K-, N-Ras expression in breast tumours
The above scatter graphs show the relationship between H-, K- and N-Ras. Spearman 
Rank correlations produced p  values <0.0005 for all correlations. However, the scatter 
plots suggested that correlation coefficients (R )>  0.4 identify the statistically significant 
correlations. Hence the strongest observed correlation was between H- and N-Ras 
expression in the cytoplasm and the nuclei o f  tumour cells.
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5.4 R af expression in Steroid Resistant Tumour Bank (STB) and NEAT 
Studies
In addition to investigating the expression and localisation of total Raf-1 in breast 
tumours, the inactive (pRaf(ser259)) and active (pRaf(ser338)) form of the protein was 
also examined. Negative controls are in Appendix 5. Table 5.4 displays the minimum, 
maximum, mean, median, lower quartile and upper quartile histoscore values for all three 
forms.
Raf-1
Cyto
Raf-1
Nuc
pRaf(ser259)
Cyto
pRaf(ser259)
Nuc
pRaf(ser338)
Cyto
pRaf(ser338)
Nuc
Minimum 0 0 0 0 30 5
Maximum 280 200 285 93 290 225
Mean 120 107 81 5 152 136
Median 123 108 71 0 157 137
LQ 83 91 30 0 120 113
UQ 153 123 120 3 185 160
Table 5.4: Descriptive Statistics for Raf Histoscores
For each antibody, descriptive statistics were performed on the generated histoscores. 
The table shows the minimum and maximum histoscore, the mean, median, lower and 
upper quartile values fo r  each antibody. LQ=Lower Quartile, UQ=Upper Quartile
5.4.1 Raf-1 Expression (STB Only)
A total of 356 (88.6%) patients’ tumours were analysed for Raf-1 expression. Raf-1 was 
detected in both the cytoplasm and nuclei of tumour cells (Figure 5.6). In the pilot study, 
Raf-1 was primarily expressed in the cytoplasm of tumour cells. However, in the STB 
study, there was a positive correlation between the levels of cytoplasmic and nuclear Raf- 
1. Those tumours that expressed increased levels of cytoplasmic Raf-1 expressed higher 
levels of nuclear Raf-1 (R2==0.375, p<0.0005). One patient was negative for both 
cytoplasmic and nuclear Raf-1, whereas three patients expressed only nuclear Raf-1.
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Figure 5.6; Raf-1 Immunohistochemistry
(aj Histogram showing the intensity o f Raf-1 expression in the cytoplasm o f  tumour cells,
(b) Histogram showing the intensity o f  Raf-1 expression in the nuclei o f  tumour cells, (c) 
Scatter graph comparing distribution o f  cytoplasmic and nuclear Raf-1 expression, (d-f) 
Breast tumour stained with Raf-1 antibody. Raf-1 was detected in both the cytoplasm and 
nuclei o f  tumour cells, (d) Negative control, (e) Example o f  tumour with low Raf-1 
expression (IHC score < UQ), (f) Example o f  tumour with high Raf-1 expression (IHC 
score > UQ).
195
The cut-off histoscores for high levels of cytoplasmic and nuclear Raf-1 expression were 
153 and 123 respectively. Of the 356 patients, 90 and 89 individuals were classified as 
expressing high levels of Raf-1 in the cytoplasm and nuclei of their tumours respectively. 
Furthermore, 109 patients (30.7%) expressed high levels of Raf-1 in one subcellular 
compartment, either in the cytoplasm or the nuclei, whereas 35 patients (9.9%) exhibited 
increased expression of both cytoplasmic and nuclear Raf-1 in their tumours.
5.4.2 pRaf(ser259) Expression (STB & NEAT)
A total of 683 (316 NEAT & 367 STB patients) patient tumours were analysed for 
expression of inactive Raf-1, pRaf(ser259). Generally pRaf(ser259) was only expressed 
in the cytoplasm of tumour cells; very low levels of inactive Raf-1 were detected in the 
nuclei. A total of 352 tumours were negative for pRaf(ser259) expression in the nuclei 
(51.5%), whilst only 72 tumours (10.4%) failed to express cytoplasmic pRaf(ser259). The 
frequency and intensity of pRaf(ser259) staining is shown in Figure 5.7.
High levels of cytoplasmic pRaf(ser259) (IHC score > 120) were detected in 173 
patients. Due to the large proportion of tumours that were negative for nuclear 
pRaf(Ser259), any tumour with a nuclear histoscore > 3 was considered to express high 
levels of nuclear pRaf(ser259). There were 232 such tumours. Of all the patients, 51.2 % 
(350 patients) failed to express high levels of either nuclear or cytoplasmic pRaf(ser259) 
in their tumours, 38.2% (261 patients) expressed high levels of either cytoplasmic or 
nuclear inactive Raf-1, whilst 10.5% (72 patients) expressed high levels of both.
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Figure 5.7: pRaf(ser259) Immunohistochemistry
(a) Histogram showing the intensity o f pRaf(ser259) expression in the cytoplasm o f  
tumour cells, (h) Histogram showing the intensity o f pRaf(ser259) expression in the 
nuclei o f tumour cells, (c) Scatter graph comparing distribution o f  cytoplasmic and 
nuclear pRaf(ser259) expression, (d) Breast tumour stained with pRaf(ser259) antibody. 
pRaf(ser259) was detected primarily in the cytoplasm o f tumour cells. Insert shows 
negative control.
5.4.3 pRaf(ser338) Expression (STB & NEAT)
A total o f  671 patients’ tumours (313 NEAT patients & 358 STB patients) were analysed 
for the activated form o f  Raf-1, pRaf(ser338). The protein was detected in both the
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cytoplasmic and nuclear compartments of tumour cells. The frequency and intensity of 
pRaf(Ser338) staining is shown in Figure 5.8.
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Figure 5.8: pRaf(ser338) Immunohistochemistry
(a) Histogram showing the intensity o f pRaf(ser338) expression in the cytoplasm o f  
tumour cells, (h) Histogram showing the intensity o f pRaf(ser338) expression in the 
nuclei o f  tumour cells, (c) Scatter graph comparing distribution o f cytoplasmic and 
nuclear pRaf(ser338) expression, (d-f) Breast tumour stained with pRaf(ser338) 
antibody. pRaf(ser338) was detected in both the cytoplasm and nuclei o f  tumour cells, (d) 
Negative control, (e) Example o f  tumour with low pRaf(ser338) expression (IHC score < 
CQ), (f) Example o f tumour with high pRaf(ser338) expression (IHC score > UQ).
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No tumour was negative for cytoplasmic or nuclear pRaf(ser338) expression. Tumours 
that exhibited elevated levels of cytoplasmic pRaf(ser338) also tended to present with 
strong nuclear expression (R^=0.488, p<0.0005). A total of 179 and 172 patients 
presented with tumours that expressed high levels of cytoplasmic (IHC score > 185) or 
nuclear (IHC score > 160) pRaf(ser338) respectively. Of these patients, 145 (21.6%) 
overexpressed only one form of pRaf(ser338) (cytoplasmic or nuclear) whereas 103 
(15.4%) overexpressed both.
5.4,4 Relationship between Raf-1 and phosphorylated R af expression 
(STB Study Only)
Increased expression of Raf-1, in both the cytoplasm and nuclei, was associated with 
elevated levels of both the inactive and active phosphorylated forms of Raf, pRaf(ser259) 
and pRaf(ser338) respectively (Table 5.5).
Raf-1 C yt Raf-1 Nuc
R  ^-  0.440 R  ^= 0.245pR af(ser259) C yt p<0.0005 p<0.0005
R  ^=  0.461 R  ^=  0.276pR af(ser338) C yt p<0.0005 p<0.0005
R  ^= 0.181 R  ^= 0.401pR af(ser338) Nuc p =0.001 p<0.0005
T able 5.5: C orrelations betw een Raf-1 and p R af expression
Spearman-Rank correlations were performed to analyse the relationship between 
expression o f Raf-1 and pRaf(ser259)/pRaf(ser338) in the cytoplasm and in the nuclei o f  
tumour cells. R^ = correlation coefficient, p  values < 0.008 deemed statistically 
significant, using Bonferroni ’s correction.
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5.5 p44/42 MAPK & phospho-p44/42 MAPK expression in Steroid 
Resistant Tumour Bank (STB) and NEAT Studies
The expression and localisation of p44/42 MAPK and phospho~p44/42 MAPK (pMAPK) 
was investigated in both the STB and NEAT patient cohorts. Table 5.6 presents the 
minimum, maximum, mean, median, lower quartile and upper quartile histoscore values 
for both proteins.
p44/42 MAPK 
Cyto
p44/42 MAPK 
Nuc
Phospho-p44/42 
MAPK Cyto
Phospho-p44/42 
MAPK Nuc
Minimum 0 0 0 0
Maximum 285 210 235 193
Mean 110 76 64 68
Median 110 75 60 68
LQ 68 50 25 40
UQ 147 100 95 95
Table 5.6: Descriptive Statistics for MAPK Histoscores
For each antibody, descriptive statistics were performed on the generated histoscores. 
The table shows the minimum and maximum histoscore, the mean, median, lower and 
upper quartile values for each antibody. LQ=Lower Quartile, UQ^Upper Quartile
5.5.1 p44/42 MAPK Expression
MAPK expression was investigated in tumours from 692 patients (377 STB & 315 
NEAT patients). MAPK protein was detected in the cytoplasm and nuclei of invasive 
tumour cells. Generally the levels of cytoplasmic MAPK were greater than those 
observed in the nuclei (Figure 5.9). A strong positive correlation was evident between 
cytoplasmic and nuclear localisation of MAPK (R^=0.492, p<0.0005). Two patients were 
shown to be negative for MAPK expression in their tumour, 4 patients expressed only 
cytoplasmic MAPK, whilst 5 patients were positive for nuclear MAPK alone.
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Figure 5.9: p44/42 MAPK Immunohistochemistry
(a) Histogram showing the intensity o f p44/42 MAPK expression in the cytoplasm o f  
tumour cells, (b) Histogram showing the intensity o f  p44/42 MAPK expression in the 
nuclei o f  tumour cells, (c) Scatter graph comparing distribution o f cytoplasmic and 
nuclear MAPK expression, (d-f) Breast tumour stained with MAPK antibody. MAPK was 
detected in both the cytoplasm and nuclei o f  tumour cells, (d) Negative control, (e) 
Example o f tumour with low p44/42MAPK expression (IHC score < UQ), (f) Example o f  
tumour with high p44/42MAPK expression (IHC score > UQ).
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High levels of MAPK were defined using histoscore values of 147 for cytoplasmic and 
100 for nuclear. A total of 176 and 186 patients expressed high levels of MAPK in the 
cytoplasm and nuclei of their tumours. Additionally, 170 (24.6%) patients presented with 
high tumour levels of either cytoplasmic or nuclear MAPK, whilst 96 (13.9%) patients 
expressed high levels of both in their tumours.
5.5.2 Phospho-p44/42 MAPK Expression
Expression levels of phospho-p44/42 MAPK (pMAPK) were determined in 681 patients 
(368 STB & 313 NEAT patients). As with MAPK, the phosphorylated form of this 
protein was localised to both the cytoplasm and nuclei of tumour cells. Three patients’ 
tumours were negative for cytoplasmic and nuclear pMAPK, and two were negative only 
for nuclear pMAPK. However, 43 patients (6.3%) presented with only nuclear pMAPK 
in their tumours. Nonetheless, cytoplasmic and nuclear pMAPK expression was 
positively correlated (R^=0.509, p<0.0005). Figure 5.10 displays the frequency and 
intensity of pMAPK staining in the cytoplasm and nuclei of tumour cells.
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Figure 5.10: Phospho-p44/42 MAPK immunohistochemistry
(a) Histogram showing the intensity o f  phospho-p44/42 MAPK expression in the 
cytoplasm o f tumour cells, (b) Histogram showing the intensity ofphospho-p44/42 MAPK 
expression in the nuclei o f  tumour cells, (c) Scatter graph comparing distribution o f  
cytoplasmic and nuclear phospho-MAPK expression, (d-f) Breast tumour stained with 
phospho-MAPK antibody. Phospho-MAPK was detected in both the cytoplasm and nuclei 
o f tumour cells, (d) Negative control, (e) Example o f tumour with low phospho- 
p44/42MAPK expression (IHC score < UQ), (f) Example o f tumour with high phospho- 
p44/42MAPK expression (IHC score > UQ).
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Again, patients were split into two groups: 176 tumours expressed high levels of 
cytoplasmic pMAPK (IHC score > 95) and 184 overexpressed nuclear pMAPK (IHC 
score > 93). A total of 88 tumours overexpressed both cytoplasmic and nuclear pMAPK, 
whereas 183 overexpressed pMAPK in only one cellular compartment.
5.5.3 Relationship between M APK and pMAPK expression
There was a positive correlation between expression of total cytoplasmic MAPK and
expression of its phosphorylated counterpart in the cytoplasm and the nuclei of breast 
tumour cells (p<0.0005 for both). A weak association was evident between nuclear 
MAPK and nuclear pMAPK (Table 5.7). Scatter graphs of the four correlations suggest 
that these correlations are believable, though the relationships between cytoplasmic 
MAPK and pMAPK and nuclear MAPK and pMAPK are the strongest (Figure 5.11).
MAPK Cyt MAPK Nuc
pMAPK Cyt = 0.399 p<0.0005
R ^ - 0.167 
p<0.0005
pMAPK Nuc = 0.290 p<0.0005
R^ = 0.308
p = 0.001
Table 5.7: Correlations between MAPK and pMAPK expression
Spearman-Rank correlations were performed to analyse the relationship between 
expression o f MAPK and pMAPK in the cytoplasm and in the nuclei o f  tumour cells. 
R = correlation coefficient, p  values < 0.01 deemed statistically significant, using 
Bonferroni’s correction.
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Figure 5.11: Scatter graphs comparing expression of MAPK and pMAPK in breast 
tumours
The above scatter graphs highlight the relationship between total MAPK and its 
phosphorylated form, pMAPK, in the cytoplasm and in the nuclei o f tumour cells.
5.6 Increased expression levels of H-Ras, N-Ras and Raf-1 in breast 
tumours is not a result o f gene amplification
119 patients from the STB cohort were analysed for modifications of H-Ras, N-Ras and
Raf-1, at the genetic level using FISH. Genes were considered amplified if the ratio was 
above 2.0 and deleted if the ratio was below 0.8, as recommended by the manufacturer.
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5.6.1 H-Ras FISH
FISH was successfully performed on tumours from 90 patients. No H-Ras amplifications 
were detected in any of the tumours. Flowever, 3 patients exhibited deletions of this gene: 
these patients had an average H-Ras copy number of 1.56 and an overall ratio of 0.74, All 
other patients presented with normal ratios of H-Ras copy number to chromosome 11 
(range 0.8 -  1.9, mean == 1.1). Figure 5.12 displays the frequencies of H-Ras copy number 
and chromosome 11 and the overall ratios.
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Figure 5.12: H-Ras FISH
(a) Histogram displaying the frequency o f  the number o f copies o f  chromosome 11 per 
tumour cell, (b) Histogram displaying the frequency o f the number o f  copies o f  H-Ras 
gene per tumour cell, (c) Histogram showing the overall ratio o f  chromosome number to 
H-Ras copy number in tumour cells. Genes were considered amplified i f  the ratio was 
above 2.0 and deleted i f  the ratio was below 0.8.
5.6.2 N-Ras
Breast carcinomas from 83 patients were successfully analysed for genetic modifications 
o f  N-Ras: no amplifications o f  the gene were observed. However, 3 tumours exhibited a 
deletion o f  this gene. The average gene/chrom osom e ratio for these patients was 0.6  
(Range 0.48 -  0.78). All other patients presented with normal ratios o f  N-Ras copy
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number to chromosome 1 (range 0.92 -  1.79, mean = 1.23). Figure 5.13 displays the 
frequencies o f  N-Ras copy number and chromosome 1 and the overall ratios in tumour 
cells.
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Figure 5.13: N-Ras FISH
(a) Histogram displaying the frequency o f the number o f copies o f  chromosome I per 
tumour cell, (b) Histogram displaying the frequency o f the number o f copies o f  N-Ras 
gene per tumour cell, (c) Histogram showing the overall ratio o f  chromosome number to 
N-Ras copy number in tumour cells. Genes were considered amplified i f  the ratio was 
above 2.0 and deleted i f  the ratio was below 0.8.
209
5.6.3 Raf-1
O f the 119 tumours, 90 were successfully analysed for Raf-1 and no amplifications were 
detected. Only one tumour was shown to have a deletion o f  this gene (overall ratio =  
0.58). All other tumours exhibited a normal ratio o f  chromosome 3 to Raf-1 copy number 
(Range 0.81 -  1.63, mean =  1.1). Figure 5.14 displays the frequencies o f  Raf-1 copy  
number and chromosome 3 and the overall ratios in tumour cells.
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Figure 5.14: Raf-1 FISH
(a) Histogram displaying the frequency o f the number o f copies o f  chromosome 3 per 
tumour cell, (b) Histogram displaying the frequency o f the number o f copies o f Raf-1 
gene per tumour cell, (c) Histogram showing the overall ratio o f chromosome number to 
Raf-1 copy number in tumour cells. Genes were considered amplified i f  the ratio was 
above 2.0 and deleted i f  the ratio was below 0.8.
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5.7 Discussion
It is well established that the function and activity of a protein is often dependent on its 
subcellular location. A classic example of this is the ER. As discussed in chapter 1, the 
HR is known to localise to the cytoplasm, nuclei and membrane of cells. In the nucleus 
the ER mediates transcription of E2 regulated genes, whilst membranous ER exerts more 
rapid non-genomic effects.
In the two previous chapters a nuclear form of Ras was identified and validated. 
As discussed in these chapters, this was an unexpected finding, and as yet, there is no 
known function for this nuclear protein. However, in the pilot study (chapter 3), increased 
expression of nuclear N-Ras was associated with shortened disease-free and overall 
survival time. In keeping with these findings, H-, K- and N-Ras were all detected in the 
nuclei as well as the cytoplasm of breast tumours treated with Tamoxifen (STB group).
As in the pilot study, expression levels of nuclear Ras, for all three Ras isoforms, were 
generally lower than those observed in the cytoplasm of tumour cells. No positive 
correlations were observed between the expression levels of H-, K- or N-Ras in the 
cytoplasm and nuclei of tumour cells. However, there was evidence of a relationship 
between H-Ras and N-Ras expression. In both the cytoplasm and nuclei of tumour cells, 
increased expression of H-Ras in either the cytoplasm or nuclei was positively correlated 
with increased expression of N-Ras. This is particularly significant, since in chapter 4, H- 
and N-Ras were shown to co-localise to a greater extent with each other, in comparison to 
K-Ras. Furthermore, as discussed in detail in chapters 1 and 3, both H-Ras and N-Ras 
undergo the same post-translational modifications and translocation to the plasma 
membrane, which differ from those that regulate K-Ras (117; 139). One can perhaps
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speculate that the mechanism by which H- and N- Ras are ti anslocated to the nuclei is 
also slightly different from the one that induces translocation of K-Ras.
In the pilot study, increased expression of cytoplasmic and nuclear N-Ras was 
associated with an increased risk of relapse and death, suggesting that nuclear Ras serves 
an important, albeit unknown function. However, only cytoplasmic N-Ras expression 
was found to correlate with tumour grade and hence differentiation. Possibly this implies 
that there are diverse functions associated with the different subcellular forms of Ras.
This theory is discussed in more detail in the next chapter.
Considering the hypothesis that the subcellular location of a protein is influenced 
by its activation, this study highlighted that the localisation of Raf-1, a protein expressed 
in the cytoplasm and nuclei, as well as at the plasma membrane, is dependent on its 
activation status. Inactive Raf-1, pRaf(ser259) was shown to be predominantly expressed 
in the cytoplasm of tumour cells, whereas the activated form, pRaf(ser338), was 
expressed in both the cytoplasm and the nuclei of cells. In recent years it has been 
established that a nuclear form of Raf-1 exists, which binds to and phosphorylates the 
Retinoblastoma protein (184). This IHC study confirms that Raf-1 is expressed in the 
nuclei of breast tumour cells, but also suggests that Raf-1 is activated at the plasma 
membrane and then translocates into the nucleus. The absence of pRaf(Ser259) from the 
nucleus infers that Raf-1 cannot be activated within the nucleus. Therefore, there must be 
some unknown mechanism or signal that promotes nuclear translocation of Raf-1. It 
should be noted that all three antibodies specific for Raf-1 (total, inactive or active Raf-1) 
detected negligible levels of the membranous form of the protein in breast tumours. The 
same was also true for the antibodies that recognised the three Ras isoforms. This is
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perhaps surprising since the plasma membrane is the site for activation of both Ras and 
Raf-1. The lack of membranous Ras and Raf-1 possibly suggests that there is a rapid 
turnover of the activated proteins. Evidence indicates that activation of Ras, and hence 
Raf-1, at the plasma membrane is rapid and transient (130; 139). It also emphasises that 
IHC represents only a “snapshot” of the inactivation/activation cycle of proteins.
The localisation of MAPK, like Raf-1, is to a certain extent indicative of its 
phosphorylation/activation status. Inactive, unphosphorylated MAPK is generally 
localised to the cytoplasm, partly through its interaction with MEK. Yet, because of its 
small size (<50 kDa), MAPK is able to diffuse into the nucleus, but it is rapidly 
reloealised back to the cytoplasm (195). In this study, a positive correlation was observed 
between cytoplasmic and nuclear MAPK expression (R^^O.492, p<0.0005). 
Phosphorylation of cytoplasmic MAPK results in its dimérisation and its nuclear 
translocation. Consequently, the nuclear form of MAPK is thought to be representative of 
phosphorylated MAPK. A strong positive correlation was observed between the 
cytoplasmic and nuclear phosphorylated forms of MAPK. Additionally there was a 
correlation between total MAPK expression and expression of phosphorylated MAPK in 
both the cytoplasm and nuclei of tumour cells. As expected, the strongest correlations 
were observed between cytoplasmic MAPK and pMAPK (R^=0.399, p<0.0005) and 
nuclear MAPK and pMAPK (R^=0.308, p<0.0005).
Since one mechanism by which protein expression is upregulated is gene 
amplification, it was deemed appropriate to investigate H-Ras, N-Ras and Raf-1 at the 
genetic level. However, this study failed to show any link between gene amplification 
and increased protein expression. For all three genes, no amplifications were detected.
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Accordingly, it was decided to investigate the hypothesis that increased expression of 
Ras, Raf-1 and MAPK proteins in breast tumours is associated with a poor outcome and 
failure to respond to tamoxifen and chemotherapy. The results of these studies are 
discussed in the following two chapters.
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6. The role of the Ras/Raf-l/M APK pathway in the
development of Tamoxifen resistance: Steroid Resistant 
Tumour Bank (STB) Study
6.1 Introduction
Tamoxifen, an oestrogen antagonist, is currently the most successful and least toxic drug 
treatment for the 70-80% of patients diagnosed with ER positive breast cancer (see 
Section 1.5.10.2). Despite the extensive use of tamoxifen as adjuvant treatment, failure to 
respond to treatment is a major clinical problem. Resistance to tamoxifen, either primary 
{de novo resistance) or arising during treatment (acquired resistance) causes significant 
morbidity and mortality. Alternative therapies, such as aromatase inhibitors, inhibit or 
evade tamoxifen resistance pathways. In order to optimise use of such therapies they 
should, ideally, be targeted to those patient sub-groups who are most likely to acquire 
tamoxifen resistance.
The mechanisms controlling the development of tamoxifen resistance are not fully 
understood. Previous studies show patients whose tumours overexpress HER 1-3 are less 
likely to respond to tamoxifen treatment (103-105; 107). The ligand-independent
phosphorylation and activation of the ER via signal transduction pathways, such as 
Ras/Raf-l/MEK/MAPK, is also a key factor (see Sections 1.6.6 and 1.9.1). Tamoxifen- 
resistant cells show an increase in the basal levels of phosphorylated ERo_and tamoxifen 
promotes, rather than inhibits, growth of these cells (89). It has been speculated that 
activation of the Ras pathway modifies cells response to oestrogen, increasing ERa 
activity and sensitivity to low concentrations of oestrogen, via the ability of MAPK to
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directly phosphorylate the ERa. This may partially explain the development of 
Tamoxifen resistance (29;69;107).
Therefore, this study investigated whether expression and activation of the key 
components of the Ras pathway influenced clinical outcome in patients treated with 
tamoxifen. This study tested the hypothesis that activation of the Ras/Raf-l/MAPK 
pathway drives resistance to tamoxifen in clinical breast cancers. Patients from the STB 
cohort were analysed for Ras, Raf-1 and MAPK expression and activation (discussed in 
Chapter 4), and survival analysis was performed, in terms of disease-free smwival (DFS), 
overall survival (OS), and recurrence whilst on tamoxifen (ROT).
6.2 Patient Cohort & Treatment
This study cohort was comprised of 402 ERa positive breast cancer patients. All patients 
received tamoxifen treatment for a median of five years (range 0.03-16 years). A total of 
303 patients (75.4%) received only tamoxifen, whilst the remaining 99 patients (24.6%) 
were treated with chemotherapy in addition to tamoxifen. Consequently, survival analysis 
was performed on all 402 STB patients, as a whole, but also on the sub-gi oup of patients, 
that received tamoxifen alone (303 patients). Due to the small number of patients 
receiving both tamoxifen and chemotherapy (99 patients), it was deemed inappropriate to 
perform analyses on this sub-group.
6.3 Predictive value of Ras/Raf-l/M APK pathway activation.
6.3.1 Disease Free Survival (DFS) & Recurrence on Tamoxifen (ROT) in 
402 STB patients
For the purpose of this study, the end point for disease-free survival was defined as breast 
cancer recurrence. In total 112/402 patients (27.9%) relapsed. Of these patients, 85
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relapsed whilst receiving tamoxifen treatment. Therefore, in this study, it was deemed 
appropriate to analyse both disease-free survival (DFS) -  including all patients who 
relapsed regardless of treatment status -  and recurrence on tamoxifen (ROT) -  including 
only those patients who relapsed whilst receiving tamoxifen treatment. Table 6.1 
categorises patients in terms of recurrence status. As discussed in chapters 2 and 5, 
patients were split into two groups: those that were defined as expressing low levels of 
protein in their tumours and those that expressed higher levels. For all proteins analysed, 
it was deemed most appropriate to use the histoscore upper quartile value as the cut off 
point for characterising the patients.
Recurrence Type No. of Patients
NONE 289
Overall Recurrence 112
Recurrence on Tamoxifen (ROT) 85
Recurrence < 3 years on Tamoxifen 53
Recurrence > 3 years on Tamoxifen 32
Recurrence after tamoxifen withdrawal 27
Table 6.1: Recurrence Type
Table highlighting the number o f patients with the different types o f recurrences. Overall 
Recurrence = all patients who relapsed. Recurrence on tamoxifen (ROT) = only patients 
who relapsed whilst receiving tamoxifen treatment. Recurrence < 3 years on Tamoxifen 
= patients who relapsed in the first three years o f tamoxifen treatment. Recurrence > 3 
years on Tamoxifen = patients who relapsed after three years on tamoxifen. Recurrence 
after tamoxifen withdrawal = patients who relapsed after treatment with tamoxifen 
ceased.
6.3.2 Raf-1 activation is associated with decreased disease-free survival 
time.
Activation of Raf-1 was associated with an increased risk of recurrence. Increased 
expression of activated Raf-1, pRaf(ser338), in the cytoplasm of tumour cells (IHC score 
> 185), was associated with a reduced time to recurrence in patients treated with
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tamoxifen (p=0.0022, 10.18 years vs. 13.10 years, Figure 6.1a). Similarly patients whose 
tumours expressed increased levels of nuclear pRaf(ser338) (IHC score > 165) had a 
shorter DFS (p=0.0064, 10.55 years vs. 12.51 years, Figure 6.1b). The relative risks for 
relapse associated with elevated expression of cytoplasmic or nuclear pRaf(ser338) in 
patients tumours were 1.84 (95% Cl 1.24 - 2.75, p= 0.0026) and 1.78 (95% Cl 1.17 -  
2.71, p=0.0071) respectively. Multivariate Cox-Regression revealed no evidence that 
pRaf(ser338) expression was independent of tumour size, grade or nodal status.
Increased expression of all three Ras isoforms, Raf-1, inactive Raf-1 
(pRaf(ser259)), MAPK and pMAPK, failed to show any significant association with DFS 
time of patients treated with tamoxifen.
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Figure 6.1: pRaf(ser338) Disease Free Survival Curves
Kaplan Meier survival curves showing disease-free survival (DFS) in patients whose 
tumours express cytoplasmic and nuclear pRaf(serS38). (a) Survival curve showing a 
significant reduction in DFS in patients whose tumours express high levels o f cytoplasmic 
pRaf(ser338) (p=0.0022). (b) Survival curves showing a significant reduction in DFS in 
patients whose tumours express high levels o f  nuclear pRaf(ser338) (p ^0.0064). High 
levels were defined as scores > upper quartile value, p  values represent log rank testing 
o f the differences in survival. HR^Hazard Ratio (95% Cl)
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6.3.3 The N-Ras/Raf-l/MAPK pathway and Tamoxifen resistance
Expression of N-Ras, pRaf(ser338) and MAPK were each associated with an increased
risk of relapse during tamoxifen treatment. Patients whose tumours expressed high levels 
of cytoplasmic N-Ras (IHC Score > 180), but not H- or K-Ras, were more likely to 
relapse whilst receiving tamoxifen than patients with low tumour cytoplasmic N-Ras 
(p=0.0318, 9.97 years vs. 12.27 years; relative risk 1.64, 95% Cl 1.04 -  2.58, p=0.0337, 
Figure 6.2a).
Likewise, patients expressing elevated levels of nuclear pRaf(Ser338) had a 
significantly shortened disease-free survival time during tamoxifen treatment (p=0.0052, 
10.97 years vs. 12.63 years; relative risk 1.98, 95% Cl 1.23 - 3.19, p=0.0048, Figure 
6.2b). Expression of cytoplasmic pRaf(ser338) and pRaf(ser259) was not related to 
relapse whilst on tamoxifen. Neither N-Ras nor pRaf(ser338) were independent markers 
of tamoxifen resistance in a multivariate analysis.
Patients whose tumours expressed high levels of cytoplasmic MAPK were also 
candidates for developing resistance to tamoxifen; patients whose tumours displayed high 
levels of MAPK were more likely to relapse whilst on tamoxifen (p=0.0012, 7.60 years 
vs. 12.81 years; relative risk 2.08, 95% Cl 1.32 -  3.27, Figure 6.2c). Furthermore, 
multivariate Cox-regression analysis revealed that MAPK expression was independent of 
tumour size, grade and nodal status in predicting recurrence whilst on tamoxifen 
(p==0.0368) (Table 6.2). Flowever, neither cytoplasmic nor nuclear pMAPK tumour 
expression was associated with patients’ relapse whilst on tamoxifen.
Both N-Ras and MAPK were responsible for events controlling early relapse on 
Tamoxifen, i.e., relapse within the first three years of treatment. Increased expression of 
pRaf(ser338) influenced later events in the progression of the disease (Figure 6.2).
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Figure 6.2: Recurrence on Tamoxifen Survival Curves
Kaplan Meier survival curves showing the differences in survival, in terms o f recurrence 
on tamoxifen. (a)The survival curve shows a significant increase in the number o f  
patients who express high levels o f  cytoplasmic N-Ras relapsing during tamoxifen 
treatment in comparison to those whose tumours express low levels (p=0.0318). (b)The 
survival curve shows a significant increase in the number o f patients who express high 
levels o f  nuclear pRaf(ser338) relapsing during tamoxifen treatment in comparison to 
those whose tumours express low levels (p=^0.0052). (c)The survival curve shows a 
significant increase in the number ofpatients who express high levels o f cytoplasmic 
MAPK relapsing during tamoxifen treatment in comparison to those whose tumours 
express low levels (p^O.0012). High levels were defined as scores > upper quartile value, 
p  values represent log rank testing o f the differences in survival. HR-Hazard Ratio 
(95% Cl)
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Factor Hazard Ratio p-value
Nodal Status 2.18 (1.54-3,07) p<0.00005
Tumour Grade 1.6(1.09-2.33) p=0.0138
Tumour Size 1.94(1.19-3.15) p=0.0074
Cytoplasmic MAPK 1.79(1.04-3.07) p=0.0368
Table 6.2: Recurrence on Tamoxifen Cox-Regression
Cox-Regression multivariate analysis revealed that cytoplasmic MAPK expression was 
independent o f known prognostic markers, nodal status, tumour size and grade in 
influencing response to tamoxifen treatment, p-value < 0.05 were deemed statistically 
significant. Hazard ratio relative risk associated with development o f  tamoxifen 
resistance (95% Cl).
6.3.4 Increased expression of pRaf(338) in breast tumours may identify 
patients more likely to relapse after three years of tamoxifen 
treatment
Survival analysis was also performed on the sub-group of patients who remained disease- 
free after three years on Tamoxifen, In these patients, only increased tumour levels of 
cytoplasmic and nuclear pRaf(ser338) were shown to have a significant impact on time to 
relapse and death after the first three years of tamoxifen treatment. High cytoplasmic 
levels of pRaf(ser338) were associated with an increased risk of recurrence (p=0,0006, 
8,94 years vs. 11,83 years) and death (p=0,0084, 11.76 years vs. 13.75 years) following 
the initial three years of tamoxifen treatment. The relative risks associated with relapse 
and death were 2.66 (95% Cl 1,49 -  4,75, p=0,001) and 2,94 (95% Cl 1.27 -6.8, 
p=0,0119) respectively. Likewise, patients with strong nuclear pRaf(338) expression in 
their tumours had a significantly shortened disease free (p=0.0029, 9.43 years vs. 11,20 
years) and overall survival time (p=0,0001, 11,03 years vs, 13,80 years). These patients 
showed a relative risk of 2.40 (95% Cl 1,33 -  4,36, p=0,0038) and 4.78 (95% Cl 2,06 -  
11,06, p= 0.0003) for relapse and death respectively (Figure 6,3),
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Multivariate Cox-regression analysis revealed that both cytoplasmic and nuclear 
pRaf(Ser338) expression were independent of tumour size, grade and nodal status in 
predicting for relapse and death after three years of tamoxifen treatment (Table 6.3)
222
(a) Disease Free Survival after 3 years
Cytoplasmic pRaf(ser338)
- \
M 80.0
p=0.0006
’^ "4Æi'lî(Ii(pytoplasmic pRaf(ser338), n=197
cytoplasmic pRah[ser338), ii=90
HR=2.66 (1.49-4.75)
D isease Free Survival Time (Years)
(b) Overall Survival after 3 years 
Cytoplasmic pRaf(ser338)
\ ; x
p=0,0084
), n=196
1. 1 pRaf(ser338), n=89
HR=2.94 (1.27-6.8)
10 12 14 16
Overall Survival Time (Years)
(^) Disease Free Survival after 3 years 
Nuclear pRaf(ser338) p=0.0029
nuclear pRaf(ser338), n=221
■g
CO 80.0I
I  70.0I^
 60.0
Hi^h nucleai' pRaf(ser338), n=66 
HR=2.40 (1.33-4.36)
D isease Free Survival Time (Years)
(^) Overall Survival after 3 years 
Nuclear pRaf(ser338)
L A. p-0.0001
"LTL9ffiMÇi5âLREnfïse^38), n=22I
] Hi^huucleai- pRaf(ser33 8), n=64 
HR=4.78 (2.06-11.06)__________________
10 12 14 1E
Overall Survival Time (Years)
Figure 6.3: pRaf(ser338) Survival Curves after 3 years tamoxifen treatment
Kaplan Meier survival curves showing the effects o f low and high tumour levels o f  
pRaf(ser338) on disease-free and overall survival time in patients who remained disease- 
free after three years on tamoxifen, (a,h) Survival curves showing a significant reduction 
in disease-free and overall survival time, following three years o f tamoxifen treatment, in 
patients whose tumours express high levels o f cytoplasmic pRaf(ser338) (p^0,0006 and 
p ^0,0084 respectively), (c,d) Survival curves showing a significant reduction in disease- 
free and overall survival time, following three years treatment with tamoxifen, in patients 
whose tumours express high levels o f  nuclear pRaf(ser338) (p=0.0029 and p^O.OOOl 
respectively). High levels were defined as > upper quartile value, p  values represent log 
rank testing o f the differences in survival, HR^Hazard Ratio (95% Cl)
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Factor Hazard Ratio p-Value
Disease-Free 
Survival after 3 
years tamoxifen 
treatment
Nodal Status 1.72(1.09-2.74) 0.0204
Tumour Grade 1.12(0.69-1.80) -
Tumour Size 1.72 (0.94-3.15) 0.0705
Cyto pRaf(ser338) 2.55 (1.26-5.14) 0.0056
Overall Survival 
after 3 years 
tamoxifen 
treatment
Nodal Status 2,22(1.18-4.18) 0.0041
Tumour Grade 1.64 (0.79-3.38) -
Tumour Size 1.55 (0.69-3.50) -
Cyto pRaf(ser338) 3.16(1.14-8.74) 0.0059
Disease-Free 
Survival after 3 
years tamoxifen 
treatment
Nodal Status 1.74(1.11-2.73) 0.126
Tumour Grade 1.23 (0.77-1.98) -
Tumour Size 1.74 (0.93-3.26) 0.624
Nuc pRaf(ser338) 2.49(1.22-5.09) 0.0131
Overall Survival 
after 3 years 
tamoxifen 
treatment
Nodal Status 2.14(1.16-3.95) 0.0102
Tumour Grade 1.77 (0.85-3.69) 0.0903
Tumour Size 1.37 (0.57-3.29) -
Nuc pRaf(ser33) 4.70(1.75-12.66) 0.0015
Table 6.3: Patient outcome Cox-regression after three years tamoxifen treatment
Cox-Regression multivariate analysis revealed that cytoplasmic and nuclear 
pRaf(ser338) expression was independent o f  known prognostic markers, nodal status, 
tumour size and grade, in influencing disease free and overall survival following three 
years o f  tamoxifen treatment. p~value < 0.05 were deemed statistically significant. 
Hazard ratio = relative risk associated with development o f  tamoxifen resistance (95% 
Cl).
6.4 Does increased expression o f Ras/Raf-l/M APK pathway affect 
overall survival time in 402 STB patients?
6.4.1 Overall Survival Time (OS)
The end point for overall survival was a breast cancer related death. In total there were 74 
breast cancer related deaths in this group of 402 patients.
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6.4.2 Activation of Raf-1 reduces overall survival time of patients treated 
with tamoxifen.
Activation of Raf-1 was linked to a poor outcome in patients treated with tamoxifen. 
Patients whose tumours expressed increased levels of cytoplasmic or nuclear 
pRaf(ser338) exhibited a shortened OS time (p=0.0229, 13.76 years vs. 14.87 years) and 
(p=0.0006, 11.82 years vs. 15.49 years) respectively (Figure 6.4). Elevated levels of 
cytoplasmic or nuclear pRaf(ser338) increased the risk of death in patients treated with 
tamoxifen by 1.74 (95% Cl 1.07 -  2.81, p^O.0247) and 2.29 (95% Cl 1.41 -  3.74, 
p—0.0009) times respectively. However, multivariate Cox-Regression revealed no 
evidence that pRaf(ser338) expression was an independent factor in influencing suivival.
Overall survival (OS) time for patients treated with tamoxifen was not affected by 
expression of Raf-1, pRaf(ser259), MAPK or pMAPK. Increasing levels of H-, K- and N- 
Ras in patients’ tumours also failed to influence OS.
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Figure 6.4: pRaf(ser338) Overall Survival Curves
Kaplan Meier survival curves showing overall smvival in patients whose tumours 
express cytoplasmic and nuclear pRaf(serS38). (a) Survival curve showing a significant 
reduction in overall survival time in patients whose tumours express high levels o f  
cytoplasmicpRaf(ser338) (p^O.0229). (b) Survival curve showing a significant reduction 
in overall survival time in patients whose tumours express high levels o f  nuclear 
pRaf(ser338) (p^O.0006). High levels were defined as scores > upper quartile value, p  
values represent log rank testing o f the differences in survival HR=Hazard Ratio (95% 
Cl)
6,5 Effect of increased expression of Ras/Raf-l/M APK on disease-free 
survival o f patients treated with only tamoxifen.
6.5.1 Disease Free Survival (DFS) and Recurrence on Tamoxifen (ROT)
As in section 6.3.1, the end point for disease-free survival for patients was defined as a
breast cancer relapse. In this sub group, the 303 tamoxifen only treated patients were 
analysed. In total there were 82 patients (27.1%) who relapsed. Of these, 61 relapsed 
whilst receiving tamoxifen treatment. As before, both DFS -  including all patients who 
relapsed regardless of treatment status -  and ROT -  including only those patients who 
relapsed whilst receiving tamoxifen treatment were analysed.
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6.5.2 Activation of Raf-1 and M APK is associated with a reduced disease 
free survival time in patients treated only with tamoxifen.
Increased expression of activated Raf-1 was linked to a reduction in DFS time. Patients
whose tumours expressed increased levels of cytoplasmic (p=0.0023, 10.15 years vs. 
13.27 years) and nuclear pRaf(ser338) (p=0.0020, 10.28 years vs. 12.83 years) were more 
likely to relapse quicker (Figure 6.5). Those patients with elevated tumour expression of 
either cytoplasmic or nuclear pRaf(ser338) were 2.02 (95% Cl 1.27-3.21, p=0.0028) and 
2.08 (95% Cl 1.29-3.33, p=0.0025) times more likely to relapse than those patients with 
low tumour levels.
Phosphorylation of MAPK was also associated with an increased risk of 
recurrence in patients. Increased expression of pMAPK in the cytoplasm of tumour cells 
was associated with a reduced time to recurrence in patients treated with only tamoxifen 
(p==0.0104, 8.52 years vs. 12.94 years, Figure 6.6a). Similarly, those patients whose 
tumours expressed increased levels of nuclear pMAPK had a shorter DFS (p=0.0425, 
11.38 years vs. 12.52 years, Figure 6.6b). The relative risks for relapse associated with 
higher expression levels of cytoplasmic or nuclear pMAPK in patients were 
2.04 (95% Cl 1.17-3.55, p=0.0121) and 1.61 (95% Cl 1.01-2.55, p=0.0444) respectively.
Multivariate Cox-Regression analysis revealed that only nuclear pRaf(ser338) 
expression was independent of tumour size, grade or nodal status in influencing relapse 
(p-0.0307) (Table 6.4).
DFS time for patients treated only with tamoxifen was not affected by 
overexpression of the three Ras isoforms, Raf-1, pRaf(ser259) or MAPK.
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Figure 6.5: Tamoxifen only treated patients disease free survival curves
Kaplan Meier survival curves showing disease-free survival in patients treated only with 
Tamoxifen whose tumours express cytoplasmic and nuclear pRaf(ser338). (a) Smvival 
curve showing a significant reduction in disease-free survival time in patients whose 
tumours express high levels o f  cytoplasmic pRaf(ser338) (p-0.0023). (b) Survival curves 
showing a significant reduction in disease survival time in patients whose tumours 
express high levels o f  nuclear pRaf(ser338) (p=0.0020). High levels were defined as 
scores > upper quartile value, p  values represent log rank testing o f  the differences in 
smvival, HR=Hazard Ratio (95% Cl).
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Figure 6.6: Tamoxifen only treated patients disease free survival curves
Kaplan Meier survival curves showing disease-free survival in patients treated only with 
tamoxifen whose tumours express cytoplasmic and nuclear pMAPK (a) Survival curve 
showing a significant reduction in disease-free survival time in patients whose tumours 
express high levels o f cytoplasmic pMAPK (p=0.0104). (b) Survival curves showing a 
significant reduction in disease survival time in patients whose tumours express high 
levels o f  nuclear pMAPK (p=0.0425). High levels were defined as scores > upper 
quartile value, p  values represent log rank testing o f the differences in survival. 
HR^HazardRatio (95% Cl)
Factor Hazard Ratio p-value
Nodal Status 2.01 (1.41-2.87) p=0.0002
Tumour Grade 1.47 (0.99-2.20) p=0.0552
Tumour Size 2.23 (1.31-3.81) p-0.0027
Nuclear pRaf(ser338) 1.94(1.09-3.45) p=0.0307
Table 6.4: Disease-free survival Cox-regression of patients treated only with 
tamoxifen
Cox-Regression multivariate analysis revealed that nuclear pRaf(Ser338) expression was 
independent o f known prognostic markers; nodal status, tumour size and grade, in 
influencing disease-free survival time in patients treated only with tamoxifen, p-values < 
0.05 were deemed statistically significant. Hazard ratio = relative risk associated with 
development o f tamoxifen resistance (95% Cl).
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6.5.3 Increased expression of nuclear pRaf(ser338) and cytoplasmic
MAPK is involved in the development of tamoxifen resistance in 
patients treated only with tamoxifen.
Increased expression of nuclear, but not cytoplasmic pRaf(ser338), in patients’ tumours
was associated with the development of tamoxifen resistance. These patients had a 
significantly shorter response time to tamoxifen (p=0.0006, 10.70 years vs. 13.23 years, 
Figure 6.7a). The relative risk associated with recurrence whilst on tamoxifen was 2.51 
(95% Cl 1.45-4.34, p=O.OOIO).
Increased expression of cytoplasmic MAPK was also associated with ROT. 
Patients whose tumours displayed high levels of MAPK were more likely to relapse 
whilst on tamoxifen (p=0.0021, 7.68 years vs. 13.20 years, Figure 6.7b). The relative risk 
for these patients was 2.28 (95% Cl 1.33-3,91, p=0.0028)
Furthermore, Cox-regression analysis revealed that nuclear pRaf(ser338) 
expression was independent of tumour size, grade and nodal status in influencing 
recurrence whilst on tamoxifen (p=0.0368) (Table 6.5).
Expression of the Ras isoforms, pRaf(ser259) and pMAPK, was not associated 
with ROT in those patients treated only with tamoxifen.
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Figure 6.7: Recurrence on Tamoxifen survival curves for patients treated only with 
Tamoxifen
Kaplan Meier survival curves showing the differences in survival in terms o f recurrence 
whilst on tamoxifen for patients whose tumours express either low or high levels o f  
pRaf(Ser338) or MAPK. (a) The survival curve shows a significant increase in the 
number o f patients who express high levels o f  nuclear pRaf(ser338) relapsing during 
tamoxifen treatment in comparison to those patients whose tumours express low levels 
(p^O.0006). (b) The survival curve shows a significant increase in the number o f patients 
who express high levels o f cytoplasmic MAPK relapsing during tamoxifen treatment in 
comparison to those patients whose tumours express low levels (p=0.0021). High levels 
were defined as scores > upper quartile value, p  values represent log rank testing o f  the 
differences in survival. HR=HazardRatio (95% Cl)
Factor p-value Hazard Ratio
Nodal Status p=0.0011 2.02(1.33-3.05)
Tumour Grade p=0.0094 1.93 (1.16-3.23)
Tumour Size p-0.0194 2.10(1.12-3.93)
Nuclear pRaf(ser338) p=0.0439 2.01 (1.03-3.92)
Table 6.5: Recurrence on Tamoxifen Cox-regression for patients treated only with 
tamoxifen
Cox-Regression multivariate analysis revealed that nuclear pRaf(Ser338) expression was 
independent o f known prognostic markers, nodal status, tumour size and grade, in 
influencing recurrence whilst receiving tamoxifen in patients treated only with tamoxifen, 
p-values < 0.05 were deemed statistically significant. Hazard ratio = relative risk 
associated with development o f  tamoxifen resistance (95% Cl).
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6.6 Effect of increased expression of Ras/Raf-l/M APK pathway on 
overall survival o f patients treated only with tamoxifen
6.6.1 Overall Survival (OS)
The end point for overall survival was a breast cancer related death. In total there were 55 
breast cancer related deaths in this group of 303 patients.
6.6.2 Expression and activation of Raf-1 and MAPK is linked to a 
reduction in overall survival time of patients treated only with 
tamoxifen.
Activation of Raf-1 was linked to a poor outcome in patients treated only with tamoxifen. 
Patients whose tumours expressed high levels of cytoplasmic or nuclear pRaf(ser338) 
exhibited a shortened OS time (p=0.0154, 13.60 years vs. 15.06 years) and (p=0.0008, 
11.80 years vs. 15.72 years) respectively (Figure 6.8). Increased expression of 
cytoplasmic or nuclear pRaf(ser338) raised the risk of death in patients treated with 
tamoxifen by 1.96 (95% Cl 1.13-3.42, p=0.0175) and 2.52 (95% Cl 1.44-4.41, p=0.0012) 
times respectively.
Increased expression of MAPK and pMAPK were also associated with a 
significant reduction in OS time. Patients whose tumours expressed higher levels of 
cytoplasmic and nuclear MAPK were more likely to die sooner than those with low levels 
(p-0.0331, 13.15 years vs. 15.55 years) and (p=0.0395, 13.11 years vs. 15.60 years) 
respectively (Figure 6.9a,b). The relative risk for these patients was 1.84 (95% Cl 1.04- 
3.26, p=0.0359) and 1,78 (95% Cl 1.02-3.12, p=0.0423) for cytoplasmic and nuclear 
MAPK respectively.
Likewise, patients with elevated tumour levels of nuclear pMAPK exhibited a 
shortened OS time (p=0.0336, 13,50 years vs. 16.10 years, Figure 6.9c). Increased
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expression of nuclear pMAPK increased the risk of death in patients treated with 
tamoxifen by 1.83 (95% Cl 1.04-3.24, p=0.0363) times.
Multivariate analysis failed to demonstrate that pRaf(ser338), MAPK or pMAPK 
were independent factors in influencing overall survival in patients treated only with 
tamoxifen.
Again, expression of H-, K-, N-Ras and inactive Raf-1 failed to influence outcome 
in patients treated only with tamoxifen.
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Figure 6.8: Tamoxifen only treated patients pRaf(ser338) overall survival curves
Kaplan Meier survival curves shoMnng overall survival in patients whose tumours 
express cytoplasmic and nuclear pRaf(ser338). (a) Survival curve showing a significant 
reduction in overall survival time in patients whose tumours express high levels o f  
cytoplasmic pRaf(ser338) (p=0.0154). (b) Survival curve showing a significant reduction 
in overall survival time in patients whose tumours express high levels o f nuclear 
pRaf(ser338) (p=0.0008). High levels were defined as scores > upper quartile value, p  
values represent log rank testing o f the differences in survival. HR= Hazard Ratio (95% 
Cl).
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Figure 6.9: Tamoxifen only treated patients MAPK & pMAPK overall survival 
curves
Kaplan Meier survival curves showing overall survival in patients whose tumours 
express cytoplasmic and nuclear MAPK and nuclear pMAPK (a) Survival curve showing 
a significant reduction in overall survival time in patients whose tumours express high 
levels o f cytoplasmic MAPK (p=0.0331). (b) Survival curve showing a significant 
reduction in overall survival time in patients whose tumours express high levels o f  
nuclear MAPK (p-0.0395). (c) Survival curve showing a significant reduction in overall 
survival time in patients whose tumours express high levels o f nuclear pMAPK 
(p—0.0336). High levels were defined as scores > upper quartile value, p  values 
represent log rank testing o f  the differences in survival. HR=Hazard Ratio (95% Cl)
6.7 The Ras/Raf-l/M APK pathway modifies patient outcome and 
response to treatment
The Ras/Raf-l/MAPK pathway appeared to play a crucial role in the progression of
breast cancer and response to treatment, though the effects mediated by Raf-1 and MAPK
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seemed to be partially dependent on the patient’s treatment regime. Figure 6.10  
summarises the impact o f  Ras, Raf-1 and MAPK on DFS, OS and ROT, in the entire 
STB cohort, and in the tamoxifen only treated patients.
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Figure 6.10: Association between Ras/Raf-l/MAPK pathway and patient outcome
Schematic representation o f the interaction between the Ras pathway and the oestrogen 
receptor and highlights the factors associated with DFS, OS and ROT in (a) the entire 
STB cohort and (b) in the tamoxifen only treated patients. DFS= Disease Free Survival, 
OS =  Overall Survival, ROT = Recurrence on Tamoxifen, p  values represent log rank 
testing o f the differences in survival, values < 0.05 were deemed statistically significant.
6.8 Association between Ras/Raf-l/M APK expression and known 
prognostic markers
Pearsons chi-square analysis was performed to establish if  there was any link between
expression/activation o f  Ras, Raf-1, MAPK and tumour grade, size or nodal status.
235
6.8.1 H-Ras
Cytoplasmic H-Ras was positively correlated with tumour grade (p=0.015). Patients with 
high levels of cytoplasmic H-Ras in their tumour were more likely to present with a grade 
3 tumour. No correlations were observed between H-Ras expression and tumour size or 
nodal status.
6.8.2 K-Ras
Expression of nuclear K-Ras was associated with nodal status (p==0.019). Patients who 
presented with increased levels of nuclear K-Ras in their tumour tended to be node­
positive. However, no correlation was evident between K-Ras expression and tumour 
grade or size.
6.8.3 N-Ras
A negative correlation between expression of nuclear N-Ras and tumour grade was 
evident (p=0.0001). Tumours that overexpressed nuclear N-Ras had a tendency to be of a 
lower grade (grade lor 2). There was no evidence of an association between N-Ras 
expression and tumour size or nodal status.
6.8.4 Raf-1
There were no correlations observed between Raf-1 expression and tumour size, grade or 
nodal status.
6.8.5 pRaf(ser259)
No associations were evident between pRaf(ser259) expression and tumour grade, size or 
nodal status.
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6.8.6 pRaf(ser338)
Nuclear pRaf(ser338) expression was positively correlated with node positivity 
(p=0.009), but not tumour size or grade, whilst overexpression of cytoplasmic 
pRaf(ser338) was associated with increased tumour grade (p=0.012), but not size or nodal 
status.
6.8.7 MAPK
Cytoplasmic MAPK expression was positively associated with tumour grade (p=0.025), 
size (p=0.002) and nodal status (p<0.0005). No correlations were observed between 
nuclear MAPK and known prognostic markers.
6.8.8 pMAPK
No associations were evident between pMAPK expression and tumour grade, size or 
nodal status.
6.9 Is the Ras/Raf-l/M APK pathway activated in breast tumours?
Having shown that increased expression of the individual components of the Ras/Raf-
l/MAPK pathway were associated with patient outcome, it was logical to assess whether 
the pathway was activated in tumours. Spearman Rank tests suggested a trend that 
increased levels of Ras expression, in particular N-Ras, was associated with increased 
activation of Raf-1, which subsequently was linked to increased phosphorylation of 
MAPK. However, the correlations should be observed with caution, since all the 
correlation coefficients for the various interactions were very low (Tables 6.6 & 6.7, 
Figures 6.11, 6.12 & 6.13). In particular, the scatter graphs examining the relationship 
between the Ras isoforms and inactive Raf-1, pRaf(ser259), highlight that the p-values 
should be viewed with some scepticism (Figure 6.12).
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pRaf(ser338) pRaf(ser259)
Cytoplasmic Nuclear Cytoplasmic
H-Ras
Cyto R  ^= 0.130 
p=0.015
R^= -0.052 
p=0.329
R  ^= 0.138 
p=0.009
Nuc R^= -0.163
p=0.002
R^= 0.066 
p=0.213
R  ^= -0.161
p=0.002
K-Ras
Cyto R" = 0.226 
p<0.0005
R^= 0.067
p=0.212
R  ^= 0.139
p=0.008
Nuc R^= 0.061 
p=0.250
R  ^= 0.143 
p = 0.007
R  ^= 0.249 
p<0.0005
N-Ras
Cyto R  ^= 0.274 
p<0.0005
R^= 0.028 
p=0.603
R  ^= 0.170
p=0.001
Nuc R  ^=-0.217 
p<0.0005
R^= -0.002 
p=0.971
R  ^= -0.117 
p=0.027
Table 6.6: Corre ations between Ras and Raf-1
Spearman Rank Tests were performed to analyse the relationship between overexpression 
o f the three Ras isoforms and phosphorylation o f  Raf-1, at serine 259 and serine 338, in 
the cytoplasm and nuclei. Only cytoplasmic pRaf(ser259) was analysed, because only 
very low levels o f nuclear pRaf(ser259) were detected. R^ = correlation coefficient, p  
values < 0.003 were deemed statistically significant, using Bonferroni’s correction, ns = 
nonsignificant.
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(a)
Cytoplasmic H-Ras vs Cytoplasmic pRaf(ser338)
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Figure 6.11: Scatter graphs of the interaction between Ras and pRaf(ser338)
The above scatter graphs highlight the relationship between expression o f the three Ras 
isoforms in the cytoplasm and expression o f cytoplasmic pRaf(ser338). The scatter plots 
and the correlation coefficients (R~) suggest that the strongest correlation was between 
the expression o f  cytoplasmic N-Ras and cytoplasmic pRaf(se338).
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Figure 6.12: Scatter graphs of the interaction between Ras and pRaf(ser259)
The above scatter graphs highlight the relationship between expression o f  the three Ras 
isoforms in the cytoplasm and expression o f cytoplasmic pRaf(ser259). The scatter plots 
and the correlation coefficients (R^) suggest that the correlations should be interpreted 
with caution.
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pMAPK Cyt pMAPK Nuc
R  ^= 0.495 R  ^= 0.377pRaf(ser259) Cyt p < 0.0005 p < 0.0005
R  ^= 0.333 R  ^=  0.213pRaf(ser338) Cyt p<0.0005 P<0.0005
R  ^= 0.262 R  ^= 0.300pRaf(ser338) Nuc P<0.0005 P<0.0005
Table 6.7: Correlations between pRaf and pMAPK expression
Spearman Rank Tests were performed to analyse the relationship between expression o f  
pRaf(ser259) and pMAPK, pRaf(ser338) and pMAPK. R^ = correlation coefficient, p  
values <0.008 deemed statistically significant, using Bonferroni’s correction.
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Figure 6.13: Scatter graphs of the interaction between pRaf and pMAPK
The above scatter graphs highlight the relationship between expression o f pRaf-1 and 
pMAPK. The scatter plots and the correlation coefficients (R^) suggest that de.spite p- 
values <0.008 the correlations should be observed with caution.
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6.10 Relationship between the Ras/Raf-l/M APK pathway and the 
activation and localisation of the oestrogen receptor.
Having shown that increased activation of Raf-1 and expression of MAPK was associated
with increased risk of tamoxifen resistance, and knowing that MAPK can activate ERa in 
a ligand independent manner, it was deemed appropriate to investigate the relationship 
between activation of the Ras pathway and expression and phosphorylation of ERa. 
Spearman Rank Tests were performed to analyse the relationship between expression of 
pRaf(ser338)/MAPK/pMAPK and ER/pER(serl 18)/pER(serl67) in the various 
subcellular compartments. Immunohistochemistry for ER, pER(serl 18) and pER(serl67) 
had previously been performed by Miss Sian Tovey.
6.10.1 Relationship between MAPK and ER expression
Analysis revealed that there was a very weak inverse relationship between expression of
nuclear MAPK and ER expression (Table 5,8). There appeared to be a trend towards 
tumours with increased levels of nuclear MAPK expressing lower levels of cytoplasmic 
and nuclear ER (p<0.0005 and p^O.031 respectively). Again, the correlation coefficients 
were very low, and these results should be observed with caution.
MAPK Cyto MAPK Nuc
E R C yt ns R ^ - -0.180 p<0.0005
ERN ue ns R  ^= -0.111 p=0.031
Table 6.8: Relationship between MAPK and ER expression
Spearman Rank Tests were performed to analyse the relationship between expression o f  
MAPK and ER in the cytoplasm and nuclei o f tumour cells. R^ = correlation coefficient, p  
values < 0.01 were deemed statistically significant, using Bonferroni’s correction.
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6.10.2 Relationship between Ras/Raf-l/M APK pathway and pER  
localisation.
At first glance, Spearman Rank Tests suggested that there were several statistically 
significant interactions between Raf-1, MAPK and ERa. However, closer examination of 
the p-values, correlation coefficients and scatter plots highlighted that only the interaction 
between nuclear pMAPK and nuclear pER(serl67) could be deemed believable 
(R^=0.298, p<0.0005) (Table 6.9, Figure 6.14). Figure 6.14 also shows two examples of 
scatter graphs of correlations that appear statistically significant, but have relatively low 
correlation coefficients and, therefore, should be regarded with scepticism.
pER(serll8) pER(serl67)
Cyto Nuc Memb Cyto Nuc Memb
pRaf(Ser338)
Cyto
R"=0.201
p<0.0005
R^= 0 .068  
P -0 .2 0 4
R " -0 .136
p=0.01
R W .1 0 9
p=0.045
RW .205
p<0.0005
R " -0 .159
p -0 .0 0 3
pRaf(ser338)
Nuc
R^= 0.023  
p=0.663
r M .1 7 0
P -0 .0 0 1
R ^- 0 .078  
p = 0.140
R ^- -0 .053  
p= 0.334
R'^-0.173
p=0.001
R"=0.139
p -0 .0 1 1
MAPK Cyto R^= 0.083
p=0.111
R^= 0 .066  
P -0 .2 0 5
R ^ -0 .140
p -0 .0 0 7
R^- 0 .027
p -0 .6 0 8
R^= 0 .0 2 0  
p=0.711
R " -0 .176
p=0.001
MAPK Nuc R^= -0 .086
p = 0.102
R^= -0.101  
P =0.053
R " -0 .108
p= 0.036
R^=-0.248
p<0.0005
R''=-0.172
P=0.001
R^= -0 .010  
p -0 .8 5 0
pMAPK
Cyto
R"‘= 0 .1 6 4
p = 0.002
R ^ - 0 .102  
P -0 .0 5 4
R^=0.228
p<0.0005
R^=0.206
p<0.0005
R ^ -0.115
p=0.033
R"=0.234
<0.0005
pMAPK Nuc R ^ - 0.085  
p = 0.107
R ^ -0 .106
P =0.045
R ^ = 0 .i72
p^O.OOl
R'^-0.165
p -0 .0 0 2
R^=0.298
p<0.0005
R ^ -0 .124
p=0.021
Table 6.9: Relationship between Raf-l/MAPK expression & pER expression
Spearman Rank Tests were performed to analyse the relationship between expression o f  
pRaf(serS38)/MAPK/pMAPK and pERser(l 18)/pER(serl67) in the three subcellular 
compartments, namely cytoplasm, nuclei and plasma membrane. R^ = correlation 
coefficient, p  values < 0.001 were deemed statistically significant, using Bonferroni’s 
correction.
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Figure 6.14: Scatter graphs of the interactions between MAPK and ER
Spearman Rank Tests suggested there were several statistically significant correlations 
between Raf-I, MAPK and ERcl However, examination o f the correlation coefficients 
revealed that the only believable interaction was between nuclear pMAPK and nuclear 
pER(serI67) (a). Graphs b,c show that despite p-values <0.0005, the correlations 
between cytoplasmic pMAPK and membrane pER must be viewed with some scepticism.
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6.11 Discussion
It has long been hypothesised that the interaction between growth factor receptor 
pathways and ERa mediates tamoxifen resistance. This study presents clinical evidence 
that expression and activation of the components of the Ras/Raf-l/MAPK pathway in 
clinical breast tumours is associated with a poor outcome, in particular the failure to 
respond to tamoxifen treatment (tamoxifen resistance).
While the Ras/Raf-l/MAPK pathway serves multiple purposes, two key functions 
are modulation of cell proliferation and modification of ERa. Tamoxifen functions by 
down-regulating ERa activity, inhibiting activation of oestrogen regulated genes and 
reducing cell proliferation. That Ras, Raf-1 and MAPK proteins appear to be predictive 
markers for response to treatment for patients treated with tamoxifen implies that the 
modification of ERa by the Ras pathway is crucial in the development, progression, and 
treatment responsiveness of tamoxifen treated breast tumours.
Initial analysis of the entire STB cohort (303 tamoxifen only and 99 tamoxifen 
and chemotherapy treated patients) revealed that the development of tamoxifen resistance 
was partially dependent on the expression and activation of the Ras cascade. Patients 
whose tumours overexpressed cytoplasmic N-Ras (p-0.0318) and nuclear pRaf(ser338) 
(p=0.0052) exhibited a shortened time to relapse whilst receiving tamoxifen. 
Furthermore, pRaf(ser338) was the only factor related to reduced disease-free and overall 
survival time. That of the three isoforms, only N-Ras appears to be involved in the 
mechanism that drives tamoxifen resistance confirms previous findings that the various 
Ras isoforms differ in their functions and ability to activate their downstream effectors, 
such as Raf-1 and P13K. K- and N-Ras are believed to be the more effective activators of 
Raf-1, whereas H-Ras is more efficient in activating the PI3K/Akt pathway
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(132;133;218). This, too, was suggested in our study, of the three isoforms, N-Ras 
expression appeared to be the most significantly correlated with activation of Raf-1. 
Consequently, the various Ras isoforms may regulate different pathways that mediate 
response to alternative treatments. Overexpression and activation of the N-Ras/Raf- 
1/MAPK pathway is perhaps fundamental in the acquisition of tamoxifen resistance. This 
theory is further supported by the findings from this study that MAPK is a potential 
predictive marker of response to tamoxifen treatment, since patients expressing high 
levels of MAPK in their tumours were more likely to relapse whilst receiving tamoxifen 
(p=0.0012). Additionally, MAPK, unlike Ras or Raf-1, was shown to be independent of 
known prognostic markers, namely tumour size, grade and nodal status, in predicting 
response to treatment.
MAPK controls multiple cellular processes through phosphorylating and 
activating substrates within the cytoplasm and the nuclei of cells. However, of particular 
interest is its ability to modify the activation status of ERa and ERa regulated genes. The 
relationship between MAPK and ERa has been well documented; it is known that MAPK 
directly phosphorylates ERa at serine 118, and indirectly at serine 167, via p90rsk 
(39;197;201). This ligand-independent phosphorylation of ERa results in its increased 
interactions with co-activators rather than co-repressors, which subsequently increases 
ERa-mediated transcriptional activity. It is thought that this contributes to tamoxifen 
resistance by promoting tumour growth in the presence of low levels of oestrogen. In 
addition, MAPK phosphorylates ERa co-activator proteins, such as SRC-1 and AIBl, 
enabling them to interact with ERa, which further enhances transcriptional activity and 
may promote the agonistic rather than antagonistic nature of Tamoxifen (216;217).
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Alternatively, tumour ERa levels may decrease in response to increasing 
expression levels of MAPK. Several studies have shown that overexpression and 
increased aetivation of the EGFR/HER2 pathways in ERa positive breast cancer cells can 
promote ERa loss and subsequently reduce expression of oestrogen-regulated genes, 
such as the progesterone receptor (204;208;225). Furthermore, ERa negative breast 
tumours tend to present with overexpression of the growth factor receptors and elevated 
levels of MAPK (259). Elevated MAPK activity was prominent in the tumours of patients 
exhibiting de novo tamoxifen resistance (225). Activation of MAPK in MCF-7 cells 
corresponds to increased activation of Nuclear Factor-icB, and it is thought that this is 
partially responsible for the down-regulation of ERa (206). A more recent study suggests 
that hyper-activation of MAPK in ERa positive cancer cells is a key mechanism in 
driving the change from an ERa positive to a ERa negative phenotype, and that there is a 
“hyperactive MAPK signature” set of genes that identify ERa negative tumours (208). 
Data from our study also suggests the trend that tumours expressing high levels of 
nuclear MAPK exhibit lower levels of ERa. Previous research demonstrated that patients 
whose tumours exhibited lower levels of ER had a poorer prognosis (223). Our findings 
support this, in that patients with increased levels of MAPK presented with more 
aggressive tumours. These patients were more likely to be node positive and have 
tumours that were both larger in size and higher in grade, all of which are known to be 
poor prognostic markers. However, ERa levels can be restored in MCF-7 breast cancer 
cells (205) using MEK inhibitors, therefore, the same approach might be appropriate in 
patients whose tumours overexpress MAPK.
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To further probe the role of the Ras pathway in driving tamoxifen resistance, it 
was deemed appropriate to analyse the effects of Ras, Raf-1 and MAPK expression on 
the outcome of those patients treated only with tamoxifen, thus avoiding the potential 
compounding effects of combined endocrine and chemotherapy treatments. Whilst 
clearly exploratory, due to the reduced sample size, these sub-analyses confirmed initial 
findings that activation of the Ras pathway is a crucial mechanism in the progression of 
breast cancer and development of tamoxifen resistance. In this sub-group, both elevated 
levels of pRaf(ser338) and pMAPK were associated with reduced disease free and overall 
suiwival time, strengthening the argument that activation of the Ras pathway is linked to a 
poor outcome.
The original analysis of the entire STB cohort failed to show a relationship 
between pMAPK expression and patient outcome. Previous studies have been 
inconclusive in confirming whether expression levels of pMAPK influence patient 
survival and resistance to treatment. Two clinical studies suggested that patients with low 
levels of pMAPK were more responsive to tamoxifen (223;225). Whereas in vitro 
analysis showed that tamoxifen significantly inhibited the gi’owth of MCF-7 cells 
transfected with constitutively activated MEK, and that activation of MAPK was not 
contributing to tamoxifen resistance (212). Another study investigating pMAPK, in 
untreated patients and in a mixture of differently treated patients, showed that, in only the 
untreated patients, did pMAPK correlate with overall survival (224). The differences 
observed in terms of the role of pMAPK in influencing outcome may be because we are 
comparing in vivo and in vitro studies. It might also be that the phosphorylated form of 
MAPK does not necessarily represent the activated form of the protein. It has been shown
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that both the dimérisation and nuclear localisation of MAPK are dependent on its 
phosphorylation, but not its activation status (195). It may also reflect the difficulty in 
finding reliable phosphorylated antibodies.
As in the original analyses, overexpression of nuclear pRaf(ser338) and 
cytoplasmic MAPK were once again linked with relapse whilst receiving tamoxifen 
treatment. Conversely, though, in this tamoxifen only treated group, it was pRaf(ser338) 
expression and not MAPK expression that proved to be independent of tumour size, 
grade and nodal status in predicting for tamoxifen resistance. Additionally pRaf(ser338) 
was also shown to be an independent predictive marker of reduced disease free survival. 
These findings, together with those from the analysis of the entire STB cohort, suggest 
that pRaf(ser338), as opposed to MAPK, is a better predictor of patient outcome in 
tamoxifen treated patients.
There are several implications from these findings. The first is that, whilst N-Ras 
and MAPK are associated with the development of tamoxifen resistance and emphasise 
the importance of the Ras pathway, it is nuclear pRaf(ser338) that is the principal 
candidate for identifying patients failing to respond to tamoxifen. The second is that 
elevated levels of activated Raf-1 in tumours may predict for poor response to 
Tamoxifen; however it also appears to identify patients who benefit from a combined 
treatment regime of tamoxifen and chemotherapy. Finally, that MAPK was not an 
independent predictive marker in the tamoxifen only treated patients, but was in the 
cohort of tamoxifen and chemotherapy treated patients, perhaps suggests that MAPK 
partially controls cells response to chemotherapy.
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Raf-1 is a serine-threonine kinase that plays a role in cell proliferation, 
differentiation and apoptosis, and is prominent in controlling tumour angiogenesis and 
metastasis (260). This study illustrated that upregulated activity of Raf-1 in tumours was 
related to poorly differentiated tumours (high grade) and tumour spread (node positivity). 
A recent study demonstrated that targeting of Raf-1 inhibited tumour growth, and that 
this represented an important therapeutic strategy (186). Additionally, the Ras pathway 
has been shown to interact with and activate ERa. The finding that the Ras/Raf-l/MAPK 
pathway, in particular Raf-1, are predictive markers for suivival and response to 
tamoxifen may suggest that the interaction between this pathway and ERa is fundamental 
in influencing patient outcome in response to tamoxifen.
As discussed above, the ligand-independent phosphorylation of ERa at serine 118 
is believed to be a major contributor to the development of tamoxifen resistance. 
However, increased expression of neither nuclear pMAPK nor pER(serl 18) (unpublished 
data from our group) demonstrated a significant association with relapse on tamoxifen 
treatment. This implies that, whilst MAPK driven phosphorylation of ERa is important, it 
is not the only contributing factor in the development of tamoxifen resistance. It also 
suggests that the mechanism by which nuclear pRaf(ser338) influences tamoxifen 
resistance is independent of MAPK.
It is perhaps surprising, considering the vast quantities of research that is 
undertaken to investigate the Ras/Raf-l/MAPK pathway, that Raf-1 is not the only 
effective activator of Mekl/2 and subsequently MAPK. B-Raf is considered to be a main 
activator of MEK (261-263). Activation of Raf-1 is thought to result in the transient 
phosophorylation of MAPK (261). Consequently, there are thought to be other cellular
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targets for Raf-l, and research has revealed other functions of Raf-1, such as its ability to 
regulate Rho signalling independently of MAPK (264). One other key Raf-1 substrate is 
the Retinoblastoma (RB) tumour suppressor protein.
Research has highlighted that nuclear Raf-1 binds and phosphorylates Rb protein 
independently of the MAPK cascade (184), Phosphorylation of Rb results in its 
inactivation, and the subsequent dissociation from and activation of E2F. This ultimately 
results in the cell cycle progressing from G1 to S phase. Therefore, translocation of Raf-1 
into the nucleus can facilitate cell proliferation. Studies have shown that prevention of the 
interaction between Raf-1 and Rb prevents tumour growth and angiogenesis (265). This 
corresponds with our findings that increased Raf-1 is associated with poor patient 
outcome. Furthermore, it is postulated that Rb is a key target of oestrogen, and that 
inactivation of Rb is connected to the development of resistance to anti oestrogen 
therapies, such as tamoxifen (266). Additionally, the antioestrogens, ICI 164,384 and 
OFIT (4-Hydroxy Tamoxifen), were shown to be able to prevent oestrogen-induced 
hyperphosphorylation of Rb, in T57D cells. Tamoxifen, however, was unable to do this 
(267). Interestingly, Rb has been shown to be a co-activator of the androgen receptor in 
prostate cancer cells (268;269). These results imply that activation and translocation of 
Raf-1 to the nucleus inactivates Rb, which results in increased cellular proliferation, even 
in the presence of antioestrogens.
Elevated levels of activated Raf-1 in tumours predicted for poor response to 
Tamoxifen; however it also seemed to identify those patients who would benefit from a 
combined treatment regime of tamoxifen and chemotherapy. Chemotherapy targets 
highly proliferating cells. In tumours, cell growth is driven by the classical proliferative
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factors, such as c-fos, but also by the Ras/Raf-l/MAPK-ERa interactions, which will 
enhance cells sensitivity to oestrogen, and ultimately increase proliferation. Furthermore, 
the interaction between nuclear Raf-1 and Rb will stimulate cell proliferation and growth. 
One might, therefore, predict that tumours which overexpress Ras/Raf-l/MAPK might be 
more responsive to chemotherapy. Accordingly, it seemed that those patients who 
overexpressed pRaf(ser338) had an improved outcome when treated with chemotherapy, 
in addition to tamoxifen. Comparison of the survival curves from the tamoxifen only 
treated group with the tamoxifen only and tamoxifen plus chemotherapy cohort suggested 
that chemotherapy delayed tamoxifen relapse in those patients expressing high levels of 
pRaf(ser338) but not MAPK. In the tamoxifen only treated group, increased expression 
of pRaf(ser338) and MAPK seemed to mediate early events in the development of 
tamoxifen resistance. This pattern fits with previous research that suggests that changes 
in the MAPK cascade are important in the early stages of development and maintenance 
of tamoxifen resistance (270). However, supplementary chemotherapy treatment seemed 
to temporarily negate the effects of elevated pRaf(ser338). Activation of Raf-1 seemed to 
be associated with a lack of response after 3 years of tamoxifen treatment. Increased 
tumour levels of pRaf(ser338) are indicative of poor response to Tamoxifen, but perhaps 
also of an enhanced response to chemotherapy. This supports previous findings that 
increased expression of Raf-1 in cell lines makes them more responsive to 
chemotherapeutic agents (271). Perhaps this signifies that pRaf(ser338) is a potential 
marker to identify patients for whom tamoxifen alone is insufficient adjuvant systemic 
therapy. Those patients who overexpress pRaf(Ser338) in their tumours may require 
treatments such as chemotherapy or aromatase inhibitors, in addition to tamoxifen.
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Studies are currently undei*way investigating the benefits of switching from tamoxifen to 
aromatase inhibitors (AIs) after 2-3 years of tamoxifen treatment (IBS study)(272). 
Analysis of patients who remained disease-free after 3 years tamoxifen treatment 
revealed that overexpression of pRaf(ser338) was significantly associated with shortened 
time to relapse and death. These results, again, raise the possibility that activated Raf-1 is 
a suitable marker for identifying patients who require other treatments besides tamoxifen. 
However, further research, perhaps in the TEAM or ATAC trial, is required to test the 
ability of activated Raf-1 to function as an effective predictive marker for response to 
tamoxifen treatment.
Unlike the expression of activated Raf-1, MAPK expression was an independent 
marker of tamoxifen resistance in the entire STB cohort perhaps suggesting that MAPK 
regulates response to chemotherapy. To investigate this hypothesis and to establish the 
role of both Raf-1 and MAPK in mediating response to chemotherapy, a similar study to 
this one was performed on a cohort of breast cancer patients from the NEAT/BR9601 
trial who had received adjuvant chemotherapy. The results are discussed in the following 
chapter.
In recent years, the localisation of ERa has been the focus of much research. 
Previously the presence of membrane ERa had been ignored; however, it is now 
acknowledged that ERa is localised to the cytoplasm, nuclei and membrane of cells, and 
that the functions of nuclear and membranous ERa differ. Nuclear ERa exerts genomic 
effects through regulating transcription of oestrogen-regulated genes, whereas 
membranous ERa mediates non-genomic effects via activating signal transduction 
cascades, such as the Ras/Raf-l/MAPK pathway (48-51). It is, therefore, becoming
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increasingly obvious that the subcellular localisation of proteins, as well as the extent of 
their expression, is an important factor when attempting to establish new prognostic and 
predictive markers. This was particularly apparent from the analyses of Ras and Raf-1 
proteins. Overexpression of the activated form of Raf-1, pRaf(ser338), was linked to 
reduced disease-free and overall survival in patients. pRaf(ser338) altered patient 
outcome, regardless of whether it was expressed in the cytoplasm or nuclei of tumour 
cells. However, only nuclear pRaf(ser338) was associated with recurrence on Tamoxifen, 
suggesting that the cytoplasmic and nuclear forms of these proteins have different 
functions. This argument is further strengthened by the fact that patients who 
overexpressed cytoplasmic pRaf(ser338) in their tumours were more likely to present 
with higher grade tumours (grade=3), whereas those patients who overexpressed nuclear 
pRaf(ser338) in their tumours were predisposed to be node positive. These results 
suggest that cytoplasmic pRaf(Ser338) is involved in regulating cellular differentiation, 
whereas nuclear pRaf(ser338) perhaps regulates cell motility and tumour metastasis.
The varying function of proteins, depending on their localisation, was evident 
from the findings regarding the role of Ras in breast cancer. In both this study and the 
pilot study (chapter 3), H-, K- and N-Ras were localised to both the cytoplasm and nuclei 
of tumour cells. In the pilot study, overexpression of both cytoplasmic and nuclear N-Ras 
was associated with a reduced time to relapse and death. However, in this study, only 
cytoplasmic N-Ras was linked to an increased risk of tamoxifen resistance. Nonetheless, 
this study highlights, that like Raf(ser338), the cytoplasmic and nuclear Ras isoforms 
seem to have different functions. Cytoplasmic N-Ras may be linked to an increased risk 
of relapse on tamoxifen, but its nuclear counterpart was inversely correlated with tumour
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grade. Those patients who overexpressed nuclear N-Ras were more likely to present with 
a lower grade tumour. Likewise, differences were observed between cytoplasmic and 
nuclear H-Ras. Increased expression of cytoplasmic, but not nuclear H-Ras, was 
associated with higher grade tumours, suggesting a role for cytoplasmic H-Ras in 
regulating differentiation. Similar differences were observed with K-Ras. The nuclear, 
but not cytoplasmic form of this protein, was associated with node positivity. Therefore, 
this study highlighted, not only the importance of subcellular specific functions of 
proteins, but also confirmed previous findings that the various Ras isoforms have 
different abilities to control cellular processes, such as differentiation and cell motility. 
Additionally, it again underlines the importance of the newly identified nuclear Ras, 
especially K- and N-Ras, and highlights the necessity of establishing the function of this 
nuclear protein.
This is the first study to investigate the function of the Ras/Raf-l/MAPK pathway 
in tumours of breast cancer patients treated with tamoxifen. It has demonstrated that this 
proliferative pathway is activated in breast tumours, and that this activation significantly 
contributes to the development of tamoxifen resistance in patients. These results suggest 
that activated Raf-1 is a potential predictive factor for identifying patients who are least 
likely to respond to tamoxifen and would require either additional or alternative 
therapies, such as chemotherapy, AIs or even Raf-1 inhibitors. Furthermore, this study 
laid the foundations for the research investigating the role of the Ras pathway in 
chemotherapy response, and the interactions between MAPK and ERa in breast cancer 
cell lines, all of which are discussed in the proceeding chapters.
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7. The role of the Ras/Raf-l/M APK pathway in the 
development of resistance to chemotherapy
7.1 Introduction
The results from the STB study (chapter 6) suggested that activation of the 
Ras/Raf-l/MAPK pathway was associated with the development of tamoxifen resistance. 
Activated Raf-1 was identified as a possible predictive marker for tamoxifen resistance. 
However, this study also inferred that increased expression of pRaf(ser338) in tumours 
identified a group of patients who would benefit from the combined treatment of both 
tamoxifen and chemotherapy. Furthermore, it raised questions regarding the role of 
MAPK in predicting patients’ response to chemotherapy.
Adjuvant chemotherapy is generally accepted as the treatment for women with 
node-positive breast cancer. This involves the use of cytotoxic drugs to kill cancer cells 
by direct toxic actions (as opposed to tamoxifen, which modulates a biological target). 
Following the NEAT (National breast cancer study of Epirubicin & CMF versus classical 
CMF Adjuvant Therapy) clinical trial, the combination of epirubicin and CMF is now a 
common practice in the UK.
Despite the extensive use of chemotherapy as adjuvant treatment, failure to 
respond to treatment is a major clinical problem. For the majority of chemotherapeutic 
agents to function efficiently, the tumour cells must be proliferating and in a growth 
phase. Patients who present with tumours that have only a small percentage of cells in 
growth phase, are more likely to develop resistance to chemotherapeutic agents (13). The 
exact mechanisms underlying the development of resistance to chemotherapy are not 
fully understood. However, several studies have suggested that the Ras/Raf-l/MAPK
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pathway may be involved in the development of resistance to epirubicin and doxorubicin.
This study investigated whether expression and activation of Raf-1 and MAPK 
influenced clinical outcome following treatment with chemotherapy. It tested the 
hypothesis that activation of the Ras/Raf-l/MAPK pathway drives resistance to 
chemotherapy in clinical breast cancers. Patients from the NEAT/BR9601 cohort were 
analysed for Raf-1 and MAPK expression and activation (discussed in Chapter 4), and 
survival analysis was performed, in terms of disease-free survival (DFS), and overall 
survival (OS).
7.2 Patient cohort & treatment
Patients from the BR9601 (NEAT) trial were randomly allocated to receive treatment of 
4 cycles of epirubicin, followed by 4 cycles of CMF given intravenously every three 
weeks, or treatment with 8 cycles of classical CMF given intravenously every three 
weeks (Table 7.1). Three hundred and eighty four patients were randomised in the 
original trial, and we retrieved tissue samples from 318 of these cases (84%). 155 patients 
(48.74%) received the combined treatment of Epirubicin and CMF, while the remaining 
163 patients (51.26%) received only CMF. Survival analysis was performed on all 318 
NEAT patients, but also on the two sub-groups of patients: those that received CMF 
alone and those that received it in combination with epirubicin.
The results from chapter 6 suggested that pRaf(Ser338) and MAPK expression 
might predict for response to chemotherapy in tamoxifen treated patients. To investigate 
this further, it was deemed appropriate to combine the two patient cohorts for survival 
analysis. In total there were 264 ERa positive patients (165 NEAT patients and 99 STB 
patients) who received both tamoxifen and chemotherapy. Additionally 25 ERa negative
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and 34 ERa unknown patients received both tamoxifen and chemotherapy, but these 
patients were excluded from flirther sub-analyses. Ninety-four patients from the NEAT 
study were treated with chemotherapy but not tamoxifen (79 ERa -ve, 9 ERa+ve, 6 ERa 
Unknown). Consequently, survival analysis was performed on the two sub-groups of 
patients: those that received tamoxifen in combination with chemotherapy (264 patients) 
and those that received only chemotherapy (94 patients). Table 7.2 provides details of the 
various treatments.
Treatment Dose
CMF
Cyclophosphamide : 750mg/m^ iv 
Methotrexate: 50mg/m iv 
5-fluorouracil: 600mg/m^ iv
Epirubicin Epirubicin: lOOmg/m^ iv
Table 7.1: BR9601/NEAT Chemotherapy Treatment
Treatment STB Patients NEAT Patients Combined Patients
Tamoxifen 303 na 303
Tamoxifen & 
Chemotherapy 99 165 264
Chemotherapy na
ERa +ve: 9 
ERa -ve: 79 
ERaunknown: 6
94
Table 7.2: Treatment regimes from STB and NEAT studies
The STB and NEAT cohort o f  patients were combinedfor survival analysis. Patients were 
treated with one o f three regimes: tamoxifen alone, tamoxifen and chemotherapy 
combined, or chemotherapy alone.
7.3 Ras/Raf-l/M APK pathway is activated in breast tumours
As in the STB study, Spearman Rank Tests revealed that the Raf-1/MAPK pathway was 
activated in the tumours of the NEAT patients. Patients who expressed higher levels of 
activated Raf-1 in either the cytoplasm or nuclei of tumour cells, also presented with 
increased levels of cytoplasmic and nuclear pMAPK (Table 7.3).
258
pMAPK Cyt pMAPK Nuc
=0.505 R  ^=0.413pRaf(ser259) Cyt p<0.0005 p<0.0005
R  ^=0.588 R^= 0.234pRaf(ser338) Cyt p<0.0005 p<0.0005
R^= 0.403 R  ^=0.296pRaf(ser338) Nuc p<0.0005 p<0.0005
Table 7.3: NEAT pRaf and pMAPK correlations
Spearman Rank Tests were performed to analyse the relationship between expression o f  
pRaf(ser259) andpMAPK, pRaf(ser338) andpMAPK. R^ = correlation coefficient. 
Using Bonferroni corrections, p  values <0. 008 deemed statistically significant.
7.4 Relationship between Ras/Raf-l/M APK pathway and disease-free 
survival in patients treated with chemotherapy.
7.4.1 Disease Free Survival (DFS)
The end point for measuring disease-free survival, regardless of treatment received, was 
local, regional or distant recurrence. In total 111 patients (34.9%) relapsed, 87 patients 
suffered from an initial distant recurrence (metastasis), whilst regional and local 
recurrences occurred in 10 and 14 patients respectively. A further 20 patients whose first 
relapse was either local or regional also suffered from a secondary distant recurrence 
(Table 7.4). Survival analyses were performed on all patients who relapsed, regardless of 
their type of recurrence, and on only those patients who suffered a distant recurrence. 
Additionally, analyses were performed on the two treatment groups (Epi/CMF & CMF 
alone) in combination and individually. As described in chapter 5, for survival analysis, 
patients were split into two groups: those that were defined as expressing low levels of 
protein and those that expressed higher levels. For all proteins analysed, it was deemed 
most appropriate to use the histoscore upper quartile value as the cut off point for 
characterising the patients into their groups.
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Recurrence Recurrence Type Total No. Epi/CMF CMF only
NONE 207 113 94
Distant 87 37 50jSt Regional 10 3 7
Local 14 2 122nd Distant 20 5 15
Table 7.4: NEATl Recurrence Type
The end point for disease-free survival was a local, regional or distant recurrence. 
Information was available regarding patients ’ primary and secondary recurrences. The 
table presents the frequency o f each type o f recurrence and highlights the number o f  
patients from each treatment group who relapsed.
7.4.2 Overexpression of Raf-1 and M APK does not impact on patients^ 
disease-free survival.
Survival analyses performed on all patients (Epi/CMF & CMF alone) revealed no
significant association between tumour expression of pRaf(ser259), pRaf(ser338), 
MAPK, or pMAPK and risk of breast cancer recurrence whilst receiving chemotherapy. 
There was also no evidence of pRaf(Ser259), pRaf(ser338), MAPK or pMAPK being 
linked to tumour metastasis (distant recurrences only).
7.4.3 Overexpression of neither Raf-1 nor MAPK preferentially affects 
disease-free survival time in patients treated with either 
Epirubicin/CMF or CMF alone.
Patients were split into their two treatment groups (Epi/CMF vs CMF alone) and disease-
free survival analysis performed. However, in both treatment groups, increased 
expression of Raf-1 (inactive or active) and MAPK failed to alter disease-free survival 
time.
7.5 Relationship between Ras/Raf-l/M APK pathway and overall 
survival in patients treated with chemotherapy.
7.5.1 Overall Survival (OS)
The end point for overall survival was a breast cancer related death. Within this study 
there were 84 breast cancer related deaths; 50 of these were patients receiving only CMF
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treatment, while the remaining 34 patients received both Epirubicin and CMF. Again, 
analyses were performed on the patient group, as a whole, and individually on the two 
treatment groups.
7.5.2 Overexpression of Raf-1 and M APK does not impact on patients’ 
disease-free survival.
Overall survival (OS) time for all NEAT patients (treated with Epi/CMF or CMF alone)
was not affected by overexpression of pRaf(ser259), pRaf(ser338), MAPK or pMAPK.
7.5.3 Overexpression of neither Raf-1 nor M APK aATects overall survival 
time in patients treated with either Epirubicin/CMF or CMF 
alone.
Again, patients were split into their two treatment groups (Epi/CMF vs CMF alone) and 
overall survival analysis performed. However, in both treatment groups overexpression of 
inactive or active Raf-1, MAPK and pMAPK was not associated with reduced overall 
survival time.
7.6 Role of Raf-1 and M APK in predicting outcome in patients treated 
with tamoxifen and chemotherapy
A total of 264 patients from both the NEAT and STB cohorts were treated with both
tamoxifen and chemotherapy. Within this sub-group of patients there were 79 breast 
cancer relapses and 51 breast cancer related deaths. Survival analysis was performed 
relative to disease-free survival (DFS) and overall survival (OS), to investigate the effects 
of receiving both tamoxifen and chemotherapy on patient outcome. Relapse whilst on 
tamoxifen (ROT) was not analysed, as data regarding tamoxifen relapse was not available 
for the NEAT patients.
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7.6.1 Raf-1 and M APK are not predictive factors for outcome in patients 
treated with both tamoxifen and chemotherapy
Survival analyses performed on patients receiving both treatments revealed no significant
association between tumour expression of pRaf(ser259), pRaf(ser338), MAPK, or 
pMAPK and shortened DFS or OS time.
7.7 Role of Raf-1 and MAPK in predicting outcome in patients treated 
only with chemotherapy
Ninety-four patients from the NEAT cohort received only chemotherapy, of which 38
patients experienced a breast cancer recurrence whilst 35 patients suffered a breast cancer 
related death. Survival analysis was performed for disease-free and overall survival.
7.7.1 Raf-1 and MAPK are not predictive for response to chemotherapy 
treatment
Expression of inactive or active Raf-1, MAPK, and pMAPK was not associated with 
outcome in patients treated only with chemotherapy.
7.8 Association between Raf-l/M APK  expression and known prognostic 
markers
Pearsons chi-square analysis was performed to establish if there was any link between 
expression/activation of Raf-1 and MAPK and tumour grade, size, ERa or nodal status. 
No associations were evident between pRaf(ser259) and pRaf(ser338) expression and 
tumour grade, size, ERa or nodal status. However, nuclear MAPK and cytoplasmic 
pMAPK expression were negatively correlated with tumour grade (p=0.011 and p=0.017 
respectively). Tumours that expressed high levels of either nuclear MAPK or cytoplasmic 
pMAPK were more likely to be of a lower grade (grade =1 or 2). There were no 
significant correlations between MAPK and pMAPK expression and tumour size, ERa or 
nodal status.
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7.9 Discussion
As the incidences of breast cancer in women continue to increase, so too does the need to 
establish new treatments while also improve existing therapies. One way to do this is to 
further our understanding of the mechanisms that cause current therapies to fail. 
Chemotherapy is known to improve patient survival, yet resistance to chemotherapeutic 
agents is an ever-increasing problem. The factors driving resistance are unconfirmed. 
This study tested the hypothesis that Raf-1 and MAPK, factors that regulate cell 
proliferation, ultimately predict outcome in terms of disease-free and overall survival in 
patients treated with chemotherapy.
The Ras/Raf-l/MAPK pathway is a key regulator of cell proliferation and the 
effectiveness of chemotherapy is believed to be dependent on cellular proliferation. It is 
perhaps surprising that this study revealed no evidence that expression or activation of 
the components of this pathway influenced response to chemotherapeutic agents.
Neither Raf-1 (active or inactive) nor MAPK expression levels were shown to 
influence the disease-free or overall survival time of patients treated with either CMF or 
CMF and Epirubicin. These results suggest that the Ras/Raf-l/MAPK pathway is not 
primarily involved in the acquisition of chemotherapy resistance.
The function of Raf-1 and MAPK in mediating response to chemotherapeutic 
agents is controversial. Previously all research investigating the relationship between the 
Ras/Raf-l/MAPK pathway and anthracycline resistance had been performed in cell lines. 
These studies suggested that both Raf-1 and MAPK played a role in the development of 
resistance to epirubicin and doxorubicin. Two studies (154;227) showed that increased 
expression and activation of Raf-1 was associated with resistance to doxorubicin induced 
apoptosis in MCF-7 breast cancer cells. Conversely, another study suggested that down-
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regulation of Raf-l was associated with paclitaxel resistance in breast cancer cells (271). 
Likewise, the extent to which p42/44 MAPK influences resistance to anthracycline 
treatment is also complex. Anthracyclines can induce and inhibit activation of MAPK 
under certain conditions. As a result, MAPK activation has sometimes been associated 
with protecting cells from drug-induced apoptosis, while in other incidences it promotes 
cell death (230;273). A more recent study (274) highlighted that treatment with 
anthracyclines leads to activation of MAPK in breast epithelial and carcinoma cells, and 
that this activation may in turn inhibit the anti-tumour activity of the anthracyclines. The 
increase in MAPK activity was also shown to correlate with an increase in 
phosphorylation of p90RSK and BAD. Phosphorylation of BAD at Serine 112 is anti- 
apoptotic, since it prevents it from binding to B c 1 - x l ,  It would seem from this study that 
activation of the MAPK pathway inhibits the anti-tumour effects of anthracyclines. 
Preliminary studies by this same group suggested that inhibition of MAPK enhanced 
doxorubicin or epirubicin induced apoptosis.
Llowever, our study failed to reveal any significant relationship between either 
expression/activation of Raf-1 and MAPK and chemotherapy resistance. A previous 
study investigating the response of prostate cancer cells to either doxorubicin or 
paclitaxel failed to show a link between the Ras cascade and drug resistance (275). 
Nonetheless, a study of chemotherapy resistance in MCF-7 breast cancer cells suggested 
that PI3K/Akt pathway, as opposed to the Raf-l/MAPK pathway, may play a more 
significant role in mediating chemo-resistance (229). A similar finding was observed in 
the study of small cell lung cancer cells, which showed that inhibition of the P13K/Akt, 
but not the Ras/Raf-l/MAPK pathway, overcame resistance to chemotherapy (276). For
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chemotherapy to be effective, cell death has to outweigh cell proliferation. It may be 
necessary to analyse both the proliferative Ras/Raf-l/MAPK pathway and the anti- 
apoptotic PI3K/Akt pathway in the NEAT study. Perhaps in clinical breast tumours the 
anti-apoptotic proteins downstream of Raf-1 and MAPK, such as p90RSK, Bcl-2 or Bad, 
may be more appropriate targets for predicting chemotherapy resistance. This was 
suggested in a study of MCF-7 cancer cells, which demonstrated that activation of Raf-1 
in Bcl-2 overexpressing cells resulted in greater resistance to doxorubicin, in comparison 
with cells lacking Bcl-2 overexpression (227).
In addition to highlighting pRaf(ser338), and to a lesser extent, MAPK as 
predictive markers for tamoxifen resistance, results from the previous STB study (chapter 
6) suggested the possibility that overexpression of pRaf(ser338) identified patients who 
benefited from the combined treatment of tamoxifen and chemotherapy, and that MAPK 
perhaps controlled response to chemotherapy. Unfortunately, these hypotheses were not 
proven, as this study failed to demonstrate any predictive capabilities of Raf-1 or MAPK 
for chemotherapy response in patients treated with chemotherapy alone or in combination 
with tamoxifen.
Tamoxifen down-regulates ERa activity, inhibiting activation of oestrogen 
regulated genes and reducing cell proliferation. Chemotherapy targets proliferating cells 
either directly, in the case of antimetabolites, such as methotrexate, or indirectly via 
production of DNA damage. Our findings that Raf-1 and MAPK expression is predictive 
for Tamoxifen but not chemotherapy response can be interpreted in two ways. The 
Ras/Raf-l/MAPK pathway is responsible for phosphorylating multiple substrates, such as 
the pro-proliferative c-fos and the anti-apoptotic p90RSK. One other key substrate is the
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ER. Therefore, the unexpected finding that Ras/Raf-l/MAPK are predictive markers for 
survival and response to Tamoxifen but not chemotherapy may indicate that it is the 
interaction between this pathway and the ER that fundamentally influences patient 
outcome. If this is true, then perhaps Raf-1 and MAPK are only predictive for response in 
ER positive patients; therefore, possibly the NEAT study was underpowered in terms of 
ER positive patients, preventing full investigation of the effects of the Ras pathway on 
chemotherapy response. A larger cohort of ER positive chemotherapy treated patients is 
required to analyse the potential of Raf-1 and MAPK as predictive markers. However, if 
their predictive power is dependent on its interaction with ER, they may not be the most 
appropriate markers for response to chemotherapy: it may be more advisable to 
investigate anti-apoptotic factors downstream of MAPK, such as BAD.
Chemotherapy targets highly proliferating cells. In tumours, cell growth is driven 
by classical proliferative factors, such as c-fos, but also by the MAPK-ERa interactions 
that will enhance cells sensitivity to oestrogen, ultimately increasing proliferation. 
Perhaps the reason we failed to demonstrate Raf-1 or MAPK as predictive for 
chemotherapy response is that, in the ER positive NEAT, patients the chemotherapy 
cancels out the effects of the MAPK-ERa driven proliferation. These results suggest that 
the combined treatment of tamoxifen and chemotherapy is beneficial in patients who 
overexpress Raf-1 and MAPK, to such an extent that they have a prognosis similar to 
those patients who expressed lower levels of the proteins. This argument was 
strengthened by our observation that, in the 303 tamoxifen only treated patients, Raf-1 
and MAPK continued to predict for response on tamoxifen (Chapter 6). However, neither 
Raf-1 nor MAPK expression was predictive for outcome or response to chemotherapy in
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all the NEAT chemotherapy treated patients or in the 264 patients from both STB and 
NEAT cohorts who received both tamoxifen and chemotherapy. Possibly this signifies 
that pRaf(ser338), and to a lesser extent, MAPK is a potential marker to identify patients 
for whom tamoxifen alone is insufficient adjuvant systemic therapy. Those patients who 
overexpress pRaf(Ser338) and MAPK in their tumours may require treatments, such as 
chemotherapy or aromatase inhibitors, in addition to tamoxifen. As discussed in the 
previous chapter, further research, in larger studies, such as the TEAM or ATAC study, is 
needed to confirm our findings.
When undertaking this study, the role of the Ras/Raf/MAPK pathway in 
mediating response to chemotherapy was unconfirmed. Work from the STB study 
(Chapter 6) had alluded to the possibility that overexpression of pRaf(ser338) in tumours 
identified patients who benefited from the combined treatment of tamoxifen and 
chemotherapy, and that MAPK was involved in controlling response to chemotherapy. 
However, the NEAT study failed to demonstrate any significant association between 
expression of either of these proteins and chemotherapy treated patients’ outcome. 
Consequently, the roles of Raf and MAPK in driving chemotherapy response remain 
controversial, and further work, perhaps in larger patient cohorts, is required to try and 
enhance our understanding of the phenomenon that is chemotherapy resistance.
267
8. Relationship between MAPK and the Oestrogen Receptor
8.1 Introduction
Tamoxifen is currently one of the most effective but least toxic drug therapies for ERa 
positive breast cancers. As discussed in chapter 1, Tamoxifen, an oestrogen antagonist, is 
a non-steroid ligand that acts as a selective oestrogen receptor modulator (SERM). It 
functions by competitively inhibiting the interaction of oestrogen (E2) with ERa, by 
directly binding to the AF-2 transcriptional activation domain receptor. Hence, it blocks 
the effects of E2 and subsequently inhibits the activity of the receptor. However, 
resistance to tamoxifen treatment, either at primary treatment {de novo), or arising during 
treatment (acquired), is the cause of significant morbidity and mortality.
The mechanisms driving the development of Tamoxifen resistance are not fully 
understood; however, there are several hypotheses. ERa can be activated in a ligand- 
dependent manner, via E2, or in a ligand-independent manner, via signal transduction 
pathways. Research suggests that activation of the Ras/Raf-l/MAPK pathway contributes 
to the development of tamoxifen resistance through phosphorylating and activating the 
ERa. Results from chapter 6 suggested that increased expression of activated Raf-1, 
pRaf(ser338), and MAPK in patients’ tumours was associated with a greater risk of 
relapsing on Tamoxifen. MAPK directly and indirectly phosphorylates ERa at serine 118 
and serine 167, respectively (29;39;197). The interaction between MAPK and ERa is 
well documented, though it is unclear if it occurs in the cytoplasm or nuclei of cells.
This study aimed to compare the ligand-dependent and ligand-independent 
phosphorylation and activation of the ERa and since ERa phosphorylation via MAPK 
seems to be an important factor in the development of Tamoxifen resistance, to ultimately
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probe the relationship between MAPK and the ERa. In vitro analysis of MCF-7 breast 
cancer cells was performed to investigate the interactions between MAPK and ER. There 
were three key elements to this study: time course treatments to compare the ligand- 
dependent and independent activation of the ERa and immunofluorescence (IF) and 
subcellular fractionation experiments to monitor the localisation of MAPK and ERa 
following stimulation with E2, Heregulin (HRG) and MAPK inhibitors.
8.2 Immunofluorescent localisation of pMAPK, ER, pE R (serll8) and 
pER(serl67) in MCF-7 breast cancer cells following treatment with 
Oestrogen, Heregulin and Felodipine.
To visualise the response and localisation of MAPK and ERa following ligand-
dependent and independent activation, an immunofluorescent (IF) study was designed. 
Cells were exposed to E2, HRG and Felodipine (FEE). FEE is a calcium antagonist that 
prevents phosphorylated MAPK from translocating into the nucleus. This enabled the 
localisation of MAPK and ERa to be monitored following ligand-dependent and 
independent phosphorylation, whilst the presence of FEE addressed whether MAPK 
interacts with and phosphorylates ERa in the cytoplasm or nuclei of cells. In total, there 
were 16 treatments over six time points; cells were incubated with InM/lOnM HRG and 
E2, both individually and in combination, and in the presence and absence of 30pM FEE, 
for 5, 15, 30 minutes, and 1, 2 and 3 hours. Table 2.10 lists all the drug treatments given 
to the MCF-7 cells. The localisation of pMAPK, ERa, pER(serll8) and pER(serl67) 
was observed. The major focus of this study was on the nuclear localisation of the 
proteins, as it was easier to monitor any differences in the extent of protein expression in 
the nuclei rather than the cytoplasm.
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8.2.1 Localisation of pMAPK
In untreated MCF-7 cells, pMAPK was predominantly localised to the cytoplasm; almost 
no nuclear pMAPK was detected. Throughout all treatments, the levels of cytoplasmic 
pMAPK remained generally high. However, treatment with both HRG and E2 stimulated 
nuclear translocation of pMAPK. Of the two treatments, HRG was the more effeetive 
activator of MAPK. For both treatments, maximum levels of nuclear pMAPK were 
observed after 5 minutes, though the expression levels were much higher when 
stimulated with HRG. After 5 minute treatments with both drugs, the levels of nuclear 
pMAPK dropped dramatically, but were shown to gradually increase again after Ihour 
(Figures 8.1 & 8.2). Similar trends were observed for the InM and lOnM treatments, 
though as expeeted the lOnM drugs induced a stronger response. Surprisingly, when both 
drugs were given in combination, there was a reduction in the levels of nuclear pMAPK, 
in comparison to the levels obseiwed when the two drugs were given individually. After 
the 2 and 3 hour treatments, the two drugs seemed to work synergistically to promote 
nuclear translocation of pMAPK (Figures 8.1 & 8.2). Treatment with FEE prevented the 
nuclear translocation of pMAPK in MCF-7 cells, even in the presence of ITRG or E2 
(Figures 8.3-8.5).
The expression levels of pMAPK appeared to fluctuate quite significantly in 
response to the different treatments. Therefore, as described in section 2.6.4 an IF scoring 
system was established in an attempt to semi-quantify the levels of pMAPK protein 
localised to the nuclei. Unfortunately, it was impossible to score the levels of cytoplasmic 
pMAPK. Scoring a proportion of all treated cells confirmed the results generated from 
visualising the cells down a fluorescent microscope, but it allowed the results to be
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presented in a numerieal context. Figures 8.6a, b further highlight the effects, of HRG, 
E2 and FEE, on the nuclear localisation of pMAPK.
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Figure 8.1: pMAPK IF on MCF-7 cells treated with InM HRG and InM E2
Immunofluorescence o f MCF-7 cells stimulated with InM  HRG and InM  E2, individually 
and in combination, fo r 0, 5, 15, 30 minutes. I, 2, 3 hours and treated with pMAPK 
antibody and Fluorescein avidin D (green). pMAPK was localised to both the cytoplasm 
and nuclei o f  cells. Nuclei stained with DAP I (blue).
272
lOnM HRG 10nME2 10nM HRG & lOnm E2
0 mins
5 mins
15 mins
30 mins
1 hr
2 hrs
3 hrs
Figure 8.2: pMAPK IF on MCF-7 cells treated with lOnM HRG and lOnM E2
Immunofluorescence o f MCF-7 cells stimulated with lOnM HRG and lOnM E2, 
individually and in combination, fo r 0, 5, 15, 30 minutes, 1, 2, 3 hours and treated with 
pMAPK antibody and Fluorescein avidin D (green). pMAPK was localised to both the 
cytoplasm and nuclei o f  cells. Nuclei stained with DAPl (blue).
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Figure 8.3: pMAPK IF on MCF-7 cells treated with InM/lOnM HRG and 30mM 
Felodipine
Im m unofluorescence o f  M C F -7 ce lls  s tim u la ted  w ith  In M /lO nM  HRG, in the ab sen ce  a n d  p resen ce  o f  
SOfjM F elodipine, f o r  0, 5, 15, 30  m inutes. I, 2, 3 hours a n d  tre a te d  w ith  pM A P K  a n tib o d y  a n d  F luorescein  
a v id in  D  (green). p E R (se r l 18) w a s lo c a lise d  to  both  the cy to p la sm  a n d  nuclei o f  cells. N uclei s ta in e d  w ith  
D A P l (blue).
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Figure 8.4: pMAPK IF on MCF-7 cells treated with InM/lOnM E2 and 30mM 
Felodipine
Im m unofluorescence o f  M C F -7 ce lls  s tim u la ted  w ith  In M /lO n M  E2, in the a b sen ce  a n d  p re sen ce  o f  3 0 p M  
F elodipine, f o r  0, 5, 15, 30  m inutes. I, 2, 3 hours a n d  tre a te d  w ith  pM A P K  a n tib o d y  a n d  F luorescein  av id in  
D  (green). p M A P K  w a s lo c a lise d  to  b o th  the cy to p la sm  a n d  nuclei o f  cells. N u clei s ta in e d  w ith  D A P l  
(blue).
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Figure 8.5: pMAPK IF on MCF-7 cells treated with InM HRG/E2, lOnM HRG/E2 
and 30mM Felodipine
Im m unofluorescence o f  M C F -7 ce lls  s tim u la ted  w ith  In M  H RG /E2 a n d  lO nM  H RG/E2, in the ab sen ce  a n d  
p resen ce  o f  30 p M  F elodipine, f o r  0, 5, 15, 30  m inutes. I, 2, 3 hours a n d  tre a te d  w ith  p M A P K  a n tib o d y  a n d  
F luoresce in  a v id in  D  (green). p M A P K  w a s lo c a lise d  to  bo th  the cyto p la sm  a n d  nu clei o f  cells. N uclei 
s ta in e d  w ith  D A P l (blue).
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(a) Effect of 1nM HRG, 1nM E2 & 30^M FB. on nuclear localisation of pMAPK
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(b) E ffect o f lOnM HRG, 10nM E2 & 30|iM PEL o n  n u c le a r  looaliaa tion  o f pMAPK
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Figure 8.6: Line Graphs of Nuclear Distribution of pMAPK
MCF-7 cells were treated with Heregulin (HRG), Oestrogen (E2) and Felodipine (FEL 
fo r 0, 5, 15 30 mins and 1,2 and 3hours, and immunofluorescence performed to detect 
pMAPK. A proportion o f the cells were scored for nuclear expression ofpMAPK in order 
to semi-quantify the effects o f  the various treatments on pMAPK nuclear localisation. The 
graphs show the levels o f  pMAPK expressed in the nuclei during the course o f  treatments 
with (a) InM  HRG, InM  E2 and 30pM FEL and (b) lOnM HRG, lOnM E2 and 30pM  
FEL.
I l l
8.2.2 Localisation of ER
ER was detected in the cytoplasm and nuclei of untreated MCF-7 cells. The levels of 
cytoplasmic ERa appeared to remain high throughout the treatments. Additionally, the 
levels of nuclear ERa did not seem to fluctuate greatly in response to the various 
treatments (Figure 8.7).
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Figure 8.7; ERa IF on MCF-7 cells treated with lOnM HRG, lOnM E2 and 30mM 
Felodipine
Im m unofluorescence o f  M C F -7 cells, s tim u la ted  w ith  lO nM  H R G  a n d  lO nM  E2, s in g ly  a n d  in com bination, 
a n d  in the absen ce  a n d  p re sen ce  o f  3 0 p M  F elodipine, f o r  0, 5, 15, 30  m inutes. I, 2, 3 hours. C e lls  w ere  
tr e a te d  w ith  E R a  a n tib o d y  a n d  F luorescein  av id in  D  (green). ERa w a s lo ca lise d  to  both  the cyto p la sm  a n d  
nuclei o f  cells. N uclei s ta in e d  w ith  D A P l (blue).
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8.2.3 Localisation of pER(serll8)
Untreated MCF-7 cells displayed cytoplasmic pER(seiT18) but almost no nuclear 
pER(serll8). The levels of cytoplasmic pER(serll8) in cells appeared to be high, 
regardless of the treatment. As with pMAPK, nuclear localisation of pER(serll8) varied 
in response to both the drug used and the incubation time. Therefore, the levels of nuclear 
pER(serl 18) were semi-quantified using the IF scoring system.
Treatment of eells with both InM and lOnM E2 induced a rapid influx of 
pER(serU8) into the nuclei. The maximum level of nuclear pER(seiT18) was observed 
after the 15 minute treatments. A decrease in the expression of nuclear pER(serl 18) was 
witnessed following the longer treatment times, though levels did start to rise again after 
3 hours. Conversely, a 5 minute treatment with InM and lOnM HRG resulted in a 
substantial increase in the levels of pER(l 18) localised to the nuclei. However, the levels 
were lower than that observed following E2 stimulation. Additionally, there was an 
immediate depletion in the levels of nuclear pER(seiT18), following the 15 and 30 minute 
treatments. There was almost no nuclear pER(serl 18) detectable; however, it was present 
in the cytoplasm. Nuclear pER(serll8) levels were shown to slightly increase after 2 
hours (Figure 8.8 & 8.9).
In cells treated with both E2 and FIRG for 5 minutes, nuclear pER(seiT 18) was 
detected at relatively high levels although levels were lower than those seen with E2 
treatment alone. After 15 and 30 minutes, there was a considerable reduction in 
expression of nuclear pER(serll8); however, cytoplasmic pER(serll8) remained. The 
levels remained low until 2 hours, when a second peak of nuclear pER(serll8) 
expression was observed (Figure 8.8 & 8.9).
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Treatment of the cells with FEL produced different results, depending on which 
drug it was combined with. Its presence did not seem to have a major effect on the E2- 
dependent phosphorylation and localisation of pER(seiT 18) (Figure 8.10), whereas when 
it was given in combination with HRG, a substantial decrease in the localisation of 
pER(serl 18) to the nuclei of MCF-7 cells was observed (Figure 8.11). When cells were 
treated with all three drugs, the levels of nuclear pER(seiT18) were lower than when 
treated with E2 alone, but were generally higher than those observed when E2 and HRG 
were given in combination (Figure 8.12). This suggested that the presence of FEL 
partially overrides the effects of HRG on the ER.
These trends are depicted in both the IF pictures (Figures 8.8-8.12) and in the 
graphs generated from the IF scores (Figure 8.13).
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Figure 8.8: pER(serll8) IF on MCF-7 cells treated with InM HRG and InM E2
Immunofluorescence o f MCF-7 cells stimulated with InM  HRG and InM  E2, individually 
and in combination, fo r  0, 5, 15, 30 minutes, 1, 2, 3 hours and treated with pER(serll8) 
antibody and Fluorescein avidin D (green). pER(serl 18) was localised to both the 
cytoplasm and nuclei o f  cells. Nuclei stained with DAPl (blue).
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Figure 8.9: pER(serll8) IF on MCF-7 cells treated with lOnM HRG and lOnM E2
Immunofluorescence o f MCF-7 cells stimulated with lOnM HRG and lOnM E2, 
individually and in combination, for 0, 5, 15, 30 minutes, 1, 2, 3 hours and treated with 
pER(serl 18) antibody and Fluorescein avidin D (green). pER(serl 18) was localised to 
both the cytoplasm and nuclei o f  cells. Nuclei stained with DAPl (blue).
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Figure 8.10: pER(serll8) IF on MCF-7 cells treated with InM and lOnM HRG and 
30mM Felodipine
Immunofluorescence o f  MCF-7 cells stimulated with InM/lOnM Heregulin (HRG), in the 
absence and presence o f 30pM  Felodipine (FEL), for 0, 5, 15, 30 minutes, 1, 2, 3 hours 
and treated with pER(serl 18) antibody and Fluorescein avidin D (green). pER(serl 18) 
was localised primarily in the cytoplasm o f cells. Nuclei stained with DAPl (blue).
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Figure 8.11: pER(serll8) IF on MCF-7 cells treated with InM/lOnM E2 and 30mM 
Felodipine
Immunofluorescence o f MCF-7 cells stimulated with InM/IOnM E2, in the absence and 
presence o f 30pM  Felodipine, fo r  0, 5, 15, 30 minutes, 1, 2, 3 hours and treated with 
pER(serl 18) antibody and Fluorescein avidin D (green). pER(serl 18) was localised to 
both the cytoplasm and nuclei o f  cells. Nuclei stained with DAPl (blue).
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Figure 8.12: pER(serll8) IF on MCF-7 cells treated with InM HRG/E2, lOnM 
HRG/E2 and 30mM Felodipine
Immunofluorescence o f MCF-7 cells stimulated with InM  HRG/E2 and lOnM HRG/E2, 
in the absence and presence o f 30pM  Felodipine, fo r 0, 5, 15, 30 minutes, 1, 2, 3 hours 
and treated with pER(serl 18) antibody and Fluorescein avidin D (green). 
pER(serl 18)MAPK was localised to both the cytoplasm and nuclei o f  cells. Nuclei 
stained with DAPl (blue).
286
(a) Effect of 1nM HRG, InM E2 & 30^M FEL on nuclear localisation of 
pB^ser118)
90
80
70
80
50
30
20
10
0
• InM HRG
- 1nM H R G & 30uM FB . 
InM H RG A  1nME2
■ 1nME2
- InM E2 & 30uM  FB_
- InM HRG& InM E2 & 30uM  FB .
• Unt r e a t  ed  wit h  DM SO& B  OH
- 30uM  FB . only
ISm lns 30m l n s
T r a a t m a n t  T im a
(b)
Effect of 10nM HRG, lOnM E2 & 30m M FB. on nuclear localisation of 
pER(ser118)
50
40
30
20
0
ISm lns SOmins Ih r 2 h rs
-lO nM H R G
- lOnM H R G & 30uM  FB . 
tOnMHRGA 1GnME2
>10nM E 2& 30uM FB -
- lOnM HRG& lOnM E2 & 30uM  F B .
- Unt re a t  e d  w it h  DMSO& B  OH 
•3 0 u M F Q .o n ly
T r a a t m a n t  T im a
Figure 8.13: Line Graphs of Nuclear Distribution of pER(serllS)
MCF-7 cells were treated with Heregulin (HRG), Oestrogen (E2) and Felodipine (FEL) 
fo r 0, 5, 15, 30 mins and 1,2 and Shours, and immunofluorescence performed to detect 
pER(serl 18). A proportion o f the cells were scored for nuclear expression o f  
pER(serl 18) in order to semi-quantify the effects o f the various treatments on 
pER(serl 18) nuclear localisation. The graphs show the levels o f  pER(serl 18) expressed 
in the nuclei during the course o f treatments with (a) InM  HRG, InM  E2 and 30pM  FEL 
and(h) lOnMHRG, lOnME2 and 30pM FEL.
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8.2.4 Localisation of pER(serl67)
Analysis of the localisation of pER(serl67) generated some unexpected results. In the 
untreated cells, expression of pER(serl67) was constrained to the cytoplasm, as was 
observed with pER(serll8). However, stimulation with neither E2 nor HRG induced 
nuclear expression of pER(serl67). At no time point from 5 minutes to 3 hours, with any 
treatment, was pER(serl67) detected in the nuclei of cells, though it was expressed in the 
cytoplasm. The absence of nuclear pER(seiT67) is highlighted in Figure 8.14, which 
depicts the localisation of pER(seiT67) in MCF-7 cells following a selection of 
treatments. Interestingly, pER(serl67) may not have localised to the nuclei, but it was 
expressed at the plasma membrane (Figure 8.15).
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Figure 8.14: pER(serl67) IF on MCF-7 cells treated with lOnM HRG, lOuM E2 and 
30mM Felodipine
Immunofluorescence o f MCF-7 cells, stimulated with lOnM HRG and lOnM E2, singly 
and in combination, and in the absence and presence o f 30pM  Felodipine, fo r 0, 5, 15, 30 
minutes, 1, 2, 3 hours. Cells were treated with pER(serl67) antibody and Fluorescein 
avidin D (green). pER(serI67) was localised to only the cytoplasm o f cells. Nuclei 
stained with DAPl (blue).
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Figure 8.15: Immunofluorescent detection of membranous pER(serl67)
Immunofluorescence o f MCF-7 cells stimulated with Heregulin (HRG), Oestrogen (E2) 
and Felodipine (FEL) and treated with pER(serl67) antibody and Fluorescein Avidin D. 
pER(serl67) was not detected in the nuclei o f cells, but was evident at the plasma 
membrane, as highlighted by the arrows.
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8.3 Investigation of nuclear localisation o f pMAPK and pE R (serll8) in 
MCF-7 cells
The interesting results generated from the preliminary IF study, regarding the localisation 
of pMAPK and pER(serU8), prompted a more thorough investigation of their 
localisation following stimulation with HRG, E2 and FEL. In this more in depth IF study, 
it was deemed appropriate to only investigate the 5, 15 and 30 minute treatments, as these 
were identified as the key time points in the preliminary study. As described in chapter 2, 
during the course of an IF experiment, each treatment was performed in quadruplicate, 
and each experiment was performed three times. Therefore, in total, there were 12 sets of 
treated cells for each condition. Once again, the levels of nuclear pMAPK and 
pER(seiT18) were semi-quantified using the IF scoring method.
8.3.1 Effects of HRG, E2 and FEL on pMAPK and pE R (serll8) 
localisation
The three individual IF experiments produced similar results (Figure 8.16 - 8.19). As in 
the preliminary study, untreated MCF-7 cells displayed strong levels of cytoplasmic 
pMAPK and pER(serl 18), but almost no expression was detected in the nuclei. After 5 
minutes of InM/lOnM E2 stimulation, there was a rapid influx of pER(serl 18) into the 
nuclei; strong levels were also detected in the cytoplasm. These nuclear levels were 
maintained throughout the 15 and 30 minute treatments. Likewise, cells treated with 
InM/lOnM HRG for 5 minutes presented with nuclear pER(serl 18), but at levels much 
lower than those observed following E2 stimulation. Additionally, there was a major 
decrease in the levels of nuclear pER(serll8). Following the 15 and 30 minute HRG 
treatments, there was almost no nuclear pER(seiT18) detectable. However, it was still 
present in the cytoplasm. In cells treated with both E2 and ITRG for 5 minutes, nuclear
291
pER(serll8) was visible; however, levels were comparable with those seen with HRG 
treatment alone. After 15 and 30 minutes, the levels of nuclear pER(seiT 18) once again 
dropped, and pER(seiT 18) was predominantly expressed in the cytoplasm.
Both HRG and E2 stimulated pMAPK translocation to the nucleus, though HRG 
was once again shown to be the more effective activator of the two. HRG and B2 were 
shown to function synergistically; combined treatment of the two drugs increased the 
nuclear levels of pMAPK in comparison with either treatment alone, especially when 
given for 15 and 30 minutes.
Felodipine prevented nuclear translocation of pMAPK, following treatment with 
both HRG and E2, when given individually and in combination. It also reduced the levels 
of nuclear pER(seiT18) following HRG stimulation; however, it seemed to have less 
effect on the E2 phosphorylation of ER. In cells treated with all three drugs, nuclear 
levels of pER(seiT 18) were lower than when cells were treated with E2 alone, but were 
generally higher than those observed following HRG treatment, alone or in combination 
with E2.
To ensure that the observed effects on pMAPK and pER(serl 18) localisation were 
due to the activity of the drugs alone and not a consequence of other factors, such as the 
presence of DMSO and EtOH, several controls were included. These controls are 
described in chapter 2. Neither the presence of DMSO, nor EtOH, altered the localisation 
of pMAPK and pER(serll8). Cells were also treated with FEL alone, to determine its 
effects on protein expression; it too failed to have any effects. These controls are included 
in the graphs (Figures 8.16 - 8.19), which display the trends of nuclear expression for 
both pMAPK and pER(seii 18), following the various treatments.
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Figure 8.16: Nuclear Distribution of pER(serllS) in MCF-7 cells treated with InM 
HRG, InM E2 & 30mM FEL
MCF-7 cells were treated with InM  Heregulin (HRG), InM Oestrogen (E2) and 30/jM  
Felodipine (FEL) for 0, 5, 15 and 30 mins, and immunofluorescence performed to detect 
pER(serI 18). The experiment was performed 3 times, and a proportion o f the cells were 
scored for nuclear expression o f pER(serl 18). The graphs show the levels o f  
pER(serl 18) expressed in the nuclei during the course o f  treatments for each o f the 
individual experiments (a-c) and the average from all 3 experiments (d).
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Figure 8.17: Nuclear Distribution of pER(serllS) in MCF-7 cells treated with lOnM 
HRG, lOnM E2 & 30mM FEL
MCF-7 cells were treated with lOnM Heregulin (HRG), lOnM Oestrogen (E2) and 30juM 
Felodipine (FEL) for 0, 5, 15 and 30 mins, and immunofluorescence performed to detect 
pER(serll8). The experiment was performed 3 times, and a proportion o f the cells were 
scored for nuclear expression o f pER(serl 18). The graphs show the levels o f  
pER(serl 18) expressed in the nuclei during the course o f treatments for each o f the 
individual experiments (a-c) and the average from all 3 experiments (d).
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Figure 8.18: Nuclear Distribution of MAPK in MCF-7 cells treated with InM HRG, 
InM E2 & 30mM FEL
MCF-7 cells were treated with InM  Heregulin (HRG), InM  Oestrogen (E2) and 30/uM 
Felodipine (FEL) for 0, 5, 15 and 30 mins, and immunofluorescence performed to detect 
pMAPK. The experiment was performed 3 times, and a proportion o f  the cells were 
scored for nuclear expression o f pMAPK. The graphs show the levels o f pMAPK 
expressed in the nuclei during the course o f  treatments for each o f the individual 
experiments (a-c) and the average from all 3 experiments (d).
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Figure 8.19: Nuclear Distribution of pMAPK in MCF-7 cells treated with lOnM 
HRG, lOnM E2 & 30mM FEL
MCF-7 cells were treated with lOnM Heregulin (HRG), 1 OnM Oestrogen (E2) and 30/iM 
Felodipine (FEL) for 0, 5, 15 and 30 mins, and immunofluorescence performed to detect 
pMAPK. The experiment was performed 3 times, and a proportion o f the cells were 
scored for nuclear expression o f  pMAPK. The graphs show the levels o f  pMAPK 
expressed in the nuclei during the course o f  treatments for each o f the individual 
experiments (a-c) and the average from all 3 experiments (d).
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8.4 Activation of MAPK and ER in MCF-7 breast cancer cells following 
treatment with Oestrogen and Heregulin
An in vitro study was designed to investigate the effects of HRG and E2 on the activation
status of MAPK and ER in MCF-7 breast cancer cells. Time course treatments were set 
up, whereby cells were stimulated with HRG or E2, singly and in combination, for 5, 15 
and 30 minutes. Table 2.12 lists the drug treatments. Western blotting was used to 
monitor the levels of pMAPK and pER (described in sections 2.7 & 2.9)
8.4.1 Activation of MAPK
Treatment of MCF-7 cells, with HRG or E2, stimulated increased expression of pMAPK. 
(Figure 8.1); However, of the two drugs, HRG proved the most effective activator of 
MAPK. Maximum activation of MAPK appeared to occur following the 15 minute HRG 
treatment. Combined treatment of HRG and E2 seemed to induce greater levels of 
pMAPK, suggesting that these two drugs functioned in an additive or synergistic manner 
(Figure 8.20).
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Figure 8.20: Expression levels of pMAPK in MCF-7 cells following time course 
treatments
MCF-7 cells were stimulated with InM/1 OnM Heregulin (HRG) and Oestrogen (E2), 
singly and in combination, fo r 5, 15 and 30 minutes. Western blotting was performed on 
25pg cell lysate and samples probed for pMAPK (44/42kDa) expression.
UT= Untreated control without DMSO, EtOH, UT time pt = 5, 15, or 30 minute 
untreated control with DMSO, ETOH
8.4.2 Activation of ER
• pER(serll8)
The p E R (serll8 ) antibody seemed to be batch specific. The batch used for the 
immunofluorescent studies worked well in western blotting; however, subsequent batches 
failed to produce similar results. It was, therefore, impossible to obtain western blots for 
all the samples using pER(serl 18).
Treatment o f  MCF-7 cells with I OnM E2 stimulated phosphorylation o f  ERa at 
serine 1 18. Conversely treatment with HRG did not seem to significantly increase 
expression levels o f  pER(serl 18). It also appeared in the five and fifteen treatments that
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the presence o f  HRG reduced the levels o f  E2 stimulated phosphorylation. However, 
after the 15 minutes, the combined treatment with both E2 and HRG seemed to induce 
increased expression levels o f  pER(serl 18) (Figure 8.21).
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Figure 8.21: Expression levels o f  p E R (se r ll8 )  in M C F-7 cells follow ing tim e course  
treatm ents
MCF-7 cells were stimulated with lOnM Heregulin (HRG) and Oestrogen (E2), singly 
and in combination, for 5, 15 and 30 minutes. Western blotting was performed on 25pg  
cell lysate and samples probed fo r  pER(serl 18) (66kDa) expression. Tubulin was used as 
a loading control. UT= Untreated control without DMSO, EtOH, UT time pt = 5, 15, or 
30 minute untreated control with DMSO, ETOH
•  pE R (serl67): Unfortunately, after com pleting the immunofluorescent studies, 
the pER (serl67) antibody was withdrawn from the market, and the replacement antibody 
proved non-specific. Therefore, it was im possible to measure the levels o f  pER (serl67) in 
MCF-7 cells, following the various treatments.
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8.5 Investigation of localisation of pMAPK and pE R (serll8) in MCF-7 
cells using subcellular fractionation
Having investigated the localisation of MAPK and ER in the IF studies, it was deemed
appropriate to further probe the distribution of these proteins using a subcellular 
fractionation approach. The IF study indicated that the major changes in cellular 
localisation occurred at the 5 and 15 minute time points. Accordingly, subcellular 
fractionation, generating membrane, cytoplasmic and nuclear fractions, was performed, 
following 5 and 15 minute stimulations. As in the IF study, MCF-7 cells were treated 
with InM/1 OnM ITRG and E2, singly and in combination, and in the presence and 
absence of 30mM FEL. Additionally, for the 15 minute treatment, the MEK inhibitor, 
U0126, which prevents activation of MAPK, was used in combination with HRG and E2. 
A list of all treatments is provided in Table 2.14 and 2.15. Western blotting was 
performed on the protein fractions using antibodies specific to pMAPK and pER(seiT18). 
Unfortunately, the localisation of pER(serl67) could not be investigated further, since the 
antibody was withdrawn from the market, and the replacement antibody was shown to be 
non-specific in the time course treatment experiments.
8.5.1 Effects of HRG, E2, FEL and Ü0I26 on pMAPK localisation
Subcellular fractionation produced similar results to those from the IF study. Stimulation
of MCF-7 cells with HRG and E2 resulted in nuclear expression of pMAPK. As with the 
IF study, HRG seemed to induce greater nuclear translocation of pMAPK than E2, but 
both drugs did seem to function synergistically in promoting nuclear expression of 
pMAPK. Yet again, FEL demonstrated its ability to prevent nuclear translocation of 
pMAPK following treatment with either HRG or E2. However, it appeared to be less
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effective when given in combination with both HRG and E2 (Figure 8.20c,d). Treatment 
with U0126 inhibited activation of MAPK, even in the presence of HRG or E2.
In comparison, treatment with EIRG, E2 or FEL did not seem to induce major 
changes in the expression of membranous or cytoplasmic pMAPK. pMAPK was detected 
in both membrane and cytoplasmic fractions, regardless of treatment (Figure 8.22a,b,e,f).
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Figure 8.22: Detection of pMAPK in protein fractions following 5 minute treatment 
with HRG, E2 and FEL
MCF-7 cells were treated with 1/1 OnM Heregulin (HRG) and Oestrogen (E2), singly and 
in combination, and in the presence or absence o f  Felodipine (FEL), fo r 5 minutes. 
Subcellular fractionation was then performed, generating membranous, cytoplasmic and 
nuclear fractions. Western blotting was performed on 25pg o f membrane (a), nuclear (b), 
and cytoplasmic (c) protein fractions and samples probed for pMAPK (44/42kDa) 
expression. Actin and Tubulin were used as loading controls. UT= Untreated control 
without DMSO & EtOH, UT time pt = 5 minute untreated control with DMSO & ETOH, 
FEL control = 30pM  Felodipine only
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8.5.2 Effects o f HRG, E2, FEL and U0126 on pER(serll8)localisation
The results from the IF study meant that the nuclear localisation of pER(seiT18) was of
particular interest. Unfortunately, due to unforeseen problems with the pER(serll8) 
antibody, western blots could not be obtained for all the protein fractions. Only the 15 
minute nuclear fraction western blot was available for analysis (Figure 8.23), However, 
the results from this did confirm the findings from the IF study. In the control cells, in 
particular UT time pt, FEL control & U0126 control, there was almost no pER(serll8) 
detectable in the nuclei. However, following a 15 minute stimulation with InM/lOnM E2, 
there was an obvious increase in the levels of nuclear pER(serl 18). In contrast, the levels 
of nuclear pER(serl 18) were much lower following treatment with InM/lOnM HRG. 
Levels were comparable with those seen in the UT cells. Furthermore, combined 
treatment with E2 and HRG did induce some nuclear pER(serl 18) expression, but the 
levels were considerably lower than those evident in cells treated only with E2.
As with the IF study, FEL severely reduced nuclear expression of pER(serl 18) 
following HRG treatment. Likewise, the combined treatment of U0126 and HRG 
substantially reduced the presence of pER(seiil8) in the nuclei of MCF-7 cells. U0126 
reduced the levels of pER(seiT18) following treatment with InM E2, but appeared to 
have no effect on those stimulated with lOnM E2. Felodipine did appear to reduce the 
levels of nuclear pER(serI 18) following E2 stimulation, but to a lesser extent than 
observed with HRG. Interestingly, the addition of either FEL or U0126 to cells treated 
with both E2 and HRG seemed to negate the inhibitory effects of HRG on E2 dependent 
localisation of pER(serl 18). Of the two, U0126 appeared to be the most effective in over 
riding the effects of HRG and inducing nuclear expression of pER(serl 18).
303
' —  —  —. —. —-  — —' —  —» — — Tubulin
P i
l i
s i l l  g g 5 5A" R" o S Ç O oJÿ>S Ç
1 1  S KA» R»
i  i  
I I
Nuclear
is Tubulin
B BFp R»; s
Nuclear
S g B B BO O A» R» Rp » fr X X ^
" i l l9f (ü>C
;  i
Figure 8.23: Detection of pER (serll8) in nuclear protein fractions following 15 
minute treatment with HRG, E2, FEL and U0126
MCF-7 cells were treated with 1/1 OnM Heregulin (HRG) and Oestrogen (E2), singly and 
in combination, and in the presence or absence o f Felodipine (FEL), for 15 minutes. 
Subcellular fractionation was then performed. Western blotting was performed on 25pg  
o f nuclear protein fractions and samples probed for pER(serl 18) (66kDa) expression. 
Tubulin was used a loading control. UT= Untreated control without DMSO & EtOH, UT 
time pt = 15 minute untreated control with DMSO & ETOH, FEL control= 30pM 
Felodipine only
8.6 Discussion
The relationship between MAPK and ERa is well documented; however, our 
understanding o f  the interaction between the two is sparse. It is undisputed that MAPK 
can activate ERa in a ligand-independent manner, via phosphorylation o f  serines 118 and 
167, but what are the consequences o f  this ligand-independent activity? Furthermore, it is 
accepted that there is cross talk between the ERa and the growth factor receptors (RTKs), 
but to what extent does the ligand-independent activation o f  ER a differ from that o f  
ligand-dependent activity? The study aimed to investigate the interaction and localisation 
o f  MAPK and ERa, and to provide information regarding the ligand-dependent and 
independent phosphorylation/activation o f  ERa.
This study not only confirmed previous findings regarding the activation o f  ERa  
but also produced several interesting discoveries. Results from the localisation studies 
indicated that ligand-mediated phosphorylation was associated with rapid but sustained
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nuclear localisation of ERa, probably due to E2 binding. In both the IF and subcellular 
fractionation studies, stimulation of MCF-7 cells with E2, for only 5 minutes, resulted in 
a considerable increase in the levels of nuclear pER(seiT 18), when compared to untreated 
cells. These findings are in keeping with previous studies, which have shown that E2 
binding to ERa promotes nuclear translocation of the receptor. Furthermore, there is 
evidence that E2 stimulation is associated with changes in the intranuclear distribution of 
ERa, and that these changes occur rapidly (277). It is thought that the alterations in ERa 
localisation enable it to associate with the nuclear matrix and recruit co-activators, such 
as AIBl. Flence, this ligand-dependent nuclear localisation is essential for ERa 
transcriptional activity. However, the original IF study demonstrated that the levels of 
nuclear pER(serllS) were shown to gradually decrease during the longer incubation 
times with E2. ERa expression levels are maintained via a balance of synthesis and 
degradation. Research has suggested that binding of ligands, such as E2, enhances 
receptor degradation. One study showed a decrease in the levels of nuclear ERa 
following a two hour treatment with lOnM E2 (278). Therefore, the reduction in nuclear 
expression of pER(seii 18) may be a consequence of agonist mediated ERa degradation.
This study also confirmed that ERa is phosphorylated at serine 118 in a ligand- 
independent manner, via MAPK(29;39). However, in contrast to E2 stimulation, 
treatment with HRG induced rapid but transient phosphorylation of ERa. Maximum 
levels of nuclear pER(seiT18) were observed following 5 minute stimulation with HRG, 
and levels were shown to drop dramatically with longer treatments. These findings are in 
keeping with other studies which show that ligand-dependent phosphorylation and 
activation of ERa is sustained, but that ligand-independent activity is short-lived in
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comparison (29;279). These noticeable differences between HRG and E2 mediated 
phosphorylation of ERa support the fact that E2 mediated phosphorylation of serine 118 
relies on a kinase other than MAPK. Previous research has indicated that the kinase, 
CDK7, is necessary for ligand-dependent phosphorylation of serine 118 (29;280;281). 
Additionally, in this study, prevention of nuclear translocation of pMAPK, using FEL, 
and inhibition of MAPK activation, using U0126, did not appear to have a major effect 
on E2 regulated expression of nuclear pER(serl 18). This confirmed that MAPK is not the 
kinase responsible for E2 mediated phosphorylation of the receptor. Conversely, 
inhibition of MAPK severely impaired the ligand-independent phosphorylation of ERa. 
In the IF and fractionation studies, treatment with FIRG in the presence of FEL reduced 
expression of nuclear pER(serl 18), to almost non-existent levels. The same observations 
were made following inhibition with U0126 in the 15 minute fractionation experiment. 
These findings confirmed that MAPK is the kinase responsible for phosphorylating serine 
118 in a ligand-independent manner, via activation of the RTKs. However, more 
interestingly, they implied that phosphorylation and activation of MAPK is not sufficient 
to promote nuclear expression of pER(serU8). For pER(serll8) to be expressed in the 
nuclei of cells, pMAPK must also translocate into the nucleus. Other studies have 
previously shown that MAPK induces nuclear localisation of the ERa; however, they 
failed to demonstrate that MAPK translocation in to the nucleus was also required 
(277;282). There are two possible explanations as to why preventing nuclear expression 
of pMAPK should inhibit pER(seiT18) nuclear expression. The first is that pMAPK 
directly phosphorylates ERa in the nuclei of cells; therefore translocation of MAPK into 
the nucleus is compulsory. The second is that pMAPK phosphorylates ERa in the
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cytoplasm, and that the phosphorylated receptor “piggy backs” into the nucleus with 
pMAPK. Studies have identified the E2-dependent nuclear localisation signal at amino 
acids 256-303 (283), but perhaps phosphorylation of ERa at serine 118 and 167 via 
MAPK is insufficient to promote nuclear translocation. Therefore, ERa is dependent on 
MAPK to facilitate its transport from the cytoplasm into the nucleus. Perhaps 
cytoplasmic pMAPK sequesters pER in the cytoplasm. The fact that FEL was shown to 
lower the levels of nuclear pER(seiT18) only slightly, following treatment with E2, 
possibly suggests that the containment of pMAPK within the cytoplasm commandeered 
low levels of the activated receptor within the cytoplasm. Having observed that nuclear 
translocation of pMAPK is essential for the ligand-independent expression of 
pER(serl 18) in the nucleus of cells, the next step is to further elucidate the mechanism by 
which nuclear pMAPK regulates localisation ofpER(Serll8).
Considering that the effects of E2 on ERa were supposedly independent of 
MAPK, the combined treatment of MCF-7 cells with E2 and HRG produced some very 
interesting results. One might have expected that, since the two drugs phosphorylated 
ERa via different mechanisms, that they might function in an additive or synergistic 
manner to promote nuclear localisation of pER(serll8). Alternatively, one might have 
predicted that, as the principal ligand for ERa, E2 would be the driving force in 
regulating the phosphorylation, activation and localisation of the receptor. However, 
neither of these scenarios proved to be true. Co-stimulation with both E2 and HRG 
suggested that the two drugs did not co-operate synergistically, but that, in fact, HRG, 
and not E2, mediated signalling determined the subcellular localisation of ERa. Despite 
the presence of E2, which translocated ERa to the nucleus in the absence of ITRG, in
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cells treated with both drugs there was a substantial reduction in nuclear pER(serll8). 
Unexpectedly, HRG appeared to inhibit E2 mediated effects. This is dissimilar to the 
findings of another group that suggested that constitutive activation of the growth factor 
pathways was incompatible with E2 signalling, and that, of the two, E2 effects dominated 
(220). Conversely, in the IF and fractionation studies, the two drugs appeared to work 
synergistically to increase the levels of nuclear pMAPK expression. Perhaps, this 
increased expression of nuclear pMAPK enhanced the activation of ERa by direct 
phosphorylation, and subsequently resulted in its rapid deactivation, due to degradation, 
or its relocalisation from the nucleus to the cytoplasm or plasma membrane. Both these 
possibilities are dependent on the nuclear export of the receptor. To be degraded, ERa is 
exported from the cytoplasm to the nucleus via CRMl (284). It is speculated that the 
interaction between ERa and its co-activator AIBl is not only crucial for ER-mediated 
transcription, but is also a key step in the degradation process. Studies have shown that 
suppression of AIBl stabilises ERa In the presence of E2 (285). Hence, activation of 
AIBl may be an important factor in the degradation of ERa. Activation of the co­
activators is dependent on phosphorylation, and besides its ability to directly 
phosphorylate ERa, MAPK can also phosphorylate and activate AIBL Perhaps, the 
elevated levels of pMAPK in the nucleus led to increased phosphorylation and activation 
of ERa and AIBl, which ultimately resulted in the degradation of the two.
An alternative explanation is that the increased expression of pMAPK caused 
pER(serll8) to relocalise from the nucleus to either the cytoplasm or membrane. This 
theory supports the findings of another group, which provided evidence that
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overexpression of HER2, and increased activation of MAPK, in breast cancer cells, 
promoted the translocation of ERa from the nuclei to the cytoplasm (286).
The suggestion that MAPK is a key factor in driving the HRG mediated signalling 
and inhibiting the E2 dependent effects of ERa is sustained by the results from the IF and 
fractionation studies, when MCF-7 cells were treated with HRG and E2 in the presence 
of the inhibitors. Both MAPK inhibitors, particularly U0126, in the 15 minute 
fractionation experiment, seemed to negate the inhibitory effects of HRG on E2, in terms 
of nuclear localisation of pER(serl 18). Increased levels of nuclear pER(serl 18) were 
evident in the IF and fractionation studies, following treatment with HRG, E2 and the 
MAPK inhibitors, in comparison to cells only treated with HRG and E2. These results 
imply that prevention of MAPK activation and translocation to the nucleus permits 
activated ERa to remain in the nuclei of cells. Hence, activated MAPK must be involved 
in the export of ERa from the nucleus, though at present the mechanism and function of 
this is unknown. Additional, in vitro studies are required to further enhance our 
understanding of the relationship between MAPK and ERa.
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9. General Discussion
The main aim of this thesis was to investigate the role of the Ras/Raf-l/MAPK pathway 
in the development and progression of breast cancer, and to determine if it influenced 
patient outcome and response to treatments targeted against both ERa and proliferating 
cells. Two of the key functions of the Ras cascade are controlling cell proliferation and 
altering the phosphorylation and activation status of ERa in a ligand-independent 
manner. The research presented in this thesis tested the hypothesis that activation of this 
pathway is an indicator of response to endocrine and cytotoxic therapies.
Tamoxifen, an oestrogen antagonist, is currently the most successful and least 
toxic drug treatment for the 70-80% of patients diagnosed with ERa positive breast 
cancer. It competitively inhibits oestrogen binding and favours ERa interactions with co­
repressors, subsequently down-regulating ERa mediated gene transcription and inhibiting 
proliferation (38; 107).
The majority of chemotherapeutic agents function most effectively against 
proliferating tumour cells in growth phase (287). It has been suggested that tumours with 
low proliferative indices may respond poorly to these therapeutic agents. However, 
proliferative indices are poor predictors of chemotherapeutic response (288).
Tamoxifen and chemotherapy are key treatments for breast cancer; however, 
resistance to both therapies is a major problem and is significantly related to patient 
relapse and death. The exact mechanisms that drive resistance are not completely 
understood; however, the Ras/Raf-l/MAPK pathway has been implicated in mediating 
response to both treatments.
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Expression of the Ras/Raf-l/MAPK proteins was assessed in breast tumours from 
three different patient cohorts. The initial pilot study was comprised of a mixture of ERa 
positive and negative patients, whose treatment included tamoxifen, chemotherapy and 
radiotherapy. The second group was a cohort of ERa positive patients, all of whom 
received Tamoxifen treatment for a median of five years (STB Study). The final cohort 
consisted of patients from the NEAT/BR9601 clinical trial, who randomly received one 
of two chemotherapeutic regimes: epirubicin followed by CMF, or CMF alone.
The findings from the pilot study suggested that the Ras pathway is in part 
responsible for mediating patient outcome. Elevated expression of N-Ras in breast 
tumours was associated with shortened disease-free survival (DFS) and overall survival
(OS) time (Figure 3.9). This laid the foundation for the two studies investigating the role 
of the Ras, Raf-1 and MAPK proteins in influencing response to tamoxifen and 
chemotherapy. The results of these studies, firstly, suggested that the Ras/Raf-l/MAPK 
pathway was a functional signalling cascade in clinical breast tumours. Analysis 
suggested that increased expression of Ras, in particular N-Ras, was associated with 
increased levels of activated Raf-1, which in turn was linked to activation of MAPK. 
Additionally, there was an association between pMAPK and inactive Raf-1, 
pRaf(ser259). This is further evidence of an intact signalling pathway, since several 
studies have demonstrated that downregulation of Raf-1 is partly dependent on negative 
feedback following mitogen stimulation. Inhibition of MEK and MAPK signalling 
preserves Raf-1 in its active conformation (178;181). Secondly, it was implied that 
increased expression and activation of the Ras cascade predicted for poor outcome on 
tamoxifen but not chemotherapy.
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Initial analysis of the entire STB cohort (303 tamoxifen treated and 99 tamoxifen 
& chemotherapy treated patients) suggested that N-Ras, pRaf(ser338) and MAPK were 
all associated with an increased risk of relapsing whilst receiving Tamoxifen. Previous in 
vitro studies have demonstrated that constitutive activation of Ras and Raf-1 in MCF-7 
cells induces hormone-independent growth (220), whilst increased expression of MAPK 
has been shown to be associated with the growth of ERa positive cell lines during 
adaptation to long-term E2 deprivation and the development of tamoxifen resistance in 
these cell lines(221;259;289). Clinical studies investigating expression of phosphorylated 
MAPK have been slightly contradictory. pMAPK has been shown not to be involved in 
the development of tamoxifen resistance, but has also been associated with both a poor 
and an improved outcome on tamoxifen (212;213;223;224;226). These findings, in 
addition to our own, suggested that increased expression and activation of the Ras/Raf- 
l/MAPK pathway was a contributing factor in the development of tamoxifen resistance. 
However, additional analysis of only the tamoxifen treated patients demonstrated that, 
whilst N-Ras and MAPK served to highlight the importance of the Ras pathway in 
mediating response to tamoxifen, pRaf(ser338) was the key factor in reducing response 
time to tamoxifen treatment. Increased expression of activated Raf-1 in patients’ tumours 
was also associated with reduced DFS and OS time. Furthermore, pRaf(ser338) 
expression was shown to be independent of known prognostic markers, namely tumour 
size, grade and nodal status, in predicting for tamoxifen relapse (Table 6.5). Conversely, 
in the NEAT study, neither Raf-1 nor MAPK tumour expression was associated with 
outcome in patients treated with chemotherapy, regardless of whether they received 
Epirubicin and CMF or CMF alone.
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This study is important, not only because it examines multiple components of the 
MAPK cascade, as opposed to single proteins in clinical breast tumours, but also because 
it investigates the extent to which expression of these proteins predicts patients’ response 
to different treatments. The observation that the Ras/Raf-l/MAPK pathway mediates 
response to tamoxifen but not chemotherapy might be slightly unexpected. Since the Raf- 
1/MAPK pathway regulates cell proliferation, and since chemotherapeutic agents are 
believed to be more effective in highly proliferating cells, one might have speculated that 
this pathway would predict for response to chemotherapy. However, previous studies 
investigating the role of the Raf-1 cascade in mediating response to chemotherapy have 
been performed in cell lines and have been inconclusive. Several studies have suggested 
that the Ras/Raf-l/MAPK pathway is linked to response to epirubicin and doxorubicin 
treatment. In vitro Raf-l (154;227) and MAPK (273) expression is associated with 
increased proliferation and anthracycline resistance. Yet, increased MAPK activation is 
also linked to enhanced apoptosis and anthracycline sensitivity (230).
When considering reasons why the Ras pathway might predict for response to 
tamoxifen but not chemotherapy, it is necessary to take into account the two populations 
of patients analysed. The STB cohort was treated routinely with Tamoxifen, whilst the 
NEAT patients were all part of a clinical trial (BR9601) designed to compare the effects 
of CMF alone against that of sequential Epirubicin followed by CMF. Subsequently, 
comparison of the STB and NEAT cohorts revealed that the NEAT patients presented 
with more aggressive tumours: they tended to be larger and of a higher grade. Generally 
these patients also presented with an increased number of positive lymph nodes in 
comparison with the STB patients. Furthermore, only 63% of the NEAT patients were
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ERa positive. Additionally the percentage of breast cancer recurrences and breast cancer 
specific deaths was higher in the NEAT cohort, as opposed to the STB cohort (34.9% 
versus 27.9% and 26.4% versus 18.4% respectively). It was not surprising that the NEAT 
patients displayed more aggressive tumours than the STB patients, since they had been 
selected to receive the more severe treatment of chemotherapy. Only 99 patients from the 
STB cohort received chemotherapy in addition to tamoxifen.
That neither Raf-1 nor MAPK were predictive for outcome in the NEAT patients 
might be an indicator that these proteins are involved in the early stages of 
tumourigenesis and cancer progression. Previous research has demonstrated an increase 
in the levels of active MAPK in approximately 50% of breast tumours, in comparison 
with their normal breast tissue (213). Additionally, activated MAPK was shown to be 
associated with lymph node métastasés. The levels of active MAPK in lymph node 
métastasés were significantly higher than those in the primary breast tumour (213). 
Therefore, increased expression of MAPK might be a marker for lymph node métastasés 
and might identify patients who require more aggressive treatments. Perhaps Raf-1 and 
MAPK tumour expression levels can help identify those patients most likely to benefit 
from chemotherapy. However, if it is the case that increased expression levels of Raf-1 
and MAPK are predictive for more aggressive tumours and poorer outcome, possibly 
these levels become redundant in predicting for outcome in a group of patients, such as 
the NEAT cohort, who all generally presented with aggressive tumours and positive 
lymph nodes. In this cohort no association was observed between Raf-1 or MAPK 
expression and nodal status, perhaps due to the fact that 86.3% of patients were node 
positive. Consequently, neither Raf-1 nor MAPK expression levels were significantly
314
linked with DFS or OS. Conversely, in the less aggressive STB tumours, both nuclear 
pRaf(ser338) and cytoplasmic MAPK tumour levels were positively correlated with 
nodal status and associated with an increased risk of relapsing on tamoxifen. Perhaps in 
the less aggressive tumours, the Ras pathway was still significantly contributing to 
tumour progression and, therefore, was predictive for patient outcome, whereas the more 
advanced NEAT tumours were less dependent on the Ras, Raf-1, and MAPK proteins.
In addition to activating the Raf-1/MAPK cascade, Ras also stimulates the 
apoptotic P13K/AKT pathway. AKT phosphorylates substrates that directly or indirectly 
regulate apoptosis, such as BAD, caspase 9 and forkhead transcription factors (290-292). 
Furthermore, Raf-1 has been identified as an AKT target. Activation of AKT can induce 
inactivation of Raf-1 via phosphorylation of serine 259, subsequently downregulating 
activity of this proliferative pathway (173). Consequently, it might be that AKT and its 
downstream factors are more appropriate markers for response to chemotherapy. This has 
been suggested in several in vitro studies (229;276).
However, the theory that tumour expression of Raf-1 and MAPK might help 
identify patients who would perhaps benefit from chemotherapy was also suggested in 
the STB study. In the tamoxifen only treated patients, elevated levels of activated Raf-1 
in tumours predicted for poor response to tamoxifen, independently of tumour size, grade 
or nodal status. However, when the 99 tamoxifen and chemotherapy treated patients were 
included in the analysis, high levels of pRaf(ser338) continued to predict for tamoxifen 
relapse, but not independently of the known prognostic markers. In the entire cohort, it 
was MAPK expression that was independently associated with quicker relapse whilst 
receiving tamoxifen. In the tamoxifen only treated patients, both pRaf(ser338) and
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MAPK seemed to regulate early events involved in the development of tamoxifen 
resistance, whereas in those patients who received both tamoxifen and chemotherapy, the 
negative effects of pRaf(ser338) seemed to be delayed. This suggests that the additional 
treatment of chemotherapy, for patients expressing high levels of pRaf(ser338), improved 
their outcome and delayed the development of tamoxifen resistance. However, the 
number of patients receiving both treatments in the STB study was relatively small. It 
was; therefore, appropriate to combine patients from the STB and NEAT cohorts who 
received both tamoxifen and chemotherapy. In this sub-group of patients neither 
pRaf(ser338) nor MAPK expression levels were associated with patient outcome. One 
possible explanation for this is that the addition of chemotherapy reduces the proliferative 
effects of Raf-1/MAPK. Chemotherapy compensates for the shortened response time to 
tamoxifen in those patients who express high tumour levels of these proteins, to such an 
extent that they have a similar prognosis to those who expressed lower levels. However, 
the results from these analyses should be viewed with some caution, as it was two 
different groups of patients that were combined for analysis. Ideally, the role of Raf-1 and 
MAPK should be further investigated in a larger cohort of patients to compare the clinical 
effects of tamoxifen and chemotherapy, both singly and in combination, to determine if 
either of these proteins are potential predictive markers for patients who should receive 
tamoxifen in combination with chemotherapy. Recently the International Clinical Breast 
Cancer Study Group Trial 13-93, which compared the disease-free survival of lymph 
node positive, premenopausal women who received adjuvant chemotherapy, followed by 
either tamoxifen or no further treatment, demonstrated that tamoxifen after adjuvant 
chemotherapy significantly improved treatment outcome (293).
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A recent in vitro study has also reported that tamoxifen can modulate the 
cytotoxicity of anthracyclines, such as epirubicin in breast cancer cell lines (294). The 
effectiveness of chemotherapeutic agents is often limited by multi-drug resistance (MDR) 
(295). The mechanisms controlling MDR are not completely understood, although 
overexpression of P-glycoprotein (P-gp) on the cell membrane is often associated with its 
development (296). P-gp is an ATP-dependent membrane transporter that functions as an 
efflux pump for chemotherapeutic agents. P-gp is expressed in 40-50% of breast cancers, 
with larger tumours more likely to express this protein (297). Following chemotherapy, 
there is an increase in the percentage of tumours expressing P-gp, from 40-50% to 60- 
70% (297). Consequently, much research has focused on identifying agents that will 
down-regulate P-gp mediated chemotherapy resistance. Several studies have recognised 
that tamoxifen has the potential to modify the effectiveness of therapies, such as 
epirubicin (294;296). Pretreatment of MCF-7 and NCl-adr breast cancer cells with 
tamoxifen enhanced the cytoxicity of epirubicin in these cells by 4.3 and 6.5 folds 
respectively (294). All these findings suggest that the combined treatment of tamoxifen 
and chemotherapy is an important therapy option, but given the aggressive nature of 
chemotherapy, only those patients likely to benefit from the additional treatment should 
be targeted. Further investigation is required to determine if pRaf(ser338) or MAPK 
might represent possible predictive markers to identify those patients requiring additional 
treatments to tamoxifen.
Tamoxifen functions by down-regulating ERa activity and transcription of E2- 
regulated genes, whilst chemotherapy uses cytotoxic drugs to kill proliferating cancer 
cells, preventing them from multiplying, invading and metastasing. The Ras/Raf-
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I/MAPK pathway phosphorylates and activates multiple substrates, such as the pro- 
proliferative, c-fos (196), and the anti-apoptotic, p90RSK (197); one other key substrate 
is ERa (39;197;201). The unexpected finding that the Ras/Raf-l/MAPK proteins, in 
particular Raf-1, are potential predictive markers for survival and response to Tamoxifen, 
but not chemotherapy, suggests that it is the interaction between this pathway and ERa, 
and not its ability to regulate cell proliferation, that is fundamental in influencing patient 
outcome.
ERa contains two activation domains, AFl and AF2, which regulate 
transcription. AF2 contains the Ligand Binding Domain (LBD), and its activity requires 
the binding of E2. AFl is activated by phosphorylation of several sites, including Serine 
118 and Serine 167, which are phosphorylated, following the binding of E2 to AF2. E2 
causes a conformational change in ERa, resulting in dimérisation and binding to 
oestrogen response elements in promoter regions of E2-regulated genes (29;39;40). Co­
activators and co-repressors modulate the activity of the ER (67;298-300). However, 
ERa can also be phosphorylated in a ligand-independent manner (29;39;95;96). This 
results in activation of the receptor and subsequent transcription of E2-regulated genes 
and cell proliferation. The ligand-independent phosphorylation of ERa at serine 118 is 
believed to be a major contributor to the development of tamoxifen resistance.
The discovery that pRaf(ser338) and MAPK expression both correlated with loss 
of sensitivity to tamoxifen prompted further investigation of the interactions between this 
pathway and ERa. The relationship between the Ras/Raf-l/MAPK pathway and ERa has 
been well documented; MAPK directly and indirectly phosphorylates ERa in a ligand- 
independent manner at serines 118 and 167, which enhances interactions with
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coactivators rather than co-repressors, and subsequently increases transcriptional activity 
of the receptor (39;197;201). It is thought that this plays a key role in the development of 
tamoxifen resistance, by promoting the agonistic activities of Tamoxifen and tumour 
growth (69;301). Tamoxifen-resistant cells show increased levels of activated MAPK, 
phosphorylated ERa and transcription of oestrogen-regulated genes. Tamoxifen 
promotes, rather than inhibits, growth of these cells (50;222). However, our 
understanding of the mechanistic nature of the MAPK and ERa interactions is limited. It 
is accepted that MAPK phosphorylates ERa at serine 118, but what is the subcellular 
location for this interaction, and does this ligand-independent phosphorylation of ERa 
induce the same effects as E2 mediated activation?
In vitro studies were designed to probe the ligand-dependent and ligand- 
independent phosphorylation of ERa, and to investigate the subcellular localisation of the 
activated receptor. There were several key findings from these studies. The first 
confirmed previous research that E2 stimulated phosphorylation of ERa at serine 118 and 
its nuclear translocation, independently of MAPK. CDK7 has previously been identified 
as the kinase mediating E2 phosphorylation of serine 118 (44). However, MAPK was 
necessary for the ligand-independent phosphorylation of the receptor. Previous studies 
have shown that MAPK induced nuclear expression of ERa (277;282); however, they 
failed to demonstrate that nuclear translocation of pMAPK was required to generate 
expression of nuclear pER(serll8). Throughout the studies presented here, the nucleus 
has been identified as a key subcellular location for the Ras pathway. Ras was 
unexpectedly localised to the nuclei of tumour cells, and was shown to be associated with 
poor outcome in the pilot study. Nuclear but not cytoplasmic pRaf(ser338) was identified
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as a possible predictive marker for tamoxifen relapse, and finally expression of nuclear 
pMAPK was necessary for expression of nuclear pER(serl 18). It is unknown whether the 
nucleus represents an alternative site for activation of the Ras pathway; however, it would 
appear that expression of these nuclear proteins is important in cancer development, 
progression and response to treatment. Further work is obviously required to understand 
the mechanisms controlling nuclear expression or activation of the Ras cascade.
In undertaking these in vitro studies we hoped to increase our understanding of 
the relationship between the ligand-dependent and independent activation of ERa, as 
knowledge of this is limited. We had hypothesised that treatment of MCF-7 cells with 
both HRG and E2 would have an additive effect on the phosphorylation and activation of 
ER, since they both operate via different mechanisms. However, this proved not to be the 
case. Surprisingly, co-stimulation with both E2 and HRG suggested that the effects of 
HRG mediated signalling were dominant over those of E2. These studies produced the 
novel finding that HRG, as opposed to E2, determined the subcellular localisation of ER 
in breast cancer cells. Despite the presence of E2, which translocated ER to the nucleus in 
the absence of HRG, in MCF-7 cells treated with both drugs, there was a substantial 
reduction in the levels of nuclear pER(serI 18). These new and intriguing findings suggest 
that the ligand-independent phosphorylation of ERa modifies its subcellular localisation, 
even in the presence of E2, the principal ligand of the receptor. However, as discussed in 
chapter 8, this is via an unknown mechanism and further in vitro work is necessary to 
determine this.
That the ligand-independent activation of ERa can alter it subcellular location 
may have important implications for the responsiveness of tumours to endocrine
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therapies, such as tamoxifen. Tamoxiten binds to ERa and down-regulates its activity in 
the nuclei of tumour cells. Previous clinical studies have demonstrated that expression of 
pER(serll8) and pER(serl67) in the nuclei of breast tumour cells is associated with an 
improved outcome in patients treated with tamoxifen (226;302;303). It was speculated 
that phosphorylation of the receptor was indicative of an intact ligand-dependent ERa 
signalling pathway, and that expression of the phosphorylated receptor in the nuclei of 
tumour cells represented a predictive marker for response to tamoxifen. Consequently, if 
ligand-independent activation of ERa can override the ligand-dependent effects and 
prevent nuclear expression of phosphorylated ERa, this may explain the loss of 
sensitivity to tamoxifen and poorer outcome associated with activation of the Ras 
pathway. It has previously been demonstrated that overexpression of HER2 and increased 
activation of MAPK resulted in the translocation of ERa from the nucleus to the 
cytoplasm(286). Furthermore, it has been suggested that HER2 mediated tamoxifen 
resistance is a consequence of its interaction with membranous ER (107).
For a long time, the Ras/Raf-l/MAPK pathway has been considered an attractive 
target for anticancer therapies. The research presented here, further highlights the 
importance of these proteins as possible therapeutic targets. Increased expression of these 
proteins in tumours was associated with the development of tamoxifen resistance and 
identified those patients who required additional therapies, such as chemotherapy or AIs. 
As the effectiveness of AIs in treating breast cancer patients, continues to be highlighted, 
the need to identify patients most suitable for this treatment glows. The results from the 
STB suggest that pRaf(ser338) might be a potential marker for patients more likely to 
benefit from AIs, as opposed to Tamoxifen, or a combined treatment of the two.
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However, this would need to be investigated further, perhaps in the lES, TEAM or 
ATAC trial.
N-Ras, pRaf(ser338) and MAPK were all associated with relapse on tamoxifen 
suggesting that therapies targeted against these proteins might be beneficial in 
combination with tamoxifen. Combined treatment of Ras/Raf-l/MAPK inhibitors with 
tamoxifen might potentially delay or reverse tamoxifen resistance. Research has shown 
that the use of FTIs targeted against Ras, in combination with Tamoxifen, increases the 
antitumour effect of both drugs (234), Several clinical trials are currently investigating 
the effects of FTIs in combination with tamoxifen, to determine if the presence of FTIs 
can delay the development of tamoxifen resistance (304). A recent study of 
Farnesy 1thiosalicy 1 ic acid (FTS), which inhibits Ras binding to its membrane acceptor 
sites, revealed that FTS induced apoptosis and inhibited proliferation in wild-type and E2 
deprived MCF-7 cells. It is speculated that FTS may be useful in the treatment of 
patients, in combination with tamoxifen or AIs (305). Since FTIs and FTS impact Ras 
activation, this would ultimately influence the levels of activated Raf-1 and MAPK. This 
would be crucial, since in our study it was pRaf(ser338) that was identified as the key 
target. The importance of Raf-I in regulating tumour growth was further highlighted by 
an in vitro study that reported that the RTK inhibitor AG 879 inhibits proliferation of 
breast cancer cells by down-regulating expression of the Raf-1 gene (306). Other 
treatment options are Raf-1 inhibitors, such as Sorafenib (BAY 43-9006), and MEK 
inhibitors, such as PD0325901 (242). Clinical trials are currently underway investigating 
the effectiveness of these treatments in combination with endocrine therapies. Despite our 
findings that expression levels of neither Raf-1 nor MAPK in patients tumours
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significantly altered response to chemotherapy, it is also thought that therapies directed 
against these proteins, such as MEK inhibitors, would increase the cytotoxicity of 
chemotherapy agents (242).
The Ras/Raf-l/MAPK pathway controls multiple cellular processes, such as 
proliferation, differentiation, apoptosis, senescence, migration and invasion, all of which 
are fundamental in tumour growth. The research presented in this thesis demonstrates that 
the Ras cascade plays an important role in regulating breast tumourigenesis, in mediating 
response to Tamoxifen, and in modifying the phosphorylation and activation status of 
ERa. The activated form of Raf-1 has been identified as a possible predictive marker of 
tamoxifen response. Furthermore, these studies have highlighted a possible mechanism 
by which activation of this pathway contributes to the development of tamoxifen 
resistance. It appeared that that the ligand-independent phosphorylation and activation of 
ERa was dominant over the ligand-dependent effects, and that it was able to modify the 
subcellular localisation of the receptor.
It is becoming clear that multiple signal transduction mechanisms are involved in 
the development of resistance to current breast cancer therapeutic options. The current 
study highlights, using both in vivo and in vitro approaches, that the MAPK cascade is 
associated with development of tamoxifen resistance in a sub cohort of patients. 
However, reports from the literature also highlight that other cascades, such as 
PI3K/AKT, which is known to interact with the MAPK pathway, also have a role in the 
development of resistance. As the number of women diagnosed with breast cancer 
continues to rise, so too does the need for improved treatment options for these patients. 
To achieve this, we need to further our understanding of the mechanisms that drive
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treatment failure and identify markers that are predictive for response to these treatments. 
This will ultimately enable clinicians to treat and predict individual patients outcome 
more effectively.
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Appendix 1
Negative Cytoplasm (0+) 
Weak Cytoplasm (1+)
Weak Cytoplasm (1+) Weak Cytoplasm (1+) 
Moderate Cytoplasm (2+)
?
Moderate Cytoplasm (2+) Strong Cytoplasm (3+)
Strong Cytoplasm (3+)
Following immunohistochemistry all tumours were scored for cytoplasmic and nuclear 
staining, using a semi-quantitative weighted histoscore method. The intensity o f staining 
was categorised as negative (0), weak (1), moderate (2) and strong (3) and the 
percentage o f tumour cells within each category estimated. The above figures highlight 
the different intensities o f  cytoplasmic staining.
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Appendix 2
Negative Nuclei (0+) Negative Nuclei (0+) 
Weak Nuclei (1+) 
Moderate Nuclei (2+)
't m i
Moderate Nuclei (2+) 
Strong Nuclei (3+)
Following immunohistochemistry all tumours were scored for cytoplasmic and nuclear 
staining, using a semi-quantitative weighted histoscore method. The intensity o f staining 
was categorised as negative (0), weak (1), moderate (2) and strong (3) and the 
percentage o f tumour cells within each category estimated. The above figures highlight 
the different intensities o f nuclear staining.
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Appendix 3
Negative Nuclei (0+) Negative Nuclei (0+) 
Weak Nuclei (1+) 
Moderate Nuclei (2+)
Weak Nuclei (2+) 
Strong Nuclei (3+)
In order to semi-quantijy the levels o f  fluorescent protein detected, a scoring method 
similar to that o f the histoscore was devised. Only protein expressed within the nuclei 
was scored using this method. As with the histoscores, the intensity o f  nuclear staining 
was categorised as negative (0), weak/speckled (1), moderate (2) and strong (3). The 
above figures highlight the intensity o f  nuclear fluorescent staining.
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Appendix 4
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Subcellular markers were used to ensure that the protein fractions generated from the 
fractionation experiments were specific fo r their subcellular location, (a) The membrane 
marker was a Sodium Potassium ATPase (112kDa, 150kDa) and was detected only in the 
membrane fractions (M). (b) The nuclear marker was Retinoblastoma (105kDa) and was 
detected only in the nuclear fraction (N).
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Appendix 5
Pan-Ras Ras Ab-1 H -R as
N-Ras
Phospho-Raf(ser338)
■"v
K-Ras
•  i
'p'-.
* - :■ '
4,% .;/# ...
Raf-1
m &
Phospho-Raf(ser259) p44/42 MAPK
g m
Phospho-p44/42 MAPK
Negative controls were included in each IHC run. The above figures represent the 
negative controls for each antibody used.
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